| Pathways |
Up/Down |
Enrichment rank cutoff |
Precision |
Recall |
F1 score (beta=0.25) |
F1 score AUC (corrected) |
F1 score AUC rank |
Cardiotoxic TKIs |
Non cardiotoxic TKIs |
| Mitotic chromosome condensation |
Down |
10 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN08) |
ceritinib (MSN05;MSN09) |
| Mitochondrial fission |
Down |
12.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN09) |
| Mitochondrial fusion |
Up |
14 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Mitochondrial transport |
Up |
16 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sorafenib (MSN01) |
|
| Mitotic chromosome condensation |
Up |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN06;MSN09) |
| Mitotic chromosome condensation |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN06);nilotinib (MSN06;MSN09) |
| Mitotic chromosome condensation |
Up |
13.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
sorafenib (MSN05) |
imatinib (MSN06);nilotinib (MSN06;MSN09) |
| Mitotic chromosome condensation |
Up |
16 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
ponatinib (MSN01;MSN08);sorafenib (MSN05) |
imatinib (MSN06);nilotinib (MSN06;MSN09) |
| Mitotic chromosome condensation |
Up |
18 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
ponatinib (MSN01;MSN08);sorafenib (MSN05) |
imatinib (MSN06);nilotinib (MSN01;MSN06;MSN09) |
| Mitotic chromosome condensation |
Up |
19.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
ponatinib (MSN01;MSN08);sorafenib (MSN05) |
imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN09) |
| Mitotic chromosome condensation |
Up |
23.5 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
ponatinib (MSN01;MSN08);sorafenib (MSN05) |
imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic chromosome condensation |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09) |
| Mitotic chromosome condensation |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN09) |
| Mitochondrial ADP import and ATP export |
Up |
24.5 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06;MSN08) |
imatinib (MSN05;MSN06) |
| Mitotic chromosome condensation |
Down |
12 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN08) |
ceritinib (MSN05;MSN09) |
| Mitotic chromosome condensation |
Down |
13 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN05;MSN08) |
ceritinib (MSN05;MSN09) |
| Mitotic chromosome condensation |
Down |
14.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN05;MSN08) |
ceritinib (MSN05;MSN09);cetuximab (MSN01) |
| Mitotic chromosome condensation |
Down |
15 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN05;MSN08) |
ceritinib (MSN05;MSN09);cetuximab (MSN01);erlotinib (MSN09) |
| Mitotic chromosome condensation |
Down |
16 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN05;MSN08) |
ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN09) |
| Mitotic chromosome condensation |
Down |
16.5 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN05;MSN08) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN09) |
| Mitotic chromosome condensation |
Down |
20.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN09) |
| Mitotic chromosome condensation |
Down |
26 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN09) |
| Mitotic chromosome condensation |
Down |
29.5 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
3 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sorafenib (MSN01;MSN08) |
|
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
5 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
sorafenib (MSN01;MSN08;MSN09) |
nilotinib (MSN01);ruxolitinib (MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
5.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
sorafenib (MSN01;MSN08;MSN09) |
imatinib (MSN06);nilotinib (MSN01);ruxolitinib (MSN02) |
| Microtubule polymerization |
Down |
5.5 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
bevacizumab (MSN09);pazopanib (MSN08;MSN09) |
rituximab (MSN06;MSN09) |
| Microtubule destabilization |
Up |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN09) |
| Microtubule destabilization |
Up |
14 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02;MSN09) |
| Microtubule destabilization |
Up |
18 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN08);ruxolitinib (MSN02;MSN09) |
| Microtubule destabilization |
Up |
20 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01;MSN08);ruxolitinib (MSN02;MSN09) |
| Microtubule destabilization |
Down |
12.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN08) |
| Microtubule destabilization |
Down |
22.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);erlotinib (MSN08) |
| Microtubule destabilization |
Down |
23 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);erlotinib (MSN01;MSN08) |
| Microtubule destabilization |
Down |
25 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);erlotinib (MSN01;MSN05;MSN08) |
| Microtubule destabilization |
Down |
26.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Microtubule polymerization |
Down |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN08) |
|
| Microtubule polymerization |
Down |
4.5 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
bevacizumab (MSN09);pazopanib (MSN08;MSN09) |
|
| Microtubule polymerization |
Down |
5 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
bevacizumab (MSN09);pazopanib (MSN08;MSN09) |
rituximab (MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
6 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
ponatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN06);nilotinib (MSN01;MSN08);ruxolitinib (MSN02) |
| Microtubule stabilization |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05) |
| Microtubule stabilization |
Down |
15 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN06) |
| Mineralocorticoid receptor signaling |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN06) |
| Mineralocorticoid receptor signaling |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02);dasatinib (MSN06) |
| Mineralocorticoid receptor signaling |
Down |
11.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN06) |
|
| Mineralocorticoid receptor signaling |
Down |
15 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sunitinib (MSN05;MSN06) |
|
| Mitochondrial ADP import and ATP export |
Up |
9 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN05) |
|
| Mitochondrial ADP import and ATP export |
Up |
11.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
pazopanib (MSN05;MSN08) |
|
| Mitochondrial ADP import and ATP export |
Up |
13 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
pazopanib (MSN05;MSN06;MSN08) |
|
| Mitochondrial ADP import and ATP export |
Up |
14.5 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
pazopanib (MSN05;MSN06;MSN08) |
imatinib (MSN05) |
| Mitochondrial ADP import and ATP export |
Up |
18.5 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06;MSN08) |
imatinib (MSN05) |
| Mitotic spindle assembly |
Down |
5 |
0.2692308 |
0.1521739 |
0.2575758 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08);erlotinib (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
21.5 |
0.2692308 |
0.1521739 |
0.2575758 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle assembly |
Up |
2 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08) |
|
| Mitotic spindle assembly |
Up |
3 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08) |
axitinib (MSN08);dasatinib (MSN05);imatinib (MSN05) |
| Mitotic spindle assembly |
Up |
4 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN09) |
axitinib (MSN08);cabozantinib (MSN08);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08) |
| Mitotic spindle assembly |
Up |
5 |
0.4090909 |
0.1956522 |
0.3844221 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN08);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);nilotinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01) |
| Mitotic spindle assembly |
Up |
6 |
0.3461539 |
0.1956522 |
0.3311689 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN08);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Mitotic spindle assembly |
Up |
8 |
0.3333333 |
0.1956522 |
0.3200837 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN08);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Mitotic spindle assembly |
Up |
9 |
0.3214286 |
0.1956522 |
0.3097166 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN08);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Mitotic spindle assembly |
Up |
9.5 |
0.3103448 |
0.1956522 |
0.3 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN08;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Mitotic spindle assembly |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08) |
| Mitotic spindle assembly |
Down |
3 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN01);ceritinib (MSN08;MSN09);cetuximab (MSN01);gefitinib (MSN05;MSN06;MSN09) |
| Mitotic spindle assembly |
Down |
4 |
0.1666667 |
0.06521739 |
0.1526946 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN09) |
afatinib (MSN01;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
19 |
0.28 |
0.1521739 |
0.2668161 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle assembly |
Down |
6 |
0.2666667 |
0.173913 |
0.2585552 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle assembly |
Down |
7 |
0.2580645 |
0.173913 |
0.2509225 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle assembly |
Down |
8 |
0.25 |
0.173913 |
0.2437276 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle assembly |
Down |
10.5 |
0.2727273 |
0.1956522 |
0.2665506 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle assembly |
Down |
23 |
0.2941177 |
0.2173913 |
0.2881356 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN05) |
| Mitotic spindle disassembly |
Up |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09);dasatinib (MSN05) |
| Mitotic spindle disassembly |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN05;MSN09);dasatinib (MSN05) |
| Mitotic spindle disassembly |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05) |
| Mitotic spindle disassembly |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05);imatinib (MSN01) |
| Mitotic spindle disassembly |
Up |
13 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
sorafenib (MSN08) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05);imatinib (MSN01) |
| Mitotic spindle disassembly |
Up |
13.5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
sorafenib (MSN08) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05);imatinib (MSN01);ruxolitinib (MSN06) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
6.5 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN06);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
6.5 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
ponatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN06);nilotinib (MSN01;MSN06;MSN08;MSN09);ruxolitinib (MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
7 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
ponatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN06;MSN08;MSN09);ruxolitinib (MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
8 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
ponatinib (MSN01;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
9.5 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
ponatinib (MSN01;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
10 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
11.5 |
0.5 |
0.1956522 |
0.4580838 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
15.5 |
0.4736842 |
0.1956522 |
0.4371428 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN08);ruxolitinib (MSN01;MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Up |
17 |
0.45 |
0.1956522 |
0.4180328 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01;MSN02) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN08) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN09);gefitinib (MSN08) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
6 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN06);gefitinib (MSN01;MSN05;MSN06;MSN08) |
| Microtubule crosslinking and bundling |
Down |
21 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
lapatinib (MSN05);pazopanib (MSN05;MSN06) |
ruxolitinib (MSN01);vemurafenib (MSN08) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
7 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
trametinib (MSN01;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN05;MSN06);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
7.5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
trametinib (MSN01;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN05;MSN06);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
8 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN05;MSN06);cetuximab (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
8.5 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN05;MSN06);cetuximab (MSN01);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
9 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
9.5 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
10.5 |
0.2105263 |
0.08695652 |
0.1942857 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN08;MSN09);ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
11.5 |
0.2380952 |
0.1086956 |
0.222513 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
14 |
0.2272727 |
0.1086956 |
0.2135678 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
16 |
0.2608696 |
0.1304348 |
0.2463769 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic H3 phosphorylation and dephosphorylation |
Down |
16.5 |
0.25 |
0.1304348 |
0.2372093 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Methionine cycle |
Up |
21 |
0.5384616 |
0.1521739 |
0.468504 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);ponatinib (MSN09);trastuzumab (MSN02;MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01) |
| Methionine cycle |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01);dasatinib (MSN01) |
| Methionine cycle |
Up |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN06);dasatinib (MSN01) |
| Methionine cycle |
Up |
12 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trastuzumab (MSN05) |
crizotinib (MSN01;MSN06);dasatinib (MSN01) |
| Methionine cycle |
Up |
13.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trastuzumab (MSN05) |
crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05) |
| Methionine cycle |
Up |
14 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trastuzumab (MSN05) |
crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
15 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trastuzumab (MSN05) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
17.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
trastuzumab (MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
18 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
trastuzumab (MSN02;MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
18.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
bevacizumab (MSN06);trastuzumab (MSN02;MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
19.5 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);trastuzumab (MSN02;MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
20 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);trastuzumab (MSN02;MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
19 |
0.3235294 |
0.2391304 |
0.3169491 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Methionine cycle |
Up |
24.5 |
0.5714286 |
0.173913 |
0.5037037 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);ponatinib (MSN09);trastuzumab (MSN02;MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
26 |
0.6 |
0.1956522 |
0.534965 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN09);trastuzumab (MSN02;MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Up |
27.5 |
0.625 |
0.2173913 |
0.5629139 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN08;MSN09);trastuzumab (MSN02;MSN05);vandetanib (MSN09) |
bosutinib (MSN01);crizotinib (MSN01;MSN06);dasatinib (MSN01);vemurafenib (MSN05;MSN09) |
| Methionine cycle |
Down |
13.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN08) |
|
| Methionine cycle |
Down |
14 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN08) |
regorafenib (MSN01) |
| Methionine cycle |
Down |
14.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN08) |
regorafenib (MSN01);rituximab (MSN06) |
| Methionine cycle |
Down |
15 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN05;MSN08) |
regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| Methionine cycle |
Down |
15.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN05;MSN08) |
regorafenib (MSN01;MSN08);rituximab (MSN05;MSN06);vemurafenib (MSN09) |
| Methionine cycle |
Down |
16 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN01;MSN05;MSN08) |
regorafenib (MSN01;MSN08);rituximab (MSN05;MSN06);vemurafenib (MSN09) |
| Methionine cycle |
Down |
16.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN01;MSN05;MSN08) |
cabozantinib (MSN08);regorafenib (MSN01;MSN08);rituximab (MSN05;MSN06);vemurafenib (MSN09) |
| Methionine cycle |
Down |
17 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
sorafenib (MSN01;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN06;MSN08);regorafenib (MSN01;MSN06;MSN08);rituximab (MSN05;MSN06);vemurafenib (MSN09) |
| Methionine cycle |
Down |
19 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
sorafenib (MSN01;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN06;MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06);vemurafenib (MSN09) |
| Metaphase to anaphase checkpoint |
Up |
6 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Mammalian target of rapamycin signaling pathway |
Down |
19 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN01;MSN08) |
|
| Mammalian target of rapamycin signaling pathway |
Down |
22 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN01;MSN05;MSN08) |
|
| Mammalian target of rapamycin signaling pathway |
Down |
23 |
1 |
0.1086956 |
0.674603 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09) |
|
| MAPK signaling pathway |
Up |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01) |
| MAPK signaling pathway |
Up |
29 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01;MSN08) |
| MAPK signaling pathway |
Down |
18 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN08) |
| MAPK signaling pathway |
Down |
23 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08);ceritinib (MSN06);cetuximab (MSN01);vemurafenib (MSN08) |
| MAPK signaling pathway |
Down |
31 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trametinib (MSN01) |
afatinib (MSN08);ceritinib (MSN06);cetuximab (MSN01);vemurafenib (MSN08) |
| Metaphase to anaphase checkpoint |
Up |
2 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sorafenib (MSN05;MSN09) |
|
| Metaphase to anaphase checkpoint |
Up |
3 |
0.4117647 |
0.1521739 |
0.3742138 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
imatinib (MSN01;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN05);ruxolitinib (MSN01;MSN02) |
| Metaphase to anaphase checkpoint |
Up |
4 |
0.4090909 |
0.1956522 |
0.3844221 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09) |
| Metaphase to anaphase checkpoint |
Up |
5 |
0.375 |
0.1956522 |
0.355814 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Methionine cycle |
Down |
19.5 |
0.3888889 |
0.1521739 |
0.3562874 |
NaN |
NaN |
sorafenib (MSN01;MSN05;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN06;MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06);vemurafenib (MSN09) |
| Metaphase to anaphase checkpoint |
Down |
3 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05) |
afatinib (MSN05;MSN09);ceritinib (MSN06);gefitinib (MSN01;MSN08) |
| Metaphase to anaphase checkpoint |
Down |
4 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN09);ceritinib (MSN06;MSN09);cetuximab (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
5 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
6 |
0.2608696 |
0.1304348 |
0.2463769 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
7 |
0.24 |
0.1304348 |
0.2286996 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
8 |
0.2692308 |
0.1521739 |
0.2575758 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
9 |
0.2962963 |
0.173913 |
0.2845188 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
10 |
0.2857143 |
0.173913 |
0.2753036 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
13 |
0.3103448 |
0.1956522 |
0.3 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
14 |
0.3333333 |
0.2173913 |
0.3231939 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN02);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Metaphase to anaphase checkpoint |
Down |
15 |
0.34375 |
0.2391304 |
0.3351255 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Microfibril scaffold organization |
Down |
22.5 |
0.4444444 |
0.173913 |
0.4071856 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02);sorafenib (MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN05;MSN06);dasatinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Up |
29.5 |
0.3142857 |
0.2391304 |
0.3085808 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Down |
11.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN08) |
rituximab (MSN08) |
| Microfibril scaffold organization |
Down |
12.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
vandetanib (MSN08) |
nilotinib (MSN01);rituximab (MSN08) |
| Microfibril scaffold organization |
Down |
13.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
sorafenib (MSN08);vandetanib (MSN08) |
nilotinib (MSN01);rituximab (MSN08) |
| Microfibril scaffold organization |
Down |
15.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
sorafenib (MSN08);vandetanib (MSN08) |
nilotinib (MSN01);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Down |
16 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN08);vandetanib (MSN08) |
nilotinib (MSN01);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Down |
17 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN08);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05);cabozantinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Down |
18 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02);sorafenib (MSN08);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05);cabozantinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Down |
18.5 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02);sorafenib (MSN08);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Down |
19.5 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02);sorafenib (MSN05;MSN08;MSN09);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Down |
21 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02);sorafenib (MSN05;MSN08;MSN09);trastuzumab (MSN05);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Down |
21.5 |
0.5 |
0.173913 |
0.4503311 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02);sorafenib (MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Up |
24.5 |
0.3235294 |
0.2391304 |
0.3169491 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Down |
25 |
0.4736842 |
0.1956522 |
0.4371428 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);ponatinib (MSN02);sorafenib (MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN05;MSN06);dasatinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microfibril scaffold organization |
Down |
26 |
0.5 |
0.2173913 |
0.4644809 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);ponatinib (MSN02);sorafenib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN05;MSN06);dasatinib (MSN06);nilotinib (MSN01);regorafenib (MSN06);rituximab (MSN05;MSN08) |
| Microtubule crosslinking and bundling |
Up |
2 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Microtubule crosslinking and bundling |
Up |
3.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN09) |
cabozantinib (MSN02) |
| Microtubule crosslinking and bundling |
Up |
4.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN09) |
cabozantinib (MSN02;MSN05);ceritinib (MSN09) |
| Microtubule crosslinking and bundling |
Up |
6 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
dabrafenib (MSN09) |
cabozantinib (MSN02;MSN05;MSN08);ceritinib (MSN09);cetuximab (MSN05) |
| Microtubule crosslinking and bundling |
Up |
9 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
dabrafenib (MSN09) |
cabozantinib (MSN02;MSN05;MSN06;MSN08);ceritinib (MSN09);cetuximab (MSN05) |
| Microtubule crosslinking and bundling |
Up |
13 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
dabrafenib (MSN09);sorafenib (MSN09) |
cabozantinib (MSN02;MSN05;MSN06;MSN08);ceritinib (MSN09);cetuximab (MSN05) |
| Microtubule crosslinking and bundling |
Down |
3 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN06) |
|
| Microtubule crosslinking and bundling |
Down |
9 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
pazopanib (MSN06) |
vemurafenib (MSN08) |
| Microtubule crosslinking and bundling |
Down |
11.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
pazopanib (MSN05;MSN06) |
ruxolitinib (MSN01);vemurafenib (MSN08) |
| Microfibril scaffold organization |
Up |
13 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
sunitinib (MSN01;MSN05;MSN09) |
bosutinib (MSN09);ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN08;MSN09) |
| Methionine cycle |
Down |
20 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN06;MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06);vemurafenib (MSN09) |
| Methionine cycle |
Down |
21 |
0.4 |
0.173913 |
0.3715847 |
NaN |
NaN |
lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN06;MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06);ruxolitinib (MSN02);vemurafenib (MSN09) |
| Methionine cycle |
Down |
22.5 |
0.3809524 |
0.173913 |
0.356021 |
NaN |
NaN |
lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN05;MSN06;MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06);ruxolitinib (MSN02);vemurafenib (MSN09) |
| Methionine cycle |
Down |
26.5 |
0.3636364 |
0.173913 |
0.3417086 |
NaN |
NaN |
lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN05;MSN06;MSN08);cetuximab (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06);ruxolitinib (MSN02);vemurafenib (MSN09) |
| Methionine cycle |
Down |
28.5 |
0.3478261 |
0.173913 |
0.3285024 |
NaN |
NaN |
lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN01);cabozantinib (MSN05;MSN06;MSN08);cetuximab (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06);ruxolitinib (MSN02);vemurafenib (MSN09) |
| Methionine cycle |
Down |
31.5 |
0.3333333 |
0.173913 |
0.3162791 |
NaN |
NaN |
lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08);sunitinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN01);cabozantinib (MSN05;MSN06;MSN08);cetuximab (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06);ruxolitinib (MSN02);vemurafenib (MSN09) |
| Microfibril scaffold organization |
Up |
2 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN01) |
|
| Microfibril scaffold organization |
Up |
3 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sunitinib (MSN01;MSN09) |
|
| Microfibril scaffold organization |
Up |
6 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
sunitinib (MSN01;MSN09) |
ceritinib (MSN08) |
| Microfibril scaffold organization |
Up |
11 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
sunitinib (MSN01;MSN09) |
ceritinib (MSN08);crizotinib (MSN01;MSN05);tofacitinib (MSN01) |
| Microfibril scaffold organization |
Up |
11.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
sunitinib (MSN01;MSN09) |
ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08);tofacitinib (MSN01;MSN09) |
| Microfibril scaffold organization |
Up |
12.5 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
sunitinib (MSN01;MSN09) |
bosutinib (MSN09);ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08);ruxolitinib (MSN05);tofacitinib (MSN01;MSN09) |
| Mitotic spindle disassembly |
Up |
14.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
sorafenib (MSN08) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05);imatinib (MSN01;MSN05);ruxolitinib (MSN06) |
| Microfibril scaffold organization |
Up |
14.5 |
0.2142857 |
0.06521739 |
0.1888889 |
NaN |
NaN |
sunitinib (MSN01;MSN05;MSN09) |
bosutinib (MSN09);ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
15 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
sunitinib (MSN01;MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN09);ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
15.5 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN09);ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
16 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN09);ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
17 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN08);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
18.5 |
0.3333333 |
0.173913 |
0.3162791 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN08);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
19.5 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN08);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
20 |
0.3703704 |
0.2173913 |
0.3556485 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN08);cetuximab (MSN01;MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
20.5 |
0.3333333 |
0.2173913 |
0.3231939 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
22.5 |
0.3125 |
0.2173913 |
0.3046595 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Microfibril scaffold organization |
Up |
23.5 |
0.3030303 |
0.2173913 |
0.2961673 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Nuclear envelope maintenance |
Up |
21 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN06;MSN08;MSN09) |
| Notch receptor signaling |
Up |
15 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
bevacizumab (MSN09) |
axitinib (MSN09);ceritinib (MSN09);cetuximab (MSN01);regorafenib (MSN05) |
| Notch receptor signaling |
Up |
18 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN05) |
axitinib (MSN09);ceritinib (MSN08;MSN09);cetuximab (MSN01);regorafenib (MSN05) |
| Notch receptor signaling |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02) |
| Notch receptor signaling |
Down |
4 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN09) |
cabozantinib (MSN02) |
| Notch receptor signaling |
Down |
5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
vandetanib (MSN05;MSN09) |
cabozantinib (MSN02);ruxolitinib (MSN08) |
| Notch receptor signaling |
Down |
10 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
vandetanib (MSN05;MSN09) |
cabozantinib (MSN02);dasatinib (MSN09);ruxolitinib (MSN06;MSN08;MSN09) |
| Notch receptor signaling |
Down |
14 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
vandetanib (MSN05;MSN09) |
cabozantinib (MSN02);dasatinib (MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Notch receptor signaling |
Down |
28 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
vandetanib (MSN05;MSN09) |
cabozantinib (MSN02);dasatinib (MSN09);erlotinib (MSN01);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Notch receptor signaling |
Down |
30 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
vandetanib (MSN05;MSN09) |
cabozantinib (MSN02);dasatinib (MSN09);erlotinib (MSN01;MSN05);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Notch receptor signaling |
Down |
31 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
vandetanib (MSN05;MSN09) |
cabozantinib (MSN02);dasatinib (MSN09);erlotinib (MSN01;MSN05;MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Nuclear envelope maintenance |
Up |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN09) |
| Nuclear envelope maintenance |
Up |
19.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN06;MSN09) |
| Notch receptor signaling |
Up |
11 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
bevacizumab (MSN09) |
axitinib (MSN09);ceritinib (MSN09);cetuximab (MSN01) |
| Nuclear intermediate filaments |
Up |
13.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sorafenib (MSN01) |
|
| Nuclear intermediate filaments |
Up |
14 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sorafenib (MSN01) |
ruxolitinib (MSN02) |
| Nuclear intermediate filaments |
Up |
19 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sorafenib (MSN01) |
nilotinib (MSN09);ruxolitinib (MSN02) |
| Nuclear intermediate filaments |
Up |
19.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
sorafenib (MSN01) |
nilotinib (MSN06;MSN09);ruxolitinib (MSN02) |
| Nuclear intermediate filaments |
Up |
21 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sorafenib (MSN01) |
nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02) |
| Nuclear intermediate filaments |
Down |
22 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN05) |
|
| Nuclear intermediate filaments |
Down |
23 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trametinib (MSN05;MSN08) |
erlotinib (MSN01) |
| Nuclear intermediate filaments |
Down |
26.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
trametinib (MSN05;MSN08) |
erlotinib (MSN01;MSN09) |
| Nuclear intermediate filaments |
Down |
27 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
trametinib (MSN05;MSN08) |
erlotinib (MSN01;MSN08;MSN09) |
| Nuclear intermediate filaments |
Down |
27.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
trametinib (MSN05;MSN08) |
ceritinib (MSN05);erlotinib (MSN01;MSN08;MSN09) |
| Nuclear mRNA export |
Up |
18 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN06) |
|
| Nuclear mRNA export |
Up |
20 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sunitinib (MSN02;MSN06) |
|
| Non-vesicular phospholipid transport |
Up |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01);ceritinib (MSN08);rituximab (MSN06) |
| Neuregulin receptor signaling |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN06) |
| Neuregulin receptor signaling |
Down |
10 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN01) |
imatinib (MSN06) |
| Neuregulin receptor signaling |
Down |
17 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN01) |
crizotinib (MSN09);imatinib (MSN06) |
| Neuregulin receptor signaling |
Down |
24.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN01) |
crizotinib (MSN06;MSN09);imatinib (MSN06) |
| Neuronal membrane repolarization during action potential and hyperpolarization |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN09) |
| Neuronal pacemaker current generation |
Down |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08) |
| Nodal growth differentiation factor receptor signaling |
Up |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09) |
| Nodal growth differentiation factor receptor signaling |
Up |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);cetuximab (MSN05) |
| NOD-like receptor signaling |
Up |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN06) |
| NOD-like receptor signaling |
Up |
20 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN01;MSN06) |
| Non-vesicular phospholipid transport |
Up |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN06) |
| Non-vesicular phospholipid transport |
Up |
13.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01);rituximab (MSN06) |
| Nucleosome assembly |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02) |
| Non-vesicular phospholipid transport |
Down |
5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN06) |
bosutinib (MSN01) |
| Non-vesicular phospholipid transport |
Down |
6 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN06) |
bosutinib (MSN01);cabozantinib (MSN09) |
| Non-vesicular phospholipid transport |
Down |
7 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN06) |
bosutinib (MSN01);cabozantinib (MSN09);regorafenib (MSN05) |
| Non-vesicular phospholipid transport |
Down |
7.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
dabrafenib (MSN06) |
bosutinib (MSN01);cabozantinib (MSN09);dasatinib (MSN08);regorafenib (MSN05) |
| Non-vesicular phospholipid transport |
Down |
8 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
dabrafenib (MSN06) |
bosutinib (MSN01;MSN09);cabozantinib (MSN09);dasatinib (MSN08);regorafenib (MSN05) |
| Non-vesicular phospholipid transport |
Down |
9 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
dabrafenib (MSN06) |
bosutinib (MSN01;MSN09);cabozantinib (MSN09);crizotinib (MSN01);dasatinib (MSN08);regorafenib (MSN05) |
| Non-vesicular phospholipid transport |
Down |
9.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
dabrafenib (MSN06) |
axitinib (MSN06);bosutinib (MSN01;MSN09);cabozantinib (MSN09);crizotinib (MSN01);dasatinib (MSN08);regorafenib (MSN05) |
| Non-vesicular phospholipid transport |
Down |
11.5 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06) |
axitinib (MSN06);bosutinib (MSN01;MSN09);cabozantinib (MSN09);crizotinib (MSN01;MSN06);dasatinib (MSN08);regorafenib (MSN05) |
| Non-vesicular phospholipid transport |
Down |
12.5 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06) |
axitinib (MSN06);bosutinib (MSN01;MSN09);cabozantinib (MSN09);crizotinib (MSN01;MSN06);dasatinib (MSN05;MSN08);regorafenib (MSN05) |
| Notch receptor signaling |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09) |
| Notch receptor signaling |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);ceritinib (MSN09);cetuximab (MSN01) |
| Osteopontin receptor signaling |
Up |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06);ruxolitinib (MSN05);vemurafenib (MSN01;MSN05) |
| Osteonectin receptor signaling |
Down |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);nilotinib (MSN01);regorafenib (MSN05);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);nilotinib (MSN01);regorafenib (MSN05;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
lapatinib (MSN06) |
axitinib (MSN09);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
6 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
lapatinib (MSN06) |
axitinib (MSN09);cetuximab (MSN08);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
6.5 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
lapatinib (MSN06) |
axitinib (MSN09);cetuximab (MSN08);dasatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
7.5 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
lapatinib (MSN06;MSN09) |
axitinib (MSN09);cetuximab (MSN08);dasatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
8.5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
lapatinib (MSN06;MSN09);trastuzumab (MSN02) |
axitinib (MSN09);cabozantinib (MSN02);cetuximab (MSN08);dasatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
9.5 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
lapatinib (MSN06;MSN09);trastuzumab (MSN02) |
axitinib (MSN09);cabozantinib (MSN02);cetuximab (MSN08);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
14 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
lapatinib (MSN06;MSN09);trastuzumab (MSN01;MSN02) |
axitinib (MSN09);cabozantinib (MSN02);cetuximab (MSN08);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Down |
16.5 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN09);trastuzumab (MSN01;MSN02) |
axitinib (MSN09);cabozantinib (MSN02);cetuximab (MSN08);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN06) |
| Osteopontin receptor signaling |
Up |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN01) |
| Osteonectin receptor signaling |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);nilotinib (MSN01) |
| Osteopontin receptor signaling |
Up |
8 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
crizotinib (MSN06);ruxolitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06) |
| Osteopontin receptor signaling |
Up |
8.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
crizotinib (MSN06);rituximab (MSN05);ruxolitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06) |
| Osteopontin receptor signaling |
Up |
9 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
bosutinib (MSN09);crizotinib (MSN06);rituximab (MSN05);ruxolitinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06) |
| Osteopontin receptor signaling |
Up |
9.5 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
bosutinib (MSN09);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteopontin receptor signaling |
Up |
10 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN05;MSN09);bosutinib (MSN09);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteopontin receptor signaling |
Up |
10.5 |
0.2222222 |
0.08695652 |
0.2035928 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN09);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteopontin receptor signaling |
Up |
11 |
0.2105263 |
0.08695652 |
0.1942857 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN09);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteopontin receptor signaling |
Up |
11.5 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN09);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteopontin receptor signaling |
Up |
12 |
0.2916667 |
0.1521739 |
0.2767442 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN09);ceritinib (MSN09);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteopontin receptor signaling |
Up |
13 |
0.28 |
0.1521739 |
0.2668161 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN09);ceritinib (MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteopontin receptor signaling |
Up |
13.5 |
0.2692308 |
0.1521739 |
0.2575758 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteonectin receptor signaling |
Up |
2 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
bosutinib (MSN09);cabozantinib (MSN02;MSN06;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Nucleosome assembly |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02);ruxolitinib (MSN02) |
| Nucleosome assembly |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08) |
| Nucleosome assembly |
Down |
18 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN08);erlotinib (MSN09) |
| Nucleosome assembly |
Down |
25 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN08;MSN09);erlotinib (MSN09) |
| Nucleosome assembly |
Down |
35 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trametinib (MSN05) |
ceritinib (MSN05;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| Oncostatin-M receptor signaling |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN01) |
| Oncostatin-M receptor signaling |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN01;MSN05;MSN09) |
| Oncostatin-M receptor signaling |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Oncostatin-M receptor signaling |
Down |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN01);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Oncostatin-M receptor signaling |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN01;MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Osteonectin receptor signaling |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02);dasatinib (MSN08);gefitinib (MSN01) |
| Osteonectin receptor signaling |
Up |
1.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
vandetanib (MSN08) |
cabozantinib (MSN02);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);vemurafenib (MSN08) |
| Neuregulin receptor signaling |
Up |
19 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
ponatinib (MSN05) |
cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN09);ruxolitinib (MSN06) |
| Osteonectin receptor signaling |
Up |
2.5 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
bosutinib (MSN09);cabozantinib (MSN02;MSN05;MSN06;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
3 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN09);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);tofacitinib (MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
3.5 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);tofacitinib (MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
4 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);sunitinib (MSN02);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);tofacitinib (MSN01;MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
5 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
bevacizumab (MSN06;MSN08;MSN09);sunitinib (MSN02;MSN05);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
5.5 |
0.3461539 |
0.1956522 |
0.3311689 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02;MSN05);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
6 |
0.4137931 |
0.2608696 |
0.4 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);sunitinib (MSN02;MSN05;MSN06;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
7.5 |
0.4193548 |
0.2826087 |
0.407749 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);rituximab (MSN06;MSN08);tofacitinib (MSN01;MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
11.5 |
0.4242424 |
0.3043478 |
0.4146341 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN08);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);rituximab (MSN06;MSN08);tofacitinib (MSN01;MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Up |
16 |
0.4117647 |
0.3043478 |
0.4033898 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN08);crizotinib (MSN01);dasatinib (MSN08);gefitinib (MSN01);imatinib (MSN06);rituximab (MSN06;MSN08);tofacitinib (MSN01;MSN05);vemurafenib (MSN06;MSN08) |
| Osteonectin receptor signaling |
Down |
2.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN01) |
| Muscarinic receptor signaling |
Up |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06;MSN08);cetuximab (MSN02) |
| Mitotic spindle disassembly |
Down |
24.5 |
0.3043478 |
0.1521739 |
0.2874396 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN01;MSN06) |
| Mitotic spindle disassembly |
Down |
25 |
0.2916667 |
0.1521739 |
0.2767442 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN01;MSN06;MSN08) |
| Mitotic spindle disassembly |
Down |
26 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN01;MSN06;MSN08) |
| Mitotic spindle disassembly |
Down |
27.5 |
0.3571429 |
0.2173913 |
0.3441296 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Down |
29.5 |
0.3448276 |
0.2173913 |
0.3333333 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Down |
30.5 |
0.3666667 |
0.2391304 |
0.3555134 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Down |
31.5 |
0.3636364 |
0.2608696 |
0.3554007 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Down |
32 |
0.3529412 |
0.2608696 |
0.3457627 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Down |
33 |
0.3333333 |
0.2608696 |
0.3279742 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);erlotinib (MSN01;MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Down |
35 |
0.3243243 |
0.2608696 |
0.3197492 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Muscarinic receptor signaling |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06) |
| Muscarinic receptor signaling |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06;MSN08) |
| Mitotic spindle disassembly |
Down |
22 |
0.3333333 |
0.1521739 |
0.3115183 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN01) |
| Muscarinic receptor signaling |
Up |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06;MSN08);cetuximab (MSN02);regorafenib (MSN06) |
| Muscarinic receptor signaling |
Up |
18 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06;MSN08);cetuximab (MSN02);regorafenib (MSN06;MSN08) |
| Muscarinic receptor signaling |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN01) |
| Muscarinic receptor signaling |
Down |
7.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
lapatinib (MSN06) |
nilotinib (MSN01);tofacitinib (MSN08) |
| Muscarinic receptor signaling |
Down |
8 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
lapatinib (MSN06);ponatinib (MSN02) |
nilotinib (MSN01);tofacitinib (MSN08) |
| Myofibril formation |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN09) |
| Myofibril formation |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN01;MSN05;MSN09) |
| Myofibril formation |
Up |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN01;MSN05;MSN08;MSN09) |
| Myofibril formation |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN01;MSN05;MSN08;MSN09);tofacitinib (MSN09) |
| Myofibril formation |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05);cetuximab (MSN01;MSN05;MSN08;MSN09);tofacitinib (MSN09) |
| Myofibril formation |
Up |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05);cetuximab (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN05);tofacitinib (MSN09) |
| Myofibril formation |
Up |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05);axitinib (MSN06);cetuximab (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN05);tofacitinib (MSN09) |
| Mitotic spindle disassembly |
Up |
26 |
0.3333333 |
0.1956522 |
0.3200837 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
15 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
ponatinib (MSN02);sorafenib (MSN01;MSN08) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05);imatinib (MSN01;MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
16 |
0.3571429 |
0.1086956 |
0.3148148 |
NaN |
NaN |
ponatinib (MSN02;MSN09);sorafenib (MSN01;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05);imatinib (MSN01;MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
16.5 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
ponatinib (MSN02;MSN09);sorafenib (MSN01;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
17 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
ponatinib (MSN02;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
17.5 |
0.4117647 |
0.1521739 |
0.3742138 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
19 |
0.3888889 |
0.1521739 |
0.3562874 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);regorafenib (MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
20.5 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);regorafenib (MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
21.5 |
0.45 |
0.1956522 |
0.4180328 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);regorafenib (MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
23 |
0.4090909 |
0.1956522 |
0.3844221 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);nilotinib (MSN05);regorafenib (MSN05);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
23.5 |
0.3913043 |
0.1956522 |
0.3695652 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05);regorafenib (MSN05);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
24.5 |
0.375 |
0.1956522 |
0.355814 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05);regorafenib (MSN05);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
25 |
0.3461539 |
0.1956522 |
0.3311689 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06);regorafenib (MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| Myofibril formation |
Up |
15 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05);axitinib (MSN06);cetuximab (MSN01;MSN02;MSN05;MSN08;MSN09);dasatinib (MSN05);tofacitinib (MSN09) |
| Mitotic spindle disassembly |
Up |
26.5 |
0.3214286 |
0.1956522 |
0.3097166 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| Mitotic spindle disassembly |
Up |
29.5 |
0.3103448 |
0.1956522 |
0.3 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN05;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| Mitotic spindle disassembly |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08) |
| Mitotic spindle disassembly |
Down |
10 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
vandetanib (MSN05) |
afatinib (MSN01);ceritinib (MSN08) |
| Mitotic spindle disassembly |
Down |
12 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
vandetanib (MSN05) |
afatinib (MSN01);ceritinib (MSN08);cetuximab (MSN08) |
| Mitotic spindle disassembly |
Down |
15 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
trastuzumab (MSN09);vandetanib (MSN05) |
afatinib (MSN01);ceritinib (MSN08);cetuximab (MSN06;MSN08) |
| Mitotic spindle disassembly |
Down |
15.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
trastuzumab (MSN09);vandetanib (MSN05) |
afatinib (MSN01);ceritinib (MSN08);cetuximab (MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Down |
18.5 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08);trastuzumab (MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN06);ceritinib (MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Mitotic spindle disassembly |
Down |
19.5 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08);trastuzumab (MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN06);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06) |
| Mitotic spindle disassembly |
Down |
20.5 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08);trastuzumab (MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06) |
| Mitotic spindle disassembly |
Down |
21 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08;MSN09);trastuzumab (MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN01) |
| Natriuretic peptide receptor signaling |
Down |
26.5 |
0.4285714 |
0.326087 |
0.4207921 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01;MSN05;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
10.5 |
0.5263158 |
0.2173913 |
0.4857143 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN06);trastuzumab (MSN05;MSN09);vandetanib (MSN09) |
cetuximab (MSN02);erlotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
11.5 |
0.5 |
0.2173913 |
0.4644809 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN06);trastuzumab (MSN05;MSN09);vandetanib (MSN09) |
cetuximab (MSN02);erlotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
13 |
0.5238096 |
0.2391304 |
0.4895289 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN06);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
cetuximab (MSN02);erlotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
13.5 |
0.5217391 |
0.2608696 |
0.4927537 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN08);cetuximab (MSN02);erlotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
14 |
0.5 |
0.2608696 |
0.4744186 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
14.5 |
0.4615385 |
0.2608696 |
0.4415585 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01);gefitinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
17.5 |
0.4285714 |
0.2608696 |
0.4129555 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01);gefitinib (MSN01;MSN06;MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
20.5 |
0.4333333 |
0.2826087 |
0.4201521 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trametinib (MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01);gefitinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
22 |
0.4516129 |
0.3043478 |
0.4391144 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01);gefitinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
22.5 |
0.4375 |
0.3043478 |
0.4265233 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
23 |
0.4545455 |
0.326087 |
0.4442509 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
25 |
0.4411765 |
0.326087 |
0.4322034 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
9.5 |
0.5555556 |
0.2173913 |
0.5089821 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN06);trastuzumab (MSN05;MSN09);vandetanib (MSN09) |
cetuximab (MSN02);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);vemurafenib (MSN06;MSN08) |
| Natriuretic peptide receptor signaling |
Down |
27 |
0.4166667 |
0.326087 |
0.4099679 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);ruxolitinib (MSN01);vemurafenib (MSN06;MSN08) |
| Necroptosis induction |
Up |
10.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN05) |
|
| Necroptosis induction |
Up |
14 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN05;MSN09) |
|
| Necroptosis induction |
Up |
15 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
dabrafenib (MSN05;MSN09);lapatinib (MSN01) |
|
| Neuregulin receptor signaling |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN09) |
| Neuregulin receptor signaling |
Up |
7 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
ponatinib (MSN05) |
erlotinib (MSN09) |
| Neuregulin receptor signaling |
Up |
10.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
ponatinib (MSN05) |
erlotinib (MSN09);ruxolitinib (MSN06) |
| Neuregulin receptor signaling |
Up |
13 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
ponatinib (MSN05) |
cetuximab (MSN05);erlotinib (MSN09);ruxolitinib (MSN06) |
| Neuregulin receptor signaling |
Up |
14 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
ponatinib (MSN05) |
cetuximab (MSN01;MSN05);erlotinib (MSN09);ruxolitinib (MSN06) |
| Neuregulin receptor signaling |
Up |
15 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
ponatinib (MSN05) |
cetuximab (MSN01;MSN05;MSN08;MSN09);erlotinib (MSN09);ruxolitinib (MSN06) |
| Neuregulin receptor signaling |
Up |
16.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
ponatinib (MSN05) |
cetuximab (MSN01;MSN02;MSN05;MSN08;MSN09);erlotinib (MSN09);ruxolitinib (MSN06) |
| Natriuretic peptide receptor signaling |
Up |
10 |
0.2 |
0.08695652 |
0.1857923 |
NaN |
NaN |
bevacizumab (MSN09);dabrafenib (MSN05;MSN08);trastuzumab (MSN09) |
axitinib (MSN01;MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Myofibril formation |
Up |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05);axitinib (MSN06);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05);tofacitinib (MSN09) |
| Natriuretic peptide receptor signaling |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01;MSN05;MSN09);dasatinib (MSN05) |
| Natriuretic peptide receptor signaling |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05) |
| Natriuretic peptide receptor signaling |
Up |
2.5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trastuzumab (MSN09) |
bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05) |
| Natriuretic peptide receptor signaling |
Up |
3 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trastuzumab (MSN09) |
bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05;MSN06) |
| Natriuretic peptide receptor signaling |
Up |
3.5 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
trastuzumab (MSN09) |
axitinib (MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05;MSN06) |
| Natriuretic peptide receptor signaling |
Up |
4 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
trastuzumab (MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN06;MSN09);dasatinib (MSN05;MSN06) |
| Natriuretic peptide receptor signaling |
Up |
4.5 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
trastuzumab (MSN09) |
axitinib (MSN01;MSN05;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN06;MSN09);dasatinib (MSN05;MSN06) |
| Natriuretic peptide receptor signaling |
Up |
5 |
0.07142857 |
0.02173913 |
0.06296296 |
NaN |
NaN |
trastuzumab (MSN09) |
axitinib (MSN01;MSN05;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05;MSN06) |
| Natriuretic peptide receptor signaling |
Up |
5.5 |
0.0625 |
0.02173913 |
0.05629139 |
NaN |
NaN |
trastuzumab (MSN09) |
axitinib (MSN01;MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05;MSN06);tofacitinib (MSN05) |
| Natriuretic peptide receptor signaling |
Up |
6 |
0.1176471 |
0.04347826 |
0.1069183 |
NaN |
NaN |
dabrafenib (MSN05);trastuzumab (MSN09) |
axitinib (MSN01;MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05;MSN06);tofacitinib (MSN05) |
| Natriuretic peptide receptor signaling |
Up |
7.5 |
0.2105263 |
0.08695652 |
0.1942857 |
NaN |
NaN |
bevacizumab (MSN09);dabrafenib (MSN05;MSN08);trastuzumab (MSN09) |
axitinib (MSN01;MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05;MSN06);tofacitinib (MSN05) |
| Mammalian target of rapamycin signaling pathway |
Down |
16 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN08) |
|
| Natriuretic peptide receptor signaling |
Up |
10.5 |
0.2380952 |
0.1086956 |
0.222513 |
NaN |
NaN |
bevacizumab (MSN09);dabrafenib (MSN05;MSN08;MSN09);trastuzumab (MSN09) |
axitinib (MSN01;MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Natriuretic peptide receptor signaling |
Up |
15 |
0.2272727 |
0.1086956 |
0.2135678 |
NaN |
NaN |
bevacizumab (MSN09);dabrafenib (MSN05;MSN08;MSN09);trastuzumab (MSN09) |
axitinib (MSN01;MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05;MSN06;MSN08);nilotinib (MSN01);tofacitinib (MSN05) |
| Natriuretic peptide receptor signaling |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Natriuretic peptide receptor signaling |
Down |
2.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN09) |
rituximab (MSN08) |
| Natriuretic peptide receptor signaling |
Down |
4 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
vandetanib (MSN09) |
regorafenib (MSN01);rituximab (MSN08) |
| Natriuretic peptide receptor signaling |
Down |
5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
lapatinib (MSN01);vandetanib (MSN09) |
regorafenib (MSN01);rituximab (MSN08) |
| Natriuretic peptide receptor signaling |
Down |
5.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
lapatinib (MSN01);vandetanib (MSN09) |
cetuximab (MSN02);regorafenib (MSN01);rituximab (MSN08) |
| Natriuretic peptide receptor signaling |
Down |
6 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
lapatinib (MSN01);vandetanib (MSN09) |
cetuximab (MSN02);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN08) |
| Natriuretic peptide receptor signaling |
Down |
7 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
lapatinib (MSN01);sunitinib (MSN02);vandetanib (MSN09) |
cetuximab (MSN02);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN08) |
| Natriuretic peptide receptor signaling |
Down |
7.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
lapatinib (MSN01;MSN06);sunitinib (MSN02;MSN06);vandetanib (MSN09) |
cetuximab (MSN02);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN08) |
| Natriuretic peptide receptor signaling |
Down |
9 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08);sunitinib (MSN02;MSN06);vandetanib (MSN09) |
cetuximab (MSN02);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN08);vemurafenib (MSN06;MSN08) |
| Inhibin receptor signaling |
Down |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01) |
| Hyaluronan-mediated motility receptor signaling |
Down |
30.5 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Down |
31.5 |
0.4444444 |
0.173913 |
0.4071856 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01) |
| Hyaluronan-mediated motility receptor signaling |
Down |
32 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01) |
| Hyaluronan-mediated motility receptor signaling |
Down |
33 |
0.3809524 |
0.173913 |
0.356021 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08) |
| Hyaluronan-mediated motility receptor signaling |
Down |
35 |
0.3636364 |
0.173913 |
0.3417086 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Inhibin receptor signaling |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN05) |
| Inhibin receptor signaling |
Up |
6.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
bevacizumab (MSN06) |
cabozantinib (MSN05) |
| Inhibin receptor signaling |
Up |
9 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
bevacizumab (MSN06);vandetanib (MSN05) |
cabozantinib (MSN05) |
| Inhibin receptor signaling |
Up |
9.5 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);vandetanib (MSN05) |
cabozantinib (MSN05) |
| Inhibin receptor signaling |
Up |
10.5 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);vandetanib (MSN05) |
cabozantinib (MSN05);cetuximab (MSN02) |
| Inhibin receptor signaling |
Up |
12.5 |
0.7142857 |
0.1086956 |
0.5379746 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05) |
cabozantinib (MSN05);cetuximab (MSN02) |
| Inhibin receptor signaling |
Up |
17 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05) |
cabozantinib (MSN01;MSN05);cetuximab (MSN02) |
| Hyaluronan-mediated motility receptor signaling |
Down |
29.5 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09) |
| Inhibin receptor signaling |
Down |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01;MSN08) |
| Inhibin receptor signaling |
Down |
8 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sunitinib (MSN05) |
regorafenib (MSN01;MSN08) |
| Inhibin receptor signaling |
Down |
9 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
sunitinib (MSN05;MSN09) |
regorafenib (MSN01;MSN08) |
| Inhibin receptor signaling |
Down |
10 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
sunitinib (MSN05;MSN09) |
regorafenib (MSN01;MSN06;MSN08) |
| Inhibin receptor signaling |
Down |
10.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
sunitinib (MSN05;MSN09) |
regorafenib (MSN01;MSN06;MSN08);vemurafenib (MSN06) |
| Inhibin receptor signaling |
Down |
11 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
sunitinib (MSN05;MSN09) |
dasatinib (MSN01);regorafenib (MSN01;MSN06;MSN08);vemurafenib (MSN06) |
| Inhibin receptor signaling |
Down |
11.5 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
sunitinib (MSN05;MSN09) |
dasatinib (MSN01;MSN09);regorafenib (MSN01;MSN06;MSN08);vemurafenib (MSN06;MSN08) |
| Inhibin receptor signaling |
Down |
12.5 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
sunitinib (MSN05;MSN09) |
crizotinib (MSN01);dasatinib (MSN01;MSN09);regorafenib (MSN01;MSN06;MSN08);vemurafenib (MSN06;MSN08) |
| Inhibin receptor signaling |
Down |
14 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
lapatinib (MSN08);sunitinib (MSN05;MSN09) |
crizotinib (MSN01);dasatinib (MSN01;MSN09);regorafenib (MSN01;MSN06;MSN08);vemurafenib (MSN06;MSN08) |
| Inhibin receptor signaling |
Down |
15 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
lapatinib (MSN08);sunitinib (MSN05;MSN09) |
crizotinib (MSN01;MSN06);dasatinib (MSN01;MSN09);regorafenib (MSN01;MSN06;MSN08);vemurafenib (MSN06;MSN08) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
1.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
2 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);lapatinib (MSN05) |
ceritinib (MSN05;MSN08) |
| Hyaluronan-mediated motility receptor signaling |
Up |
26.5 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
nilotinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN02) |
| Hyaluronan synthesis |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN09) |
| Hyaluronan synthesis |
Down |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN05;MSN09) |
| Hyaluronan synthesis |
Down |
13.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN06);vemurafenib (MSN05;MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Up |
16 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
ponatinib (MSN09);sorafenib (MSN09) |
|
| Hyaluronan-mediated motility receptor signaling |
Up |
17 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
ponatinib (MSN09);sorafenib (MSN05;MSN09) |
|
| Hyaluronan-mediated motility receptor signaling |
Up |
17.5 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
ponatinib (MSN06;MSN09);sorafenib (MSN05;MSN09) |
|
| Hyaluronan-mediated motility receptor signaling |
Up |
20.5 |
1 |
0.1086956 |
0.674603 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN09);sorafenib (MSN05;MSN09) |
|
| Hyaluronan-mediated motility receptor signaling |
Up |
21.5 |
1 |
0.1304348 |
0.7183099 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
|
| Hyaluronan-mediated motility receptor signaling |
Up |
23 |
0.75 |
0.1304348 |
0.5862069 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
nilotinib (MSN05);ruxolitinib (MSN02) |
| Hyaluronan-mediated motility receptor signaling |
Up |
23.5 |
0.6666667 |
0.1304348 |
0.5368421 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
nilotinib (MSN01;MSN05);ruxolitinib (MSN02) |
| Hyaluronan-mediated motility receptor signaling |
Up |
25 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
nilotinib (MSN01;MSN05;MSN06);regorafenib (MSN08);ruxolitinib (MSN02) |
| Hyaluronan-mediated motility receptor signaling |
Up |
26 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
nilotinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN08);ruxolitinib (MSN02) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
3 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05) |
ceritinib (MSN05;MSN06;MSN08) |
| Hyaluronan-mediated motility receptor signaling |
Up |
29.5 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN02) |
| Hyaluronan-mediated motility receptor signaling |
Down |
10 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN05) |
|
| Hyaluronan-mediated motility receptor signaling |
Down |
14 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN05) |
axitinib (MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Down |
15 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
vandetanib (MSN05) |
axitinib (MSN09);cetuximab (MSN06) |
| Hyaluronan-mediated motility receptor signaling |
Down |
15.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
vandetanib (MSN05) |
axitinib (MSN09);cetuximab (MSN05;MSN06;MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Down |
18.5 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
trastuzumab (MSN02);vandetanib (MSN05) |
axitinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Down |
20.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
trastuzumab (MSN02);vandetanib (MSN05) |
axitinib (MSN09);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Down |
21 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
lapatinib (MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05);axitinib (MSN09);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Down |
24.5 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
lapatinib (MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Down |
26 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN01);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN09) |
| Hyaluronan-mediated motility receptor signaling |
Down |
27.5 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN09);trastuzumab (MSN02);vandetanib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN09);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN09) |
| Inhibition of apoptosis |
Up |
27.5 |
0.6363636 |
0.3043478 |
0.59799 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN08;MSN09);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);nilotinib (MSN05);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
12 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN01);trastuzumab (MSN05;MSN09) |
gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN08) |
| Inhibition of apoptosis |
Up |
13.5 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN01);trastuzumab (MSN05;MSN09) |
cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN08) |
| Inhibition of apoptosis |
Up |
14 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN08) |
| Inhibition of apoptosis |
Up |
14.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN08) |
| Inhibition of apoptosis |
Up |
15.5 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN08);sunitinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN08) |
| Inhibition of apoptosis |
Up |
16.5 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN08);sunitinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
17 |
0.5333334 |
0.173913 |
0.4755246 |
NaN |
NaN |
ponatinib (MSN02;MSN05);sorafenib (MSN08);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
19 |
0.5625 |
0.1956522 |
0.5066226 |
NaN |
NaN |
ponatinib (MSN02;MSN05;MSN09);sorafenib (MSN08);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
20 |
0.5882353 |
0.2173913 |
0.5345912 |
NaN |
NaN |
ponatinib (MSN02;MSN05;MSN06;MSN09);sorafenib (MSN08);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
21 |
0.6111111 |
0.2391304 |
0.5598803 |
NaN |
NaN |
ponatinib (MSN02;MSN05;MSN06;MSN09);sorafenib (MSN08;MSN09);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
23 |
0.65 |
0.2826087 |
0.6038251 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN05;MSN06;MSN09);sorafenib (MSN05;MSN08;MSN09);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
24 |
0.6666667 |
0.3043478 |
0.6230367 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN08;MSN09);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
10 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09) |
gefitinib (MSN01);ruxolitinib (MSN08) |
| Inhibition of apoptosis |
Up |
28 |
0.5833333 |
0.3043478 |
0.5534883 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN08;MSN09);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
28.5 |
0.56 |
0.3043478 |
0.5336323 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN08;MSN09);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);nilotinib (MSN01;MSN05;MSN06;MSN09);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Up |
34 |
0.5384616 |
0.3043478 |
0.5151516 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN08;MSN09);sunitinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08);gefitinib (MSN01);imatinib (MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN06;MSN08) |
| Inhibition of apoptosis |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN08) |
| Inhibition of apoptosis |
Down |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN01;MSN08) |
| Inhibition of apoptosis |
Down |
6 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
vandetanib (MSN08) |
cetuximab (MSN01;MSN08;MSN09) |
| Inhibition of apoptosis |
Down |
8 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
vandetanib (MSN08) |
cetuximab (MSN01;MSN06;MSN08;MSN09) |
| Inhibition of apoptosis |
Down |
10 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
vandetanib (MSN08) |
cetuximab (MSN01;MSN06;MSN08;MSN09);imatinib (MSN01) |
| Inhibition of apoptosis |
Down |
12 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
vandetanib (MSN08) |
cetuximab (MSN01;MSN06;MSN08;MSN09);imatinib (MSN01);rituximab (MSN06) |
| Inhibition of apoptosis |
Down |
13 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
vandetanib (MSN08) |
afatinib (MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);imatinib (MSN01);rituximab (MSN06) |
| Inhibition of apoptosis |
Down |
14 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05) |
| Inhibition of apoptosis |
Down |
15 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05);vemurafenib (MSN01) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
3.5 |
0.35 |
0.1521739 |
0.3251366 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN06;MSN08);cetuximab (MSN02;MSN06;MSN08;MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN08) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
3.5 |
0.6666667 |
0.1304348 |
0.5368421 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08) |
ceritinib (MSN05;MSN06;MSN08) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
4 |
0.6 |
0.1304348 |
0.4951456 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08) |
ceritinib (MSN01;MSN05;MSN06;MSN08) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
13 |
0.6363636 |
0.1521739 |
0.5360361 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN08) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
15.5 |
0.5833333 |
0.1521739 |
0.5 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN08);crizotinib (MSN05) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
16 |
0.5384616 |
0.1521739 |
0.468504 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN08);crizotinib (MSN05);dasatinib (MSN05) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
17 |
0.5 |
0.1521739 |
0.4407408 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN08);crizotinib (MSN05;MSN06);dasatinib (MSN05) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
17.5 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06);dasatinib (MSN05) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
18.5 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Up |
22 |
0.4117647 |
0.1521739 |
0.3742138 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN05);ruxolitinib (MSN08) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
1 |
0.7142857 |
0.1086956 |
0.5379746 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06);trastuzumab (MSN05) |
nilotinib (MSN01);tofacitinib (MSN08) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
2 |
0.4117647 |
0.1521739 |
0.3742138 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05) |
axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02;MSN06;MSN08;MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN08) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
3 |
0.368421 |
0.1521739 |
0.3399999 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN06);cetuximab (MSN02;MSN06;MSN08;MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN08) |
| Hyaluronan synthesis |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN05) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
4 |
0.3043478 |
0.1521739 |
0.2874396 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05) |
axitinib (MSN01;MSN08);bosutinib (MSN08);cabozantinib (MSN06;MSN08);cetuximab (MSN02;MSN06;MSN08;MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
4.5 |
0.2692308 |
0.1521739 |
0.2575758 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05) |
axitinib (MSN01;MSN08);bosutinib (MSN08);cabozantinib (MSN02;MSN06;MSN08);cetuximab (MSN02;MSN06;MSN08;MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN06) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
5 |
0.2758621 |
0.173913 |
0.2666667 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
axitinib (MSN01;MSN08);bosutinib (MSN05;MSN08);cabozantinib (MSN02;MSN06;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN06) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
5.5 |
0.2580645 |
0.173913 |
0.2509225 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
axitinib (MSN01;MSN08);bosutinib (MSN05;MSN08);cabozantinib (MSN02;MSN05;MSN06;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN06) |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
6 |
0.2727273 |
0.1956522 |
0.2665506 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN01;MSN08);bosutinib (MSN05;MSN08);cabozantinib (MSN02;MSN05;MSN06;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN06;MS |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
7.5 |
0.2857143 |
0.2173913 |
0.2805281 |
NaN |
NaN |
dabrafenib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN01;MSN08);bosutinib (MSN05;MSN08);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN09);dasatinib (MSN01);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MS |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
8 |
0.2777778 |
0.2173913 |
0.2733119 |
NaN |
NaN |
dabrafenib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN01;MSN08);bosutinib (MSN05;MSN08);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN09);dasatinib (MSN01);imatinib (MSN05);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafeni |
| Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
14.5 |
0.2702703 |
0.2173913 |
0.2664577 |
NaN |
NaN |
dabrafenib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN01;MSN08);bosutinib (MSN05;MSN08);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN09);dasatinib (MSN01);erlotinib (MSN05);imatinib (MSN05);nilotinib (MSN01);tofacitinib (MSN01;MSN05;MSN06 |
| Inhibition of apoptosis |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN01) |
| Inhibition of apoptosis |
Up |
8 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
ponatinib (MSN05) |
gefitinib (MSN01) |
| Inhibition of apoptosis |
Up |
9 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
ponatinib (MSN05) |
gefitinib (MSN01);ruxolitinib (MSN08) |
| Heparin-binding EGF-like growth factor receptor signaling |
Up |
18.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trametinib (MSN08) |
crizotinib (MSN01;MSN09);dasatinib (MSN01);erlotinib (MSN01;MSN09) |
| Hemoglobin and myoglobin synthesis |
Up |
12.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
trametinib (MSN05;MSN08) |
|
| Hemoglobin and myoglobin synthesis |
Up |
13 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09) |
|
| Hemoglobin and myoglobin synthesis |
Up |
16 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09) |
dasatinib (MSN05) |
| Hemoglobin and myoglobin synthesis |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01) |
| Hemoglobin and myoglobin synthesis |
Down |
12.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01);ceritinib (MSN08) |
| Hemoglobin and myoglobin synthesis |
Down |
16 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
ponatinib (MSN05) |
cabozantinib (MSN01);ceritinib (MSN08) |
| Heparin and heparan sulfate synthesis |
Down |
13.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN08) |
| Heparin-binding EGF-like growth factor receptor signaling |
Up |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01) |
| Heparin-binding EGF-like growth factor receptor signaling |
Up |
12.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN08) |
dasatinib (MSN01) |
| Heparin-binding EGF-like growth factor receptor signaling |
Up |
14.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN08) |
dasatinib (MSN01);erlotinib (MSN01) |
| Heparin-binding EGF-like growth factor receptor signaling |
Up |
16 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN08) |
dasatinib (MSN01);erlotinib (MSN01;MSN09) |
| Heparin-binding EGF-like growth factor receptor signaling |
Up |
17.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trametinib (MSN08) |
crizotinib (MSN01);dasatinib (MSN01);erlotinib (MSN01;MSN09) |
| Hemoglobin and myoglobin synthesis |
Up |
6.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN05) |
|
| Heparin-binding EGF-like growth factor receptor signaling |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN09) |
| Heparin-binding EGF-like growth factor receptor signaling |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02;MSN09) |
| Heparin-binding EGF-like growth factor receptor signaling |
Down |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN05);ruxolitinib (MSN02;MSN09) |
| Hepatocyte growth factor receptor signaling |
Up |
2 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN09) |
|
| Hepatocyte growth factor receptor signaling |
Up |
9 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
gefitinib (MSN06) |
| Hepatocyte growth factor receptor signaling |
Up |
11 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
crizotinib (MSN01;MSN05);gefitinib (MSN06) |
| Hepatocyte growth factor receptor signaling |
Up |
11.5 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN06) |
| Hepatocyte growth factor receptor signaling |
Up |
12 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06) |
| Hepatocyte growth factor receptor signaling |
Up |
12.5 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06) |
| Hepatocyte growth factor receptor signaling |
Up |
13 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01) |
| Hepatocyte growth factor receptor signaling |
Up |
13.5 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05) |
| Hepatocyte growth factor receptor signaling |
Up |
14 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hedgehog receptor signaling |
Up |
14 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
lapatinib (MSN08;MSN09) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Growth differentiation factor receptor signaling |
Down |
11 |
0.75 |
0.1956522 |
0.6428572 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);vandetanib (MSN09) |
crizotinib (MSN05;MSN08);dasatinib (MSN06) |
| Growth differentiation factor receptor signaling |
Down |
12.5 |
0.6923077 |
0.1956522 |
0.6023622 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);vandetanib (MSN09) |
crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN06) |
| Growth differentiation factor receptor signaling |
Down |
13 |
0.6428571 |
0.1956522 |
0.5666665 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);vandetanib (MSN09) |
crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN06) |
| Growth differentiation factor receptor signaling |
Down |
14 |
0.6666667 |
0.2173913 |
0.5944056 |
NaN |
NaN |
lapatinib (MSN01;MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);vandetanib (MSN09) |
crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN06) |
| Growth differentiation factor receptor signaling |
Down |
14.5 |
0.625 |
0.2173913 |
0.5629139 |
NaN |
NaN |
lapatinib (MSN01;MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);vandetanib (MSN09) |
crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN06);imatinib (MSN05) |
| Growth differentiation factor receptor signaling |
Down |
15 |
0.5555556 |
0.2173913 |
0.5089821 |
NaN |
NaN |
lapatinib (MSN01;MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);vandetanib (MSN09) |
axitinib (MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);imatinib (MSN05) |
| Growth differentiation factor receptor signaling |
Down |
20 |
0.5789474 |
0.2391304 |
0.5342858 |
NaN |
NaN |
lapatinib (MSN01;MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN01);vandetanib (MSN09) |
axitinib (MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);imatinib (MSN05) |
| Hedgehog receptor signaling |
Up |
6 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN08) |
|
| Hedgehog receptor signaling |
Up |
8 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
lapatinib (MSN08) |
gefitinib (MSN08) |
| Hedgehog receptor signaling |
Up |
10 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
lapatinib (MSN08) |
gefitinib (MSN01;MSN06;MSN08) |
| Hedgehog receptor signaling |
Up |
11 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
lapatinib (MSN08) |
gefitinib (MSN01;MSN06;MSN08;MSN09) |
| Hedgehog receptor signaling |
Up |
13 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
lapatinib (MSN08) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Hepatocyte growth factor receptor signaling |
Up |
15 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01);bosutinib (MSN01;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hedgehog receptor signaling |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01) |
| Heme degradation to bilirubin |
Up |
3.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN08) |
|
| Heme degradation to bilirubin |
Up |
8 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
lapatinib (MSN08) |
erlotinib (MSN05) |
| Heme degradation to bilirubin |
Up |
10.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
lapatinib (MSN08) |
erlotinib (MSN05;MSN08) |
| Heme degradation to bilirubin |
Up |
13 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
lapatinib (MSN08);trametinib (MSN09) |
erlotinib (MSN05;MSN08) |
| Heme degradation to bilirubin |
Up |
14.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
lapatinib (MSN08);trametinib (MSN09) |
erlotinib (MSN01;MSN05;MSN08) |
| Heme degradation to bilirubin |
Up |
15 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05);trametinib (MSN09) |
erlotinib (MSN01;MSN05;MSN08) |
| Heme degradation to bilirubin |
Up |
16 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05);trametinib (MSN09) |
erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Heme degradation to bilirubin |
Up |
16.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05);trametinib (MSN09) |
axitinib (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Heme degradation to bilirubin |
Down |
6 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN01) |
|
| Hemidesmosome organization |
Up |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09) |
| Histone methylation and demethylation |
Down |
18.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
21 |
0.2413793 |
0.1521739 |
0.2333333 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);cetuximab (MSN02;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN08);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN08;MS |
| Hepatocyte growth factor receptor signaling |
Down |
23 |
0.2333333 |
0.1521739 |
0.2262357 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);cetuximab (MSN02;MSN05;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN08);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MS |
| Hepatocyte growth factor receptor signaling |
Down |
24 |
0.2258064 |
0.1521739 |
0.2195572 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);ceritinib (MSN01);cetuximab (MSN02;MSN05;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN08);tofacitinib (MSN05);vemurafen |
| Hepatocyte growth factor receptor signaling |
Down |
25 |
0.25 |
0.173913 |
0.2437276 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);ceritinib (MSN01);cetuximab (MSN02;MSN05;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN08);tofacitinib (MSN05);vemurafen |
| Hepatocyte growth factor receptor signaling |
Down |
26.5 |
0.2424242 |
0.173913 |
0.2369338 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);ceritinib (MSN01);cetuximab (MSN01;MSN02;MSN05;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN08);tofacitinib (MSN05);vem |
| Hepatocyte growth factor receptor signaling |
Down |
29.5 |
0.2352941 |
0.173913 |
0.2305085 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);ceritinib (MSN01);cetuximab (MSN01;MSN02;MSN05;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN08);tofacitinib (MSN0 |
| HIF-1 receptor signaling pathway |
Up |
5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN08) |
|
| HIF-1 receptor signaling pathway |
Up |
7.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN08) |
afatinib (MSN06) |
| HIF-1 receptor signaling pathway |
Up |
8.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN08) |
afatinib (MSN06;MSN08) |
| HIF-1 receptor signaling pathway |
Up |
9.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN08) |
afatinib (MSN06;MSN08);cetuximab (MSN09) |
| HIF-1 receptor signaling pathway |
Up |
10 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trametinib (MSN08) |
afatinib (MSN06;MSN08);cetuximab (MSN05;MSN08;MSN09) |
| HIF-1 receptor signaling pathway |
Up |
11 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trametinib (MSN08) |
afatinib (MSN06;MSN08);cetuximab (MSN05;MSN06;MSN08;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
20 |
0.2592593 |
0.1521739 |
0.248954 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);cetuximab (MSN02;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN08);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN09) |
| Homologous recombination DSB repair |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN09) |
| Homologous recombination DSB repair |
Down |
14 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN08;MSN09) |
| Homologous recombination DSB repair |
Down |
15 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN01;MSN08;MSN09) |
| Homologous recombination DSB repair |
Down |
32 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);erlotinib (MSN01;MSN08;MSN09) |
| Homologous recombination DSB repair |
Down |
40 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN09);erlotinib (MSN01;MSN08;MSN09) |
| Hyaluronan receptor CD44 signaling |
Up |
13 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN09) |
|
| Hyaluronan receptor CD44 signaling |
Up |
14.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN09) |
erlotinib (MSN01) |
| Hyaluronan receptor CD44 signaling |
Up |
15.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN09) |
crizotinib (MSN05);erlotinib (MSN01) |
| Hyaluronan receptor CD44 signaling |
Up |
16 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN09) |
crizotinib (MSN05);erlotinib (MSN01;MSN09) |
| Hyaluronan receptor CD44 signaling |
Up |
17.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trametinib (MSN09) |
crizotinib (MSN01;MSN05);erlotinib (MSN01;MSN09) |
| Hyaluronan receptor CD44 signaling |
Up |
18.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trametinib (MSN09) |
crizotinib (MSN01;MSN05;MSN09);erlotinib (MSN01;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
11.5 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);cetuximab (MSN02);imatinib (MSN05);ruxolitinib (MSN01;MSN05;MSN08) |
| Hepatocyte growth factor receptor signaling |
Up |
17 |
0.1333333 |
0.04347826 |
0.1188811 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01);bosutinib (MSN01;MSN05;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Up |
18 |
0.1176471 |
0.04347826 |
0.1069183 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Up |
18.5 |
0.1666667 |
0.06521739 |
0.1526946 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Up |
19.5 |
0.1578947 |
0.06521739 |
0.1457143 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Up |
21 |
0.15 |
0.06521739 |
0.1393443 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN09);trametinib (MSN09) |
axitinib (MSN01;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Up |
25.5 |
0.1904762 |
0.08695652 |
0.1780105 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN09);sorafenib (MSN09);trametinib (MSN09) |
axitinib (MSN01;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Up |
28.5 |
0.2272727 |
0.1086956 |
0.2135678 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN09);sorafenib (MSN05;MSN09);trametinib (MSN09) |
axitinib (MSN01;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08);gefitinib (MSN05;MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
1 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN08) |
|
| Hepatocyte growth factor receptor signaling |
Down |
3 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sunitinib (MSN08) |
ruxolitinib (MSN01;MSN05) |
| Hepatocyte growth factor receptor signaling |
Down |
4 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
sunitinib (MSN06;MSN08) |
ruxolitinib (MSN01;MSN05;MSN08) |
| Acetylcholine-mediated control of postsynaptic potential |
Up |
4.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN05) |
|
| Hepatocyte growth factor receptor signaling |
Down |
7.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);imatinib (MSN05);ruxolitinib (MSN01;MSN05;MSN08) |
| Inhibition of apoptosis |
Down |
16 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01) |
| Hepatocyte growth factor receptor signaling |
Down |
12 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);cetuximab (MSN02);imatinib (MSN05);rituximab (MSN09);ruxolitinib (MSN01;MSN05;MSN08) |
| Hepatocyte growth factor receptor signaling |
Down |
12.5 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);cetuximab (MSN02);imatinib (MSN05);rituximab (MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN05) |
| Hepatocyte growth factor receptor signaling |
Down |
14 |
0.3571429 |
0.1086956 |
0.3148148 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);cetuximab (MSN02);imatinib (MSN05);nilotinib (MSN05);rituximab (MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN05) |
| Hepatocyte growth factor receptor signaling |
Down |
15 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);cetuximab (MSN02);imatinib (MSN05);nilotinib (MSN05);rituximab (MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
15.5 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);bosutinib (MSN01);cetuximab (MSN02);imatinib (MSN05);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
16 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);bosutinib (MSN01);cetuximab (MSN02);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
16.5 |
0.2631579 |
0.1086956 |
0.2428571 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN09);bosutinib (MSN01);cabozantinib (MSN08);cetuximab (MSN02);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
17 |
0.2272727 |
0.1086956 |
0.2135678 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05);cabozantinib (MSN08);cetuximab (MSN02);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
17.5 |
0.25 |
0.1304348 |
0.2372093 |
NaN |
NaN |
ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05);cabozantinib (MSN08);cetuximab (MSN02;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
18.5 |
0.24 |
0.1304348 |
0.2286996 |
NaN |
NaN |
ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);cetuximab (MSN02;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN08);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
19 |
0.2307692 |
0.1304348 |
0.2207792 |
NaN |
NaN |
ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN08);cetuximab (MSN02;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN08);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN09) |
| Lipogenesis |
Up |
15 |
0.6363636 |
0.1521739 |
0.5360361 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN09) |
cabozantinib (MSN02);erlotinib (MSN01);imatinib (MSN01);ruxolitinib (MSN05) |
| Lipid droplet fusion |
Up |
11.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
bevacizumab (MSN05;MSN06) |
|
| Lipid droplet fusion |
Up |
12.5 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08) |
|
| Lipid droplet fusion |
Up |
18.5 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09) |
|
| Lipid droplet fusion |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01) |
| Lipid droplet mitochondria interaction |
Down |
13.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN06) |
| Lipogenesis |
Up |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN01) |
|
| Lipogenesis |
Up |
10 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
lapatinib (MSN01;MSN08) |
|
| Lipogenesis |
Up |
10.5 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
lapatinib (MSN01;MSN08);pazopanib (MSN09) |
|
| Lipogenesis |
Up |
11 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
lapatinib (MSN01;MSN08);pazopanib (MSN09) |
erlotinib (MSN01) |
| Lipogenesis |
Up |
12 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
lapatinib (MSN01;MSN08);pazopanib (MSN05;MSN09) |
cabozantinib (MSN02);erlotinib (MSN01) |
| Lipogenesis |
Up |
12.5 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
lapatinib (MSN01;MSN08;MSN09);pazopanib (MSN05;MSN09) |
cabozantinib (MSN02);erlotinib (MSN01);ruxolitinib (MSN05) |
| Lipogenesis |
Up |
13 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
lapatinib (MSN01;MSN08;MSN09);pazopanib (MSN05;MSN09) |
cabozantinib (MSN02);erlotinib (MSN01);imatinib (MSN01);ruxolitinib (MSN05) |
| Lipid droplet fusion |
Up |
10.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
bevacizumab (MSN06) |
|
| Lipogenesis |
Up |
15.5 |
0.6923077 |
0.1956522 |
0.6023622 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);erlotinib (MSN01);imatinib (MSN01);ruxolitinib (MSN05) |
| Lipogenesis |
Up |
16 |
0.6428571 |
0.1956522 |
0.5666665 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);erlotinib (MSN01);imatinib (MSN01;MSN09);ruxolitinib (MSN05) |
| Lipogenesis |
Up |
16.5 |
0.6 |
0.1956522 |
0.534965 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);ceritinib (MSN09);erlotinib (MSN01);imatinib (MSN01;MSN09);ruxolitinib (MSN05) |
| Lipogenesis |
Up |
17 |
0.5625 |
0.1956522 |
0.5066226 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);ceritinib (MSN09);erlotinib (MSN01);imatinib (MSN01;MSN09);ruxolitinib (MSN05;MSN08) |
| Lipogenesis |
Up |
17.5 |
0.5294118 |
0.1956522 |
0.4811321 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);ceritinib (MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);ruxolitinib (MSN05;MSN08) |
| Lipogenesis |
Up |
18 |
0.5 |
0.1956522 |
0.4580838 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);ceritinib (MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);rituximab (MSN09);ruxolitinib (MSN05;MSN08) |
| Lipogenesis |
Up |
18.5 |
0.5263158 |
0.2173913 |
0.4857143 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);ceritinib (MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);rituximab (MSN09);ruxolitinib (MSN05;MSN08) |
| Lipogenesis |
Up |
19.5 |
0.5714286 |
0.2608696 |
0.5340314 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);ceritinib (MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);rituximab (MSN09);ruxolitinib (MSN05;MSN08) |
| Lipogenesis |
Up |
20 |
0.5909091 |
0.2826087 |
0.5552764 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);ceritinib (MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);rituximab (MSN09);ruxolitinib (MSN05;MSN08) |
| Lipogenesis |
Up |
20.5 |
0.5652174 |
0.2826087 |
0.5338164 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02);ceritinib (MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);rituximab (MSN09);ruxolitinib (MSN05;MSN08) |
| Lipogenesis |
Up |
21 |
0.52 |
0.2826087 |
0.4955157 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);rituximab (MSN08;MSN09);ruxolitinib (MSN05;MSN08) |
| Lipogenesis |
Up |
22.5 |
0.4482759 |
0.2826087 |
0.4333333 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);regorafenib (MSN06);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Ketone body metabolism |
Up |
13.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN08) |
|
| JAK-STAT signaling pathway |
Down |
8 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sorafenib (MSN09) |
bosutinib (MSN05);ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
9 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
sorafenib (MSN09) |
axitinib (MSN08);bosutinib (MSN05);ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
11 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
sorafenib (MSN09) |
axitinib (MSN08);bosutinib (MSN05;MSN08);nilotinib (MSN01);ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
12 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
sorafenib (MSN09) |
axitinib (MSN08);bosutinib (MSN05;MSN08);nilotinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
13 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
sorafenib (MSN09) |
axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08);nilotinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
14 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
sorafenib (MSN01;MSN09) |
axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08);nilotinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
15 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
sorafenib (MSN01;MSN09) |
axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
15.5 |
0.2142857 |
0.06521739 |
0.1888889 |
NaN |
NaN |
ponatinib (MSN09);sorafenib (MSN01;MSN09) |
axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN01);regorafenib (MSN01;MSN05);ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
16 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09);sorafenib (MSN01;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN01);regorafenib (MSN01;MSN05);ruxolitinib (MSN06;MSN09);tofacitinib (MSN05);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
17 |
0.2631579 |
0.1086956 |
0.2428571 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09);sorafenib (MSN01;MSN05;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN01);regorafenib (MSN01;MSN05);ruxolitinib (MSN06;MSN09);tofacitinib (MSN05;MSN08);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
18 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09);sorafenib (MSN01;MSN05;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN01);regorafenib (MSN01;MSN05);ruxolitinib (MSN02;MSN06;MSN09);tofacitinib (MSN05;MSN08);vemurafenib (MSN06) |
| JAK-STAT signaling pathway |
Down |
22.5 |
0.2380952 |
0.1086956 |
0.222513 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09);sorafenib (MSN01;MSN05;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN08);nilotinib (MSN01);regorafenib (MSN01;MSN05);ruxolitinib (MSN02;MSN06;MSN09);tofacitinib (MSN05;MSN08);vemurafenib (MSN06) |
| Lipogenesis |
Up |
23.5 |
0.4333333 |
0.2826087 |
0.4201521 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN01;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);regorafenib (MSN06);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Ketone body metabolism |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN06) |
| Lamellipodium organization |
Down |
14 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN09) |
| Lamellipodium organization |
Down |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN08);imatinib (MSN09) |
| Lectin complement pathway |
Up |
9 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Leptin receptor signaling |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN01) |
| Leptin receptor signaling |
Down |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN06);tofacitinib (MSN01) |
| Leptin receptor signaling |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN06);tofacitinib (MSN01;MSN05;MSN09) |
| Leptin receptor signaling |
Down |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN06);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Leptin receptor signaling |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN01;MSN06;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Leptin receptor signaling |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Leptin receptor signaling |
Down |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Macrophage migration inhibitory factor signaling |
Down |
5.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN08) |
axitinib (MSN09);regorafenib (MSN08) |
| Lysine metabolism |
Up |
16 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN08) |
ruxolitinib (MSN05) |
| Lysine metabolism |
Up |
16.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN08) |
axitinib (MSN05);ruxolitinib (MSN05) |
| Lysine metabolism |
Up |
22 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN08) |
axitinib (MSN05);ruxolitinib (MSN05;MSN08) |
| Lysosomal glycosaminoglycan degradation |
Up |
20 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Macrophage migration inhibitory factor signaling |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN09) |
| Macrophage migration inhibitory factor signaling |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN09);dasatinib (MSN09) |
| Macrophage migration inhibitory factor signaling |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN05;MSN09);dasatinib (MSN09) |
| Macrophage migration inhibitory factor signaling |
Up |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN05;MSN06;MSN09);dasatinib (MSN09) |
| Macrophage migration inhibitory factor signaling |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN09) |
| Macrophage migration inhibitory factor signaling |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN09);erlotinib (MSN05) |
| Macrophage migration inhibitory factor signaling |
Down |
1 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN08) |
|
| Macrophage migration inhibitory factor signaling |
Down |
5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN08) |
regorafenib (MSN08) |
| Lysine metabolism |
Up |
12.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN08) |
|
| Macrophage migration inhibitory factor signaling |
Down |
6 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN08) |
axitinib (MSN01;MSN09);regorafenib (MSN08) |
| Macrophage migration inhibitory factor signaling |
Down |
7.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN05;MSN08) |
axitinib (MSN01;MSN09);regorafenib (MSN06;MSN08);vemurafenib (MSN01) |
| Macrophage migration inhibitory factor signaling |
Down |
14 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN05;MSN08) |
axitinib (MSN01;MSN09);ceritinib (MSN01);regorafenib (MSN06;MSN08);vemurafenib (MSN01) |
| Macrophage migration inhibitory factor signaling |
Down |
16.5 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN05;MSN08) |
axitinib (MSN01;MSN09);ceritinib (MSN01;MSN08);regorafenib (MSN06;MSN08);vemurafenib (MSN01) |
| Mammalian target of rapamycin signaling pathway |
Up |
6 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN08) |
|
| Mammalian target of rapamycin signaling pathway |
Up |
7 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
pazopanib (MSN06;MSN08) |
afatinib (MSN01) |
| Mammalian target of rapamycin signaling pathway |
Up |
8 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
pazopanib (MSN06;MSN08) |
afatinib (MSN01);erlotinib (MSN09) |
| Mammalian target of rapamycin signaling pathway |
Up |
9 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
pazopanib (MSN06;MSN08;MSN09) |
afatinib (MSN01);erlotinib (MSN09) |
| Mammalian target of rapamycin signaling pathway |
Up |
10 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
pazopanib (MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN01);erlotinib (MSN09) |
| Mammalian target of rapamycin signaling pathway |
Up |
13 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN05);erlotinib (MSN09) |
| Mammalian target of rapamycin signaling pathway |
Down |
7 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Lipogenesis |
Down |
14 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
ponatinib (MSN05);vandetanib (MSN08) |
bosutinib (MSN08);cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN05;MSN08) |
| Lipogenesis |
Up |
24 |
0.4193548 |
0.2826087 |
0.407749 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN01;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);regorafenib (MSN05;MSN06);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Lipogenesis |
Up |
24.5 |
0.4375 |
0.3043478 |
0.4265233 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN01;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);regorafenib (MSN05;MSN06);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Lipogenesis |
Up |
25.5 |
0.4545455 |
0.326087 |
0.4442509 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN01;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);regorafenib (MSN05;MSN06);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Lipogenesis |
Up |
28.5 |
0.4705882 |
0.3478261 |
0.461017 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN01;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);regorafenib (MSN05;MSN06);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Lipogenesis |
Up |
29.5 |
0.4571429 |
0.3478261 |
0.4488449 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN01;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);regorafenib (MSN05;MSN06);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN05;MSN06;MSN08;MSN09) |
| Lipogenesis |
Up |
31 |
0.4444444 |
0.3478261 |
0.437299 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09);sunitinib (MSN02) |
cabozantinib (MSN02;MSN06);ceritinib (MSN01;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN09);regorafenib (MSN05;MSN06;MSN08);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN05;MSN06;MSN08;MSN09) |
| Lipogenesis |
Down |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN08) |
| Lipogenesis |
Down |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN06);vemurafenib (MSN08) |
| Lipogenesis |
Down |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN08) |
| Lipogenesis |
Down |
11.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
vandetanib (MSN08) |
cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN08) |
| Lipogenesis |
Down |
12.5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
vandetanib (MSN08) |
cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN05;MSN08) |
| Lipogenesis |
Down |
13.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
vandetanib (MSN08) |
bosutinib (MSN08);cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN05;MSN08) |
| JAK-STAT signaling pathway |
Down |
7 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
sorafenib (MSN09) |
ruxolitinib (MSN06;MSN09);vemurafenib (MSN06) |
| Lipogenesis |
Down |
15.5 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
ponatinib (MSN05);vandetanib (MSN08) |
bosutinib (MSN01;MSN08);cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN05;MSN08) |
| Lipogenesis |
Down |
17 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
ponatinib (MSN05);vandetanib (MSN08) |
bosutinib (MSN01;MSN05;MSN08);cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN08) |
| Lipogenesis |
Down |
18.5 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
ponatinib (MSN05);vandetanib (MSN08) |
bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN08) |
| Lipogenesis |
Down |
20.5 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
ponatinib (MSN05);vandetanib (MSN08) |
bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Lipogenesis |
Down |
21 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05);vandetanib (MSN08) |
bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Lipogenesis |
Down |
21.5 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Lipogenesis |
Down |
22.5 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Lipogenesis |
Down |
24.5 |
0.2222222 |
0.08695652 |
0.2035928 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN06);bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Lipogenesis |
Down |
28.5 |
0.2105263 |
0.08695652 |
0.1942857 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN06);bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Lipogenesis |
Down |
29.5 |
0.2 |
0.08695652 |
0.1857923 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Lipogenesis |
Down |
31.5 |
0.1904762 |
0.08695652 |
0.1780105 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN02);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Interferon beta receptor signaling |
Down |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sorafenib (MSN09) |
|
| Integrin-mediated leukocyte rolling |
Down |
20.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN01) |
dasatinib (MSN09) |
| Interferon alpha receptor signaling |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05) |
| Interferon alpha receptor signaling |
Up |
5.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN01) |
ceritinib (MSN05) |
| Interferon alpha receptor signaling |
Up |
8 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN01) |
ceritinib (MSN05) |
| Interferon alpha receptor signaling |
Up |
10.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN01) |
ceritinib (MSN01;MSN05) |
| Interferon alpha receptor signaling |
Up |
17 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN01) |
cabozantinib (MSN01);ceritinib (MSN01;MSN05) |
| Interferon alpha receptor signaling |
Down |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sorafenib (MSN05) |
|
| Interferon alpha receptor signaling |
Down |
6 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sorafenib (MSN05;MSN09) |
|
| Interferon beta receptor signaling |
Up |
5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN05) |
|
| Interferon beta receptor signaling |
Up |
7 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
lapatinib (MSN05;MSN06) |
|
| Interferon beta receptor signaling |
Up |
11 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06) |
|
| Interferon beta receptor signaling |
Up |
13.5 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06) |
cabozantinib (MSN01) |
| Integrin-mediated leukocyte rolling |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN09) |
| Interleukin 6 receptor signaling |
Up |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05) |
| Interleukin 6 receptor signaling |
Up |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN09) |
| Interleukin 6 receptor signaling |
Up |
20.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN06;MSN09) |
| Interleukin 6 receptor signaling |
Up |
23.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN01;MSN05;MSN06;MSN09) |
| Interleukin 6 receptor signaling |
Down |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN05) |
| Interleukin 6 receptor signaling |
Down |
21 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02);tofacitinib (MSN05) |
| Interleukin 7 receptor signaling |
Up |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05) |
| Interleukin 7 receptor signaling |
Up |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN09) |
| Interleukin 7 receptor signaling |
Up |
20.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN06;MSN09) |
| Interleukin 7 receptor signaling |
Up |
23.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN01;MSN05;MSN06;MSN09) |
| Interleukin 7 receptor signaling |
Down |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN05) |
| Interleukin 7 receptor signaling |
Down |
21 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02);tofacitinib (MSN05) |
| Inositol metabolism and transport |
Up |
18.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
bevacizumab (MSN06) |
vemurafenib (MSN08) |
| Inhibition of apoptosis |
Down |
16.5 |
0.1333333 |
0.04347826 |
0.1188811 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01;MSN08) |
| Inhibition of apoptosis |
Down |
18.5 |
0.125 |
0.04347826 |
0.1125828 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);erlotinib (MSN01);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01;MSN08) |
| Inhibition of apoptosis |
Down |
19 |
0.1111111 |
0.04347826 |
0.1017964 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);erlotinib (MSN01);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01;MSN08) |
| Inhibition of apoptosis |
Down |
20.5 |
0.1052632 |
0.04347826 |
0.0971429 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);erlotinib (MSN01);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01;MSN08) |
| Inhibition of apoptosis |
Down |
22 |
0.1 |
0.04347826 |
0.09289617 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06);erlotinib (MSN01);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01;MSN08) |
| Inhibition of apoptosis |
Down |
25 |
0.09090909 |
0.04347826 |
0.08542714 |
NaN |
NaN |
vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06);erlotinib (MSN01);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01;MSN08) |
| Inhibition of apoptosis |
Down |
25.5 |
0.1304348 |
0.06521739 |
0.1231884 |
NaN |
NaN |
trastuzumab (MSN01);vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06);erlotinib (MSN01);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01;MSN08) |
| Inhibition of apoptosis |
Down |
34.5 |
0.125 |
0.06521739 |
0.1186047 |
NaN |
NaN |
trastuzumab (MSN01);vandetanib (MSN05;MSN08) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06);erlotinib (MSN01);gefitinib (MSN05);imatinib (MSN01);rituximab (MSN06);tofacitinib (MSN01;MSN05;MSN09);vemurafenib (MSN01;MSN08) |
| Inhibition of matrix metalloproteinase and adamalysin activity |
Up |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05) |
| Inhibition of matrix metalloproteinase and adamalysin activity |
Up |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);crizotinib (MSN01) |
| Inhibition of matrix metalloproteinase and adamalysin activity |
Down |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02) |
| Inositol metabolism and transport |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN08) |
| Intracellular bridge assembly |
Up |
7 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN02) |
|
| Inositol metabolism and transport |
Up |
19.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
bevacizumab (MSN05;MSN06) |
bosutinib (MSN08);vemurafenib (MSN08) |
| Inositol metabolism and transport |
Up |
20 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08) |
bosutinib (MSN08);vemurafenib (MSN08) |
| Inositol metabolism and transport |
Up |
22.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08) |
bosutinib (MSN08);rituximab (MSN06);vemurafenib (MSN08) |
| Inositol metabolism and transport |
Up |
24.5 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09) |
bosutinib (MSN08);rituximab (MSN06);vemurafenib (MSN08) |
| Insulin receptor signaling |
Up |
14 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09) |
| Insulin receptor signaling |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN08) |
| Insulin receptor signaling |
Down |
18 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trastuzumab (MSN09) |
bosutinib (MSN08) |
| Insulin receptor signaling |
Down |
19 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
bosutinib (MSN08) |
| Insulin receptor signaling |
Down |
21 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
bosutinib (MSN08);cetuximab (MSN09) |
| Insulin receptor signaling |
Down |
24 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
trastuzumab (MSN02;MSN05;MSN09) |
bosutinib (MSN08);cetuximab (MSN09) |
| Integrin-mediated leukocyte rolling |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN09);ruxolitinib (MSN06) |
| JAK-STAT signaling pathway |
Up |
10 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
lapatinib (MSN06);sunitinib (MSN06;MSN08);trastuzumab (MSN01) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);vemurafenib (MSN01) |
| Intrinsic apoptosis pathway |
Up |
12 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN08;MSN09) |
erlotinib (MSN08) |
| Intrinsic apoptosis pathway |
Up |
13 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN08;MSN09) |
ceritinib (MSN09);erlotinib (MSN08) |
| Intrinsic apoptosis pathway |
Up |
14.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN08;MSN09) |
axitinib (MSN09);ceritinib (MSN09);erlotinib (MSN08) |
| Intrinsic apoptosis pathway |
Up |
17 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN08;MSN09) |
axitinib (MSN09);ceritinib (MSN09);cetuximab (MSN05);erlotinib (MSN08) |
| Intrinsic apoptosis pathway |
Up |
18 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN08;MSN09) |
axitinib (MSN09);ceritinib (MSN09);cetuximab (MSN05;MSN08);erlotinib (MSN08) |
| Intrinsic apoptosis pathway |
Down |
5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Intrinsic apoptosis pathway |
Down |
13 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
pazopanib (MSN01) |
dasatinib (MSN08) |
| JAK-STAT signaling pathway |
Up |
2 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN06) |
|
| JAK-STAT signaling pathway |
Up |
3 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
lapatinib (MSN06) |
ceritinib (MSN05) |
| JAK-STAT signaling pathway |
Up |
5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN06);trastuzumab (MSN01) |
ceritinib (MSN05) |
| JAK-STAT signaling pathway |
Up |
6 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
lapatinib (MSN06);sunitinib (MSN08);trastuzumab (MSN01) |
ceritinib (MSN05) |
| JAK-STAT signaling pathway |
Up |
8 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
lapatinib (MSN06);sunitinib (MSN06;MSN08);trastuzumab (MSN01) |
cabozantinib (MSN01);ceritinib (MSN01;MSN05) |
| Intrinsic apoptosis pathway |
Up |
10.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN08;MSN09) |
erlotinib (MSN08) |
| JAK-STAT signaling pathway |
Up |
10.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
lapatinib (MSN06;MSN09);sunitinib (MSN06;MSN08);trastuzumab (MSN01) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);vemurafenib (MSN01) |
| JAK-STAT signaling pathway |
Up |
11 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN09);sunitinib (MSN06;MSN08);trastuzumab (MSN01) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);vemurafenib (MSN01) |
| JAK-STAT signaling pathway |
Up |
13.5 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN09);sunitinib (MSN06;MSN08);trastuzumab (MSN01) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);imatinib (MSN09);vemurafenib (MSN01) |
| JAK-STAT signaling pathway |
Up |
15 |
0.5714286 |
0.173913 |
0.5037037 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN05;MSN06;MSN09);sunitinib (MSN06;MSN08);trastuzumab (MSN01);vandetanib (MSN08) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);imatinib (MSN09);vemurafenib (MSN01) |
| JAK-STAT signaling pathway |
Up |
16 |
0.625 |
0.2173913 |
0.5629139 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN06;MSN08);trastuzumab (MSN01);vandetanib (MSN05;MSN08) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);imatinib (MSN09);vemurafenib (MSN01) |
| JAK-STAT signaling pathway |
Up |
18 |
0.6470588 |
0.2391304 |
0.5880503 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN01;MSN05;MSN06;MSN09);ponatinib (MSN02);sunitinib (MSN06;MSN08);trastuzumab (MSN01);vandetanib (MSN05;MSN08) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);imatinib (MSN09);vemurafenib (MSN01) |
| JAK-STAT signaling pathway |
Up |
19.5 |
0.6111111 |
0.2391304 |
0.5598803 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN01;MSN05;MSN06;MSN09);ponatinib (MSN02);sunitinib (MSN06;MSN08);trastuzumab (MSN01);vandetanib (MSN05;MSN08) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);imatinib (MSN09);rituximab (MSN08);vemurafenib (MSN01) |
| JAK-STAT signaling pathway |
Up |
21 |
0.6315789 |
0.2608696 |
0.5828571 |
NaN |
NaN |
bevacizumab (MSN09);dabrafenib (MSN08);lapatinib (MSN01;MSN05;MSN06;MSN09);ponatinib (MSN02);sunitinib (MSN06;MSN08);trastuzumab (MSN01);vandetanib (MSN05;MSN08) |
cabozantinib (MSN01;MSN02);ceritinib (MSN01;MSN05);imatinib (MSN09);rituximab (MSN08);vemurafenib (MSN01) |
| JAK-STAT signaling pathway |
Down |
2 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sorafenib (MSN09) |
|
| JAK-STAT signaling pathway |
Down |
5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sorafenib (MSN09) |
ruxolitinib (MSN06) |
| JAK-STAT signaling pathway |
Down |
6 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sorafenib (MSN09) |
ruxolitinib (MSN06;MSN09) |
| Intracellular bridge assembly |
Down |
8 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
lapatinib (MSN05;MSN09) |
afatinib (MSN05;MSN08);gefitinib (MSN08) |
| Intracellular bridge assembly |
Up |
8 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
ponatinib (MSN01;MSN02);sorafenib (MSN08;MSN09) |
|
| Intracellular bridge assembly |
Up |
9 |
0.7142857 |
0.1086956 |
0.5379746 |
NaN |
NaN |
ponatinib (MSN01;MSN02);sorafenib (MSN05;MSN08;MSN09) |
nilotinib (MSN01);ruxolitinib (MSN02) |
| Intracellular bridge assembly |
Up |
10 |
0.6666667 |
0.1304348 |
0.5368421 |
NaN |
NaN |
ponatinib (MSN01;MSN02);sorafenib (MSN01;MSN05;MSN08;MSN09) |
nilotinib (MSN01;MSN08);ruxolitinib (MSN02) |
| Intracellular bridge assembly |
Up |
11 |
0.7 |
0.1521739 |
0.5776699 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
nilotinib (MSN01;MSN08);ruxolitinib (MSN02) |
| Intracellular bridge assembly |
Up |
12 |
0.5833333 |
0.1521739 |
0.5 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
nilotinib (MSN01;MSN06;MSN08;MSN09);ruxolitinib (MSN02) |
| Intracellular bridge assembly |
Up |
13 |
0.5384616 |
0.1521739 |
0.468504 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02) |
| Intracellular bridge assembly |
Up |
13.5 |
0.5 |
0.1521739 |
0.4407408 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02) |
| Intracellular bridge assembly |
Up |
15.5 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02) |
| Intracellular bridge assembly |
Up |
20 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02) |
| Intracellular bridge assembly |
Down |
4.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN09) |
|
| Intracellular bridge assembly |
Down |
6 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
lapatinib (MSN05;MSN09) |
|
| Intracellular bridge assembly |
Down |
7 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN05;MSN09) |
afatinib (MSN08) |
| Osteopontin receptor signaling |
Up |
15 |
0.2857143 |
0.173913 |
0.2753036 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Intracellular bridge assembly |
Down |
9 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
lapatinib (MSN05;MSN09) |
afatinib (MSN05;MSN08);ceritinib (MSN06);gefitinib (MSN08) |
| Intracellular bridge assembly |
Down |
10 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN06);gefitinib (MSN01;MSN08) |
| Intracellular bridge assembly |
Down |
12 |
0.3076923 |
0.08695652 |
0.2677165 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN06);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| Intracellular bridge assembly |
Down |
13 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN06);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Intracellular bridge assembly |
Down |
14 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN06);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Intracellular bridge assembly |
Down |
15.5 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN06;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Intracellular bridge assembly |
Down |
16 |
0.3333333 |
0.1304348 |
0.3053892 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN06;MSN09);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Intracellular bridge assembly |
Down |
16.5 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Intracellular bridge assembly |
Down |
17 |
0.2857143 |
0.1304348 |
0.2670157 |
NaN |
NaN |
lapatinib (MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Intrinsic apoptosis pathway |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN08) |
| Intrinsic apoptosis pathway |
Up |
8 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
lapatinib (MSN08) |
erlotinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
4 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
trastuzumab (MSN05);vandetanib (MSN05;MSN08) |
axitinib (MSN01);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05);rituximab (MSN05;MSN09) |
| Thrombospondin receptor signaling |
Up |
6.5 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
dabrafenib (MSN05);sunitinib (MSN06) |
axitinib (MSN08);cabozantinib (MSN01;MSN05;MSN06);ceritinib (MSN01);dasatinib (MSN08);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
7.5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
dabrafenib (MSN05);sunitinib (MSN01;MSN06) |
axitinib (MSN08);cabozantinib (MSN01;MSN05;MSN06);ceritinib (MSN01);dasatinib (MSN08);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
9 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);sunitinib (MSN01;MSN06) |
axitinib (MSN08);cabozantinib (MSN01;MSN05;MSN06);ceritinib (MSN01;MSN06);dasatinib (MSN08);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
12.5 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);ponatinib (MSN08);sunitinib (MSN01;MSN06) |
axitinib (MSN08);cabozantinib (MSN01;MSN05;MSN06);ceritinib (MSN01;MSN06);dasatinib (MSN08);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
14.5 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);ponatinib (MSN08);sunitinib (MSN01;MSN06) |
axitinib (MSN08);cabozantinib (MSN01;MSN05;MSN06);ceritinib (MSN01;MSN06);dasatinib (MSN08);nilotinib (MSN08);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
15.5 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);ponatinib (MSN08);sunitinib (MSN01;MSN06) |
axitinib (MSN08);cabozantinib (MSN01;MSN05;MSN06);ceritinib (MSN01;MSN06);dasatinib (MSN08);nilotinib (MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
16.5 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);ponatinib (MSN08);sunitinib (MSN01;MSN06) |
axitinib (MSN08);cabozantinib (MSN01;MSN05;MSN06);ceritinib (MSN01;MSN06);dasatinib (MSN08);nilotinib (MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01) |
| Thrombospondin receptor signaling |
Down |
2 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
trastuzumab (MSN05);vandetanib (MSN05;MSN08) |
axitinib (MSN01) |
| Thrombospondin receptor signaling |
Down |
2.5 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
trastuzumab (MSN05);vandetanib (MSN05;MSN08) |
axitinib (MSN01);nilotinib (MSN01) |
| Thrombospondin receptor signaling |
Down |
3 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
trastuzumab (MSN05);vandetanib (MSN05;MSN08) |
axitinib (MSN01);imatinib (MSN01);nilotinib (MSN01);rituximab (MSN09) |
| Thrombospondin receptor signaling |
Down |
3.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
trastuzumab (MSN05);vandetanib (MSN05;MSN08) |
axitinib (MSN01);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05);rituximab (MSN09) |
| Thrombospondin receptor signaling |
Up |
6 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
dabrafenib (MSN05);sunitinib (MSN06) |
axitinib (MSN08);cabozantinib (MSN01;MSN05);ceritinib (MSN01);dasatinib (MSN08);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Down |
4.5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
trastuzumab (MSN05);vandetanib (MSN05;MSN08) |
axitinib (MSN01;MSN06);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
5 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
trastuzumab (MSN05);vandetanib (MSN05;MSN08) |
axitinib (MSN01;MSN06);bosutinib (MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
6 |
0.4444444 |
0.173913 |
0.4071856 |
NaN |
NaN |
sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN01;MSN06);bosutinib (MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
7.5 |
0.4736842 |
0.1956522 |
0.4371428 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN01;MSN06);bosutinib (MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
8.5 |
0.4761905 |
0.2173913 |
0.4450262 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08) |
afatinib (MSN08);axitinib (MSN01;MSN06);bosutinib (MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
12.5 |
0.4545455 |
0.2173913 |
0.4271357 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08) |
afatinib (MSN08);axitinib (MSN01;MSN06);bosutinib (MSN08);gefitinib (MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
14 |
0.4782609 |
0.2391304 |
0.4516909 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08) |
afatinib (MSN08);axitinib (MSN01;MSN06);bosutinib (MSN08);gefitinib (MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
15.5 |
0.5 |
0.2608696 |
0.4744186 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08) |
afatinib (MSN08);axitinib (MSN01;MSN06);bosutinib (MSN08);gefitinib (MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
16.5 |
0.48 |
0.2608696 |
0.4573991 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08) |
afatinib (MSN08);axitinib (MSN01;MSN06);bosutinib (MSN08);erlotinib (MSN05);gefitinib (MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Thrombospondin receptor signaling |
Down |
17.5 |
0.4615385 |
0.2608696 |
0.4415585 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN02);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08) |
afatinib (MSN08);axitinib (MSN01;MSN06);bosutinib (MSN08);erlotinib (MSN05);gefitinib (MSN05;MSN08);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN05;MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN08) |
| Tight junction organization |
Up |
2 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
bevacizumab (MSN05;MSN08) |
|
| Tight junction organization |
Up |
9 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09) |
|
| Thin myofilament organization |
Up |
7 |
0.3043478 |
0.1521739 |
0.2874396 |
NaN |
NaN |
dabrafenib (MSN01);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Thick myofilament organization |
Down |
3 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
ponatinib (MSN09) |
nilotinib (MSN08) |
| Thick myofilament organization |
Down |
4 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
ponatinib (MSN09) |
nilotinib (MSN06;MSN08) |
| Thick myofilament organization |
Down |
5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
ponatinib (MSN06;MSN09) |
nilotinib (MSN06;MSN08) |
| Thin myofilament organization |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN08);dasatinib (MSN09) |
| Thin myofilament organization |
Up |
1.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05);bosutinib (MSN08);dasatinib (MSN09) |
| Thin myofilament organization |
Up |
2 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN01;MSN05) |
afatinib (MSN05);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08);dasatinib (MSN01;MSN05;MSN09) |
| Thin myofilament organization |
Up |
3 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05) |
afatinib (MSN05);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08);dasatinib (MSN01;MSN05;MSN09) |
| Thin myofilament organization |
Up |
3.5 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05) |
afatinib (MSN05);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN09) |
| Thin myofilament organization |
Up |
4 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09) |
afatinib (MSN05);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN09) |
| Thin myofilament organization |
Up |
5 |
0.2631579 |
0.1086956 |
0.2428571 |
NaN |
NaN |
trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09) |
afatinib (MSN05);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN01);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Thin myofilament organization |
Up |
6 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN01);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Thin myofilament organization |
Up |
6.5 |
0.3181818 |
0.1521739 |
0.298995 |
NaN |
NaN |
dabrafenib (MSN01);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN01);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Tight junction organization |
Up |
10 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09) |
rituximab (MSN08) |
| Thin myofilament organization |
Up |
7.5 |
0.28 |
0.1521739 |
0.2668161 |
NaN |
NaN |
dabrafenib (MSN01);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Thin myofilament organization |
Up |
8 |
0.2692308 |
0.1521739 |
0.2575758 |
NaN |
NaN |
dabrafenib (MSN01);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Thin myofilament organization |
Up |
11 |
0.2857143 |
0.173913 |
0.2753036 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN01) |
| Thin myofilament organization |
Up |
12 |
0.2758621 |
0.173913 |
0.2666667 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN01) |
| Thrombospondin receptor signaling |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN09) |
| Thrombospondin receptor signaling |
Up |
1.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
2.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN05);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01;MSN05);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);cabozantinib (MSN01;MSN05);dasatinib (MSN08);vemurafenib (MSN01;MSN08;MSN09) |
| Thrombospondin receptor signaling |
Up |
5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
dabrafenib (MSN05) |
axitinib (MSN08);cabozantinib (MSN01;MSN05);dasatinib (MSN08);vemurafenib (MSN01;MSN08;MSN09) |
| Tropoelastin synthesis |
Up |
21 |
0.3125 |
0.2173913 |
0.3046595 |
NaN |
NaN |
pazopanib (MSN01;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN06;MSN08);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
10 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN08);trametinib (MSN01) |
axitinib (MSN01;MSN06);cabozantinib (MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
11 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01);cabozantinib (MSN08);cetuximab (MSN01);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
11.5 |
0.3888889 |
0.1521739 |
0.3562874 |
NaN |
NaN |
pazopanib (MSN08);sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01);cabozantinib (MSN08);cetuximab (MSN01);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
12 |
0.368421 |
0.1521739 |
0.3399999 |
NaN |
NaN |
pazopanib (MSN08);sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01);cabozantinib (MSN08);cetuximab (MSN01);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
12.5 |
0.35 |
0.1521739 |
0.3251366 |
NaN |
NaN |
pazopanib (MSN08);sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05);cabozantinib (MSN08);cetuximab (MSN01);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
13 |
0.375 |
0.1956522 |
0.355814 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05);cabozantinib (MSN08);cetuximab (MSN01;MSN02;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
13.5 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN08);cetuximab (MSN01;MSN02;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
14 |
0.3333333 |
0.1956522 |
0.3200837 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
15 |
0.3214286 |
0.1956522 |
0.3097166 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
16 |
0.3103448 |
0.1956522 |
0.3 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
16.5 |
0.3 |
0.1956522 |
0.2908745 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN06;MSN08);ceritinib (MSN01);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
18.5 |
0.3225806 |
0.2173913 |
0.3136531 |
NaN |
NaN |
pazopanib (MSN01;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN06;MSN08);ceritinib (MSN01);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
9 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
sunitinib (MSN05);trametinib (MSN01) |
cabozantinib (MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
21.5 |
0.3030303 |
0.2173913 |
0.2961673 |
NaN |
NaN |
pazopanib (MSN01;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
23.5 |
0.2941177 |
0.2173913 |
0.2881356 |
NaN |
NaN |
pazopanib (MSN01;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN09);nilotinib (MSN01);rituximab (MSN05;MSN06;MSN08;MSN09);vemuraf |
| Tropoelastin synthesis |
Up |
24.5 |
0.2857143 |
0.2173913 |
0.2805281 |
NaN |
NaN |
pazopanib (MSN01;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN06;MSN09);nilotinib (MSN01);rituximab (MSN05;MSN06;MSN08;MSN09);v |
| Tropoelastin synthesis |
Up |
25 |
0.2777778 |
0.2173913 |
0.2733119 |
NaN |
NaN |
pazopanib (MSN01;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN06;MSN09);nilotinib (MSN01;MSN06);rituximab (MSN05;MSN06;MSN08;MS |
| Tropoelastin synthesis |
Up |
26 |
0.2702703 |
0.2173913 |
0.2664577 |
NaN |
NaN |
pazopanib (MSN01;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN06;MSN09);nilotinib (MSN01;MSN06;MSN09);rituximab (MSN05;MSN06;MS |
| Tropoelastin synthesis |
Up |
29.5 |
0.2631579 |
0.2173913 |
0.2599388 |
NaN |
NaN |
pazopanib (MSN01;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN01;MSN06;MSN08);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN08);erlotinib (MSN01;MSN09);imatinib (MSN06;MSN09);nilotinib (MSN01;MSN06;MSN08;MSN09);rituximab (MSN05;MS |
| Tropoelastin synthesis |
Down |
4.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN08) |
|
| Tropoelastin synthesis |
Down |
7.5 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
pazopanib (MSN09);vandetanib (MSN08;MSN09) |
|
| Tropoelastin synthesis |
Down |
8 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
pazopanib (MSN09);sorafenib (MSN08);vandetanib (MSN08;MSN09) |
nilotinib (MSN05) |
| Tropoelastin synthesis |
Down |
8.5 |
0.8333333 |
0.1086956 |
0.5985914 |
NaN |
NaN |
pazopanib (MSN09);ponatinib (MSN05);sorafenib (MSN08);vandetanib (MSN08;MSN09) |
nilotinib (MSN05) |
| Tropoelastin synthesis |
Down |
9 |
0.8571429 |
0.1304348 |
0.6455697 |
NaN |
NaN |
pazopanib (MSN09);ponatinib (MSN05);sorafenib (MSN01;MSN08);vandetanib (MSN08;MSN09) |
nilotinib (MSN05) |
| Tropoelastin synthesis |
Down |
9.5 |
0.875 |
0.1521739 |
0.6839081 |
NaN |
NaN |
pazopanib (MSN09);ponatinib (MSN05;MSN08);sorafenib (MSN01;MSN08);vandetanib (MSN08;MSN09) |
nilotinib (MSN05) |
| Translation initiation |
Up |
15 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Tight junction organization |
Up |
13 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09);sunitinib (MSN02) |
axitinib (MSN09);bosutinib (MSN01);rituximab (MSN05;MSN08) |
| Tight junction organization |
Up |
14 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
axitinib (MSN09);bosutinib (MSN01);rituximab (MSN05;MSN08) |
| Tight junction organization |
Up |
16.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
axitinib (MSN09);bosutinib (MSN01);rituximab (MSN05;MSN08;MSN09) |
| Tight junction organization |
Up |
21 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02) |
axitinib (MSN09);bosutinib (MSN01);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Tight junction organization |
Down |
3 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
pazopanib (MSN05) |
cabozantinib (MSN01) |
| Tight junction organization |
Down |
9 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN06);pazopanib (MSN05) |
cabozantinib (MSN01) |
| Tight junction organization |
Down |
11 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
lapatinib (MSN06;MSN08);pazopanib (MSN05) |
cabozantinib (MSN01) |
| Tight junction organization |
Down |
13 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
lapatinib (MSN06;MSN08);pazopanib (MSN05) |
cabozantinib (MSN01);imatinib (MSN01);vemurafenib (MSN09) |
| Tight junction organization |
Down |
14 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
lapatinib (MSN06;MSN08);pazopanib (MSN05) |
cabozantinib (MSN01);ceritinib (MSN08);imatinib (MSN01);vemurafenib (MSN09) |
| Tight junction organization |
Down |
23 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
lapatinib (MSN06;MSN08);pazopanib (MSN05);trametinib (MSN09) |
cabozantinib (MSN01);ceritinib (MSN08);imatinib (MSN01);vemurafenib (MSN09) |
| Transcription by rna polymerase II |
Down |
15 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN08) |
| Translation elongation |
Down |
20 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09) |
| Thick myofilament organization |
Up |
18.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
trastuzumab (MSN01;MSN02) |
crizotinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN01;MSN05) |
| Transmembrane glucose transport |
Up |
6 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Transmembrane glucose transport |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN01) |
| Transmembrane glucose transport |
Down |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05);vemurafenib (MSN01) |
| Transmembrane glucose transport |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);bosutinib (MSN05);vemurafenib (MSN01) |
| Transmembrane glucose transport |
Down |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);bosutinib (MSN05);gefitinib (MSN09);vemurafenib (MSN01) |
| Transmembrane glucose transport |
Down |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);bosutinib (MSN05);gefitinib (MSN05;MSN09);vemurafenib (MSN01) |
| Transsulfuration pathway |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN09) |
| Tropoelastin synthesis |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN09) |
| Tropoelastin synthesis |
Up |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
8 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN01) |
erlotinib (MSN01;MSN09);vemurafenib (MSN01) |
| Tropoelastin synthesis |
Up |
8.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trametinib (MSN01) |
erlotinib (MSN01;MSN09);rituximab (MSN05);vemurafenib (MSN01) |
| Sister chromatid segregation |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09);dasatinib (MSN05) |
| Sister chromatid attachment to mitotic spindle |
Down |
13 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
14 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN05;MSN09);erlotinib (MSN01;MSN05;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
15 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN05;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
17 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01);bosutinib (MSN05);ceritinib (MSN05;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
23 |
0.2608696 |
0.1304348 |
0.2463769 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01);bosutinib (MSN05);ceritinib (MSN05;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
24 |
0.25 |
0.1304348 |
0.2372093 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01);bosutinib (MSN05);ceritinib (MSN01;MSN05;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
25 |
0.24 |
0.1304348 |
0.2286996 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01);bosutinib (MSN05);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
26.5 |
0.2307692 |
0.1304348 |
0.2207792 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01);bosutinib (MSN05);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid cohesion |
Down |
16 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN05) |
|
| Sister chromatid cohesion |
Down |
22 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN05) |
erlotinib (MSN09) |
| Sister chromatid cohesion |
Down |
23 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN05) |
ceritinib (MSN05);erlotinib (MSN08;MSN09) |
| Sister chromatid segregation |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
12 |
0.3571429 |
0.1086956 |
0.3148148 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid segregation |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09);dasatinib (MSN05);regorafenib (MSN06) |
| Sister chromatid segregation |
Up |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05);regorafenib (MSN06) |
| Sister chromatid segregation |
Up |
6 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
sorafenib (MSN01;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN06) |
| Sister chromatid segregation |
Up |
6.5 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
sorafenib (MSN01;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05);imatinib (MSN01);nilotinib (MSN01);regorafenib (MSN06) |
| Sister chromatid segregation |
Up |
7 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
ponatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05);imatinib (MSN01);nilotinib (MSN01;MSN08);regorafenib (MSN05;MSN06);ruxolitinib (MSN02) |
| Sister chromatid segregation |
Up |
8 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
ponatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05);imatinib (MSN01);nilotinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN02) |
| Sister chromatid segregation |
Up |
8.5 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
ponatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05);imatinib (MSN01;MSN05);nilotinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02) |
| Sister chromatid segregation |
Up |
9 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
ponatinib (MSN01;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05);imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02) |
| Sister chromatid segregation |
Up |
10 |
0.24 |
0.1304348 |
0.2286996 |
NaN |
NaN |
ponatinib (MSN01;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02) |
| Sister chromatid segregation |
Up |
11 |
0.2692308 |
0.1521739 |
0.2575758 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02) |
| Sister chromatid segregation |
Up |
11.5 |
0.2962963 |
0.173913 |
0.2845188 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02) |
| Sister chromatid segregation |
Up |
13.5 |
0.3214286 |
0.1956522 |
0.3097166 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02) |
| Sister chromatid attachment to mitotic spindle |
Up |
22.5 |
0.3043478 |
0.1521739 |
0.2874396 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Up |
7 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
ponatinib (MSN02);sorafenib (MSN09) |
imatinib (MSN01);nilotinib (MSN01) |
| Sister chromatid attachment to mitotic spindle |
Up |
8 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
ponatinib (MSN02;MSN06);sorafenib (MSN05;MSN09) |
imatinib (MSN01);nilotinib (MSN01;MSN08) |
| Sister chromatid attachment to mitotic spindle |
Up |
9 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
ponatinib (MSN02;MSN06);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01);nilotinib (MSN01;MSN08);regorafenib (MSN08) |
| Sister chromatid attachment to mitotic spindle |
Up |
10 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN08) |
| Sister chromatid attachment to mitotic spindle |
Up |
10.5 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08) |
| Sister chromatid attachment to mitotic spindle |
Up |
13 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);vemurafenib (MSN06) |
| Sister chromatid attachment to mitotic spindle |
Up |
13.5 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);vemurafenib (MSN05;MSN06) |
| Sister chromatid attachment to mitotic spindle |
Up |
14 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);vemurafenib (MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Up |
16 |
0.3333333 |
0.1304348 |
0.3053892 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Up |
17.5 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Up |
20.5 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Up |
21 |
0.3333333 |
0.1521739 |
0.3115183 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
3 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN05) |
|
| Sister chromatid attachment to mitotic spindle |
Up |
24 |
0.2916667 |
0.1521739 |
0.2767442 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Up |
26 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Up |
29.5 |
0.3076923 |
0.173913 |
0.2943723 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN01;MSN05);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08) |
| Sister chromatid attachment to mitotic spindle |
Down |
7 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN05) |
afatinib (MSN05;MSN08) |
| Sister chromatid attachment to mitotic spindle |
Down |
7.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN05) |
afatinib (MSN05;MSN08;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
9 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01) |
| Sister chromatid attachment to mitotic spindle |
Down |
9.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN06) |
| Sister chromatid attachment to mitotic spindle |
Down |
10 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN06) |
| Sister chromatid attachment to mitotic spindle |
Down |
10.5 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Sister chromatid attachment to mitotic spindle |
Down |
11 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Tenascin receptor signaling |
Down |
15.5 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN09);pazopanib (MSN08) |
dasatinib (MSN06;MSN09);gefitinib (MSN06;MSN08);imatinib (MSN09) |
| Sphingolipid metabolism |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN09) |
| Sulfonation |
Up |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Syndecan receptor signaling |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN01) |
| Telomere replication and maintenance |
Down |
24 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN09) |
| Telomere replication and maintenance |
Down |
25 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN08;MSN09) |
| Telomere replication and maintenance |
Down |
27 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05;MSN08;MSN09) |
| Tenascin receptor signaling |
Down |
2 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
bevacizumab (MSN06);pazopanib (MSN08) |
|
| Tenascin receptor signaling |
Down |
3 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);pazopanib (MSN08) |
|
| Tenascin receptor signaling |
Down |
4 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);pazopanib (MSN08) |
dasatinib (MSN06) |
| Tenascin receptor signaling |
Down |
5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);pazopanib (MSN08) |
dasatinib (MSN06;MSN09);imatinib (MSN09) |
| Tenascin receptor signaling |
Down |
10 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN09);pazopanib (MSN08) |
dasatinib (MSN06;MSN09);imatinib (MSN09) |
| Tenascin receptor signaling |
Down |
12.5 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN09);pazopanib (MSN08) |
dasatinib (MSN06;MSN09);gefitinib (MSN08);imatinib (MSN09) |
| Sodium transmembrane transport |
Down |
21 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
ponatinib (MSN08) |
crizotinib (MSN08);tofacitinib (MSN08);vemurafenib (MSN09) |
| Tenascin receptor signaling |
Down |
16 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN09);pazopanib (MSN08) |
dasatinib (MSN06;MSN09);gefitinib (MSN06;MSN08;MSN09);imatinib (MSN09) |
| Tenascin receptor signaling |
Down |
17.5 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN09);pazopanib (MSN08) |
dasatinib (MSN06;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09) |
| Tenascin receptor signaling |
Down |
20.5 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN09);pazopanib (MSN08) |
dasatinib (MSN06;MSN09);erlotinib (MSN01);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09) |
| Tenascin receptor signaling |
Down |
21.5 |
0.3076923 |
0.08695652 |
0.2677165 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN09);pazopanib (MSN08) |
dasatinib (MSN06;MSN09);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09) |
| Thick myofilament organization |
Up |
1 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trastuzumab (MSN02) |
|
| Thick myofilament organization |
Up |
3 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
trastuzumab (MSN01;MSN02) |
|
| Thick myofilament organization |
Up |
10 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trastuzumab (MSN01;MSN02) |
dasatinib (MSN01) |
| Thick myofilament organization |
Up |
15.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
trastuzumab (MSN01;MSN02) |
crizotinib (MSN05);dasatinib (MSN01) |
| Thick myofilament organization |
Up |
16 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
trastuzumab (MSN01;MSN02) |
crizotinib (MSN05);dasatinib (MSN01;MSN05) |
| Thick myofilament organization |
Up |
17 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
trastuzumab (MSN01;MSN02) |
crizotinib (MSN05;MSN06);dasatinib (MSN01;MSN05) |
| Thick myofilament organization |
Up |
17.5 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
trastuzumab (MSN01;MSN02) |
crizotinib (MSN01;MSN05;MSN06);dasatinib (MSN01;MSN05) |
| Sister chromatid segregation |
Down |
12 |
0.3870968 |
0.2608696 |
0.3763838 |
NaN |
NaN |
lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
4 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sunitinib (MSN05) |
ceritinib (MSN08) |
| Sister chromatid segregation |
Down |
5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sunitinib (MSN05) |
ceritinib (MSN08);gefitinib (MSN08) |
| Sister chromatid segregation |
Down |
6 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
sunitinib (MSN05;MSN09) |
afatinib (MSN09);ceritinib (MSN08);gefitinib (MSN08) |
| Sister chromatid segregation |
Down |
7 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
sunitinib (MSN05;MSN09) |
afatinib (MSN09);ceritinib (MSN01;MSN08);cetuximab (MSN05);gefitinib (MSN01;MSN08) |
| Sister chromatid segregation |
Down |
7.5 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
sunitinib (MSN05;MSN06;MSN09) |
afatinib (MSN09);ceritinib (MSN01;MSN08);cetuximab (MSN05);gefitinib (MSN01;MSN08) |
| Sister chromatid segregation |
Down |
8 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
sunitinib (MSN05;MSN06;MSN09);trametinib (MSN01;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
8.5 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
sunitinib (MSN05;MSN06;MSN09);trametinib (MSN01;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
9 |
0.4 |
0.173913 |
0.3715847 |
NaN |
NaN |
lapatinib (MSN05;MSN08);sunitinib (MSN05;MSN06;MSN09);trametinib (MSN01;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
9.5 |
0.4782609 |
0.2391304 |
0.4516909 |
NaN |
NaN |
lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
10.5 |
0.44 |
0.2391304 |
0.4192825 |
NaN |
NaN |
lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN05;MSN08;MSN09);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
11 |
0.4444444 |
0.2608696 |
0.4267782 |
NaN |
NaN |
lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN05;MSN08;MSN09);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
11.5 |
0.4285714 |
0.2608696 |
0.4129555 |
NaN |
NaN |
lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN08;MSN09);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Tropoelastin synthesis |
Down |
10 |
0.75 |
0.1956522 |
0.6428572 |
NaN |
NaN |
bevacizumab (MSN08);pazopanib (MSN09);ponatinib (MSN05;MSN08);sorafenib (MSN01;MSN08);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);nilotinib (MSN05);regorafenib (MSN01) |
| Sister chromatid segregation |
Down |
12.5 |
0.375 |
0.2608696 |
0.3655914 |
NaN |
NaN |
lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
13 |
0.4117647 |
0.3043478 |
0.4033898 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
13.5 |
0.4 |
0.3043478 |
0.3927393 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
14.5 |
0.3888889 |
0.3043478 |
0.3826367 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sister chromatid segregation |
Down |
17.5 |
0.4054054 |
0.326087 |
0.3996865 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN06;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Sodium transmembrane transport |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01) |
| Sodium transmembrane transport |
Up |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01);cabozantinib (MSN02) |
| Sodium transmembrane transport |
Up |
15 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
vandetanib (MSN09) |
bosutinib (MSN01);cabozantinib (MSN02;MSN08) |
| Sodium transmembrane transport |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN09) |
| Sodium transmembrane transport |
Down |
14 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
ponatinib (MSN08) |
vemurafenib (MSN09) |
| Sodium transmembrane transport |
Down |
16 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
ponatinib (MSN08) |
tofacitinib (MSN08);vemurafenib (MSN09) |
| WNT-Beta-catenin signaling pathway |
Up |
1 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
ponatinib (MSN05) |
ceritinib (MSN09) |
| Vimentin-like intermediate filament dynamics |
Down |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN06) |
| Vitamin D receptor signaling |
Down |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02) |
| Vitamin K metabolism |
Down |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN09) |
| Water transmembrane transport |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN01) |
| Water transmembrane transport |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08);gefitinib (MSN01) |
| Water transmembrane transport |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05;MSN08);gefitinib (MSN01;MSN05;MSN09) |
| Water transmembrane transport |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05;MSN06;MSN08);gefitinib (MSN01;MSN05;MSN09) |
| Water transmembrane transport |
Up |
5.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN05;MSN06;MSN08);gefitinib (MSN01;MSN05;MSN09) |
| Water transmembrane transport |
Up |
6 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN09);vemurafenib (MSN06) |
| Water transmembrane transport |
Up |
8 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN09);gefitinib (MSN01;MSN05;MSN09);vemurafenib (MSN06) |
| Water transmembrane transport |
Up |
9 |
0.1333333 |
0.04347826 |
0.1188811 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN09);vemurafenib (MSN06) |
| Water transmembrane transport |
Up |
10.5 |
0.125 |
0.04347826 |
0.1125828 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN09);vemurafenib (MSN06) |
| Vimentin-like intermediate filament dynamics |
Up |
18.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN09);dasatinib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
2 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN08) |
afatinib (MSN09);ceritinib (MSN09) |
| WNT-Beta-catenin signaling pathway |
Up |
3 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN08) |
afatinib (MSN09);ceritinib (MSN09);vemurafenib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
4 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN08) |
afatinib (MSN08;MSN09);ceritinib (MSN09);vemurafenib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
5 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN08);trastuzumab (MSN02) |
afatinib (MSN08;MSN09);ceritinib (MSN09);vemurafenib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
6 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN05;MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN08;MSN09);ceritinib (MSN09);regorafenib (MSN06);vemurafenib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
8 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN05;MSN08);trametinib (MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN08;MSN09);ceritinib (MSN09);regorafenib (MSN06);vemurafenib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
9 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN05;MSN08);trametinib (MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN09);gefitinib (MSN09);regorafenib (MSN06);vemurafenib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
10 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN05;MSN08);trametinib (MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN09);gefitinib (MSN09);regorafenib (MSN06;MSN08);tofacitinib (MSN08);vemurafenib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
11 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN05;MSN08);trametinib (MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN05);ceritinib (MSN09);gefitinib (MSN09);regorafenib (MSN06;MSN08);ruxolitinib (MSN05);tofacitinib (MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
12 |
0.2916667 |
0.1521739 |
0.2767442 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN01;MSN05);ceritinib (MSN09);gefitinib (MSN09);regorafenib (MSN06;MSN08);ruxolitinib (MSN01;MSN05);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
13 |
0.28 |
0.1521739 |
0.2668161 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN06;MSN08);ruxolitinib (MSN01;MSN05);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
15 |
0.3076923 |
0.173913 |
0.2943723 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN01;MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN06;MSN08);ruxolitinib (MSN01;MSN05);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| Versican synthesis |
Down |
20.5 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN08);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);regorafenib (MSN05) |
| Versican synthesis |
Up |
21.5 |
0.5384616 |
0.1521739 |
0.468504 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08;MSN09);ponatinib (MSN09);sorafenib (MSN05;MSN09) |
axitinib (MSN01);cabozantinib (MSN01;MSN05;MSN06);rituximab (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Up |
24.5 |
0.5 |
0.1521739 |
0.4407408 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08;MSN09);ponatinib (MSN09);sorafenib (MSN05;MSN09) |
axitinib (MSN01);cabozantinib (MSN01;MSN05;MSN06);imatinib (MSN06);rituximab (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01) |
| Versican synthesis |
Down |
11.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01);regorafenib (MSN05) |
| Versican synthesis |
Down |
12 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01);cetuximab (MSN08);crizotinib (MSN05);regorafenib (MSN05) |
| Versican synthesis |
Down |
14.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01);cetuximab (MSN08);crizotinib (MSN01;MSN05);regorafenib (MSN05) |
| Versican synthesis |
Down |
15 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
lapatinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN01);cetuximab (MSN06;MSN08);crizotinib (MSN01;MSN05;MSN09);regorafenib (MSN05) |
| Versican synthesis |
Down |
15.5 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
lapatinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN01);cetuximab (MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN06);regorafenib (MSN05) |
| Versican synthesis |
Down |
16.5 |
0.2142857 |
0.06521739 |
0.1888889 |
NaN |
NaN |
lapatinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);cetuximab (MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN06);regorafenib (MSN05) |
| Versican synthesis |
Down |
17.5 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
lapatinib (MSN01;MSN06);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);cetuximab (MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);regorafenib (MSN05) |
| Versican synthesis |
Down |
18.5 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN08);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN06);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);regorafenib (MSN05) |
| Versican synthesis |
Down |
19.5 |
0.2857143 |
0.1304348 |
0.2670157 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN08);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN06);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);regorafenib (MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
16 |
0.2962963 |
0.173913 |
0.2845188 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN05);sunitinib (MSN01;MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN05);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| Versican synthesis |
Down |
21 |
0.28 |
0.1521739 |
0.2668161 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);gefitinib (MSN01);regorafenib (MSN05) |
| Versican synthesis |
Down |
24.5 |
0.2592593 |
0.1521739 |
0.248954 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);gefitinib (MSN01;MSN06);regorafenib (MSN05) |
| Versican synthesis |
Down |
25 |
0.25 |
0.1521739 |
0.2408907 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);gefitinib (MSN01;MSN06;MSN08);regorafenib (MSN05) |
| Versican synthesis |
Down |
26 |
0.2758621 |
0.173913 |
0.2666667 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);gefitinib (MSN01;MSN06;MSN08);regorafenib (MSN05) |
| Versican synthesis |
Down |
27.5 |
0.3125 |
0.2173913 |
0.3046595 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);gefitinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN05) |
| Versican synthesis |
Down |
30.5 |
0.3333333 |
0.2391304 |
0.325784 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);gefitinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN05) |
| Versican synthesis |
Down |
31.5 |
0.3333333 |
0.2608696 |
0.3279742 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN05) |
| Versican synthesis |
Down |
33 |
0.3157895 |
0.2608696 |
0.3119266 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN01;MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN05) |
| Versican synthesis |
Down |
35 |
0.3076923 |
0.2608696 |
0.3044776 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN05) |
| Vimentin-like intermediate filament dynamics |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN05) |
| Vimentin-like intermediate filament dynamics |
Up |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01);dasatinib (MSN05) |
| Z-disc organization |
Down |
4 |
0.3913043 |
0.1956522 |
0.3695652 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN01;MSN02) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN08;MSN09);tofacitinib (MSN05;MSN08;MSN09) |
| Z-disc organization |
Up |
4 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN05);dasatinib (MSN06) |
| Z-disc organization |
Up |
5 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN06);bosutinib (MSN08);ceritinib (MSN09);cetuximab (MSN01;MSN05);dasatinib (MSN06) |
| Z-disc organization |
Up |
6 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN01;MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN06);bosutinib (MSN08);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN09);dasatinib (MSN06) |
| Z-disc organization |
Up |
8 |
0.1875 |
0.06521739 |
0.1688742 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN01;MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN06);bosutinib (MSN08);ceritinib (MSN05;MSN09);cetuximab (MSN01;MSN05;MSN09);dasatinib (MSN05;MSN06;MSN08;MSN09) |
| Z-disc organization |
Up |
9 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
lapatinib (MSN01);trametinib (MSN01);trastuzumab (MSN01;MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN06);bosutinib (MSN08);ceritinib (MSN05;MSN09);cetuximab (MSN01;MSN05;MSN09);dasatinib (MSN05;MSN06;MSN08;MSN09) |
| Z-disc organization |
Up |
12 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
lapatinib (MSN01;MSN05);trametinib (MSN01);trastuzumab (MSN01;MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN06);bosutinib (MSN08);ceritinib (MSN05;MSN09);cetuximab (MSN01;MSN05;MSN09);dasatinib (MSN05;MSN06;MSN08;MSN09) |
| Z-disc organization |
Up |
15 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
lapatinib (MSN01;MSN05);trametinib (MSN01);trastuzumab (MSN01;MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06);bosutinib (MSN08);ceritinib (MSN05;MSN09);cetuximab (MSN01;MSN05;MSN09);dasatinib (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01) |
| Z-disc organization |
Up |
16 |
0.2272727 |
0.1086956 |
0.2135678 |
NaN |
NaN |
lapatinib (MSN01;MSN05);trametinib (MSN01);trastuzumab (MSN01;MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN08);ceritinib (MSN05;MSN09);cetuximab (MSN01;MSN05;MSN09);dasatinib (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN09) |
| Z-disc organization |
Up |
20.5 |
0.2608696 |
0.1304348 |
0.2463769 |
NaN |
NaN |
lapatinib (MSN01;MSN05);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN09) |
afatinib (MSN05;MSN08);axitinib (MSN01;MSN06;MSN09);bosutinib (MSN08);ceritinib (MSN05;MSN09);cetuximab (MSN01;MSN05;MSN09);dasatinib (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN09) |
| Z-disc organization |
Down |
1 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN05) |
nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN08);ruxolitinib (MSN01;MSN02;MSN08;MSN09) |
| Z-disc organization |
Down |
2 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN02) |
nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01;MSN02;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Z-disc organization |
Down |
3 |
0.4 |
0.173913 |
0.3715847 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN02) |
nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01;MSN02;MSN08;MSN09);tofacitinib (MSN05;MSN08;MSN09) |
| Z-disc organization |
Up |
3 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN05;MSN08);ceritinib (MSN09);cetuximab (MSN01;MSN05);dasatinib (MSN06) |
| Z-disc organization |
Down |
5 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN01;MSN02) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Z-disc organization |
Down |
6 |
0.4137931 |
0.2608696 |
0.4 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Z-disc organization |
Down |
7 |
0.4 |
0.2608696 |
0.3878327 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Z-disc organization |
Down |
12 |
0.4193548 |
0.2826087 |
0.407749 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Z-disc organization |
Down |
14 |
0.3939394 |
0.2826087 |
0.3850174 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05) |
| Z-disc organization |
Down |
14.5 |
0.3823529 |
0.2826087 |
0.3745762 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06) |
cabozantinib (MSN06);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05) |
| Z-disc organization |
Down |
15 |
0.3888889 |
0.3043478 |
0.3826367 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06) |
cabozantinib (MSN06;MSN08);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05) |
| Z-disc organization |
Down |
16 |
0.4054054 |
0.326087 |
0.3996865 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06);vandetanib (MSN09) |
cabozantinib (MSN06;MSN08);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05) |
| Z-disc organization |
Down |
17 |
0.3947369 |
0.326087 |
0.3899083 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06);vandetanib (MSN09) |
cabozantinib (MSN06;MSN08);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05;MSN09) |
| Z-disc organization |
Down |
18 |
0.4102564 |
0.3478261 |
0.4059701 |
NaN |
NaN |
dabrafenib (MSN01;MSN06;MSN08);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06);vandetanib (MSN09) |
cabozantinib (MSN06;MSN08);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05;MSN09) |
| Z-disc organization |
Down |
22 |
0.425 |
0.3695652 |
0.4212828 |
NaN |
NaN |
dabrafenib (MSN01;MSN06;MSN08);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06);vandetanib (MSN09) |
cabozantinib (MSN06;MSN08);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05;MSN09) |
| WNT-Beta-catenin signaling pathway |
Down |
9 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN05;MSN09) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01);crizotinib (MSN01);dasatinib (MSN01;MSN08);imatinib (MSN05;MSN06;MSN09) |
| WNT-Beta-catenin signaling pathway |
Up |
17 |
0.3103448 |
0.1956522 |
0.3 |
NaN |
NaN |
lapatinib (MSN06;MSN09);ponatinib (MSN05);sunitinib (MSN01;MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05;MSN08);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN05);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
18 |
0.3 |
0.1956522 |
0.2908745 |
NaN |
NaN |
lapatinib (MSN06;MSN09);ponatinib (MSN05);sunitinib (MSN01;MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05;MSN08);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
19 |
0.3225806 |
0.2173913 |
0.3136531 |
NaN |
NaN |
lapatinib (MSN06;MSN09);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05;MSN08);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
20 |
0.3235294 |
0.2391304 |
0.3169491 |
NaN |
NaN |
lapatinib (MSN06;MSN09);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05;MSN08);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN09);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
22 |
0.3428572 |
0.2608696 |
0.3366337 |
NaN |
NaN |
lapatinib (MSN06;MSN09);ponatinib (MSN05;MSN06);sunitinib (MSN01;MSN02;MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05;MSN08);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN09);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Up |
26 |
0.3611111 |
0.2826087 |
0.3553055 |
NaN |
NaN |
lapatinib (MSN06;MSN09);ponatinib (MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN08);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN02) |
afatinib (MSN01;MSN05;MSN08;MSN09);axitinib (MSN05;MSN08);cabozantinib (MSN01;MSN05);ceritinib (MSN01;MSN09);gefitinib (MSN09);regorafenib (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN09);tofacitinib (MSN06;MSN08);vemurafenib (MSN01;MSN05) |
| WNT-Beta-catenin signaling pathway |
Down |
1 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sorafenib (MSN09) |
cabozantinib (MSN01) |
| WNT-Beta-catenin signaling pathway |
Down |
2 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN05;MSN09) |
cabozantinib (MSN01);dasatinib (MSN08);imatinib (MSN09) |
| WNT-Beta-catenin signaling pathway |
Down |
3 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN05;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN01);dasatinib (MSN08);imatinib (MSN06;MSN09) |
| WNT-Beta-catenin signaling pathway |
Down |
6 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN05;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN01);dasatinib (MSN08);imatinib (MSN05;MSN06;MSN09) |
| WNT-Beta-catenin signaling pathway |
Down |
7 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN05;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN01);crizotinib (MSN01);dasatinib (MSN08);imatinib (MSN05;MSN06;MSN09) |
| WNT-Beta-catenin signaling pathway |
Down |
8 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
pazopanib (MSN01);sorafenib (MSN05;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN01);crizotinib (MSN01);dasatinib (MSN01;MSN08);imatinib (MSN05;MSN06;MSN09) |
| Versican synthesis |
Up |
17 |
0.5833333 |
0.1521739 |
0.5 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08;MSN09);ponatinib (MSN09);sorafenib (MSN05;MSN09) |
axitinib (MSN01);cabozantinib (MSN05;MSN06);rituximab (MSN05);vemurafenib (MSN06) |
| WNT-Beta-catenin signaling pathway |
Down |
10 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
pazopanib (MSN01;MSN05);sorafenib (MSN05;MSN09) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01);crizotinib (MSN01);dasatinib (MSN01;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| WNT-Beta-catenin signaling pathway |
Down |
11 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
pazopanib (MSN01;MSN05);sorafenib (MSN05;MSN09) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01);crizotinib (MSN01);dasatinib (MSN01;MSN05;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| WNT-Beta-catenin signaling pathway |
Down |
12 |
0.3333333 |
0.1304348 |
0.3053892 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06);sorafenib (MSN05;MSN09);trastuzumab (MSN05) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01);crizotinib (MSN01);dasatinib (MSN01;MSN05;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| WNT-Beta-catenin signaling pathway |
Down |
13 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06);sorafenib (MSN05;MSN09);trastuzumab (MSN05) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02);crizotinib (MSN01);dasatinib (MSN01;MSN05;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| WNT-Beta-catenin signaling pathway |
Down |
18 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06);sorafenib (MSN05;MSN09);trastuzumab (MSN05) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02);crizotinib (MSN01;MSN09);dasatinib (MSN01;MSN05;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| WNT-Beta-catenin signaling pathway |
Down |
18.5 |
0.2857143 |
0.1304348 |
0.2670157 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06);sorafenib (MSN05;MSN09);trastuzumab (MSN05) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN09);crizotinib (MSN01;MSN09);dasatinib (MSN01;MSN05;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| WNT-Beta-catenin signaling pathway |
Down |
19 |
0.3043478 |
0.1521739 |
0.2874396 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06);sorafenib (MSN05;MSN09);trastuzumab (MSN05;MSN09) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN09);crizotinib (MSN01;MSN05;MSN09);dasatinib (MSN01;MSN05;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| WNT-Beta-catenin signaling pathway |
Down |
20 |
0.2916667 |
0.1521739 |
0.2767442 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06);sorafenib (MSN05;MSN09);trastuzumab (MSN05;MSN09) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN09);cetuximab (MSN06);crizotinib (MSN01;MSN05;MSN09);dasatinib (MSN01;MSN05;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| WNT-Beta-catenin signaling pathway |
Down |
25 |
0.28 |
0.1521739 |
0.2668161 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN06);sorafenib (MSN05;MSN09);trastuzumab (MSN05;MSN09) |
bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN09);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN05;MSN09);dasatinib (MSN01;MSN05;MSN08);imatinib (MSN05;MSN06;MSN09);rituximab (MSN08) |
| Z-disc organization |
Up |
1 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
dasatinib (MSN06) |
| Z-disc organization |
Up |
2 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN09) |
afatinib (MSN08);cetuximab (MSN01;MSN05);dasatinib (MSN06) |
| Vascular endothelial growth factor receptor signaling |
Down |
9 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
ponatinib (MSN02;MSN08) |
bosutinib (MSN01;MSN05;MSN09);crizotinib (MSN08);dasatinib (MSN06;MSN08;MSN09);nilotinib (MSN01;MSN08) |
| Urea cycle |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01) |
| Urea cycle |
Down |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01);ruxolitinib (MSN09) |
| Urea cycle |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01);ruxolitinib (MSN06;MSN08;MSN09) |
| Urea cycle |
Down |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN01);imatinib (MSN01);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Urea cycle |
Down |
22.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);cetuximab (MSN01);imatinib (MSN01);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Vascular endothelial growth factor receptor signaling |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05);dasatinib (MSN09) |
| Vascular endothelial growth factor receptor signaling |
Down |
4 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
ponatinib (MSN08) |
bosutinib (MSN05);dasatinib (MSN09) |
| Vascular endothelial growth factor receptor signaling |
Down |
5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
ponatinib (MSN08) |
bosutinib (MSN01;MSN05);dasatinib (MSN09) |
| Vascular endothelial growth factor receptor signaling |
Down |
6 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
ponatinib (MSN08) |
bosutinib (MSN01;MSN05);dasatinib (MSN09);nilotinib (MSN01) |
| Vascular endothelial growth factor receptor signaling |
Down |
6.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
ponatinib (MSN08) |
bosutinib (MSN01;MSN05);dasatinib (MSN09);nilotinib (MSN01;MSN08) |
| Vascular endothelial growth factor receptor signaling |
Down |
7.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
ponatinib (MSN08) |
bosutinib (MSN01;MSN05);dasatinib (MSN06;MSN08;MSN09);nilotinib (MSN01;MSN08) |
| Vascular endothelial growth factor receptor signaling |
Down |
8 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
ponatinib (MSN08) |
bosutinib (MSN01;MSN05;MSN09);dasatinib (MSN06;MSN08;MSN09);nilotinib (MSN01;MSN08) |
| Urea cycle |
Up |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01) |
| Vascular endothelial growth factor receptor signaling |
Down |
26 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
ponatinib (MSN02;MSN08) |
bosutinib (MSN01;MSN05;MSN09);crizotinib (MSN08);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN01);nilotinib (MSN01;MSN08) |
| Vasoactive intestinal peptide receptor signaling |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN01) |
| Vasoactive intestinal peptide receptor signaling |
Up |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN01;MSN05) |
| Vasoactive intestinal peptide receptor signaling |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN01;MSN05;MSN08) |
| Vasoactive intestinal peptide receptor signaling |
Up |
10.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trametinib (MSN01) |
erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Up |
12.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN01) |
erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Up |
13 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN01) |
erlotinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN01;MSN06) |
| Vasoactive intestinal peptide receptor signaling |
Up |
13.5 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
lapatinib (MSN09);trametinib (MSN01) |
erlotinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06) |
| Vasoactive intestinal peptide receptor signaling |
Up |
14 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN09);trametinib (MSN01) |
axitinib (MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06) |
| Vasoactive intestinal peptide receptor signaling |
Up |
15 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
lapatinib (MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01) |
axitinib (MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06) |
| Vasoactive intestinal peptide receptor signaling |
Up |
16 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
lapatinib (MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01) |
afatinib (MSN06);axitinib (MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Vasoactive intestinal peptide receptor signaling |
Up |
17 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
lapatinib (MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN06);axitinib (MSN06);bosutinib (MSN05);cetuximab (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Tropoelastin synthesis |
Down |
18 |
0.4489796 |
0.4782609 |
0.4506024 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN06);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN08;MSN09);tofacitinib (MSN01;MSN05;M |
| Tropoelastin synthesis |
Down |
11 |
0.6470588 |
0.2391304 |
0.5880503 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);pazopanib (MSN09);ponatinib (MSN05;MSN06;MSN08);sorafenib (MSN01;MSN08);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);nilotinib (MSN05);regorafenib (MSN01;MSN08);tofacitinib (MSN05);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
11.5 |
0.65 |
0.2826087 |
0.6038251 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01);pazopanib (MSN09);ponatinib (MSN05;MSN06;MSN08);sorafenib (MSN01;MSN08);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN08);tofacitinib (MSN05);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
12 |
0.6521739 |
0.326087 |
0.615942 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN09);ponatinib (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);crizotinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN08);tofacitinib (MSN05);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
12.5 |
0.5862069 |
0.3695652 |
0.5666667 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN09);ponatinib (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);crizotinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
13 |
0.5666667 |
0.3695652 |
0.5494297 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN09);ponatinib (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);crizotinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02);tofacitinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
13.5 |
0.5483871 |
0.3695652 |
0.5332104 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN09);ponatinib (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);crizotinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
14 |
0.5294118 |
0.3913043 |
0.5186441 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);crizotinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
14.5 |
0.5135135 |
0.4130435 |
0.5062696 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN09);crizotinib (MSN05);dasatinib (MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
15 |
0.5128205 |
0.4347826 |
0.5074626 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN09);crizotinib (MSN05;MSN09);dasatinib (MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN05) |
| Tropoelastin synthesis |
Down |
15.5 |
0.4651163 |
0.4347826 |
0.4632153 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN0 |
| Tropoelastin synthesis |
Down |
16.5 |
0.4666667 |
0.4565217 |
0.4660574 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN05;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib |
| Tropoelastin synthesis |
Down |
17.5 |
0.4583333 |
0.4782609 |
0.4594595 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN06);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Up |
17.5 |
0.35 |
0.1521739 |
0.3251366 |
NaN |
NaN |
lapatinib (MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01);vandetanib (MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN06);bosutinib (MSN05);cetuximab (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Tropoelastin synthesis |
Down |
18.5 |
0.4807692 |
0.5434783 |
0.4840547 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN08;MSN09);tofacitinib (MSN01;MSN05;M |
| Tropoelastin synthesis |
Down |
19.5 |
0.4716981 |
0.5434783 |
0.4753915 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN08;MSN09);tofacitinib (MSN01;M |
| Tropoelastin synthesis |
Down |
20.5 |
0.4545455 |
0.5434783 |
0.4589633 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN06);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN08;MSN |
| Tropoelastin synthesis |
Down |
21 |
0.4385965 |
0.5434783 |
0.4436325 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN06);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN |
| Tropoelastin synthesis |
Down |
22 |
0.4482759 |
0.5652174 |
0.4537988 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN |
afatinib (MSN01;MSN05;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN06);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN |
| Tropoelastin synthesis |
Down |
24.5 |
0.440678 |
0.5652174 |
0.4464647 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN |
afatinib (MSN01;MSN05;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN06);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitini |
| Tropoelastin synthesis |
Down |
27.5 |
0.4516129 |
0.6086956 |
0.4585742 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);va |
afatinib (MSN01;MSN05;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN06);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxo |
| Tropoelastin synthesis |
Down |
29.5 |
0.4444444 |
0.6086956 |
0.4516128 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);va |
afatinib (MSN01;MSN05;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN06;MSN09);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08 |
| Tropoelastin synthesis |
Down |
30.5 |
0.453125 |
0.6304348 |
0.4607477 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN |
afatinib (MSN01;MSN05;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN06;MSN09);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08 |
| Tropoelastin synthesis |
Down |
31.5 |
0.4545455 |
0.6521739 |
0.4627949 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN |
afatinib (MSN01;MSN05;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN06;MSN09);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06 |
| Tropoelastin synthesis |
Down |
32 |
0.4477612 |
0.6521739 |
0.4561717 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN06;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN |
afatinib (MSN01;MSN05;MSN08);cabozantinib (MSN05;MSN09);ceritinib (MSN05;MSN06;MSN09);crizotinib (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05 |
| Versican receptor signaling |
Down |
26.5 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
lapatinib (MSN01;MSN06);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN06);cetuximab (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN06);regorafenib (MSN05) |
| Versican receptor signaling |
Up |
28.5 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);ponatinib (MSN09);sorafenib (MSN05;MSN09) |
axitinib (MSN01);cabozantinib (MSN05;MSN06);rituximab (MSN05);vemurafenib (MSN06) |
| Versican receptor signaling |
Down |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01) |
| Versican receptor signaling |
Down |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01);cetuximab (MSN08) |
| Versican receptor signaling |
Down |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01);cetuximab (MSN08);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
20 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01);cetuximab (MSN08);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
21 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
lapatinib (MSN01);trastuzumab (MSN05) |
afatinib (MSN01);cetuximab (MSN08);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
21.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
lapatinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);cetuximab (MSN08);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
22.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
lapatinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);cetuximab (MSN06;MSN08);dasatinib (MSN06);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
23 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
lapatinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);cetuximab (MSN06;MSN08;MSN09);dasatinib (MSN06);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
24.5 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
lapatinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN01;MSN06);cetuximab (MSN06;MSN08;MSN09);dasatinib (MSN06);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
25 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
lapatinib (MSN01;MSN06);trastuzumab (MSN05;MSN09) |
afatinib (MSN01;MSN06);cetuximab (MSN06;MSN08;MSN09);dasatinib (MSN06);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
26 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
lapatinib (MSN01;MSN06);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN06);cetuximab (MSN06;MSN08;MSN09);dasatinib (MSN06);regorafenib (MSN05) |
| Versican receptor signaling |
Up |
25.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);ponatinib (MSN09);sorafenib (MSN09) |
axitinib (MSN01);cabozantinib (MSN05;MSN06);rituximab (MSN05);vemurafenib (MSN06) |
| Versican receptor signaling |
Down |
28.5 |
0.3571429 |
0.1086956 |
0.3148148 |
NaN |
NaN |
lapatinib (MSN01;MSN06);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06);cetuximab (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN06);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
29.5 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
lapatinib (MSN01;MSN06);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08);cetuximab (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN06);regorafenib (MSN05) |
| Versican receptor signaling |
Down |
31.5 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
lapatinib (MSN01;MSN06);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN06);regorafenib (MSN05) |
| Versican synthesis |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Up |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN05);rituximab (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Up |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01);cabozantinib (MSN05);rituximab (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Up |
10.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
dabrafenib (MSN05) |
axitinib (MSN01);cabozantinib (MSN05);rituximab (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Up |
11 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
dabrafenib (MSN05;MSN06) |
axitinib (MSN01);cabozantinib (MSN05);rituximab (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Up |
13.5 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08) |
axitinib (MSN01);cabozantinib (MSN05);rituximab (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Up |
14 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN01);cabozantinib (MSN05;MSN06);rituximab (MSN05);vemurafenib (MSN06) |
| Versican synthesis |
Up |
16 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08;MSN09);ponatinib (MSN09);sorafenib (MSN09) |
axitinib (MSN01);cabozantinib (MSN05;MSN06);rituximab (MSN05);vemurafenib (MSN06) |
| Vasoactive intestinal peptide receptor signaling |
Down |
16.5 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06;MSN08;MSN09);sunitinib (MSN02) |
imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Up |
18 |
0.3636364 |
0.173913 |
0.3417086 |
NaN |
NaN |
lapatinib (MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN06;MSN09);bosutinib (MSN05);cetuximab (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Vasoactive intestinal peptide receptor signaling |
Up |
18.5 |
0.3913043 |
0.1956522 |
0.3695652 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN06;MSN09);bosutinib (MSN05);cetuximab (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Vasoactive intestinal peptide receptor signaling |
Up |
20 |
0.375 |
0.1956522 |
0.355814 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN06;MSN09);bosutinib (MSN05);cetuximab (MSN01;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Vasoactive intestinal peptide receptor signaling |
Up |
20.5 |
0.3461539 |
0.1956522 |
0.3311689 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN06;MSN09);bosutinib (MSN05);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Vasoactive intestinal peptide receptor signaling |
Up |
23.5 |
0.3333333 |
0.1956522 |
0.3200837 |
NaN |
NaN |
lapatinib (MSN01;MSN05;MSN09);sunitinib (MSN08;MSN09);trametinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN06;MSN09);bosutinib (MSN05);ceritinib (MSN01;MSN06);cetuximab (MSN01;MSN05;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08) |
| Vasoactive intestinal peptide receptor signaling |
Down |
6 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Vasoactive intestinal peptide receptor signaling |
Down |
13 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN09) |
nilotinib (MSN06;MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Down |
14 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
dabrafenib (MSN09) |
nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01) |
| Vasoactive intestinal peptide receptor signaling |
Down |
14.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
bevacizumab (MSN08);dabrafenib (MSN09) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01);rituximab (MSN06) |
| Vasoactive intestinal peptide receptor signaling |
Down |
15 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
bevacizumab (MSN08);dabrafenib (MSN09) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Down |
15.5 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);dabrafenib (MSN08;MSN09) |
nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Down |
16 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);dabrafenib (MSN06;MSN08;MSN09) |
imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| Sister chromatid attachment to mitotic spindle |
Up |
5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN02) |
|
| Vasoactive intestinal peptide receptor signaling |
Down |
17 |
0.4444444 |
0.173913 |
0.4071856 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06;MSN08;MSN09);sunitinib (MSN02) |
bosutinib (MSN05);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Down |
18.5 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06;MSN08;MSN09);sunitinib (MSN02) |
bosutinib (MSN05;MSN09);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Down |
19 |
0.4 |
0.173913 |
0.3715847 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06;MSN08;MSN09);sunitinib (MSN02) |
bosutinib (MSN05;MSN09);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| Vasoactive intestinal peptide receptor signaling |
Down |
22.5 |
0.3809524 |
0.173913 |
0.356021 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06;MSN08;MSN09);sunitinib (MSN02) |
bosutinib (MSN05;MSN09);cabozantinib (MSN05);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06);vemurafenib (MSN09) |
| VDJ recombination |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05) |
| VDJ recombination |
Down |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08) |
| Versican receptor signaling |
Up |
12 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN05) |
cabozantinib (MSN05) |
| Versican receptor signaling |
Up |
13 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
dabrafenib (MSN05;MSN06) |
axitinib (MSN01);cabozantinib (MSN05);vemurafenib (MSN06) |
| Versican receptor signaling |
Up |
15.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
dabrafenib (MSN05;MSN06) |
axitinib (MSN01);cabozantinib (MSN05);rituximab (MSN05);vemurafenib (MSN06) |
| Versican receptor signaling |
Up |
16 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08) |
axitinib (MSN01);cabozantinib (MSN05);rituximab (MSN05);vemurafenib (MSN06) |
| Versican receptor signaling |
Up |
21 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);ponatinib (MSN09) |
axitinib (MSN01);cabozantinib (MSN05;MSN06);rituximab (MSN05);vemurafenib (MSN06) |
| Proteasomal regulatory particle organization |
Up |
21.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sunitinib (MSN02) |
regorafenib (MSN01;MSN05;MSN06;MSN08) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
14 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
cetuximab (MSN02) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
15 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
cetuximab (MSN02);regorafenib (MSN08) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
15.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN08) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
17 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN06;MSN08) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
17.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN02;MSN08);imatinib (MSN01);regorafenib (MSN06;MSN08) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
19 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN02;MSN08);imatinib (MSN01);regorafenib (MSN05;MSN06;MSN08) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
19.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
sorafenib (MSN09);vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN02;MSN08);imatinib (MSN01);regorafenib (MSN05;MSN06;MSN08) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
22.5 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
sorafenib (MSN09);vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN02;MSN06;MSN08);imatinib (MSN01);regorafenib (MSN05;MSN06;MSN08) |
| Proteasomal regulatory particle organization |
Up |
5.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN02) |
|
| Proteasomal regulatory particle organization |
Up |
13 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sunitinib (MSN02) |
regorafenib (MSN06) |
| Proteasomal regulatory particle organization |
Up |
13.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sunitinib (MSN02) |
regorafenib (MSN05;MSN06) |
| Proteasomal regulatory particle organization |
Up |
20.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
sunitinib (MSN02) |
regorafenib (MSN05;MSN06;MSN08) |
| Prostaglandin PGF2 alpha receptor signaling |
Down |
11.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN08) |
cetuximab (MSN02) |
| Proteasomal regulatory particle organization |
Down |
11.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN06) |
|
| Proteasomal regulatory particle organization |
Down |
13.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
lapatinib (MSN06) |
axitinib (MSN05) |
| Protein folding in mitochondria |
Up |
5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Protein folding in mitochondria |
Up |
12.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
pazopanib (MSN01;MSN09) |
|
| Protein folding in mitochondria |
Up |
13 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
pazopanib (MSN01;MSN09) |
regorafenib (MSN01) |
| Protein folding in mitochondria |
Up |
13.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
pazopanib (MSN01;MSN09) |
imatinib (MSN06);regorafenib (MSN01) |
| Protein folding in mitochondria |
Up |
15 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN09) |
imatinib (MSN06);regorafenib (MSN01) |
| Protein folding in mitochondria |
Up |
20 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN09) |
imatinib (MSN05;MSN06);regorafenib (MSN01) |
| Protein N-linked glycosylation in ER |
Up |
7 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN06) |
|
| Protein polyubiquitination |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05) |
| Protein polyubiquitination |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05);erlotinib (MSN05) |
| Protein polyubiquitination |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08) |
| Prostaglandin E2 receptor signaling |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN08);rituximab (MSN06) |
| Progesterone receptor signaling |
Down |
13 |
0.625 |
0.2173913 |
0.5629139 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN06);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09);regorafenib (MSN06);rituximab (MSN05);ruxolitinib (MSN02) |
| Progesterone receptor signaling |
Down |
14 |
0.5555556 |
0.2173913 |
0.5089821 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN06);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09);regorafenib (MSN06);rituximab (MSN05);ruxolitinib (MSN02;MSN08;MSN09) |
| Progesterone receptor signaling |
Down |
14.5 |
0.5789474 |
0.2391304 |
0.5342858 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN06);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09);regorafenib (MSN06);rituximab (MSN05);ruxolitinib (MSN02;MSN08;MSN09) |
| Progesterone receptor signaling |
Down |
15.5 |
0.55 |
0.2391304 |
0.5109289 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN06);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09);regorafenib (MSN06);rituximab (MSN05);ruxolitinib (MSN02;MSN06;MSN08;MSN09) |
| Progesterone receptor signaling |
Down |
18 |
0.5238096 |
0.2391304 |
0.4895289 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN06);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);imatinib (MSN05);nilotinib (MSN05;MSN09);regorafenib (MSN06);rituximab (MSN05);ruxolitinib (MSN02;MSN06;MSN08;MSN09) |
| Prolactin receptor signaling |
Down |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08) |
| Proline metabolism |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05) |
| Prostacycline receptor signaling |
Down |
11.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN08) |
|
| Prostacycline receptor signaling |
Down |
14 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
|
| Prostacycline receptor signaling |
Down |
15.5 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
dabrafenib (MSN08);vandetanib (MSN08;MSN09) |
|
| Prostacycline receptor signaling |
Down |
17 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
dabrafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
|
| Prostaglandin E2 receptor signaling |
Down |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN06) |
| Protein polyubiquitination |
Up |
11 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
sunitinib (MSN05) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05) |
| Prostaglandin E2 receptor signaling |
Down |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN08);rituximab (MSN05;MSN06) |
| Prostaglandin E2 receptor signaling |
Down |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN08);rituximab (MSN05;MSN06);vemurafenib (MSN09) |
| Prostaglandin E2 receptor signaling |
Down |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN08);rituximab (MSN05;MSN06);ruxolitinib (MSN05);vemurafenib (MSN09) |
| Prostaglandin PGF2 alpha receptor signaling |
Up |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06) |
| Prostaglandin PGF2 alpha receptor signaling |
Up |
14 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06);tofacitinib (MSN06) |
| Prostaglandin PGF2 alpha receptor signaling |
Up |
15 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sunitinib (MSN08) |
crizotinib (MSN06);tofacitinib (MSN06) |
| Prostaglandin PGF2 alpha receptor signaling |
Up |
15.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
sunitinib (MSN02;MSN08) |
crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN06) |
| Prostaglandin PGF2 alpha receptor signaling |
Up |
16 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
sunitinib (MSN02;MSN06;MSN08) |
crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN06) |
| Prostaglandin PGF2 alpha receptor signaling |
Up |
18.5 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN02;MSN06;MSN08) |
crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN06) |
| Prostaglandin PGF2 alpha receptor signaling |
Up |
19.5 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN02;MSN06;MSN08) |
bosutinib (MSN08);crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN06) |
| Prostaglandin PGF2 alpha receptor signaling |
Up |
24.5 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);sunitinib (MSN02;MSN06;MSN08) |
bosutinib (MSN08);crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN06) |
| Removal of caspase inhibition |
Up |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN01) |
| Pyrimidine synthesis and salvage |
Down |
31 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Pyrimidine synthesis and salvage |
Down |
32 |
0.3333333 |
0.1304348 |
0.3053892 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Recycling endosome dynamics |
Down |
8 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN06) |
|
| Recycling endosome dynamics |
Down |
10 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
pazopanib (MSN06;MSN09) |
|
| Recycling endosome dynamics |
Down |
15 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
pazopanib (MSN06;MSN09) |
ruxolitinib (MSN02) |
| Recycling endosome dynamics |
Down |
19 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
pazopanib (MSN06;MSN09) |
ruxolitinib (MSN02;MSN06) |
| Regulation of coagulation cascade by protein C |
Up |
1.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN08) |
|
| Regulation of coagulation cascade by protein C |
Up |
3 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN08) |
axitinib (MSN06) |
| Regulation of coagulation cascade by protein C |
Up |
4 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
vandetanib (MSN08) |
axitinib (MSN06);vemurafenib (MSN08) |
| Regulation of coagulation cascade by protein C |
Up |
6 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
sunitinib (MSN06);vandetanib (MSN08) |
axitinib (MSN06);vemurafenib (MSN08) |
| Regulation of coagulation cascade by protein C |
Up |
6.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
sunitinib (MSN06);vandetanib (MSN08) |
axitinib (MSN06);cabozantinib (MSN06);vemurafenib (MSN08) |
| Regulation of coagulation cascade by protein C |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06) |
| Pyrimidine synthesis and salvage |
Down |
29 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Removal of caspase inhibition |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01);gefitinib (MSN01) |
| Removal of caspase inhibition |
Up |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN06);gefitinib (MSN01) |
| Removal of caspase inhibition |
Up |
12 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trastuzumab (MSN05) |
crizotinib (MSN01;MSN06);gefitinib (MSN01) |
| Removal of caspase inhibition |
Up |
14 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
crizotinib (MSN01;MSN06);gefitinib (MSN01) |
| Removal of caspase inhibition |
Up |
18 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
trastuzumab (MSN02;MSN05;MSN09) |
crizotinib (MSN01;MSN06);gefitinib (MSN01) |
| Removal of caspase inhibition |
Up |
19.5 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
trastuzumab (MSN02;MSN05;MSN09) |
bosutinib (MSN08);crizotinib (MSN01;MSN06);gefitinib (MSN01) |
| Removal of caspase inhibition |
Up |
21 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN05;MSN09) |
bosutinib (MSN08);crizotinib (MSN01;MSN06);gefitinib (MSN01) |
| Removal of caspase inhibition |
Up |
25.5 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
sorafenib (MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
bosutinib (MSN08);crizotinib (MSN01;MSN06);gefitinib (MSN01) |
| Removal of caspase inhibition |
Up |
28.5 |
0.6 |
0.1304348 |
0.4951456 |
NaN |
NaN |
sorafenib (MSN05;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
bosutinib (MSN08);crizotinib (MSN01;MSN06);gefitinib (MSN01) |
| Removal of caspase inhibition |
Down |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Removal of caspase inhibition |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08;MSN09) |
| Pyrimidine catabolism |
Down |
15.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN08) |
|
| Protein polyubiquitination |
Up |
13 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
sunitinib (MSN05;MSN08) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05) |
| Protein polyubiquitination |
Up |
16 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
sunitinib (MSN05;MSN08;MSN09) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05) |
| Protein polyubiquitination |
Up |
17 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
sunitinib (MSN05;MSN08;MSN09) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05);rituximab (MSN05) |
| Protein polyubiquitination |
Up |
18 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
sunitinib (MSN02;MSN05;MSN08;MSN09) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05);rituximab (MSN05) |
| Protein polyubiquitination |
Up |
19 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
sunitinib (MSN02;MSN05;MSN08;MSN09) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05;MSN08);rituximab (MSN05) |
| Protein polyubiquitination |
Up |
20.5 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
sunitinib (MSN02;MSN05;MSN08;MSN09);trastuzumab (MSN02) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05;MSN08);rituximab (MSN05) |
| Protein polyubiquitination |
Up |
23 |
0.5 |
0.1521739 |
0.4407408 |
NaN |
NaN |
ponatinib (MSN06;MSN09);sunitinib (MSN02;MSN05;MSN08;MSN09);trastuzumab (MSN02) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05;MSN08);rituximab (MSN05) |
| Protein polyubiquitination |
Up |
25 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
ponatinib (MSN06;MSN09);sunitinib (MSN02;MSN05;MSN08;MSN09);trastuzumab (MSN02) |
bosutinib (MSN05);erlotinib (MSN05;MSN09);gefitinib (MSN08);nilotinib (MSN05;MSN08);rituximab (MSN05);ruxolitinib (MSN09) |
| Protein polyubiquitination |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05) |
| Protein polyubiquitination |
Down |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN06) |
| Protein polyubiquitination |
Down |
32 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08);crizotinib (MSN05;MSN06) |
| Purinergic P2Y receptor signaling |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01) |
| Progesterone receptor signaling |
Down |
12.5 |
0.6428571 |
0.1956522 |
0.5666665 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN06);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09);regorafenib (MSN06);rituximab (MSN05) |
| Pyrimidine catabolism |
Down |
16 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN06;MSN08) |
|
| Pyrimidine synthesis and salvage |
Up |
25.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN08) |
| Pyrimidine synthesis and salvage |
Down |
14 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08) |
|
| Pyrimidine synthesis and salvage |
Down |
17 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08) |
ceritinib (MSN06) |
| Pyrimidine synthesis and salvage |
Down |
18 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08) |
ceritinib (MSN06);gefitinib (MSN01) |
| Pyrimidine synthesis and salvage |
Down |
21.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08) |
ceritinib (MSN06);gefitinib (MSN01;MSN06;MSN08) |
| Pyrimidine synthesis and salvage |
Down |
23 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08) |
ceritinib (MSN06);gefitinib (MSN01;MSN06;MSN08) |
| Pyrimidine synthesis and salvage |
Down |
24 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN06;MSN09);gefitinib (MSN01;MSN06;MSN08) |
| Pyrimidine synthesis and salvage |
Down |
24.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN09) |
ceritinib (MSN06;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| Pyrimidine synthesis and salvage |
Down |
27 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN08;MSN09) |
ceritinib (MSN06;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| Pyrimidine synthesis and salvage |
Down |
27.5 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN06;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Perlecan synthesis |
Down |
10 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN05) |
cabozantinib (MSN06) |
| Osteopontin receptor signaling |
Down |
24.5 |
0.3947369 |
0.326087 |
0.3899083 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01;MSN09);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN06);imatinib (MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib ( |
| Osteopontin receptor signaling |
Down |
25 |
0.3846154 |
0.326087 |
0.3805971 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01;MSN09);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN06;MSN08);imatinib (MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08);tofacit |
| Osteopontin receptor signaling |
Down |
27.5 |
0.4047619 |
0.3695652 |
0.402507 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02);trametinib (MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08);t |
| Osteopontin receptor signaling |
Down |
30.5 |
0.4186046 |
0.3913043 |
0.4168937 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02);trametinib (MSN08;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08);t |
| Osteopontin receptor signaling |
Down |
31.5 |
0.4130435 |
0.4130435 |
0.4130435 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02);trametinib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN09);nilotin |
| Osteopontin receptor signaling |
Down |
32 |
0.4042553 |
0.4130435 |
0.4047619 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02);trametinib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);ceritinib (MSN05);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MS |
| Osteopontin receptor signaling |
Down |
33 |
0.3958333 |
0.4130435 |
0.3968059 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN05;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02);trametinib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);ceritinib (MSN05);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatin |
| Perlecan synthesis |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01) |
| Perlecan synthesis |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01);rituximab (MSN09) |
| Perlecan synthesis |
Up |
14 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN09) |
dasatinib (MSN01);rituximab (MSN09) |
| Perlecan synthesis |
Up |
15 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN09) |
dasatinib (MSN01);rituximab (MSN08;MSN09) |
| Perlecan synthesis |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06) |
| Osteopontin receptor signaling |
Down |
21 |
0.4166667 |
0.326087 |
0.4099679 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);gefitinib (MSN01);imatinib (MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Perlecan synthesis |
Down |
14.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
vandetanib (MSN05) |
cabozantinib (MSN06;MSN09) |
| Perlecan synthesis |
Down |
17.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
lapatinib (MSN06);vandetanib (MSN05) |
cabozantinib (MSN06;MSN09) |
| Peroxisome proliferator-activated receptor alpha signaling |
Up |
10.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN09) |
|
| Peroxisome proliferator-activated receptor alpha signaling |
Up |
12 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
pazopanib (MSN05;MSN09) |
|
| Peroxisome proliferator-activated receptor alpha signaling |
Up |
15.5 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
pazopanib (MSN05;MSN08;MSN09) |
|
| Phosphoglyceride biosynthesis |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN09) |
| Phosphoglyceride biosynthesis |
Down |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08) |
| PI3 kinase AKT signaling pathway |
Down |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN08) |
| Platelet-derived growth factor receptor signaling |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06;MSN08) |
| Platelet-derived growth factor receptor signaling |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06;MSN08);ceritinib (MSN06) |
| Platelet-derived growth factor receptor signaling |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06;MSN08);ceritinib (MSN01;MSN06) |
| Osteopontin receptor signaling |
Down |
11 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02) |
afatinib (MSN01);dasatinib (MSN08);imatinib (MSN09);nilotinib (MSN05;MSN06);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Up |
16.5 |
0.2758621 |
0.173913 |
0.2666667 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);ceritinib (MSN01;MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);rituximab (MSN05);ruxolitinib (MSN05;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Osteopontin receptor signaling |
Up |
18 |
0.2666667 |
0.173913 |
0.2585552 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);ceritinib (MSN01;MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);regorafenib (MSN06);rituximab (MSN05);ruxolitinib (MSN05;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MSN05;MS |
| Osteopontin receptor signaling |
Up |
19 |
0.2580645 |
0.173913 |
0.2509225 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);ceritinib (MSN01;MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);regorafenib (MSN05;MSN06);rituximab (MSN05);ruxolitinib (MSN05;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MS |
| Osteopontin receptor signaling |
Up |
21 |
0.25 |
0.173913 |
0.2437276 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);ceritinib (MSN01;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);regorafenib (MSN05;MSN06);rituximab (MSN05);ruxolitinib (MSN05;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MS |
| Osteopontin receptor signaling |
Up |
21.5 |
0.2424242 |
0.173913 |
0.2369338 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN01;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);regorafenib (MSN05;MSN06);rituximab (MSN05);ruxolitinib (MSN05;MSN08;MSN09);tofacitinib (M |
| Osteopontin receptor signaling |
Up |
25 |
0.2352941 |
0.173913 |
0.2305085 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN01;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);regorafenib (MSN05;MSN06;MSN08);rituximab (MSN05);ruxolitinib (MSN05;MSN08;MSN09);tofaciti |
| Osteopontin receptor signaling |
Up |
26.5 |
0.2285714 |
0.173913 |
0.2244224 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN09);bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN01;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05);ruxolitinib (MSN05;MSN08;MSN09);to |
| Osteopontin receptor signaling |
Down |
8 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sorafenib (MSN08) |
nilotinib (MSN05) |
| Osteopontin receptor signaling |
Down |
8.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN08) |
nilotinib (MSN05) |
| Osteopontin receptor signaling |
Down |
9 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02) |
nilotinib (MSN05) |
| Osteopontin receptor signaling |
Down |
10 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
bevacizumab (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02) |
afatinib (MSN01);nilotinib (MSN05;MSN06) |
| Osteopontin receptor signaling |
Down |
10.5 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
bevacizumab (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02) |
afatinib (MSN01);imatinib (MSN09);nilotinib (MSN05;MSN06) |
| Platelet-derived growth factor receptor signaling |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06;MSN08);ceritinib (MSN01;MSN06);tofacitinib (MSN09) |
| Osteopontin receptor signaling |
Down |
11.5 |
0.5 |
0.1521739 |
0.4407408 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02) |
afatinib (MSN01);dasatinib (MSN08);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
12 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02) |
afatinib (MSN01);axitinib (MSN01);cetuximab (MSN08);dasatinib (MSN08);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
12.5 |
0.5 |
0.2173913 |
0.4644809 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN08);cetuximab (MSN08);dasatinib (MSN08);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
14 |
0.5238096 |
0.2391304 |
0.4895289 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN08);cetuximab (MSN08);dasatinib (MSN08);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
14.5 |
0.5217391 |
0.2608696 |
0.4927537 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN08);cetuximab (MSN08);dasatinib (MSN08;MSN09);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
15.5 |
0.4444444 |
0.2608696 |
0.4267782 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN08);cetuximab (MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN06;MSN08;MSN09);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
16.5 |
0.4285714 |
0.2608696 |
0.4129555 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN02;MSN08);cetuximab (MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN06;MSN08;MSN09);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
17.5 |
0.4137931 |
0.2608696 |
0.4 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN02;MSN08);cetuximab (MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
18 |
0.4 |
0.2608696 |
0.3878327 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN02;MSN08);cetuximab (MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
18.5 |
0.4242424 |
0.3043478 |
0.4146341 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN08);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN02;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Osteopontin receptor signaling |
Down |
19 |
0.4117647 |
0.3043478 |
0.4033898 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN05);lapatinib (MSN01;MSN08);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN01;MSN02) |
afatinib (MSN01);axitinib (MSN01;MSN08);cabozantinib (MSN02;MSN08);cetuximab (MSN01;MSN05;MSN08);crizotinib (MSN08);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08);tofacitinib (MSN05) |
| Progesterone receptor signaling |
Up |
12.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
vandetanib (MSN09) |
afatinib (MSN06);axitinib (MSN08);cabozantinib (MSN08);cetuximab (MSN01;MSN09);gefitinib (MSN05);vemurafenib (MSN08) |
| Potassium transmembrane transport |
Down |
14 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
ponatinib (MSN02) |
cabozantinib (MSN06);cetuximab (MSN06;MSN09);nilotinib (MSN08;MSN09);rituximab (MSN05);ruxolitinib (MSN06) |
| Potassium transmembrane transport |
Down |
16 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
ponatinib (MSN02) |
cabozantinib (MSN06);cetuximab (MSN06;MSN09);nilotinib (MSN08;MSN09);rituximab (MSN05);ruxolitinib (MSN06;MSN08) |
| Procollagen cleavage into collagen |
Up |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06) |
| Procollagen cleavage into collagen |
Down |
16 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN05) |
|
| Procollagen processing in the ER |
Up |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08) |
| Procollagen processing in the ER |
Down |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02) |
| Progesterone receptor signaling |
Up |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN05) |
| Progesterone receptor signaling |
Up |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN08);gefitinib (MSN05) |
| Progesterone receptor signaling |
Up |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN08);gefitinib (MSN05);vemurafenib (MSN08) |
| Progesterone receptor signaling |
Up |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);cabozantinib (MSN08);gefitinib (MSN05);vemurafenib (MSN08) |
| Progesterone receptor signaling |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);axitinib (MSN08);cabozantinib (MSN08);cetuximab (MSN01);gefitinib (MSN05);vemurafenib (MSN08) |
| Progesterone receptor signaling |
Up |
11.5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
vandetanib (MSN09) |
afatinib (MSN06);axitinib (MSN08);cabozantinib (MSN08);cetuximab (MSN01);gefitinib (MSN05);vemurafenib (MSN08) |
| Potassium transmembrane transport |
Down |
13 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
ponatinib (MSN02) |
cabozantinib (MSN06);cetuximab (MSN06;MSN09);nilotinib (MSN08;MSN09);rituximab (MSN05) |
| Progesterone receptor signaling |
Up |
14 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
vandetanib (MSN09) |
afatinib (MSN06);axitinib (MSN08);cabozantinib (MSN08);cetuximab (MSN01;MSN06;MSN09);gefitinib (MSN05);vemurafenib (MSN08) |
| Progesterone receptor signaling |
Up |
15 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
vandetanib (MSN09) |
afatinib (MSN06);axitinib (MSN08);cabozantinib (MSN08);cetuximab (MSN01;MSN06;MSN09);gefitinib (MSN05);rituximab (MSN08);vemurafenib (MSN08) |
| Progesterone receptor signaling |
Up |
16.5 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
vandetanib (MSN09) |
afatinib (MSN06);axitinib (MSN08);cabozantinib (MSN08);ceritinib (MSN01);cetuximab (MSN01;MSN06;MSN09);gefitinib (MSN05);rituximab (MSN08);vemurafenib (MSN08) |
| Progesterone receptor signaling |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01) |
| Progesterone receptor signaling |
Down |
7.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
pazopanib (MSN09) |
cabozantinib (MSN01) |
| Progesterone receptor signaling |
Down |
8 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
pazopanib (MSN09) |
cabozantinib (MSN01);nilotinib (MSN05) |
| Progesterone receptor signaling |
Down |
9 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
pazopanib (MSN09);sorafenib (MSN01);sunitinib (MSN02) |
cabozantinib (MSN01);nilotinib (MSN05) |
| Progesterone receptor signaling |
Down |
10 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
bevacizumab (MSN08);pazopanib (MSN09);sorafenib (MSN01);sunitinib (MSN02) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09) |
| Progesterone receptor signaling |
Down |
10.5 |
0.6666667 |
0.1304348 |
0.5368421 |
NaN |
NaN |
bevacizumab (MSN08);pazopanib (MSN09);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09) |
| Progesterone receptor signaling |
Down |
11 |
0.6666667 |
0.173913 |
0.5714285 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);pazopanib (MSN09);ponatinib (MSN06);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09);rituximab (MSN05) |
| Progesterone receptor signaling |
Down |
12 |
0.6923077 |
0.1956522 |
0.6023622 |
NaN |
NaN |
bevacizumab (MSN05;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN06);sorafenib (MSN01);sunitinib (MSN02;MSN05;MSN08) |
cabozantinib (MSN01);nilotinib (MSN05;MSN09);rituximab (MSN05) |
| Platelet-derived growth factor receptor signaling |
Up |
26 |
0.3333333 |
0.173913 |
0.3162791 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN02);dasatinib (MSN06);nilotinib (MSN05);regorafenib (MSN06;MSN08);rituximab (MSN06;MSN08;MSN09);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06);dasatinib (MSN06);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);dasatinib (MSN06);regorafenib (MSN08);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
12 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
bevacizumab (MSN06) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);dasatinib (MSN06);regorafenib (MSN08);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
13 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
bevacizumab (MSN05;MSN06) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);dasatinib (MSN06);regorafenib (MSN08);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
14 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);sorafenib (MSN08) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);dasatinib (MSN06);regorafenib (MSN08);rituximab (MSN09);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
15.5 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN08) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);dasatinib (MSN06);regorafenib (MSN08);rituximab (MSN09);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
16.5 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN08) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN02);dasatinib (MSN06);regorafenib (MSN08);rituximab (MSN09);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
17 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN01;MSN08) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN02);dasatinib (MSN06);regorafenib (MSN08);rituximab (MSN06;MSN08;MSN09);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
18.5 |
0.3333333 |
0.1521739 |
0.3115183 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN01;MSN08;MSN09) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN02);dasatinib (MSN06);regorafenib (MSN08);rituximab (MSN06;MSN08;MSN09);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
20 |
0.3181818 |
0.1521739 |
0.298995 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN01;MSN08;MSN09) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN02);dasatinib (MSN06);regorafenib (MSN06;MSN08);rituximab (MSN06;MSN08;MSN09);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
20.5 |
0.3478261 |
0.173913 |
0.3285024 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN02);dasatinib (MSN06);regorafenib (MSN06;MSN08);rituximab (MSN06;MSN08;MSN09);tofacitinib (MSN09) |
| Removal of caspase inhibition |
Down |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN08);rituximab (MSN06;MSN08;MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
27 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN02);dasatinib (MSN06);imatinib (MSN06);nilotinib (MSN05);regorafenib (MSN06;MSN08);rituximab (MSN06;MSN08;MSN09);tofacitinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Up |
31 |
0.3076923 |
0.173913 |
0.2943723 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN02);dasatinib (MSN06);imatinib (MSN06);nilotinib (MSN05);regorafenib (MSN01;MSN06;MSN08);rituximab (MSN06;MSN08;MSN09);tofacitinib (MSN09) |
| Polyol pathway |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN06) |
| Polyol pathway |
Up |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN05;MSN06) |
| Polyol pathway |
Up |
13.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN05;MSN06;MSN08) |
| Potassium transmembrane transport |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06) |
| Potassium transmembrane transport |
Down |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06);nilotinib (MSN09) |
| Potassium transmembrane transport |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06);nilotinib (MSN09);rituximab (MSN05) |
| Potassium transmembrane transport |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06);nilotinib (MSN08;MSN09);rituximab (MSN05) |
| Potassium transmembrane transport |
Down |
11 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
ponatinib (MSN02) |
cabozantinib (MSN06);nilotinib (MSN08;MSN09);rituximab (MSN05) |
| Potassium transmembrane transport |
Down |
12 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
ponatinib (MSN02) |
cabozantinib (MSN06);cetuximab (MSN06);nilotinib (MSN08;MSN09);rituximab (MSN05) |
| Serine and glycine metabolism |
Down |
12 |
0.1621622 |
0.1304348 |
0.1598746 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN09) |
afatinib (MSN05;MSN06;MSN09);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01 |
| Serine and glycine metabolism |
Down |
3.5 |
0.1428571 |
0.06521739 |
0.1335078 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN09) |
axitinib (MSN06);cetuximab (MSN02);dasatinib (MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN09) |
| Serine and glycine metabolism |
Down |
4 |
0.1304348 |
0.06521739 |
0.1231884 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN09) |
axitinib (MSN06);cetuximab (MSN01;MSN02;MSN09);dasatinib (MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN09) |
| Serine and glycine metabolism |
Down |
4.5 |
0.125 |
0.06521739 |
0.1186047 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN09) |
axitinib (MSN06);cetuximab (MSN01;MSN02;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN09) |
| Serine and glycine metabolism |
Down |
5 |
0.12 |
0.06521739 |
0.1143498 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN09) |
axitinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN09) |
| Serine and glycine metabolism |
Down |
6 |
0.1111111 |
0.06521739 |
0.1066946 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN09) |
afatinib (MSN06);axitinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN09) |
| Serine and glycine metabolism |
Down |
6.5 |
0.1071429 |
0.06521739 |
0.1032389 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN06;MSN08);cetuximab (MSN01;MSN02;MSN06;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06; |
| Serine and glycine metabolism |
Down |
7 |
0.1333333 |
0.08695652 |
0.1292775 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN02;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN06;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09 |
| Serine and glycine metabolism |
Down |
8 |
0.1290323 |
0.08695652 |
0.1254613 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN02;MSN09) |
afatinib (MSN06);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08 |
| Serine and glycine metabolism |
Down |
9 |
0.125 |
0.08695652 |
0.1218638 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN02;MSN09) |
afatinib (MSN05;MSN06);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06 |
| Serine and glycine metabolism |
Down |
10 |
0.1212121 |
0.08695652 |
0.1184669 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN02;MSN09) |
afatinib (MSN05;MSN06);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05 |
| Serine and glycine metabolism |
Down |
10.5 |
0.1470588 |
0.1086956 |
0.1440678 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN01;MSN02;MSN09) |
afatinib (MSN05;MSN06);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05 |
| Serine and glycine metabolism |
Down |
11 |
0.1388889 |
0.1086956 |
0.136656 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);trastuzumab (MSN01;MSN02;MSN09) |
afatinib (MSN05;MSN06;MSN09);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01 |
| Serine and glycine metabolism |
Down |
3 |
0.1052632 |
0.04347826 |
0.0971429 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05) |
axitinib (MSN06);dasatinib (MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN08);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN09) |
| Serine and glycine metabolism |
Down |
13.5 |
0.1578947 |
0.1304348 |
0.1559633 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN09) |
afatinib (MSN05;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN09);ruxolitinib |
| Serine and glycine metabolism |
Down |
14 |
0.1794872 |
0.1521739 |
0.1776119 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN09);ruxolitinib |
| Serine and glycine metabolism |
Down |
15 |
0.175 |
0.1521739 |
0.1734694 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN09);ruxolitinib |
| Serine and glycine metabolism |
Down |
17.5 |
0.1707317 |
0.1521739 |
0.1695157 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN09);ruxoli |
| Serine and glycine metabolism |
Down |
24.5 |
0.1666667 |
0.1521739 |
0.1657382 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08);cabozantinib (MSN05);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab ( |
| Serine and glycine metabolism |
Down |
33.5 |
0.1627907 |
0.1521739 |
0.1621253 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08);cabozantinib (MSN05);ceritinib (MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06; |
| Serine and glycine metabolism |
Down |
36 |
0.1818182 |
0.173913 |
0.1813334 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trametinib (MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08);cabozantinib (MSN05);ceritinib (MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06; |
| Serine and glycine metabolism |
Down |
37 |
0.2 |
0.1956522 |
0.1997389 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05);sunitinib (MSN08);trametinib (MSN05;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08);cabozantinib (MSN05);ceritinib (MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN01;MSN06);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06; |
| Serotonin and melatonin synthesis |
Up |
12.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN08) |
|
| Serotonin and melatonin synthesis |
Up |
17 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN08) |
crizotinib (MSN06) |
| Serotonin and melatonin synthesis |
Down |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN05) |
| Serotonin inactivation |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05) |
| Semaphorin signaling |
Up |
29 |
0.5 |
0.1956522 |
0.4580838 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN09);ponatinib (MSN05);sorafenib (MSN09);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN08) |
| Selectin-mediated Leukocyte rolling |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN09);ruxolitinib (MSN06) |
| Selectin-mediated Leukocyte rolling |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN09) |
| Semaphorin signaling |
Up |
2 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN05) |
gefitinib (MSN05;MSN09) |
| Semaphorin signaling |
Up |
3 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
ponatinib (MSN05);trametinib (MSN05) |
gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Semaphorin signaling |
Up |
6 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
dabrafenib (MSN08);ponatinib (MSN05);trametinib (MSN05;MSN09) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Semaphorin signaling |
Up |
7 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
dabrafenib (MSN08);ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Semaphorin signaling |
Up |
8 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
dabrafenib (MSN08);ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);rituximab (MSN06) |
| Semaphorin signaling |
Up |
9 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN09);ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);rituximab (MSN06) |
| Semaphorin signaling |
Up |
14 |
0.5 |
0.1521739 |
0.4407408 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN09);ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN05) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);rituximab (MSN06);ruxolitinib (MSN08) |
| Semaphorin signaling |
Up |
16 |
0.5333334 |
0.173913 |
0.4755246 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN09);ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);rituximab (MSN06);ruxolitinib (MSN08) |
| Semaphorin signaling |
Up |
16.5 |
0.5 |
0.173913 |
0.4503311 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN09);ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);rituximab (MSN06;MSN09);ruxolitinib (MSN08) |
| Semaphorin signaling |
Up |
22 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN09);ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);rituximab (MSN06;MSN08;MSN09);ruxolitinib (MSN08) |
| Serotonin inactivation |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05);dasatinib (MSN01) |
| Semaphorin signaling |
Down |
2 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
pazopanib (MSN06) |
bosutinib (MSN01) |
| Semaphorin signaling |
Down |
4 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
pazopanib (MSN06) |
bosutinib (MSN01);dasatinib (MSN05;MSN09) |
| Semaphorin signaling |
Down |
6 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
pazopanib (MSN06) |
bosutinib (MSN01;MSN08;MSN09);dasatinib (MSN05;MSN06;MSN09);imatinib (MSN06) |
| Semaphorin signaling |
Down |
9 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
pazopanib (MSN06;MSN08) |
bosutinib (MSN01;MSN08;MSN09);dasatinib (MSN05;MSN06;MSN09);imatinib (MSN06) |
| Semaphorin signaling |
Down |
10 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
pazopanib (MSN06;MSN08) |
bosutinib (MSN01;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN09);imatinib (MSN06) |
| Semaphorin signaling |
Down |
12 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
pazopanib (MSN06;MSN08) |
bosutinib (MSN01;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN06) |
| Semaphorin signaling |
Down |
15 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN09) |
bosutinib (MSN01;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN06) |
| Semaphorin signaling |
Down |
17 |
0.3076923 |
0.08695652 |
0.2677165 |
NaN |
NaN |
lapatinib (MSN01);pazopanib (MSN06;MSN08);sunitinib (MSN09) |
bosutinib (MSN01;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN06) |
| Semaphorin signaling |
Down |
20 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
lapatinib (MSN01);pazopanib (MSN06;MSN08);sunitinib (MSN09) |
bosutinib (MSN01;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN06);vemurafenib (MSN08) |
| Serine and glycine metabolism |
Down |
1 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05) |
imatinib (MSN01;MSN06);regorafenib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN09) |
| Serine and glycine metabolism |
Down |
2 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN05) |
imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05);rituximab (MSN06;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06);tofacitinib (MSN06;MSN09) |
| Serotonin inactivation |
Down |
16.5 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN08);sunitinib (MSN02;MSN05;MSN06);trastuzumab (MSN01) |
cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN01;MSN09) |
| Serotonin inactivation |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN01;MSN05;MSN06;MSN09) |
| Serotonin inactivation |
Down |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
7 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trastuzumab (MSN01) |
cabozantinib (MSN01);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
11.5 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
sunitinib (MSN06);trastuzumab (MSN01) |
cabozantinib (MSN01);cetuximab (MSN02);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
13.5 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN06);trastuzumab (MSN01) |
cabozantinib (MSN01);cetuximab (MSN02);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
14 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN06);trastuzumab (MSN01) |
cabozantinib (MSN01);cetuximab (MSN02);regorafenib (MSN01);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
14.5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN06);trastuzumab (MSN01) |
cabozantinib (MSN01);cetuximab (MSN02);regorafenib (MSN01);rituximab (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
15 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN05;MSN06);trastuzumab (MSN01) |
cabozantinib (MSN01);cetuximab (MSN02);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
15.5 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
sorafenib (MSN08);sunitinib (MSN05;MSN06);trastuzumab (MSN01) |
cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
16 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN08);sunitinib (MSN05;MSN06);trastuzumab (MSN01) |
cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN08);rituximab (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
30.5 |
0.4210526 |
0.3478261 |
0.4159021 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN05;MSN08);pazopanib (MSN05;MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02;MSN06);ceritinib (MSN05;MSN06);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);nilotinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
17 |
0.3636364 |
0.173913 |
0.3417086 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN08);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05);cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN06;MSN08);rituximab (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
18.5 |
0.3478261 |
0.173913 |
0.3285024 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN08);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN06;MSN08);rituximab (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
19 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN08);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
19.5 |
0.3703704 |
0.2173913 |
0.3556485 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
20 |
0.3928571 |
0.2391304 |
0.3785425 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
21 |
0.3793103 |
0.2391304 |
0.3666666 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);ruxolitinib (MSN02);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
22.5 |
0.3666667 |
0.2391304 |
0.3555134 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02;MSN06);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);ruxolitinib (MSN02);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
23 |
0.3548387 |
0.2391304 |
0.3450184 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN01);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02;MSN06;MSN09);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);ruxolitinib (MSN02);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
25 |
0.375 |
0.2608696 |
0.3655914 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN01;MSN06);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02;MSN06;MSN09);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);ruxolitinib (MSN02);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
28.5 |
0.3636364 |
0.2608696 |
0.3554007 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN01;MSN06);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02;MSN06;MSN09);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);ruxolitinib (MSN02);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Down |
29.5 |
0.3529412 |
0.2608696 |
0.3457627 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN01;MSN06);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN08);bosutinib (MSN05;MSN09);cabozantinib (MSN01);cetuximab (MSN02;MSN06;MSN09);imatinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);ruxolitinib (MSN02);tofacitinib (MSN05);vemurafenib (MSN01;MSN05;MSN06;MSN08; |
| Serotonin inactivation |
Up |
15.5 |
0.2272727 |
0.1086956 |
0.2135678 |
NaN |
NaN |
lapatinib (MSN05;MSN08);pazopanib (MSN05);sunitinib (MSN01;MSN02) |
afatinib (MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05);dasatinib (MSN01;MSN05) |
| Serotonin inactivation |
Up |
10 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
lapatinib (MSN08) |
ceritinib (MSN05);crizotinib (MSN05);dasatinib (MSN01;MSN05) |
| Serotonin inactivation |
Up |
10.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
lapatinib (MSN08) |
ceritinib (MSN05);crizotinib (MSN05);dasatinib (MSN01;MSN05);erlotinib (MSN09) |
| Serotonin inactivation |
Up |
11 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
lapatinib (MSN08) |
ceritinib (MSN05);crizotinib (MSN05);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01) |
| Serotonin inactivation |
Up |
11.5 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
lapatinib (MSN08) |
ceritinib (MSN05);crizotinib (MSN05;MSN08);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN09) |
| Serotonin inactivation |
Up |
12 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05) |
cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN09) |
| Serotonin inactivation |
Up |
12.5 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05) |
afatinib (MSN09);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN09) |
| Serotonin inactivation |
Up |
13 |
0.125 |
0.04347826 |
0.1125828 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05) |
afatinib (MSN09);axitinib (MSN01);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN08;MSN09) |
| Serotonin inactivation |
Up |
13.5 |
0.1764706 |
0.06521739 |
0.1603774 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05);sunitinib (MSN01) |
afatinib (MSN09);axitinib (MSN01);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN08;MSN09) |
| Serotonin inactivation |
Up |
14 |
0.1578947 |
0.06521739 |
0.1457143 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05);sunitinib (MSN01) |
afatinib (MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
14.5 |
0.15 |
0.06521739 |
0.1393443 |
NaN |
NaN |
lapatinib (MSN08);pazopanib (MSN05);sunitinib (MSN01) |
afatinib (MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
15 |
0.1904762 |
0.08695652 |
0.1780105 |
NaN |
NaN |
lapatinib (MSN05;MSN08);pazopanib (MSN05);sunitinib (MSN01) |
afatinib (MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Selectin-mediated Leukocyte rolling |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN06) |
| Serotonin inactivation |
Up |
16 |
0.24 |
0.1304348 |
0.2286996 |
NaN |
NaN |
lapatinib (MSN05;MSN08);pazopanib (MSN05);sunitinib (MSN01;MSN02;MSN06) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
17 |
0.2692308 |
0.1521739 |
0.2575758 |
NaN |
NaN |
lapatinib (MSN05;MSN08);pazopanib (MSN05);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN08) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
17.5 |
0.2962963 |
0.173913 |
0.2845188 |
NaN |
NaN |
lapatinib (MSN05;MSN08);pazopanib (MSN05);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
18 |
0.3214286 |
0.1956522 |
0.3097166 |
NaN |
NaN |
lapatinib (MSN05;MSN08);pazopanib (MSN05);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
18.5 |
0.3448276 |
0.2173913 |
0.3333333 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN05;MSN08);pazopanib (MSN05);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
19.5 |
0.40625 |
0.2826087 |
0.3960573 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN05;MSN08);pazopanib (MSN05;MSN06);ponatinib (MSN02);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
20.5 |
0.3939394 |
0.2826087 |
0.3850174 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN05;MSN08);pazopanib (MSN05;MSN06);ponatinib (MSN02);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02);ceritinib (MSN05;MSN06);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
21 |
0.3823529 |
0.2826087 |
0.3745762 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN05;MSN08);pazopanib (MSN05;MSN06);ponatinib (MSN02);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02;MSN06);ceritinib (MSN05;MSN06);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
24 |
0.4 |
0.3043478 |
0.3927393 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN05;MSN08);pazopanib (MSN05;MSN06);ponatinib (MSN02;MSN06);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02;MSN06);ceritinib (MSN05;MSN06);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
26 |
0.4166667 |
0.326087 |
0.4099679 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN05;MSN08);pazopanib (MSN05;MSN06);ponatinib (MSN01;MSN02;MSN06);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02;MSN06);ceritinib (MSN05;MSN06);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Serotonin inactivation |
Up |
27.5 |
0.4324324 |
0.3478261 |
0.4263323 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN05;MSN08);pazopanib (MSN05;MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN01;MSN06);cabozantinib (MSN02;MSN06);ceritinib (MSN05;MSN06);crizotinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN09);imatinib (MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Retinol metabolism |
Up |
9 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
trastuzumab (MSN05) |
afatinib (MSN01);cabozantinib (MSN05);crizotinib (MSN05;MSN08;MSN09);rituximab (MSN08);ruxolitinib (MSN08);tofacitinib (MSN08) |
| Retinoic acid receptor signaling |
Down |
12 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN09) |
cabozantinib (MSN06) |
| Retinoic acid receptor signaling |
Down |
12.5 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN09);sorafenib (MSN01) |
cabozantinib (MSN06) |
| Retinoic acid receptor signaling |
Down |
16.5 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN09);sorafenib (MSN01) |
cabozantinib (MSN06);ruxolitinib (MSN02) |
| Retinoic acid receptor signaling |
Down |
17.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN09);sorafenib (MSN01) |
cabozantinib (MSN06);ruxolitinib (MSN02;MSN09) |
| Retinoic acid receptor signaling |
Down |
20 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN09);sorafenib (MSN01) |
cabozantinib (MSN06);ruxolitinib (MSN02;MSN06;MSN09) |
| Retinoic acid receptor signaling |
Down |
20.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN09);sorafenib (MSN01) |
cabozantinib (MSN06);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| Retinol metabolism |
Up |
1 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trastuzumab (MSN05) |
cabozantinib (MSN05) |
| Retinol metabolism |
Up |
2 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trastuzumab (MSN05) |
cabozantinib (MSN05);crizotinib (MSN05;MSN08) |
| Retinol metabolism |
Up |
4 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trastuzumab (MSN05) |
cabozantinib (MSN05);crizotinib (MSN05;MSN08);ruxolitinib (MSN08) |
| Retinol metabolism |
Up |
5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trastuzumab (MSN05) |
afatinib (MSN01);cabozantinib (MSN05);crizotinib (MSN05;MSN08);ruxolitinib (MSN08) |
| Retinol metabolism |
Up |
6 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trastuzumab (MSN05) |
afatinib (MSN01);cabozantinib (MSN05);crizotinib (MSN05;MSN08);rituximab (MSN08);ruxolitinib (MSN08) |
| Retinol metabolism |
Up |
7 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trastuzumab (MSN05) |
afatinib (MSN01);cabozantinib (MSN05);crizotinib (MSN05;MSN08;MSN09);rituximab (MSN08);ruxolitinib (MSN08) |
| Retinoic acid receptor signaling |
Down |
11 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN09) |
|
| Retinol metabolism |
Up |
9.5 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
trastuzumab (MSN05) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);rituximab (MSN08);ruxolitinib (MSN08);tofacitinib (MSN08) |
| Retinol metabolism |
Up |
10 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
trastuzumab (MSN05) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);rituximab (MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN08) |
| Retinol metabolism |
Up |
11 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);rituximab (MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
11.5 |
0.1333333 |
0.04347826 |
0.1188811 |
NaN |
NaN |
trastuzumab (MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
12 |
0.1666667 |
0.06521739 |
0.1526946 |
NaN |
NaN |
sunitinib (MSN08);trastuzumab (MSN05;MSN09) |
afatinib (MSN01;MSN06);axitinib (MSN09);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
13 |
0.2105263 |
0.08695652 |
0.1942857 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN08);trastuzumab (MSN05;MSN09) |
afatinib (MSN01;MSN06);axitinib (MSN09);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
13.5 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN09);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
14 |
0.2857143 |
0.1304348 |
0.2670157 |
NaN |
NaN |
bevacizumab (MSN06);pazopanib (MSN08);sunitinib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN09);cabozantinib (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
14.5 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
bevacizumab (MSN06);pazopanib (MSN08);sunitinib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN09);cabozantinib (MSN05;MSN09);cetuximab (MSN05);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
15 |
0.3333333 |
0.173913 |
0.3162791 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);pazopanib (MSN08);sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN09);cabozantinib (MSN05;MSN09);cetuximab (MSN05);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
15.5 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN08);sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN09);cabozantinib (MSN05;MSN09);cetuximab (MSN05);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
16 |
0.3333333 |
0.1956522 |
0.3200837 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN08);sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN08;MSN09);cabozantinib (MSN05;MSN09);cetuximab (MSN05;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Restriction point |
Down |
9 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
dabrafenib (MSN01) |
axitinib (MSN09);dasatinib (MSN01;MSN05;MSN09);imatinib (MSN09) |
| Removal of caspase inhibition |
Down |
15.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Removal of caspase inhibition |
Down |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Removal of caspase inhibition |
Down |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01);imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Removal of caspase inhibition |
Down |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01);cetuximab (MSN08);imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Removal of caspase inhibition |
Down |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01);cetuximab (MSN08);imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Removal of caspase inhibition |
Down |
20 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01);cetuximab (MSN08);imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Removal of caspase inhibition |
Down |
22.5 |
0.07142857 |
0.02173913 |
0.06296296 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01);cabozantinib (MSN05);cetuximab (MSN06;MSN08);dasatinib (MSN06);imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Removal of caspase inhibition |
Down |
23 |
0.0625 |
0.02173913 |
0.05629139 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01);cabozantinib (MSN05);cetuximab (MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Removal of caspase inhibition |
Down |
26.5 |
0.05882353 |
0.02173913 |
0.05345912 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01);cabozantinib (MSN05);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Removal of caspase inhibition |
Down |
31.5 |
0.05555556 |
0.02173913 |
0.05089821 |
NaN |
NaN |
lapatinib (MSN01) |
afatinib (MSN01;MSN09);cabozantinib (MSN05);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);imatinib (MSN01;MSN09);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Restriction point |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09) |
| Restriction point |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);dasatinib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Up |
16.5 |
0.3214286 |
0.1956522 |
0.3097166 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN08);sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN08;MSN09);cabozantinib (MSN05;MSN09);cetuximab (MSN05;MSN08;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Restriction point |
Down |
10 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
dabrafenib (MSN01) |
axitinib (MSN09);bosutinib (MSN05);dasatinib (MSN01;MSN05;MSN09);imatinib (MSN09) |
| Restriction point |
Down |
10.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
dabrafenib (MSN01) |
axitinib (MSN01;MSN09);bosutinib (MSN05);dasatinib (MSN01;MSN05;MSN09);imatinib (MSN09) |
| Restriction point |
Down |
11.5 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
dabrafenib (MSN01) |
axitinib (MSN01;MSN09);bosutinib (MSN05);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09) |
| Restriction point |
Down |
12 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
dabrafenib (MSN01) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09) |
| Restriction point |
Down |
13 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
dabrafenib (MSN01) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN05;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09) |
| Restriction point |
Down |
14 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
dabrafenib (MSN01) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN05;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09);vemurafenib (MSN01) |
| Restriction point |
Down |
33.5 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
dabrafenib (MSN01);trametinib (MSN09) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN05;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09);vemurafenib (MSN01) |
| Restriction point |
Down |
34.5 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
dabrafenib (MSN01);trametinib (MSN09) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN05;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN09);vemurafenib (MSN01) |
| Restriction point |
Down |
36 |
0.1333333 |
0.04347826 |
0.1188811 |
NaN |
NaN |
dabrafenib (MSN01);trametinib (MSN09) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN05;MSN09);ceritinib (MSN05);dasatinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01);imatinib (MSN09);vemurafenib (MSN01) |
| Restriction point |
Down |
36.5 |
0.125 |
0.04347826 |
0.1125828 |
NaN |
NaN |
dabrafenib (MSN01);trametinib (MSN09) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN05;MSN09);ceritinib (MSN05);dasatinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN08);imatinib (MSN09);vemurafenib (MSN01) |
| Retinoic acid receptor signaling |
Down |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN01) |
|
| Ribonucleotide reduction |
Down |
12.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN05) |
ceritinib (MSN08);erlotinib (MSN09) |
| Retinol metabolism |
Down |
18.5 |
0.4285714 |
0.3913043 |
0.4261838 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN05;MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06);vemurafenib (MS |
| Retinol metabolism |
Down |
19 |
0.4090909 |
0.3913043 |
0.408 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN05;MSN06);ceritinib (MSN05);erlotinib (MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN0 |
| Retinol metabolism |
Down |
20 |
0.4 |
0.3913043 |
0.3994778 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN05;MSN06);ceritinib (MSN05);cetuximab (MSN09);erlotinib (MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofacitinib |
| Retinol metabolism |
Down |
20.5 |
0.3913043 |
0.3913043 |
0.3913043 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN06);ceritinib (MSN05);cetuximab (MSN09);erlotinib (MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofac |
| Retinol metabolism |
Down |
21 |
0.3829787 |
0.3913043 |
0.3834586 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN06);ceritinib (MSN05);cetuximab (MSN05;MSN09);erlotinib (MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08) |
| Retinol metabolism |
Down |
27 |
0.375 |
0.3913043 |
0.3759214 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN06);ceritinib (MSN05);cetuximab (MSN05;MSN09);erlotinib (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06; |
| Retinol metabolism |
Down |
28 |
0.3673469 |
0.3913043 |
0.3686747 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN09);axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN06);ceritinib (MSN05);cetuximab (MSN05;MSN09);erlotinib (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);re |
| Ribonucleotide reduction |
Up |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01) |
| Ribonucleotide reduction |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01;MSN05) |
| Ribonucleotide reduction |
Up |
20 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01;MSN05);imatinib (MSN05) |
| Ribonucleotide reduction |
Down |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN09) |
| Ribonucleotide reduction |
Down |
9 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN05) |
erlotinib (MSN09) |
| Retinol metabolism |
Down |
18 |
0.4390244 |
0.3913043 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06);vemurafenib (MSN01;MS |
| Ribonucleotide reduction |
Down |
15.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN05) |
ceritinib (MSN08;MSN09);erlotinib (MSN09) |
| Ribonucleotide reduction |
Down |
16 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
dabrafenib (MSN05);ponatinib (MSN05) |
ceritinib (MSN08;MSN09);erlotinib (MSN09) |
| Ribonucleotide reduction |
Down |
16.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
dabrafenib (MSN05);ponatinib (MSN05) |
ceritinib (MSN05;MSN08;MSN09);erlotinib (MSN09) |
| Roundabout signaling |
Up |
9.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN08) |
|
| Roundabout signaling |
Down |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN05) |
|
| Roundabout signaling |
Down |
4.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
bevacizumab (MSN06);vandetanib (MSN05) |
|
| Roundabout signaling |
Down |
8 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
bevacizumab (MSN06);vandetanib (MSN05) |
bosutinib (MSN09) |
| Sarcoplasmic reticulum organization |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN08) |
| Sarcoplasmic reticulum organization |
Down |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN06;MSN08) |
| Sarcoplasmic reticulum organization |
Down |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);ruxolitinib (MSN06;MSN08) |
| Sarcoplasmic reticulum organization |
Down |
15 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);ruxolitinib (MSN01;MSN06;MSN08) |
| Retinol metabolism |
Down |
9 |
0.4285714 |
0.1956522 |
0.4005235 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);lapatinib (MSN08);pazopanib (MSN05);sunitinib (MSN06);trametinib (MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN05);bosutinib (MSN08);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Up |
17.5 |
0.3448276 |
0.2173913 |
0.3333333 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06;MSN08);sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN08;MSN09);cabozantinib (MSN05;MSN09);cetuximab (MSN05;MSN08;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN08);ruxolitinib (MSN05;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
18 |
0.3125 |
0.2173913 |
0.3046595 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06;MSN08);sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN08;MSN09);cabozantinib (MSN05;MSN09);cetuximab (MSN05;MSN08;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN05;MSN06;MSN08);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Up |
19 |
0.3030303 |
0.2173913 |
0.2961673 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06;MSN08);sunitinib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06);axitinib (MSN08;MSN09);cabozantinib (MSN05;MSN09);cetuximab (MSN05;MSN08;MSN09);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN08) |
| Retinol metabolism |
Down |
1 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN05) |
vemurafenib (MSN05) |
| Retinol metabolism |
Down |
2 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);vandetanib (MSN05) |
imatinib (MSN01);vemurafenib (MSN05) |
| Retinol metabolism |
Down |
3 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);vandetanib (MSN05) |
axitinib (MSN05);imatinib (MSN01;MSN09);nilotinib (MSN05);regorafenib (MSN06);vemurafenib (MSN05) |
| Retinol metabolism |
Down |
3.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);pazopanib (MSN05);vandetanib (MSN05) |
axitinib (MSN05);imatinib (MSN01;MSN09);nilotinib (MSN05);regorafenib (MSN06);vemurafenib (MSN05) |
| Retinol metabolism |
Down |
4 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);pazopanib (MSN05);vandetanib (MSN05) |
axitinib (MSN05);bosutinib (MSN08);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN05) |
| Retinol metabolism |
Down |
5 |
0.3076923 |
0.08695652 |
0.2677165 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);pazopanib (MSN05);vandetanib (MSN05) |
axitinib (MSN05);bosutinib (MSN08);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05) |
| Retinol metabolism |
Down |
6 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);pazopanib (MSN05);vandetanib (MSN05) |
axitinib (MSN05);bosutinib (MSN08);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
7 |
0.368421 |
0.1521739 |
0.3399999 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);lapatinib (MSN08);pazopanib (MSN05);trametinib (MSN09);vandetanib (MSN05) |
axitinib (MSN05);bosutinib (MSN08);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
7.5 |
0.4 |
0.173913 |
0.3715847 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);lapatinib (MSN08);pazopanib (MSN05);trametinib (MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN05);bosutinib (MSN08);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Hepatocyte growth factor receptor signaling |
Down |
5 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08) |
imatinib (MSN05);ruxolitinib (MSN01;MSN05;MSN08) |
| Retinol metabolism |
Down |
10 |
0.4545455 |
0.2173913 |
0.4271357 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);lapatinib (MSN08);pazopanib (MSN05);sunitinib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN05);bosutinib (MSN08);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
10.5 |
0.4782609 |
0.2391304 |
0.4516909 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sunitinib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN05);bosutinib (MSN08);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
11 |
0.5185185 |
0.3043478 |
0.4979079 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN08);sunitinib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN08);ceritinib (MSN05);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
11.5 |
0.5357143 |
0.326087 |
0.5161944 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN08);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN08);ceritinib (MSN05);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
12 |
0.483871 |
0.326087 |
0.4704797 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN08);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN08);cabozantinib (MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
12.5 |
0.4848485 |
0.3478261 |
0.4738676 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08);cabozantinib (MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
14 |
0.4571429 |
0.3478261 |
0.4488449 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06;MSN08);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
15 |
0.4324324 |
0.3478261 |
0.4263323 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06;MSN08);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofacitinib (MSN01;MSN05);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
15.5 |
0.4473684 |
0.3695652 |
0.441896 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06;MSN08);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofacitinib (MSN01;MSN05);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
16 |
0.4615385 |
0.3913043 |
0.4567164 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06;MSN08);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofacitinib (MSN01;MSN05);vemurafenib (MSN01;MSN05;MSN09) |
| Retinol metabolism |
Down |
16.5 |
0.45 |
0.3913043 |
0.4460641 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08);lapatinib (MSN08;MSN09);pazopanib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02;MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN06);ceritinib (MSN05);gefitinib (MSN05;MSN06;MSN08);imatinib (MSN01;MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06);vemurafenib (MSN01;MSN05;MS |
| Centrosome organization |
Down |
25 |
0.1875 |
0.06521739 |
0.1688742 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN08) |
afatinib (MSN05;MSN06);ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome organization |
Up |
19 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
ponatinib (MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09) |
nilotinib (MSN01;MSN06;MSN08;MSN09) |
| Centrosome organization |
Up |
28 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
ponatinib (MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09) |
imatinib (MSN06);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| Centrosome organization |
Up |
29 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
ponatinib (MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09) |
imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome organization |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN08);gefitinib (MSN08) |
| Centrosome organization |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);erlotinib (MSN08);gefitinib (MSN08) |
| Centrosome organization |
Down |
12 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN08) |
ceritinib (MSN09);erlotinib (MSN08);gefitinib (MSN08) |
| Centrosome organization |
Down |
13 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trametinib (MSN08) |
ceritinib (MSN05;MSN09);erlotinib (MSN08);gefitinib (MSN01;MSN08) |
| Centrosome organization |
Down |
16 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trametinib (MSN08) |
ceritinib (MSN05;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN01;MSN08) |
| Centrosome organization |
Down |
17 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
trametinib (MSN01;MSN08) |
afatinib (MSN06);ceritinib (MSN05;MSN09);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN08) |
| Centrosome organization |
Down |
18 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
trametinib (MSN01;MSN08) |
afatinib (MSN05;MSN06);ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN08) |
| Centrosome organization |
Down |
19 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
trametinib (MSN01;MSN08) |
afatinib (MSN05;MSN06);ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN06;MSN08) |
| Centrosome organization |
Down |
22 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN08) |
afatinib (MSN05;MSN06);ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| Centrosome organization |
Up |
18 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
ponatinib (MSN06;MSN08);sorafenib (MSN08;MSN09) |
nilotinib (MSN01;MSN06;MSN08;MSN09) |
| Centrosome organization |
Down |
26 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08) |
afatinib (MSN05;MSN06);ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Up |
1 |
0.4444444 |
0.173913 |
0.4071856 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01;MSN02) |
| Centrosome separation |
Up |
1.5 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN01;MSN02) |
| Centrosome separation |
Up |
2 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02) |
| Centrosome separation |
Up |
2.5 |
0.3461539 |
0.1956522 |
0.3311689 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02) |
| Centrosome separation |
Up |
3 |
0.3333333 |
0.1956522 |
0.3200837 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome separation |
Up |
5.5 |
0.3214286 |
0.1956522 |
0.3097166 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome separation |
Up |
7 |
0.3103448 |
0.1956522 |
0.3 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN06) |
| Centrosome separation |
Up |
9 |
0.3 |
0.1956522 |
0.2908745 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09);tofacitinib (MSN06) |
| Centrosome separation |
Up |
10.5 |
0.2903226 |
0.1956522 |
0.2822879 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09);tofacitinib (MSN06) |
| Centrosome separation |
Up |
11.5 |
0.28125 |
0.1956522 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09);tofacitinib (MSN06) |
| Centrosome maturation |
Down |
18 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06);erlotinib (MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08) |
| Centrosome maturation |
Down |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08);cetuximab (MSN01) |
| Centrosome maturation |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN06;MSN08);cetuximab (MSN01) |
| Centrosome maturation |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01);gefitinib (MSN08) |
| Centrosome maturation |
Down |
11.5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trametinib (MSN01) |
afatinib (MSN06);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01);gefitinib (MSN08) |
| Centrosome maturation |
Down |
13 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trametinib (MSN01) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01);gefitinib (MSN08) |
| Centrosome maturation |
Down |
13.5 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
trametinib (MSN01;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01);gefitinib (MSN08) |
| Centrosome maturation |
Down |
14 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
trametinib (MSN01;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01);gefitinib (MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
15 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
16.5 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
17.5 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Up |
14 |
0.2727273 |
0.1956522 |
0.2665506 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cabozantinib (MSN08;MSN09);dasatinib (MSN05;MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);ruxolitinib (MSN01;MSN02;MSN06;MSN09);tof |
| Centrosome maturation |
Down |
18.5 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN09);erlotinib (MSN01;MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
19 |
0.2272727 |
0.1086956 |
0.2135678 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
19.5 |
0.2083333 |
0.1086956 |
0.1976744 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
22.5 |
0.24 |
0.1304348 |
0.2286996 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
25 |
0.2222222 |
0.1304348 |
0.2133891 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Down |
25.5 |
0.2413793 |
0.1521739 |
0.2333333 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome organization |
Up |
9 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN06) |
|
| Centrosome organization |
Up |
11 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
ponatinib (MSN06);sorafenib (MSN08) |
nilotinib (MSN08) |
| Centrosome organization |
Up |
12 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
ponatinib (MSN06);sorafenib (MSN08;MSN09) |
nilotinib (MSN08) |
| Centrosome organization |
Up |
13 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
ponatinib (MSN06);sorafenib (MSN08;MSN09) |
nilotinib (MSN06;MSN08) |
| Centrosome organization |
Up |
17 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
ponatinib (MSN06);sorafenib (MSN08;MSN09) |
nilotinib (MSN01;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Down |
3 |
0.1 |
0.04347826 |
0.09289617 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN06;MSN08);axitinib (MSN05;MSN08);bosutinib (MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);tofacitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Up |
20.5 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
trastuzumab (MSN09) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN05;MSN08);regorafenib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Up |
22.5 |
0.07692308 |
0.02173913 |
0.06692914 |
NaN |
NaN |
trastuzumab (MSN09) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN05;MSN08);regorafenib (MSN01;MSN06);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Up |
24 |
0.07142857 |
0.02173913 |
0.06296296 |
NaN |
NaN |
trastuzumab (MSN09) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN05;MSN08);regorafenib (MSN01;MSN05;MSN06);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Up |
31 |
0.06666667 |
0.02173913 |
0.05944056 |
NaN |
NaN |
trastuzumab (MSN09) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN05;MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Down |
16 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN06) |
|
| Chaperone-mediated autophagy |
Down |
17 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN06) |
cabozantinib (MSN06) |
| Chaperone-mediated autophagy |
Down |
22.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN06) |
cabozantinib (MSN05;MSN06) |
| Chaperone-mediated autophagy |
Down |
24 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN06) |
cabozantinib (MSN05;MSN06);ceritinib (MSN01) |
| Chaperone-mediated autophagy |
Down |
25 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06) |
cabozantinib (MSN05;MSN06);ceritinib (MSN01) |
| Chaperone-mediated autophagy |
Down |
35 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06) |
cabozantinib (MSN05;MSN06);ceritinib (MSN01;MSN09) |
| Cholesterol synthesis |
Down |
1 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
trastuzumab (MSN01) |
axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02;MSN05;MSN08);tofacitinib (MSN01;MSN06);vemurafenib (MSN01;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Down |
2 |
0.0625 |
0.02173913 |
0.05629139 |
NaN |
NaN |
trastuzumab (MSN01) |
afatinib (MSN06);axitinib (MSN05;MSN08);bosutinib (MSN08);cetuximab (MSN02;MSN05;MSN08);crizotinib (MSN06);tofacitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Up |
20 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
trastuzumab (MSN09) |
afatinib (MSN01;MSN09);cetuximab (MSN01;MSN08);regorafenib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Down |
4 |
0.09090909 |
0.04347826 |
0.08542714 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN08);bosutinib (MSN05;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);tofacitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Down |
5 |
0.08695652 |
0.04347826 |
0.0821256 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN08);bosutinib (MSN05;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN09);tofacitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Down |
7 |
0.08 |
0.04347826 |
0.07623319 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN08);bosutinib (MSN01;MSN05;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);gefitinib (MSN08;MSN09);tofacitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Down |
9 |
0.07142857 |
0.04347826 |
0.0688259 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN08;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06; |
| Cholesterol synthesis |
Down |
11 |
0.06666667 |
0.04347826 |
0.06463879 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN06);dasatinib (MSN06);gefitinib (MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01; |
| Cholesterol synthesis |
Down |
12 |
0.06451613 |
0.04347826 |
0.06273063 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08);cetuximab (MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib ( |
| Cholesterol synthesis |
Down |
13 |
0.0625 |
0.04347826 |
0.0609319 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemuraf |
| Cholesterol synthesis |
Down |
20 |
0.06060606 |
0.04347826 |
0.05923345 |
NaN |
NaN |
trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN06;MSN09);v |
| Cholesterol synthesis |
Down |
26 |
0.0882353 |
0.06521739 |
0.08644069 |
NaN |
NaN |
trametinib (MSN08);trastuzumab (MSN01;MSN05) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN05;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN06;MSN09);v |
| Cholesterol-sensitive control of SREBP activation |
Down |
4.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN05) |
|
| Cholesterol-sensitive control of SREBP activation |
Down |
5.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
ponatinib (MSN05) |
cetuximab (MSN02) |
| Chaperone mediated protein folding in ER |
Up |
3 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN01;MSN06) |
|
| Centrosome separation |
Down |
1 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN06;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
1.5 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN06;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
2 |
0.24 |
0.1304348 |
0.2286996 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN09);erlotinib (MSN05;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
3 |
0.2258064 |
0.1521739 |
0.2195572 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
5 |
0.2727273 |
0.1956522 |
0.2665506 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
7 |
0.2941177 |
0.2173913 |
0.2881356 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
9 |
0.3142857 |
0.2391304 |
0.3085808 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
11 |
0.3513514 |
0.2826087 |
0.346395 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
12 |
0.368421 |
0.3043478 |
0.3639143 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Centrosome separation |
Down |
13 |
0.3589744 |
0.3043478 |
0.3552239 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);axitinib (MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Chaperone mediated protein folding in ER |
Up |
1 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN06) |
|
| Centrosome maturation |
Up |
21 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Chaperone mediated protein folding in ER |
Up |
13.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN01;MSN06) |
cabozantinib (MSN09) |
| Chaperone mediated protein folding in ER |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01) |
| Chaperone mediated protein folding in ER |
Down |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01;MSN06) |
| Chaperone-mediated autophagy |
Up |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01) |
| Chaperone-mediated autophagy |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01);tofacitinib (MSN01) |
| Chaperone-mediated autophagy |
Up |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01);tofacitinib (MSN01;MSN09) |
| Chaperone-mediated autophagy |
Up |
12.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN09);regorafenib (MSN01);tofacitinib (MSN01;MSN09) |
| Chaperone-mediated autophagy |
Up |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN09);regorafenib (MSN01);tofacitinib (MSN01;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Up |
14 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trastuzumab (MSN09) |
afatinib (MSN09);regorafenib (MSN01);tofacitinib (MSN01;MSN06;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Up |
14.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trastuzumab (MSN09) |
afatinib (MSN09);regorafenib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Chaperone-mediated autophagy |
Up |
17 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
trastuzumab (MSN09) |
afatinib (MSN01;MSN09);cetuximab (MSN01);regorafenib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cell cycle arrest in response to DNA damage |
Down |
32 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN09) |
|
| CD44-Mediated leukocyte rolling |
Down |
16 |
0.5714286 |
0.173913 |
0.5037037 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);dabrafenib (MSN06);pazopanib (MSN08);sunitinib (MSN01;MSN05;MSN06) |
bosutinib (MSN01;MSN08);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| CD44-Mediated leukocyte rolling |
Down |
16.5 |
0.625 |
0.2173913 |
0.5629139 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06);pazopanib (MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06) |
bosutinib (MSN01;MSN08);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| CD44-Mediated leukocyte rolling |
Down |
17 |
0.5882353 |
0.2173913 |
0.5345912 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06);pazopanib (MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06) |
axitinib (MSN01);bosutinib (MSN01;MSN08);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| CD44-Mediated leukocyte rolling |
Down |
17.5 |
0.6111111 |
0.2391304 |
0.5598803 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06);pazopanib (MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06) |
axitinib (MSN01);bosutinib (MSN01;MSN08);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| CD44-Mediated leukocyte rolling |
Down |
18.5 |
0.5789474 |
0.2391304 |
0.5342858 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06);pazopanib (MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06) |
axitinib (MSN01);bosutinib (MSN01;MSN08;MSN09);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| CD44-Mediated leukocyte rolling |
Down |
20.5 |
0.55 |
0.2391304 |
0.5109289 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06);pazopanib (MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06) |
axitinib (MSN01);bosutinib (MSN01;MSN08;MSN09);nilotinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| CD44-Mediated leukocyte rolling |
Down |
21.5 |
0.5714286 |
0.2608696 |
0.5340314 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06);pazopanib (MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06);trastuzumab (MSN09) |
axitinib (MSN01);bosutinib (MSN01;MSN08;MSN09);nilotinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| CD44-Mediated leukocyte rolling |
Down |
25 |
0.5909091 |
0.2826087 |
0.5552764 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06);lapatinib (MSN06);pazopanib (MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06);trastuzumab (MSN09) |
axitinib (MSN01);bosutinib (MSN01;MSN08;MSN09);nilotinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| CD44-Mediated leukocyte rolling |
Down |
26 |
0.6086956 |
0.3043478 |
0.5748792 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN06);lapatinib (MSN06);pazopanib (MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06);trastuzumab (MSN02;MSN09) |
axitinib (MSN01);bosutinib (MSN01;MSN08;MSN09);nilotinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Cell cycle arrest in response to DNA damage |
Up |
15 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sorafenib (MSN05) |
|
| Cell cycle arrest in response to DNA damage |
Up |
19 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sorafenib (MSN05) |
ruxolitinib (MSN02) |
| Cell cycle arrest in response to DNA damage |
Up |
27 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sorafenib (MSN05) |
nilotinib (MSN08);ruxolitinib (MSN02) |
| CD44-Mediated leukocyte rolling |
Down |
15.5 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN08);sunitinib (MSN05;MSN06) |
bosutinib (MSN01;MSN08);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| Cell cycle arrest in response to DNA damage |
Down |
34 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
trametinib (MSN08;MSN09) |
|
| Cell cycle arrest in response to DNA damage |
Down |
38 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trametinib (MSN08;MSN09) |
erlotinib (MSN08) |
| Cell cycle arrest in response to DNA damage |
Down |
39 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
trametinib (MSN08;MSN09) |
erlotinib (MSN08;MSN09) |
| Cellular cholesterol uptake and efflux |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09) |
| Cellular cholesterol uptake and efflux |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);cetuximab (MSN02);vemurafenib (MSN08) |
| Cellular cholesterol uptake and efflux |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN09);cetuximab (MSN02);vemurafenib (MSN08) |
| Cellular cholesterol uptake and efflux |
Up |
8 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
pazopanib (MSN09) |
ceritinib (MSN05;MSN09);cetuximab (MSN02);vemurafenib (MSN08) |
| Cellular cholesterol uptake and efflux |
Up |
10 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
pazopanib (MSN09) |
ceritinib (MSN05;MSN09);cetuximab (MSN02);vemurafenib (MSN05;MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Up |
11 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
pazopanib (MSN09) |
bosutinib (MSN09);ceritinib (MSN05;MSN09);cetuximab (MSN02);vemurafenib (MSN05;MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Up |
14 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
pazopanib (MSN09) |
bosutinib (MSN05;MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN02);vemurafenib (MSN05;MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Up |
14.5 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
pazopanib (MSN09) |
bosutinib (MSN05;MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN02;MSN05);vemurafenib (MSN05;MSN06;MSN08) |
| CD44-Mediated leukocyte rolling |
Up |
17 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
trametinib (MSN09);vandetanib (MSN08) |
afatinib (MSN01;MSN06;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN09);erlotinib (MSN01;MSN09);vemurafenib (MSN01) |
| CCN intercellular signaling protein family receptor signaling |
Down |
15.5 |
0.4166667 |
0.326087 |
0.4099679 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08;MSN09);dasatinib (MSN05;MSN09);gefitinib (MSN08);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
20 |
0.4324324 |
0.3478261 |
0.4263323 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08;MSN09);dasatinib (MSN05;MSN09);gefitinib (MSN08);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
21.5 |
0.4210526 |
0.3478261 |
0.4159021 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08;MSN09);dasatinib (MSN05;MSN09);erlotinib (MSN05);gefitinib (MSN08);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06 |
| CD44-Mediated leukocyte rolling |
Up |
9 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN09) |
|
| CD44-Mediated leukocyte rolling |
Up |
9.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN09) |
dasatinib (MSN09) |
| CD44-Mediated leukocyte rolling |
Up |
10.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN09) |
dasatinib (MSN09);erlotinib (MSN09) |
| CD44-Mediated leukocyte rolling |
Up |
11 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trametinib (MSN09) |
crizotinib (MSN01;MSN05);dasatinib (MSN09);erlotinib (MSN01;MSN09) |
| CD44-Mediated leukocyte rolling |
Up |
11.5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trametinib (MSN09) |
crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN09);erlotinib (MSN01;MSN09) |
| CD44-Mediated leukocyte rolling |
Up |
12.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN09);crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN09);erlotinib (MSN01;MSN09) |
| CD44-Mediated leukocyte rolling |
Up |
13 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN09);erlotinib (MSN01;MSN09);vemurafenib (MSN01) |
| CD44-Mediated leukocyte rolling |
Up |
16 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN06;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN09);erlotinib (MSN01;MSN09);vemurafenib (MSN01) |
| Cellular cholesterol uptake and efflux |
Up |
15 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
bevacizumab (MSN05);pazopanib (MSN09) |
bosutinib (MSN05;MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN02;MSN05);vemurafenib (MSN05;MSN06;MSN08) |
| CD44-Mediated leukocyte rolling |
Up |
17.5 |
0.2142857 |
0.06521739 |
0.1888889 |
NaN |
NaN |
trametinib (MSN09);vandetanib (MSN08;MSN09) |
afatinib (MSN01;MSN06;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN09);erlotinib (MSN01;MSN09);vemurafenib (MSN01) |
| CD44-Mediated leukocyte rolling |
Up |
18 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
trametinib (MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN06;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN09);erlotinib (MSN01;MSN09);vemurafenib (MSN01) |
| CD44-Mediated leukocyte rolling |
Up |
25.5 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
sorafenib (MSN09);trametinib (MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN06;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN09);erlotinib (MSN01;MSN09);vemurafenib (MSN01) |
| CD44-Mediated leukocyte rolling |
Up |
28.5 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
sorafenib (MSN05;MSN09);trametinib (MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN06;MSN09);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN09);erlotinib (MSN01;MSN09);vemurafenib (MSN01) |
| CD44-Mediated leukocyte rolling |
Down |
10.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN08) |
|
| CD44-Mediated leukocyte rolling |
Down |
11.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
pazopanib (MSN08);sunitinib (MSN06) |
|
| CD44-Mediated leukocyte rolling |
Down |
12.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
pazopanib (MSN08);sunitinib (MSN06) |
nilotinib (MSN01) |
| CD44-Mediated leukocyte rolling |
Down |
13 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
pazopanib (MSN08);sunitinib (MSN06) |
nilotinib (MSN01;MSN06;MSN09) |
| CD44-Mediated leukocyte rolling |
Down |
13.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
pazopanib (MSN08);sunitinib (MSN06) |
bosutinib (MSN08);nilotinib (MSN01;MSN06;MSN09) |
| CD44-Mediated leukocyte rolling |
Down |
14.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
bevacizumab (MSN08);pazopanib (MSN08);sunitinib (MSN06) |
bosutinib (MSN08);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| CD44-Mediated leukocyte rolling |
Down |
15 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
bevacizumab (MSN08);pazopanib (MSN08);sunitinib (MSN05;MSN06) |
bosutinib (MSN08);nilotinib (MSN01;MSN06;MSN08;MSN09) |
| Centrosome maturation |
Up |
8 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
ponatinib (MSN06;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN09) |
| Centrosome duplication |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN08) |
| Centrosome duplication |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Centrosome duplication |
Down |
20 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN08) |
rituximab (MSN08) |
| Centrosome duplication |
Down |
26 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN08) |
ceritinib (MSN09);rituximab (MSN08) |
| Centrosome duplication |
Down |
38 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN08) |
ceritinib (MSN05;MSN09);rituximab (MSN08) |
| Centrosome duplication |
Down |
40 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trametinib (MSN08) |
ceritinib (MSN05;MSN09);erlotinib (MSN09);rituximab (MSN08) |
| Centrosome maturation |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01) |
| Centrosome maturation |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01;MSN05);ruxolitinib (MSN09) |
| Centrosome maturation |
Up |
6.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
ponatinib (MSN06;MSN08;MSN09) |
imatinib (MSN01;MSN05);ruxolitinib (MSN09) |
| Centrosome maturation |
Up |
7 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
ponatinib (MSN06;MSN08;MSN09) |
imatinib (MSN01;MSN05);regorafenib (MSN01);ruxolitinib (MSN01;MSN09) |
| Centrosome maturation |
Up |
7.5 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
ponatinib (MSN06;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);regorafenib (MSN01);ruxolitinib (MSN01;MSN09) |
| Cellular iron uptake and export |
Down |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Centrosome maturation |
Up |
8.5 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN09) |
| Centrosome maturation |
Up |
9 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08;MSN09);sorafenib (MSN09) |
imatinib (MSN01;MSN05;MSN06);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN09) |
| Centrosome maturation |
Up |
9.5 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN09) |
imatinib (MSN01;MSN05;MSN06);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN09) |
| Centrosome maturation |
Up |
10 |
0.5 |
0.173913 |
0.4503311 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome maturation |
Up |
11 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome maturation |
Up |
12 |
0.4736842 |
0.1956522 |
0.4371428 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome maturation |
Up |
12.5 |
0.45 |
0.1956522 |
0.4180328 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN08);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome maturation |
Up |
13.5 |
0.4285714 |
0.1956522 |
0.4005235 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome maturation |
Up |
14 |
0.4090909 |
0.1956522 |
0.3844221 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome maturation |
Up |
14.5 |
0.3913043 |
0.1956522 |
0.3695652 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Centrosome maturation |
Up |
19.5 |
0.375 |
0.1956522 |
0.355814 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Cellular iron storage |
Up |
12.5 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05;MSN08) |
afatinib (MSN01);erlotinib (MSN05) |
| Cellular cholesterol uptake and efflux |
Up |
15.5 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);pazopanib (MSN09) |
bosutinib (MSN05;MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN02;MSN05);vemurafenib (MSN05;MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Up |
16.5 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);pazopanib (MSN09) |
bosutinib (MSN05;MSN09);ceritinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN02;MSN05;MSN08);vemurafenib (MSN05;MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Up |
18 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);pazopanib (MSN09);trastuzumab (MSN01) |
bosutinib (MSN05;MSN09);ceritinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN02;MSN05;MSN08);vemurafenib (MSN05;MSN06;MSN08) |
| Cellular fatty acid uptake |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN01) |
| Cellular fatty acid uptake |
Up |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN01;MSN09) |
| Cellular fatty acid uptake |
Up |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN01;MSN05;MSN09) |
| Cellular fatty acid uptake |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN06) |
| Cellular iron storage |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01) |
| Cellular iron storage |
Up |
5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN09) |
afatinib (MSN01) |
| Cellular iron storage |
Up |
6.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05) |
afatinib (MSN01) |
| Cellular iron storage |
Up |
8 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05) |
afatinib (MSN01);erlotinib (MSN05) |
| Cholesterol-sensitive control of SREBP activation |
Down |
6 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
ponatinib (MSN05) |
cetuximab (MSN02);tofacitinib (MSN05) |
| Cellular iron storage |
Up |
14.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05;MSN08) |
afatinib (MSN01);erlotinib (MSN01;MSN05) |
| Cellular iron storage |
Up |
15.5 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05;MSN08) |
afatinib (MSN01);crizotinib (MSN05);erlotinib (MSN01;MSN05) |
| Cellular iron storage |
Up |
16 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05;MSN08) |
afatinib (MSN01);crizotinib (MSN05);erlotinib (MSN01;MSN05;MSN09);ruxolitinib (MSN05) |
| Cellular iron storage |
Up |
17 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05;MSN08) |
afatinib (MSN01);crizotinib (MSN05;MSN06);erlotinib (MSN01;MSN05;MSN09);ruxolitinib (MSN05) |
| Cellular iron storage |
Up |
18.5 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05;MSN08) |
afatinib (MSN01);crizotinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN09);ruxolitinib (MSN05) |
| Cellular iron storage |
Up |
22 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
dabrafenib (MSN09);trametinib (MSN05;MSN08) |
afatinib (MSN01);crizotinib (MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN09);ruxolitinib (MSN05;MSN08) |
| Cellular iron uptake and export |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06;MSN09) |
| Cellular iron uptake and export |
Up |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06;MSN08;MSN09) |
| Cellular iron uptake and export |
Up |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06;MSN08;MSN09);imatinib (MSN09) |
| Cellular iron uptake and export |
Up |
15 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
bevacizumab (MSN05) |
crizotinib (MSN06;MSN08;MSN09);imatinib (MSN09);ruxolitinib (MSN08) |
| Cellular iron uptake and export |
Up |
20 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
bevacizumab (MSN05;MSN09) |
crizotinib (MSN06;MSN08;MSN09);imatinib (MSN09);ruxolitinib (MSN08) |
| Collagen fibril organization by fibril-associated bridges |
Down |
27.5 |
0.38 |
0.4130435 |
0.3817967 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);ceritinib (MSN05);crizotinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxo |
| Collagen fibril organization by fibril-associated bridges |
Down |
13.5 |
0.4285714 |
0.326087 |
0.4207921 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Down |
14.5 |
0.4166667 |
0.326087 |
0.4099679 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Down |
17.5 |
0.3947369 |
0.326087 |
0.3899083 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06;MSN08);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib |
| Collagen fibril organization by fibril-associated bridges |
Down |
18 |
0.3846154 |
0.326087 |
0.3805971 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06;MSN08);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemura |
| Collagen fibril organization by fibril-associated bridges |
Down |
18.5 |
0.4 |
0.3478261 |
0.3965015 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06;MSN08);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemura |
| Collagen fibril organization by fibril-associated bridges |
Down |
20.5 |
0.4047619 |
0.3695652 |
0.402507 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09); |
| Collagen fibril organization by fibril-associated bridges |
Down |
22 |
0.4186046 |
0.3913043 |
0.4168937 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09); |
| Collagen fibril organization by fibril-associated bridges |
Down |
22.5 |
0.4090909 |
0.3913043 |
0.408 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01;MSN05;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;M |
| Collagen fibril organization by fibril-associated bridges |
Down |
23 |
0.4130435 |
0.4130435 |
0.4130435 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofaciti |
| Collagen fibril organization by fibril-associated bridges |
Down |
25 |
0.4042553 |
0.4130435 |
0.4047619 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);to |
| Collagen fibril organization by fibril-associated bridges |
Down |
26.5 |
0.3958333 |
0.4130435 |
0.3968059 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN |
| Collagen fibril organization by fibril-associated bridges |
Down |
27 |
0.3877551 |
0.4130435 |
0.3891566 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN |
| Collagen fibril organization by fibril-associated bridges |
Down |
11.5 |
0.4117647 |
0.3043478 |
0.4033898 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);pazopanib (MSN05;MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05) |
| Connection of muscle sarcomere to extracellular matrix |
Up |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN09) |
| Connection of muscle sarcomere to plasma membrane |
Up |
5.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trastuzumab (MSN05) |
|
| Connection of muscle sarcomere to plasma membrane |
Up |
8 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trastuzumab (MSN05) |
cetuximab (MSN01) |
| Connection of muscle sarcomere to plasma membrane |
Up |
11 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trastuzumab (MSN05) |
cetuximab (MSN01;MSN08) |
| Connection of muscle sarcomere to plasma membrane |
Down |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02) |
| Connection of muscle sarcomere to plasma membrane |
Down |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02;MSN06) |
| Contractile ring constriction |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN05) |
| Contractile ring constriction |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN09);nilotinib (MSN05) |
| Contractile ring constriction |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05;MSN09);nilotinib (MSN05);tofacitinib (MSN06) |
| Contractile ring constriction |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05;MSN09);nilotinib (MSN05);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
5.5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
bevacizumab (MSN09) |
bosutinib (MSN05;MSN09);imatinib (MSN06);nilotinib (MSN05);tofacitinib (MSN06;MSN08) |
| Collagen fibril organization by fibril-associated bridges |
Down |
2 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);sorafenib (MSN08) |
crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05);nilotinib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Up |
8.5 |
0.1818182 |
0.1304348 |
0.1777004 |
NaN |
NaN |
bevacizumab (MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN09);regorafenib (MSN01);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08); |
| Collagen fibril organization by fibril-associated bridges |
Up |
10 |
0.1944444 |
0.1521739 |
0.1913183 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);regorafenib (MSN01);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;M |
| Collagen fibril organization by fibril-associated bridges |
Up |
10.5 |
0.1842105 |
0.1521739 |
0.1819572 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);regorafenib (MSN01;MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (M |
| Collagen fibril organization by fibril-associated bridges |
Up |
11.5 |
0.2051282 |
0.173913 |
0.2029851 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);ponatinib (MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);regorafenib (MSN01;MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (M |
| Collagen fibril organization by fibril-associated bridges |
Up |
12 |
0.2 |
0.173913 |
0.1982507 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);ponatinib (MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofaciti |
| Growth differentiation factor receptor signaling |
Down |
10 |
0.8181818 |
0.1956522 |
0.6891892 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);vandetanib (MSN09) |
crizotinib (MSN05);dasatinib (MSN06) |
| Collagen fibril organization by fibril-associated bridges |
Up |
14 |
0.2142857 |
0.1956522 |
0.2130919 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);ponatinib (MSN06;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);to |
| Collagen fibril organization by fibril-associated bridges |
Up |
14.5 |
0.2325581 |
0.2173913 |
0.2316076 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);ponatinib (MSN01;MSN06;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);to |
| Collagen fibril organization by fibril-associated bridges |
Up |
15 |
0.2272727 |
0.2173913 |
0.2266667 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);ponatinib (MSN01;MSN06;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);nilotinib (MSN01);regorafenib (MSN01;MSN05;MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN |
| Collagen fibril organization by fibril-associated bridges |
Up |
18 |
0.2222222 |
0.2173913 |
0.2219321 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);ponatinib (MSN01;MSN06;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);nilotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN |
| Collagen fibril organization by fibril-associated bridges |
Down |
1 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sorafenib (MSN08) |
|
| Contractile ring constriction |
Up |
6 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
bevacizumab (MSN09) |
bosutinib (MSN01;MSN05;MSN09);imatinib (MSN06);nilotinib (MSN05);regorafenib (MSN01);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Collagen fibril organization by fibril-associated bridges |
Down |
3 |
0.5833333 |
0.1521739 |
0.5 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);ponatinib (MSN08);sorafenib (MSN01;MSN08;MSN09) |
crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05);nilotinib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Down |
4 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);ponatinib (MSN08);sorafenib (MSN01;MSN08;MSN09) |
axitinib (MSN05);crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Down |
4.5 |
0.5555556 |
0.2173913 |
0.5089821 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
axitinib (MSN05);crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Down |
5 |
0.4761905 |
0.2173913 |
0.4450262 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06) |
| Collagen fibril organization by fibril-associated bridges |
Down |
6 |
0.4782609 |
0.2391304 |
0.4516909 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06) |
| Collagen fibril organization by fibril-associated bridges |
Down |
6.5 |
0.44 |
0.2391304 |
0.4192825 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);tofacitinib (MSN01;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Down |
7 |
0.4230769 |
0.2391304 |
0.4047619 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN02);tofacitinib (MSN01;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Down |
7.5 |
0.3928571 |
0.2391304 |
0.3785425 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Down |
8 |
0.3793103 |
0.2391304 |
0.3666666 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Down |
8.5 |
0.3666667 |
0.2391304 |
0.3555134 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Down |
9 |
0.40625 |
0.2826087 |
0.3960573 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN05;MSN08);pazopanib (MSN09);ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN01;MSN08;MSN09) |
afatinib (MSN01;MSN05);axitinib (MSN05);bosutinib (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05;MSN06;MSN09);nilotinib (MSN05;MSN06);ruxolitinib (MSN02;MSN09);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN05) |
| Contractile ring formation |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05);regorafenib (MSN05) |
| Contractile ring constriction |
Down |
10 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN05) |
axitinib (MSN06;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
10.5 |
0.3214286 |
0.1956522 |
0.3097166 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN08);axitinib (MSN06;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
11 |
0.3103448 |
0.1956522 |
0.3 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN08);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
11.5 |
0.3225806 |
0.2173913 |
0.3136531 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN05;MSN08);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
14 |
0.3125 |
0.2173913 |
0.3046595 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN05;MSN08);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
14.5 |
0.3030303 |
0.2173913 |
0.2961673 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN05;MSN08);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
15 |
0.3235294 |
0.2391304 |
0.3169491 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN05;MSN08);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
15.5 |
0.3142857 |
0.2391304 |
0.3085808 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN05;MSN08);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Contractile ring constriction |
Down |
16 |
0.3055556 |
0.2391304 |
0.3006431 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN05;MSN08;MSN09);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Contractile ring constriction |
Down |
18.5 |
0.3243243 |
0.2608696 |
0.3197492 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN05;MSN08;MSN09);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Contractile ring constriction |
Down |
24.5 |
0.3157895 |
0.2608696 |
0.3119266 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05) |
afatinib (MSN05;MSN08;MSN09);axitinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Contractile ring formation |
Up |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN05) |
| Contractile ring constriction |
Down |
9.5 |
0.3478261 |
0.173913 |
0.3285024 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN05) |
axitinib (MSN06;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN06;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring formation |
Up |
15.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05);regorafenib (MSN05;MSN08) |
| Contractile ring formation |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05);nilotinib (MSN05);regorafenib (MSN05;MSN08) |
| Contractile ring formation |
Up |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN08) |
| Cytosolic protein folding |
Up |
26.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01) |
| Decorin synthesis |
Up |
3 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN05) |
|
| Decorin synthesis |
Up |
4 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN05) |
erlotinib (MSN08) |
| Decorin synthesis |
Up |
4.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trametinib (MSN05;MSN09) |
erlotinib (MSN08) |
| Decorin synthesis |
Up |
6 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
trametinib (MSN05;MSN09) |
crizotinib (MSN08);erlotinib (MSN08);gefitinib (MSN08) |
| Decorin synthesis |
Up |
6.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
trametinib (MSN05;MSN09) |
crizotinib (MSN08);erlotinib (MSN08);gefitinib (MSN08);vemurafenib (MSN01) |
| Decorin synthesis |
Up |
7 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
lapatinib (MSN08);trametinib (MSN05;MSN09) |
crizotinib (MSN01;MSN08);dasatinib (MSN09);erlotinib (MSN08);gefitinib (MSN06;MSN08;MSN09);tofacitinib (MSN01);vemurafenib (MSN01) |
| Decorin synthesis |
Up |
7.5 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
lapatinib (MSN08);trametinib (MSN05;MSN09) |
crizotinib (MSN01;MSN06;MSN08);dasatinib (MSN09);erlotinib (MSN08);gefitinib (MSN06;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01);vemurafenib (MSN01;MSN05) |
| Contractile ring constriction |
Down |
1.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
lapatinib (MSN09) |
crizotinib (MSN06) |
| Contractile ring constriction |
Up |
6.5 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
bevacizumab (MSN09) |
bosutinib (MSN01;MSN05;MSN09);imatinib (MSN06);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
7 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
bevacizumab (MSN08;MSN09) |
bosutinib (MSN01;MSN05;MSN09);imatinib (MSN06);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
9 |
0.1333333 |
0.04347826 |
0.1188811 |
NaN |
NaN |
bevacizumab (MSN08;MSN09) |
bosutinib (MSN01;MSN05;MSN09);imatinib (MSN06);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
9.5 |
0.1875 |
0.06521739 |
0.1688742 |
NaN |
NaN |
bevacizumab (MSN08;MSN09);ponatinib (MSN09) |
bosutinib (MSN01;MSN05;MSN09);imatinib (MSN06);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
10.5 |
0.1764706 |
0.06521739 |
0.1603774 |
NaN |
NaN |
bevacizumab (MSN08;MSN09);ponatinib (MSN09) |
bosutinib (MSN01;MSN05;MSN09);imatinib (MSN06);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
11.5 |
0.2222222 |
0.08695652 |
0.2035928 |
NaN |
NaN |
bevacizumab (MSN08;MSN09);ponatinib (MSN06;MSN09) |
bosutinib (MSN01;MSN05;MSN09);imatinib (MSN06);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
12 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
bevacizumab (MSN08;MSN09);ponatinib (MSN06;MSN09);sorafenib (MSN05) |
bosutinib (MSN01;MSN05;MSN09);erlotinib (MSN05);imatinib (MSN06);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
13 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
bevacizumab (MSN08;MSN09);ponatinib (MSN01;MSN06;MSN09);sorafenib (MSN05) |
bosutinib (MSN01;MSN05;MSN09);erlotinib (MSN05);imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
14 |
0.3043478 |
0.1521739 |
0.2874396 |
NaN |
NaN |
bevacizumab (MSN08;MSN09);ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
bosutinib (MSN01;MSN05;MSN09);erlotinib (MSN05);imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Up |
18 |
0.2916667 |
0.1521739 |
0.2767442 |
NaN |
NaN |
bevacizumab (MSN08;MSN09);ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
bosutinib (MSN01;MSN05;MSN09);erlotinib (MSN05);imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06);tofacitinib (MSN06;MSN08) |
| Contractile ring constriction |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06) |
| Collagen fibril organization by fibril-associated bridges |
Up |
8 |
0.1935484 |
0.1304348 |
0.1881919 |
NaN |
NaN |
bevacizumab (MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;M |
| Contractile ring constriction |
Down |
2 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN06;MSN09) |
crizotinib (MSN06) |
| Contractile ring constriction |
Down |
4 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
lapatinib (MSN06;MSN09);trastuzumab (MSN01) |
crizotinib (MSN06) |
| Contractile ring constriction |
Down |
5 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);trastuzumab (MSN01) |
crizotinib (MSN06) |
| Contractile ring constriction |
Down |
5.5 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);trastuzumab (MSN01) |
axitinib (MSN09);crizotinib (MSN06);gefitinib (MSN01;MSN05;MSN06) |
| Contractile ring constriction |
Down |
6 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);trastuzumab (MSN01) |
axitinib (MSN09);crizotinib (MSN06;MSN08);gefitinib (MSN01;MSN05;MSN06) |
| Contractile ring constriction |
Down |
6.5 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);trastuzumab (MSN01;MSN05) |
axitinib (MSN09);crizotinib (MSN06;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
7 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN01;MSN05) |
axitinib (MSN06;MSN09);crizotinib (MSN06;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
7.5 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN08);trastuzumab (MSN01;MSN05) |
axitinib (MSN06;MSN09);crizotinib (MSN06;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
8 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN05) |
axitinib (MSN06;MSN09);cetuximab (MSN01);crizotinib (MSN06;MSN08);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
8.5 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN05) |
axitinib (MSN06;MSN09);cetuximab (MSN01;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Contractile ring constriction |
Down |
9 |
0.3809524 |
0.173913 |
0.356021 |
NaN |
NaN |
lapatinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08);trastuzumab (MSN01;MSN05) |
axitinib (MSN06;MSN09);ceritinib (MSN09);cetuximab (MSN01;MSN09);crizotinib (MSN06;MSN08);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Classical complement pathway |
Up |
13.5 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
ponatinib (MSN02);trastuzumab (MSN02);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN08) |
| Class switch recombination |
Down |
7 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
bevacizumab (MSN09) |
axitinib (MSN01) |
| Classical complement pathway |
Up |
3 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trastuzumab (MSN02) |
ceritinib (MSN08);gefitinib (MSN05;MSN09) |
| Classical complement pathway |
Up |
3.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trastuzumab (MSN02) |
ceritinib (MSN08);crizotinib (MSN06);gefitinib (MSN05;MSN09) |
| Classical complement pathway |
Up |
4 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trastuzumab (MSN02) |
ceritinib (MSN08);crizotinib (MSN06);gefitinib (MSN05;MSN08;MSN09) |
| Classical complement pathway |
Up |
5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trastuzumab (MSN02) |
ceritinib (MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Classical complement pathway |
Up |
6 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
trastuzumab (MSN02) |
ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Classical complement pathway |
Up |
6.5 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
trastuzumab (MSN02);vandetanib (MSN08) |
axitinib (MSN09);ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Classical complement pathway |
Up |
7 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
trastuzumab (MSN02);vandetanib (MSN08;MSN09) |
axitinib (MSN09);ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN08) |
| Classical complement pathway |
Up |
7.5 |
0.2142857 |
0.06521739 |
0.1888889 |
NaN |
NaN |
trastuzumab (MSN02);vandetanib (MSN08;MSN09) |
axitinib (MSN08;MSN09);ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN08) |
| Classical complement pathway |
Up |
8 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
trastuzumab (MSN02);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN08) |
| Classical complement pathway |
Up |
10 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
trastuzumab (MSN02);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);cabozantinib (MSN06);ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN08) |
| Classical complement pathway |
Up |
12 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
ponatinib (MSN02);trastuzumab (MSN02);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);cabozantinib (MSN06);ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN08) |
| Class switch recombination |
Down |
6 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
bevacizumab (MSN09) |
|
| Classical complement pathway |
Up |
21.5 |
0.2631579 |
0.1086956 |
0.2428571 |
NaN |
NaN |
ponatinib (MSN02);trastuzumab (MSN02);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);crizotinib (MSN06);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN09);ruxolitinib (MSN08) |
| Classical complement pathway |
Down |
1 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN09) |
|
| Classical complement pathway |
Down |
2 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN01);sunitinib (MSN09) |
ruxolitinib (MSN05) |
| Classical complement pathway |
Down |
2.5 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
lapatinib (MSN01);sunitinib (MSN01;MSN06;MSN09) |
ruxolitinib (MSN05) |
| Classical complement pathway |
Down |
4 |
0.8333333 |
0.1086956 |
0.5985914 |
NaN |
NaN |
lapatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN09) |
ruxolitinib (MSN05) |
| Classical complement pathway |
Down |
5 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
lapatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN09) |
axitinib (MSN05);bosutinib (MSN01);ruxolitinib (MSN05) |
| Classical complement pathway |
Down |
7 |
0.6363636 |
0.1521739 |
0.5360361 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN05) |
| Classical complement pathway |
Down |
8 |
0.5833333 |
0.1521739 |
0.5 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN05;MSN09) |
| Classical complement pathway |
Down |
8.5 |
0.5384616 |
0.1521739 |
0.468504 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN09) |
| Classical complement pathway |
Down |
9 |
0.5 |
0.1521739 |
0.4407408 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Classical complement pathway |
Down |
9.5 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
18 |
0.1818182 |
0.08695652 |
0.1708543 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN01;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);ruxolitinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
6.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
ponatinib (MSN05) |
cetuximab (MSN02);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
7 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
ponatinib (MSN05) |
bosutinib (MSN08);cetuximab (MSN02);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
7.5 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
ponatinib (MSN05) |
bosutinib (MSN08);cetuximab (MSN02);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
8.5 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
ponatinib (MSN05) |
bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
9 |
0.07692308 |
0.02173913 |
0.06692914 |
NaN |
NaN |
ponatinib (MSN05) |
bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
9.5 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09) |
bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
11.5 |
0.1764706 |
0.06521739 |
0.1603774 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09) |
axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);ruxolitinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
13.5 |
0.1666667 |
0.06521739 |
0.1526946 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09) |
afatinib (MSN08);axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);ruxolitinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
14 |
0.1578947 |
0.06521739 |
0.1457143 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN08);axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);ruxolitinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
14.5 |
0.15 |
0.06521739 |
0.1393443 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);ruxolitinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
17.5 |
0.1904762 |
0.08695652 |
0.1780105 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN01;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);rituximab (MSN05);ruxolitinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Classical complement pathway |
Down |
10 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Down |
22.5 |
0.173913 |
0.08695652 |
0.1642512 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN01;MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);axitinib (MSN08);bosutinib (MSN08);cetuximab (MSN02);crizotinib (MSN06);gefitinib (MSN05);rituximab (MSN05);ruxolitinib (MSN01);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN01;MSN08;MSN09) |
| Chondroitin sulfate and dermatan sulfate synthesis |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09) |
| Chondroitin sulfate and dermatan sulfate synthesis |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09);dasatinib (MSN06) |
| Chondroitin sulfate and dermatan sulfate synthesis |
Up |
9.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN08) |
cabozantinib (MSN09);dasatinib (MSN06) |
| Chondroitin sulfate and dermatan sulfate synthesis |
Up |
12 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN08;MSN09) |
cabozantinib (MSN09);dasatinib (MSN06) |
| Chondroitin sulfate and dermatan sulfate synthesis |
Down |
7 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN01) |
|
| Citric acid cycle |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06) |
| Class switch recombination |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN09) |
| Class switch recombination |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN06);dasatinib (MSN09) |
| Class switch recombination |
Up |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN06);dasatinib (MSN05;MSN09) |
| Class switch recombination |
Up |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN06);dasatinib (MSN05;MSN09);erlotinib (MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
2 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trastuzumab (MSN01;MSN02) |
dasatinib (MSN01) |
| Collagen fiber crosslinking |
Down |
8 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
lapatinib (MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN06;MSN09) |
| Collagen fiber crosslinking |
Down |
8.5 |
0.1875 |
0.06521739 |
0.1688742 |
NaN |
NaN |
lapatinib (MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN06;MSN09) |
| Collagen fiber crosslinking |
Down |
9 |
0.1764706 |
0.06521739 |
0.1603774 |
NaN |
NaN |
lapatinib (MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN05;MSN06;MSN09) |
| Collagen fiber crosslinking |
Down |
9.5 |
0.1666667 |
0.06521739 |
0.1526946 |
NaN |
NaN |
lapatinib (MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN05;MSN06;MSN09) |
| Collagen fiber crosslinking |
Down |
11 |
0.1578947 |
0.06521739 |
0.1457143 |
NaN |
NaN |
lapatinib (MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06;MSN09) |
| Collagen fiber crosslinking |
Down |
11.5 |
0.15 |
0.06521739 |
0.1393443 |
NaN |
NaN |
lapatinib (MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06;MSN09);imatinib (MSN05) |
| Collagen fiber crosslinking |
Down |
19 |
0.1818182 |
0.08695652 |
0.1708543 |
NaN |
NaN |
lapatinib (MSN05;MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06;MSN09);gefitinib (MSN09);imatinib (MSN05) |
| Collagen fiber crosslinking |
Down |
20 |
0.173913 |
0.08695652 |
0.1642512 |
NaN |
NaN |
lapatinib (MSN05;MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06;MSN09);gefitinib (MSN05;MSN09);imatinib (MSN05) |
| Collagen fiber crosslinking |
Down |
21.5 |
0.1666667 |
0.08695652 |
0.1581396 |
NaN |
NaN |
lapatinib (MSN05;MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06;MSN09);erlotinib (MSN05);gefitinib (MSN05;MSN09);imatinib (MSN05) |
| Collagen fiber crosslinking |
Down |
24 |
0.16 |
0.08695652 |
0.1524664 |
NaN |
NaN |
lapatinib (MSN05;MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN01;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05;MSN06;MSN09);erlotinib (MSN05;MSN08);gefitinib (MSN05;MSN09);imatinib (MSN05) |
| Collagen fibril organization by fibril-associated bridges |
Up |
1 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trastuzumab (MSN01) |
dasatinib (MSN01) |
| Collagen fiber crosslinking |
Down |
7.5 |
0.2142857 |
0.06521739 |
0.1888889 |
NaN |
NaN |
lapatinib (MSN09);pazopanib (MSN05);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN06;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
2.5 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09) |
dasatinib (MSN01) |
| Collagen fibril organization by fibril-associated bridges |
Up |
3 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09) |
dasatinib (MSN01);rituximab (MSN05);tofacitinib (MSN01;MSN08);vemurafenib (MSN01;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
3.5 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN09);dasatinib (MSN01);rituximab (MSN05);tofacitinib (MSN01;MSN08);vemurafenib (MSN01;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
4 |
0.1764706 |
0.06521739 |
0.1603774 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN09);cabozantinib (MSN06);dasatinib (MSN01);rituximab (MSN05;MSN08;MSN09);ruxolitinib (MSN06);tofacitinib (MSN01;MSN08);vemurafenib (MSN01;MSN05;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
4.5 |
0.1666667 |
0.06521739 |
0.1526946 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN09);cabozantinib (MSN06);dasatinib (MSN01);rituximab (MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN06);tofacitinib (MSN01;MSN08);vemurafenib (MSN01;MSN05;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
5 |
0.15 |
0.06521739 |
0.1393443 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN09);cabozantinib (MSN06);dasatinib (MSN01;MSN09);rituximab (MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN06);tofacitinib (MSN01;MSN08);vemurafenib (MSN01;MSN05;MSN08;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
5.5 |
0.1363636 |
0.06521739 |
0.1281407 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN09);cabozantinib (MSN06);dasatinib (MSN01;MSN09);rituximab (MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN08);vemurafenib (MSN01;MSN05;MSN08;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
6 |
0.16 |
0.08695652 |
0.1524664 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN09);cabozantinib (MSN06;MSN08);dasatinib (MSN01;MSN09);rituximab (MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN08;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
6.5 |
0.1538462 |
0.08695652 |
0.1471862 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN08;MSN09);cabozantinib (MSN06;MSN08);dasatinib (MSN01;MSN09);rituximab (MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN08;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
7 |
0.1785714 |
0.1086956 |
0.1720647 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN08;MSN09);cabozantinib (MSN06;MSN08);dasatinib (MSN01;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN08;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
7.5 |
0.2068966 |
0.1304348 |
0.2 |
NaN |
NaN |
bevacizumab (MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN08;MSN09);cabozantinib (MSN06;MSN08);dasatinib (MSN01;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN05;MSN08;MSN09) |
| Collagen fiber crosslinking |
Up |
3 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trastuzumab (MSN05) |
|
| Classical complement pathway |
Down |
11 |
0.4117647 |
0.1521739 |
0.3742138 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);cetuximab (MSN05);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Classical complement pathway |
Down |
12.5 |
0.3888889 |
0.1521739 |
0.3562874 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);cetuximab (MSN05);dasatinib (MSN05);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Classical complement pathway |
Down |
14.5 |
0.368421 |
0.1521739 |
0.3399999 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
axitinib (MSN05);bosutinib (MSN01);cetuximab (MSN01;MSN05);dasatinib (MSN05);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Coagulation cascade |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN09) |
| Coagulation cascade |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN08;MSN09);tofacitinib (MSN08) |
| Coagulation cascade |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Coagulation cascade |
Up |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08);crizotinib (MSN05;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Coagulation cascade |
Up |
21 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
sorafenib (MSN09) |
ceritinib (MSN08);crizotinib (MSN05;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Coagulation cascade |
Up |
23 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
sorafenib (MSN05;MSN09) |
ceritinib (MSN08);crizotinib (MSN05;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Coagulation cascade |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05) |
| Coagulation cascade |
Down |
15 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01);bosutinib (MSN05) |
| CCN intercellular signaling protein family receptor signaling |
Down |
15 |
0.4285714 |
0.326087 |
0.4207921 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08;MSN09);dasatinib (MSN05;MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Collagen fiber crosslinking |
Up |
4 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN01);trastuzumab (MSN05) |
|
| Collagen fiber crosslinking |
Up |
4.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN01);trastuzumab (MSN05) |
bosutinib (MSN05);ceritinib (MSN08) |
| Collagen fiber crosslinking |
Up |
7 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
dabrafenib (MSN01);trastuzumab (MSN01;MSN05) |
bosutinib (MSN05);ceritinib (MSN08) |
| Collagen fiber crosslinking |
Up |
11 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
dabrafenib (MSN01);sorafenib (MSN09);trastuzumab (MSN01;MSN05) |
bosutinib (MSN05);ceritinib (MSN08) |
| Collagen fiber crosslinking |
Down |
1.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
lapatinib (MSN09) |
|
| Collagen fiber crosslinking |
Down |
3.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN05) |
| Collagen fiber crosslinking |
Down |
4 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN05;MSN09) |
| Collagen fiber crosslinking |
Down |
5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN05;MSN09);crizotinib (MSN05);dasatinib (MSN06) |
| Collagen fiber crosslinking |
Down |
6 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN05;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN06) |
| Collagen fiber crosslinking |
Down |
6.5 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN05;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN06;MSN09) |
| Collagen fiber crosslinking |
Down |
7 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
lapatinib (MSN09);ponatinib (MSN02) |
axitinib (MSN06);cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN06;MSN09) |
| Alternative complement pathway |
Down |
6 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN08);ponatinib (MSN09);sunitinib (MSN09) |
axitinib (MSN09);bosutinib (MSN01;MSN09);crizotinib (MSN08) |
| Alternative complement pathway |
Up |
5.5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Alternative complement pathway |
Up |
6 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Alternative complement pathway |
Up |
7 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
bevacizumab (MSN08);vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Alternative complement pathway |
Up |
7.5 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Alternative complement pathway |
Up |
8 |
0.3333333 |
0.1304348 |
0.3053892 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
cabozantinib (MSN06);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Alternative complement pathway |
Up |
15.5 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
cabozantinib (MSN06);ceritinib (MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Alternative complement pathway |
Up |
18.5 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
cabozantinib (MSN06);ceritinib (MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN06) |
| Alternative complement pathway |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01) |
| Alternative complement pathway |
Down |
3.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN08) |
bosutinib (MSN01) |
| Alternative complement pathway |
Down |
4 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN08) |
bosutinib (MSN01;MSN09) |
| Alternative complement pathway |
Down |
4.5 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
dabrafenib (MSN08);ponatinib (MSN09);sunitinib (MSN09) |
bosutinib (MSN01;MSN09) |
| Alternative complement pathway |
Down |
5.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
dabrafenib (MSN08);ponatinib (MSN09);sunitinib (MSN09) |
axitinib (MSN09);bosutinib (MSN01;MSN09) |
| Alternative complement pathway |
Up |
4.5 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
cetuximab (MSN01;MSN05;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Alternative complement pathway |
Down |
7 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
dabrafenib (MSN08);ponatinib (MSN09);sunitinib (MSN09) |
axitinib (MSN06;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN08);crizotinib (MSN08) |
| Alternative complement pathway |
Down |
7.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN09);sunitinib (MSN09) |
axitinib (MSN06;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN08);crizotinib (MSN08) |
| Alternative complement pathway |
Down |
8 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN09);sunitinib (MSN01;MSN09) |
axitinib (MSN06;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN08);crizotinib (MSN08) |
| Alternative complement pathway |
Down |
9 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN09);sunitinib (MSN01;MSN09) |
axitinib (MSN06;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN08);crizotinib (MSN08);dasatinib (MSN05);ruxolitinib (MSN05) |
| Alternative complement pathway |
Down |
10 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN09);sunitinib (MSN01;MSN09) |
axitinib (MSN06;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN05;MSN08;MSN09);crizotinib (MSN08);dasatinib (MSN05);ruxolitinib (MSN05) |
| Alternative complement pathway |
Down |
10.5 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN09);sunitinib (MSN01;MSN09) |
axitinib (MSN06;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN08);dasatinib (MSN05);ruxolitinib (MSN05) |
| Alternative complement pathway |
Down |
11 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN09);sunitinib (MSN01;MSN09) |
axitinib (MSN05;MSN06;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN08);dasatinib (MSN05);ruxolitinib (MSN05) |
| Alternative complement pathway |
Down |
15 |
0.3333333 |
0.1304348 |
0.3053892 |
NaN |
NaN |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN09);sunitinib (MSN01;MSN09);trametinib (MSN01) |
axitinib (MSN05;MSN06;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN08);dasatinib (MSN05);ruxolitinib (MSN05) |
| Amyloid plaque organization |
Up |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN06) |
| Amyloid plaque organization |
Up |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01);ruxolitinib (MSN06) |
| Amyloid plaque organization |
Up |
15.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
pazopanib (MSN06) |
afatinib (MSN01);ruxolitinib (MSN06) |
| Albumin mediated blood protein transport |
Down |
14.5 |
0.4444444 |
0.173913 |
0.4071856 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);dasatinib (MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08) |
| Albumin mediated blood protein transport |
Up |
26.5 |
0.3454545 |
0.4130435 |
0.348812 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);regorafenib (MSN01);ruxolitinib (MS |
| Albumin mediated blood protein transport |
Down |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Albumin mediated blood protein transport |
Down |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01);rituximab (MSN08) |
| Albumin mediated blood protein transport |
Down |
8 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
sorafenib (MSN08) |
imatinib (MSN01);nilotinib (MSN05);rituximab (MSN08) |
| Albumin mediated blood protein transport |
Down |
8.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sorafenib (MSN08) |
imatinib (MSN01);nilotinib (MSN05);rituximab (MSN06;MSN08) |
| Albumin mediated blood protein transport |
Down |
9 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
sorafenib (MSN01;MSN08) |
imatinib (MSN01);nilotinib (MSN05);rituximab (MSN06;MSN08) |
| Albumin mediated blood protein transport |
Down |
10 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
bevacizumab (MSN08);sorafenib (MSN01;MSN08) |
afatinib (MSN01);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN06;MSN08) |
| Albumin mediated blood protein transport |
Down |
11 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);sorafenib (MSN01;MSN08) |
afatinib (MSN01);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08) |
| Albumin mediated blood protein transport |
Down |
11.5 |
0.3571429 |
0.1086956 |
0.3148148 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);sorafenib (MSN01;MSN08) |
afatinib (MSN01);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08) |
| Albumin mediated blood protein transport |
Down |
12 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08) |
afatinib (MSN01);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08) |
| Albumin mediated blood protein transport |
Down |
12.5 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08) |
| Amyloid plaque organization |
Up |
18 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN09);pazopanib (MSN06) |
afatinib (MSN01);ruxolitinib (MSN06) |
| Albumin mediated blood protein transport |
Down |
15.5 |
0.4 |
0.173913 |
0.3715847 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);cetuximab (MSN09);dasatinib (MSN06;MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08) |
| Albumin mediated blood protein transport |
Down |
16 |
0.3809524 |
0.173913 |
0.356021 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN05);cetuximab (MSN09);dasatinib (MSN06;MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08) |
| Albumin mediated blood protein transport |
Down |
16.5 |
0.3636364 |
0.173913 |
0.3417086 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN05);cetuximab (MSN09);dasatinib (MSN06;MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08);vemurafenib (MSN06) |
| Albumin mediated blood protein transport |
Down |
17.5 |
0.3478261 |
0.173913 |
0.3285024 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN05);cetuximab (MSN09);dasatinib (MSN05;MSN06;MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08);vemurafenib (MSN06) |
| Albumin mediated blood protein transport |
Down |
19.5 |
0.3333333 |
0.173913 |
0.3162791 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN05);ceritinib (MSN01);cetuximab (MSN09);dasatinib (MSN05;MSN06;MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08);vemurafenib (MSN06) |
| Albumin mediated blood protein transport |
Down |
24.5 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN05);ceritinib (MSN01);cetuximab (MSN09);dasatinib (MSN05;MSN06;MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08);vemurafenib (MSN06) |
| Albumin mediated blood protein transport |
Down |
26 |
0.3461539 |
0.1956522 |
0.3311689 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01) |
afatinib (MSN01;MSN09);axitinib (MSN05);ceritinib (MSN01);cetuximab (MSN09);dasatinib (MSN05;MSN06;MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08);vemurafenib (MSN06) |
| Albumin mediated blood protein transport |
Down |
35 |
0.3333333 |
0.1956522 |
0.3200837 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01) |
afatinib (MSN01;MSN09);axitinib (MSN05);ceritinib (MSN01);cetuximab (MSN09);dasatinib (MSN05;MSN06;MSN09);erlotinib (MSN09);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08);vemurafenib (MSN06) |
| Alternative complement pathway |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN05;MSN08;MSN09) |
| Alternative complement pathway |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN06);gefitinib (MSN05;MSN08;MSN09) |
| Alternative complement pathway |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN01;MSN09);dasatinib (MSN06);gefitinib (MSN05;MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
17.5 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
crizotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Up |
14 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
lapatinib (MSN01);sunitinib (MSN06;MSN08);trastuzumab (MSN01) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01);ceritinib (MSN01;MSN05);imatinib (MSN06);rituximab (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Up |
26 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
lapatinib (MSN01);sunitinib (MSN06;MSN08);trastuzumab (MSN01) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01);ceritinib (MSN01;MSN05);imatinib (MSN06);nilotinib (MSN01);rituximab (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
2 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sorafenib (MSN01) |
regorafenib (MSN06) |
| Antigen presentation via MHC class I molecules |
Down |
8 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sorafenib (MSN01) |
regorafenib (MSN01;MSN06) |
| Antigen presentation via MHC class I molecules |
Down |
9.5 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN08);sorafenib (MSN01;MSN09) |
regorafenib (MSN01;MSN05;MSN06;MSN08) |
| Antigen presentation via MHC class I molecules |
Down |
10 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);sorafenib (MSN01;MSN09) |
regorafenib (MSN01;MSN05;MSN06;MSN08) |
| Antigen presentation via MHC class I molecules |
Down |
10.5 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);sorafenib (MSN01;MSN09) |
regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02) |
| Antigen presentation via MHC class I molecules |
Down |
11.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02) |
| Antigen presentation via MHC class I molecules |
Down |
14 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02);tofacitinib (MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
15 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02);tofacitinib (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
16 |
0.3571429 |
0.1086956 |
0.3148148 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN09);tofacitinib (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
17 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Up |
12.5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
sunitinib (MSN06;MSN08);trastuzumab (MSN01) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01);ceritinib (MSN01;MSN05);imatinib (MSN06);rituximab (MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
18 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
crizotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
19 |
0.2631579 |
0.1086956 |
0.2428571 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
crizotinib (MSN01);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
27.5 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
crizotinib (MSN01);gefitinib (MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN08;MSN09) |
| Antigen presentation via MHC class I molecules |
Down |
28 |
0.2380952 |
0.1086956 |
0.222513 |
NaN |
NaN |
dabrafenib (MSN06;MSN08);ponatinib (MSN01);sorafenib (MSN01;MSN09) |
crizotinib (MSN01);gefitinib (MSN06;MSN08);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06;MSN08;MSN09) |
| Apoptosome assembly |
Up |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01) |
| Apoptosome assembly |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09) |
| Apoptosome assembly |
Down |
21.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09);erlotinib (MSN05) |
| Apoptosome assembly |
Down |
24.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN09);erlotinib (MSN05) |
| Aspartate and arginine metabolism |
Up |
3 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN05) |
erlotinib (MSN05;MSN09) |
| Aspartate and arginine metabolism |
Up |
6 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN09) |
cabozantinib (MSN01);erlotinib (MSN05;MSN09) |
| Aspartate and arginine metabolism |
Up |
7 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN09) |
cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09) |
| Androgen receptor signaling |
Up |
13 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
sunitinib (MSN05);trametinib (MSN05;MSN08;MSN09) |
erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN09);tofacitinib (MSN01;MSN08) |
| Amyloid plaque organization |
Down |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02) |
| Amyloid plaque organization |
Down |
15 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);cetuximab (MSN02) |
| Amyloid plaque organization |
Down |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);cabozantinib (MSN02);cetuximab (MSN02) |
| Amyloid plaque organization |
Down |
21 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08;MSN09);cabozantinib (MSN02);cetuximab (MSN02) |
| Anchoring of nuclear membrane to cytoskeleton |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09) |
| Androgen receptor signaling |
Up |
5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN05) |
|
| Androgen receptor signaling |
Up |
5.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN05) |
erlotinib (MSN05) |
| Androgen receptor signaling |
Up |
8.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN05) |
erlotinib (MSN05);gefitinib (MSN01) |
| Androgen receptor signaling |
Up |
9 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09) |
erlotinib (MSN05);gefitinib (MSN01) |
| Androgen receptor signaling |
Up |
10 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09) |
erlotinib (MSN05);gefitinib (MSN01;MSN09) |
| Androgen receptor signaling |
Up |
11 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09) |
erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN09);tofacitinib (MSN01) |
| Albumin mediated blood protein transport |
Up |
23 |
0.3518519 |
0.4130435 |
0.3549451 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN0 |
| Androgen receptor signaling |
Up |
14 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
sunitinib (MSN05;MSN09);trametinib (MSN05;MSN08;MSN09) |
erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN09);tofacitinib (MSN01;MSN08) |
| Androgen receptor signaling |
Up |
14.5 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
sunitinib (MSN05;MSN09);trametinib (MSN05;MSN08;MSN09) |
erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN09);tofacitinib (MSN01;MSN05;MSN08) |
| Androgen synthesis |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Antidiuretic hormone receptor signaling |
Up |
15.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09) |
| Antigen presentation via MHC class I molecules |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN01) |
| Antigen presentation via MHC class I molecules |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN01;MSN05) |
| Antigen presentation via MHC class I molecules |
Up |
7.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sunitinib (MSN08) |
axitinib (MSN06);bosutinib (MSN01);ceritinib (MSN01;MSN05) |
| Antigen presentation via MHC class I molecules |
Up |
8 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
sunitinib (MSN08) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01);ceritinib (MSN01;MSN05) |
| Antigen presentation via MHC class I molecules |
Up |
9 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
sunitinib (MSN08) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01);ceritinib (MSN01;MSN05);rituximab (MSN09) |
| Antigen presentation via MHC class I molecules |
Up |
10.5 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
sunitinib (MSN06;MSN08) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01);ceritinib (MSN01;MSN05);rituximab (MSN09) |
| Antigen presentation via MHC class I molecules |
Up |
12 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
sunitinib (MSN06;MSN08) |
axitinib (MSN01;MSN06;MSN09);bosutinib (MSN01);ceritinib (MSN01;MSN05);imatinib (MSN06);rituximab (MSN09) |
| Adrenergic receptor signaling |
Up |
27 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08);cetuximab (MSN02);dasatinib (MSN08);nilotinib (MSN01) |
| Activin receptor signaling |
Down |
10 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN09) |
|
| Acute-phase response |
Up |
22 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN08) |
| Adenylyl cyclase signaling pathway |
Down |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Adherens junction organization |
Up |
8 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Adherens junction organization |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN06) |
| Adherens junction organization |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN09);imatinib (MSN06) |
| Adherens junction organization |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN08;MSN09);imatinib (MSN06) |
| Adherens junction organization |
Down |
14 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN08;MSN09);imatinib (MSN06) |
| Adherens junction organization |
Down |
22 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN06) |
| Adrenergic receptor signaling |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02) |
| Adrenergic receptor signaling |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08);cetuximab (MSN02) |
| Adrenergic receptor signaling |
Up |
18 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08);cetuximab (MSN02);dasatinib (MSN08) |
| Actin polymerization |
Down |
20 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sorafenib (MSN01) |
crizotinib (MSN05;MSN08);nilotinib (MSN05);ruxolitinib (MSN01) |
| Aggrecan synthesis |
Up |
4.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN09) |
|
| Aggrecan synthesis |
Up |
6 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
trametinib (MSN08;MSN09) |
|
| Aggrecan synthesis |
Up |
6.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trametinib (MSN08;MSN09) |
vemurafenib (MSN01) |
| Aggrecan synthesis |
Up |
8 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
trametinib (MSN08;MSN09);trastuzumab (MSN09) |
vemurafenib (MSN01) |
| Aggrecan synthesis |
Up |
9 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
trametinib (MSN08;MSN09);trastuzumab (MSN09) |
bosutinib (MSN09);imatinib (MSN09);vemurafenib (MSN01) |
| Aggrecan synthesis |
Up |
9.5 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
trametinib (MSN08;MSN09);trastuzumab (MSN09) |
bosutinib (MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
10 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
trametinib (MSN08;MSN09);trastuzumab (MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
11.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
trametinib (MSN08;MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
13 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
13.5 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN08;MSN09);imatinib (MSN09);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
14.5 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN08;MSN09);ceritinib (MSN06);imatinib (MSN09);vemurafenib (MSN01;MSN08) |
| Actin filament bundling and crosslinking |
Down |
18 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
ponatinib (MSN01;MSN09) |
crizotinib (MSN08);tofacitinib (MSN09) |
| Acetylcholine-mediated control of postsynaptic potential |
Up |
5.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN02) |
|
| Acetylcholine-mediated control of postsynaptic potential |
Up |
12 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN02) |
ruxolitinib (MSN09) |
| Acetylcholine-mediated control of postsynaptic potential |
Down |
3 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Acetylcholine-mediated control of postsynaptic potential |
Down |
12 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN09) |
cabozantinib (MSN09) |
| Actin filament bundling and crosslinking |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01) |
| Actin filament bundling and crosslinking |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01);rituximab (MSN05) |
| Actin filament bundling and crosslinking |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01);ceritinib (MSN08);rituximab (MSN05) |
| Actin filament bundling and crosslinking |
Up |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01);ceritinib (MSN08;MSN09);rituximab (MSN05) |
| Actin filament bundling and crosslinking |
Down |
9.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN09) |
|
| Actin filament bundling and crosslinking |
Down |
13.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
ponatinib (MSN01;MSN09) |
|
| Actin filament bundling and crosslinking |
Down |
15 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
ponatinib (MSN01;MSN09) |
tofacitinib (MSN09) |
| Aggrecan synthesis |
Up |
15 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN08;MSN09);ceritinib (MSN06);imatinib (MSN09);vemurafenib (MSN01;MSN08) |
| Actin filament severing and depolymerization |
Down |
13 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN08) |
|
| Actin filament severing and depolymerization |
Down |
15 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN01) |
|
| Actin filament severing and depolymerization |
Down |
20.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN01) |
cabozantinib (MSN02) |
| Actin filament severing and depolymerization |
Down |
25.5 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN01;MSN09) |
cabozantinib (MSN02) |
| Actin polymerization |
Up |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Actin polymerization |
Up |
7 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN09) |
afatinib (MSN05) |
| Actin polymerization |
Up |
17 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN09) |
afatinib (MSN05);bosutinib (MSN01) |
| Actin polymerization |
Down |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN01) |
| Actin polymerization |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN05);ruxolitinib (MSN01) |
| Actin polymerization |
Down |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN08);nilotinib (MSN05);ruxolitinib (MSN01) |
| Actin polymerization |
Down |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN08);nilotinib (MSN05);ruxolitinib (MSN01) |
| Albumin mediated blood protein transport |
Up |
11 |
0.3030303 |
0.2173913 |
0.2961673 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN08;MSN09);bosutinib (MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN01; |
| Aggrecan synthesis |
Down |
24.5 |
0.2894737 |
0.2391304 |
0.2859327 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);cabozantinib (MSN02;MSN05;MSN06);cetuximab (MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MS |
| Albumin mediated blood protein transport |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN01) |
| Albumin mediated blood protein transport |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01);gefitinib (MSN01) |
| Albumin mediated blood protein transport |
Up |
6 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
ponatinib (MSN05) |
crizotinib (MSN08);dasatinib (MSN01);gefitinib (MSN01) |
| Albumin mediated blood protein transport |
Up |
6.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
ponatinib (MSN05) |
crizotinib (MSN08);dasatinib (MSN01);gefitinib (MSN01);vemurafenib (MSN01) |
| Albumin mediated blood protein transport |
Up |
7 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
ponatinib (MSN05) |
crizotinib (MSN01;MSN08);dasatinib (MSN01);gefitinib (MSN01);tofacitinib (MSN01;MSN08);vemurafenib (MSN01) |
| Albumin mediated blood protein transport |
Up |
7.5 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
ponatinib (MSN05) |
cabozantinib (MSN09);crizotinib (MSN01;MSN06;MSN08);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN01;MSN08);vemurafenib (MSN01;MSN05) |
| Albumin mediated blood protein transport |
Up |
8 |
0.1666667 |
0.06521739 |
0.1526946 |
NaN |
NaN |
ponatinib (MSN05);trastuzumab (MSN05;MSN09) |
cabozantinib (MSN02;MSN05;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05) |
| Albumin mediated blood protein transport |
Up |
9 |
0.1904762 |
0.08695652 |
0.1780105 |
NaN |
NaN |
ponatinib (MSN05);sunitinib (MSN05);trastuzumab (MSN05;MSN09) |
bosutinib (MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05) |
| Albumin mediated blood protein transport |
Up |
9.5 |
0.2 |
0.1086956 |
0.1905829 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN05);trastuzumab (MSN05;MSN09) |
bosutinib (MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN09) |
| Albumin mediated blood protein transport |
Up |
10 |
0.3 |
0.1956522 |
0.2908745 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN09);bosutinib (MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05);tofacitinib (MSN01;MSN05;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN09) |
| Aggrecan synthesis |
Down |
19.5 |
0.2972973 |
0.2391304 |
0.2931035 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN02;MSN05;MSN06);cetuximab (MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MS |
| Albumin mediated blood protein transport |
Up |
11.5 |
0.3243243 |
0.2608696 |
0.3197492 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09);vemuraf |
| Albumin mediated blood protein transport |
Up |
12 |
0.3421053 |
0.2826087 |
0.3379205 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09);vemuraf |
| Albumin mediated blood protein transport |
Up |
12.5 |
0.3333333 |
0.2826087 |
0.3298507 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MSN08;MSN09);v |
| Albumin mediated blood protein transport |
Up |
13 |
0.3333333 |
0.3043478 |
0.3314763 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN05;MS |
| Albumin mediated blood protein transport |
Up |
13.5 |
0.3181818 |
0.3043478 |
0.3173333 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05;MSN06;MSN08);tofacitinib (MS |
| Albumin mediated blood protein transport |
Up |
14 |
0.3111111 |
0.3043478 |
0.3107049 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN05;MSN06;MSN08);tofacitin |
| Albumin mediated blood protein transport |
Up |
15 |
0.3125 |
0.326087 |
0.3132678 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN02;MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN0 |
| Albumin mediated blood protein transport |
Up |
16 |
0.3265306 |
0.3478261 |
0.3277108 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN02;MSN05;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN0 |
| Albumin mediated blood protein transport |
Up |
17.5 |
0.34 |
0.3695652 |
0.3416075 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN02;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN0 |
| Albumin mediated blood protein transport |
Up |
20.5 |
0.3529412 |
0.3913043 |
0.3549884 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN0 |
| Albumin mediated blood protein transport |
Up |
21.5 |
0.3584906 |
0.4130435 |
0.3612976 |
NaN |
NaN |
lapatinib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN02;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);ruxolitinib (MSN01;MSN05;MSN06;MSN0 |
| Aggrecan synthesis |
Down |
11.5 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01);sunitinib (MSN02;MSN05) |
afatinib (MSN01);cabozantinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Aggrecan synthesis |
Up |
16.5 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN08;MSN09);ceritinib (MSN01;MSN06);imatinib (MSN09);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
18 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN08;MSN09);ceritinib (MSN01;MSN06);imatinib (MSN09);regorafenib (MSN06);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
19 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN08;MSN09);ceritinib (MSN01;MSN06);imatinib (MSN09);regorafenib (MSN05;MSN06);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
21 |
0.3333333 |
0.1304348 |
0.3053892 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08);imatinib (MSN09);regorafenib (MSN05;MSN06);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Up |
25 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN05;MSN06);bosutinib (MSN08;MSN09);ceritinib (MSN01;MSN06;MSN08);imatinib (MSN09);regorafenib (MSN05;MSN06;MSN08);vemurafenib (MSN01;MSN08) |
| Aggrecan synthesis |
Down |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Aggrecan synthesis |
Down |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
9 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sunitinib (MSN02) |
cabozantinib (MSN06);rituximab (MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
10 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
bevacizumab (MSN08);sunitinib (MSN02) |
afatinib (MSN01);cabozantinib (MSN06);rituximab (MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
10.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
bevacizumab (MSN08);sunitinib (MSN02;MSN05) |
afatinib (MSN01);cabozantinib (MSN06);rituximab (MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
11 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);sunitinib (MSN02;MSN05) |
afatinib (MSN01);cabozantinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Aspartate and arginine metabolism |
Up |
9.5 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN09) |
cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09) |
| Aggrecan synthesis |
Down |
12 |
0.5 |
0.173913 |
0.4503311 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN02;MSN05) |
afatinib (MSN01);cabozantinib (MSN06);crizotinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Aggrecan synthesis |
Down |
12.5 |
0.45 |
0.1956522 |
0.4180328 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05) |
afatinib (MSN01);cabozantinib (MSN06);crizotinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
13 |
0.4545455 |
0.2173913 |
0.4271357 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN06);crizotinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
13.5 |
0.4347826 |
0.2173913 |
0.410628 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN06);crizotinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
14 |
0.4 |
0.2173913 |
0.3811659 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN06);crizotinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
14.5 |
0.3846154 |
0.2173913 |
0.3679654 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN06);crizotinib (MSN01;MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
15 |
0.3703704 |
0.2173913 |
0.3556485 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN06);crizotinib (MSN01;MSN05;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
15.5 |
0.3125 |
0.2173913 |
0.3046595 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN05;MSN06);cetuximab (MSN05);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
16.5 |
0.2941177 |
0.2173913 |
0.2881356 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN02;MSN05;MSN06);cetuximab (MSN05);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
17.5 |
0.2857143 |
0.2173913 |
0.2805281 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN02;MSN05;MSN06);cetuximab (MSN05);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Aggrecan synthesis |
Down |
18.5 |
0.3055556 |
0.2391304 |
0.3006431 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN08);ponatinib (MSN09);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);cabozantinib (MSN02;MSN05;MSN06);cetuximab (MSN05);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cardiomyocyte pacemaker current generation |
Down |
6.5 |
0.6666667 |
0.2173913 |
0.5944056 |
NaN |
NaN |
dabrafenib (MSN06);pazopanib (MSN08);ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN08);crizotinib (MSN08);dasatinib (MSN08);nilotinib (MSN06;MSN09) |
| Cardiomyocyte pacemaker current generation |
Up |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
trametinib (MSN08) |
|
| Cardiomyocyte pacemaker current generation |
Up |
6.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
bevacizumab (MSN06);trametinib (MSN08) |
|
| Cardiomyocyte pacemaker current generation |
Up |
8.5 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
bevacizumab (MSN06);trametinib (MSN08);trastuzumab (MSN01) |
|
| Cardiomyocyte pacemaker current generation |
Up |
9.5 |
1 |
0.1086956 |
0.674603 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);trametinib (MSN08);trastuzumab (MSN01) |
|
| Cardiomyocyte pacemaker current generation |
Up |
12.5 |
1 |
0.1304348 |
0.7183099 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);trametinib (MSN08);trastuzumab (MSN01) |
|
| Cardiomyocyte pacemaker current generation |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN08) |
| Cardiomyocyte pacemaker current generation |
Down |
2 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN06) |
crizotinib (MSN08) |
| Cardiomyocyte pacemaker current generation |
Down |
3 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02;MSN06);sorafenib (MSN08);vandetanib (MSN08) |
axitinib (MSN08);crizotinib (MSN08);dasatinib (MSN08) |
| Cardiomyocyte pacemaker current generation |
Down |
4 |
0.6666667 |
0.1304348 |
0.5368421 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02;MSN06);sorafenib (MSN05;MSN08);vandetanib (MSN08) |
axitinib (MSN08);crizotinib (MSN08);dasatinib (MSN08) |
| Cardiomyocyte pacemaker current generation |
Down |
4.5 |
0.6 |
0.1304348 |
0.4951456 |
NaN |
NaN |
dabrafenib (MSN06);ponatinib (MSN02;MSN06);sorafenib (MSN05;MSN08);vandetanib (MSN08) |
axitinib (MSN08);crizotinib (MSN08);dasatinib (MSN08);nilotinib (MSN09) |
| Cardiomyocyte pacemaker current generation |
Down |
5 |
0.6363636 |
0.1521739 |
0.5360361 |
NaN |
NaN |
dabrafenib (MSN06);pazopanib (MSN08);ponatinib (MSN02;MSN06);sorafenib (MSN05;MSN08);vandetanib (MSN08) |
axitinib (MSN08);crizotinib (MSN08);dasatinib (MSN08);nilotinib (MSN09) |
| Cardiomyocyte pacemaker current generation |
Down |
6 |
0.7142857 |
0.2173913 |
0.6296296 |
NaN |
NaN |
dabrafenib (MSN06);pazopanib (MSN08);ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN08);crizotinib (MSN08);dasatinib (MSN08);nilotinib (MSN09) |
| Cardiomyocyte depolarization during action potential |
Down |
20.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
dabrafenib (MSN05) |
cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN06) |
| Cardiomyocyte pacemaker current generation |
Down |
8 |
0.6470588 |
0.2391304 |
0.5880503 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN02;MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN08);crizotinib (MSN08);dasatinib (MSN08);nilotinib (MSN06;MSN08;MSN09) |
| Cardiomyocyte pacemaker current generation |
Down |
8.5 |
0.6666667 |
0.2608696 |
0.6107785 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN08);crizotinib (MSN08);dasatinib (MSN08);nilotinib (MSN06;MSN08;MSN09) |
| Cardiomyocyte pacemaker current generation |
Down |
9 |
0.6190476 |
0.2826087 |
0.578534 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09);sunitinib (MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN08);cabozantinib (MSN08);crizotinib (MSN05;MSN08);dasatinib (MSN08);nilotinib (MSN06;MSN08;MSN09) |
| Cardiomyocyte pacemaker current generation |
Down |
15 |
0.5909091 |
0.2826087 |
0.5552764 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08);sorafenib (MSN05;MSN08;MSN09);sunitinib (MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN08);cabozantinib (MSN08);crizotinib (MSN05;MSN06;MSN08);dasatinib (MSN08);nilotinib (MSN06;MSN08;MSN09) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
3 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
|
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
4 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
trametinib (MSN05);vandetanib (MSN05;MSN08;MSN09) |
|
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
6 |
1 |
0.1086956 |
0.674603 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN05);vandetanib (MSN05;MSN08;MSN09) |
|
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
7 |
1 |
0.1304348 |
0.7183099 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
|
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
11 |
0.8571429 |
0.1304348 |
0.6455697 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
vemurafenib (MSN06) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
13 |
0.75 |
0.1304348 |
0.5862069 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);vemurafenib (MSN06) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
13.5 |
0.6666667 |
0.1304348 |
0.5368421 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);vemurafenib (MSN06;MSN08) |
| Calcitonin receptor signaling |
Up |
18 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
dabrafenib (MSN01);lapatinib (MSN05;MSN08) |
afatinib (MSN01);axitinib (MSN09);cetuximab (MSN01);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Bone morphogenetic protein receptor signaling |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01) |
| Bone morphogenetic protein receptor signaling |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN09);cabozantinib (MSN01) |
| Bone morphogenetic protein receptor signaling |
Down |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08;MSN09);cabozantinib (MSN01) |
| Bradykinin receptor signaling |
Up |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05) |
| Calcitonin receptor signaling |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01) |
| Calcitonin receptor signaling |
Up |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN01;MSN05;MSN09) |
| Calcitonin receptor signaling |
Up |
10 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
lapatinib (MSN08) |
dasatinib (MSN01;MSN05;MSN09) |
| Calcitonin receptor signaling |
Up |
11 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
lapatinib (MSN08) |
dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Calcitonin receptor signaling |
Up |
12 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
dabrafenib (MSN01);lapatinib (MSN08) |
dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Calcitonin receptor signaling |
Up |
15 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN01);lapatinib (MSN05;MSN08) |
dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Calcitonin receptor signaling |
Up |
17 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
dabrafenib (MSN01);lapatinib (MSN05;MSN08) |
afatinib (MSN01);cetuximab (MSN01);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
14 |
0.6 |
0.1304348 |
0.4951456 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);rituximab (MSN05);vemurafenib (MSN06;MSN08) |
| Calcitonin receptor signaling |
Up |
19.5 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
dabrafenib (MSN01);lapatinib (MSN05;MSN08);ponatinib (MSN02) |
afatinib (MSN01);axitinib (MSN09);cetuximab (MSN01);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Calcitonin receptor signaling |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN09) |
| Calcitonin receptor signaling |
Down |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN09);vemurafenib (MSN01) |
| Cardiomyocyte depolarization during action potential |
Up |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN05) |
| Cardiomyocyte depolarization during action potential |
Up |
8 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trastuzumab (MSN05) |
ruxolitinib (MSN05) |
| Cardiomyocyte depolarization during action potential |
Up |
11.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trastuzumab (MSN02;MSN05) |
ruxolitinib (MSN05) |
| Cardiomyocyte depolarization during action potential |
Up |
15 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
trastuzumab (MSN01;MSN02;MSN05) |
ruxolitinib (MSN05) |
| Cardiomyocyte depolarization during action potential |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06) |
| Cardiomyocyte depolarization during action potential |
Down |
12.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06;MSN08) |
| Cardiomyocyte depolarization during action potential |
Down |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN06;MSN08;MSN09) |
| Cardiomyocyte depolarization during action potential |
Down |
18.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN05) |
cabozantinib (MSN06;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
4.5 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
pazopanib (MSN01;MSN09);ponatinib (MSN09);sunitinib (MSN02;MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN05);imatinib (MSN05);rituximab (MSN06;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Up |
5.5 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
bevacizumab (MSN06;MSN09) |
afatinib (MSN06);axitinib (MSN05);ceritinib (MSN08);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
6 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
bevacizumab (MSN06;MSN09) |
afatinib (MSN06);axitinib (MSN05);ceritinib (MSN08);cetuximab (MSN06;MSN08;MSN09);crizotinib (MSN01;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
6.5 |
0.1333333 |
0.04347826 |
0.1188811 |
NaN |
NaN |
bevacizumab (MSN06;MSN09) |
afatinib (MSN06);axitinib (MSN05);ceritinib (MSN08);cetuximab (MSN06;MSN08;MSN09);crizotinib (MSN01;MSN09);dasatinib (MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
7 |
0.1875 |
0.06521739 |
0.1688742 |
NaN |
NaN |
bevacizumab (MSN06;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05);ceritinib (MSN08);cetuximab (MSN06;MSN08;MSN09);crizotinib (MSN01;MSN09);dasatinib (MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
7.5 |
0.2222222 |
0.08695652 |
0.2035928 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05);ceritinib (MSN08);cetuximab (MSN02;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN09);dasatinib (MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
9 |
0.2105263 |
0.08695652 |
0.1942857 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);axitinib (MSN05);ceritinib (MSN01;MSN08);cetuximab (MSN02;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN09);dasatinib (MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Down |
1 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| CCN intercellular signaling protein family receptor signaling |
Down |
2 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
pazopanib (MSN01);sunitinib (MSN05) |
axitinib (MSN01) |
| CCN intercellular signaling protein family receptor signaling |
Down |
3 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
pazopanib (MSN01;MSN09);sunitinib (MSN02;MSN05) |
axitinib (MSN01);imatinib (MSN05) |
| CCN intercellular signaling protein family receptor signaling |
Down |
3.5 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
pazopanib (MSN01;MSN09);sunitinib (MSN02;MSN05) |
axitinib (MSN01);cabozantinib (MSN05);imatinib (MSN05) |
| CCN intercellular signaling protein family receptor signaling |
Down |
4 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
pazopanib (MSN01;MSN09);sunitinib (MSN02;MSN05) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN05);imatinib (MSN05);rituximab (MSN06;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Up |
5 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
bevacizumab (MSN06) |
afatinib (MSN06);axitinib (MSN05);ceritinib (MSN08);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Down |
5 |
0.5555556 |
0.2173913 |
0.5089821 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01);cabozantinib (MSN05);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
5.5 |
0.5263158 |
0.2173913 |
0.4857143 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
6 |
0.5 |
0.2173913 |
0.4644809 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN06) |
| CCN intercellular signaling protein family receptor signaling |
Down |
6.5 |
0.5 |
0.2391304 |
0.4698493 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05);dasatinib (MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN06) |
| CCN intercellular signaling protein family receptor signaling |
Down |
7 |
0.4444444 |
0.2608696 |
0.4267782 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08);dasatinib (MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN06);vemurafenib (MSN05;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
7.5 |
0.4482759 |
0.2826087 |
0.4333333 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08);dasatinib (MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN06);vemurafenib (MSN01;MSN05;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
8 |
0.4333333 |
0.2826087 |
0.4201521 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08);dasatinib (MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
8.5 |
0.4193548 |
0.2826087 |
0.407749 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08);dasatinib (MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
9 |
0.40625 |
0.2826087 |
0.3960573 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08);dasatinib (MSN05;MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
10 |
0.3939394 |
0.2826087 |
0.3850174 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08;MSN09);dasatinib (MSN05;MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| CCN intercellular signaling protein family receptor signaling |
Down |
10.5 |
0.4117647 |
0.3043478 |
0.4033898 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN05;MSN09);ponatinib (MSN01;MSN09);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN01);axitinib (MSN01;MSN09);cabozantinib (MSN05;MSN08;MSN09);dasatinib (MSN05;MSN09);imatinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09);ruxolitinib (MSN01;MSN06);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
29 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN06;MSN08);ponatinib (MSN05);sunitinib (MSN08) |
afatinib (MSN06;MSN08;MSN09);axitinib (MSN01);cabozantinib (MSN01);imatinib (MSN06);nilotinib (MSN05);rituximab (MSN09);ruxolitinib (MSN06) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
19 |
0.5833333 |
0.1521739 |
0.5 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN05;MSN09);trastuzumab (MSN01);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);rituximab (MSN05);ruxolitinib (MSN06);vemurafenib (MSN06;MSN08) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Up |
19.5 |
0.5 |
0.1521739 |
0.4407408 |
NaN |
NaN |
lapatinib (MSN06);trametinib (MSN05;MSN09);trastuzumab (MSN01);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN06);rituximab (MSN05;MSN06;MSN08);ruxolitinib (MSN06);vemurafenib (MSN06;MSN08) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN08) |
|
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sunitinib (MSN08) |
axitinib (MSN01);cabozantinib (MSN01) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
8 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
pazopanib (MSN08);sunitinib (MSN08) |
axitinib (MSN01);cabozantinib (MSN01);imatinib (MSN06) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
10 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN08) |
axitinib (MSN01);cabozantinib (MSN01);imatinib (MSN06);rituximab (MSN09) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
11 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
pazopanib (MSN06;MSN08);sunitinib (MSN08) |
axitinib (MSN01);cabozantinib (MSN01);imatinib (MSN06);nilotinib (MSN05);rituximab (MSN09) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
12 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN06;MSN08);ponatinib (MSN05);sunitinib (MSN08) |
axitinib (MSN01);cabozantinib (MSN01);imatinib (MSN06);nilotinib (MSN05);rituximab (MSN09) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
21 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN06;MSN08);ponatinib (MSN05);sunitinib (MSN08) |
axitinib (MSN01);cabozantinib (MSN01);imatinib (MSN06);nilotinib (MSN05);rituximab (MSN09);ruxolitinib (MSN06) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
23 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN06;MSN08);ponatinib (MSN05);sunitinib (MSN08) |
afatinib (MSN06);axitinib (MSN01);cabozantinib (MSN01);imatinib (MSN06);nilotinib (MSN05);rituximab (MSN09);ruxolitinib (MSN06) |
| Cardiomyocyte repolarization during action potential and hyperpolarization |
Down |
27 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
dabrafenib (MSN01;MSN06);pazopanib (MSN06;MSN08);ponatinib (MSN05);sunitinib (MSN08) |
afatinib (MSN06;MSN08);axitinib (MSN01);cabozantinib (MSN01);imatinib (MSN06);nilotinib (MSN05);rituximab (MSN09);ruxolitinib (MSN06) |
| Biglycan synthesis |
Up |
29.5 |
0.2195122 |
0.1956522 |
0.2179487 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);nilotinib (MSN05;MSN08);regorafenib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN02;M |
| Carnitine shuttle |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN09) |
| Carnitine shuttle |
Up |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN09);rituximab (MSN06) |
| Caveolin-mediated endocytosis |
Up |
1.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05) |
| Caveolin-mediated endocytosis |
Up |
13 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN09) |
ceritinib (MSN05) |
| Caveolin-mediated endocytosis |
Down |
2 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN09) |
|
| CCN intercellular signaling protein family receptor signaling |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);tofacitinib (MSN01;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
2.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);axitinib (MSN05);tofacitinib (MSN01;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);axitinib (MSN05);cetuximab (MSN06);crizotinib (MSN09);tofacitinib (MSN01;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);axitinib (MSN05);cetuximab (MSN06);crizotinib (MSN01;MSN09);tofacitinib (MSN01;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);axitinib (MSN05);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN09);tofacitinib (MSN01;MSN05;MSN08) |
| CCN intercellular signaling protein family receptor signaling |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);axitinib (MSN05);ceritinib (MSN08);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08) |
| Axonal intermediate filament dynamics |
Down |
7 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sunitinib (MSN08) |
crizotinib (MSN09);rituximab (MSN05) |
| Aspartate and arginine metabolism |
Down |
33.5 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trametinib (MSN09);trastuzumab (MSN01;MSN02) |
ceritinib (MSN09);cetuximab (MSN01);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Axonal intermediate filament dynamics |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN08) |
| Axonal intermediate filament dynamics |
Up |
1.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05);cetuximab (MSN08) |
| Axonal intermediate filament dynamics |
Up |
4.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
ponatinib (MSN05) |
afatinib (MSN05;MSN09);cetuximab (MSN08);vemurafenib (MSN09) |
| Axonal intermediate filament dynamics |
Up |
5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
ponatinib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN06);cetuximab (MSN08);vemurafenib (MSN05;MSN06;MSN09) |
| Axonal intermediate filament dynamics |
Up |
6 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
ponatinib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN06);cetuximab (MSN08);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Axonal intermediate filament dynamics |
Up |
6.5 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
ponatinib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN01;MSN06;MSN09);cetuximab (MSN08);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Axonal intermediate filament dynamics |
Up |
7.5 |
0.07692308 |
0.02173913 |
0.06692914 |
NaN |
NaN |
ponatinib (MSN05) |
afatinib (MSN05;MSN09);axitinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN05;MSN08);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Axonal intermediate filament dynamics |
Up |
8 |
0.07142857 |
0.02173913 |
0.06296296 |
NaN |
NaN |
ponatinib (MSN05) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN05;MSN08);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Axonal intermediate filament dynamics |
Up |
17 |
0.06666667 |
0.02173913 |
0.05944056 |
NaN |
NaN |
ponatinib (MSN05) |
afatinib (MSN01;MSN05;MSN09);axitinib (MSN01;MSN06;MSN08;MSN09);cetuximab (MSN05;MSN08);ruxolitinib (MSN02);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Axonal intermediate filament dynamics |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN09);rituximab (MSN05) |
| Aspartate and arginine metabolism |
Down |
32 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
lapatinib (MSN05;MSN08);trastuzumab (MSN01;MSN02) |
ceritinib (MSN09);cetuximab (MSN01);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Axonal intermediate filament dynamics |
Down |
9 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sunitinib (MSN08) |
crizotinib (MSN01;MSN08;MSN09);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
9.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
sunitinib (MSN08) |
crizotinib (MSN01;MSN08;MSN09);dasatinib (MSN01);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
11.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
lapatinib (MSN06);sunitinib (MSN08) |
crizotinib (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN01);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
12 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
lapatinib (MSN06;MSN08);sunitinib (MSN08) |
crizotinib (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN01);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
16.5 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);sunitinib (MSN08) |
ceritinib (MSN01);crizotinib (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
19.5 |
0.3076923 |
0.08695652 |
0.2677165 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);sunitinib (MSN08) |
ceritinib (MSN01);crizotinib (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01;MSN08);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
24.5 |
0.3571429 |
0.1086956 |
0.3148148 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);sunitinib (MSN08);trametinib (MSN05) |
ceritinib (MSN01);crizotinib (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN01);gefitinib (MSN01;MSN08);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
26 |
0.3333333 |
0.1086956 |
0.2972028 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);sunitinib (MSN08);trametinib (MSN05) |
ceritinib (MSN01);crizotinib (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN01);erlotinib (MSN01);gefitinib (MSN01;MSN08);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
28 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);sunitinib (MSN08);trametinib (MSN05) |
ceritinib (MSN01);crizotinib (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN01);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN08);rituximab (MSN05) |
| Axonal intermediate filament dynamics |
Down |
29.5 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
lapatinib (MSN06;MSN08;MSN09);sunitinib (MSN08);trametinib (MSN05) |
ceritinib (MSN01);crizotinib (MSN01;MSN06;MSN08;MSN09);dasatinib (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN08);rituximab (MSN05) |
| Base excision repair |
Up |
33 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN08) |
| Aspartate and arginine metabolism |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN01;MSN02;MSN06;MSN08;MSN09) |
| Aspartate and arginine metabolism |
Up |
11 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN09) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09) |
| Aspartate and arginine metabolism |
Up |
11.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09) |
| Aspartate and arginine metabolism |
Up |
16.5 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09) |
| Aspartate and arginine metabolism |
Up |
18 |
0.5833333 |
0.1521739 |
0.5 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN01) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09) |
| Aspartate and arginine metabolism |
Up |
19 |
0.6153846 |
0.173913 |
0.535433 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN01;MSN08) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09) |
| Aspartate and arginine metabolism |
Up |
24 |
0.5714286 |
0.173913 |
0.5037037 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN01;MSN08) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09);nilotinib (MSN09) |
| Aspartate and arginine metabolism |
Up |
25 |
0.5333334 |
0.173913 |
0.4755246 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN01;MSN08) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09);nilotinib (MSN05;MSN09) |
| Aspartate and arginine metabolism |
Up |
27 |
0.5 |
0.173913 |
0.4503311 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN01;MSN08) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09);nilotinib (MSN05;MSN06;MSN09) |
| Aspartate and arginine metabolism |
Up |
32 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN01;MSN08) |
afatinib (MSN01);cabozantinib (MSN01);erlotinib (MSN01;MSN05;MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09) |
| Aspartate and arginine metabolism |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN06) |
| Aspartate and arginine metabolism |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN06;MSN08;MSN09) |
| Base excision repair |
Down |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN06) |
| Aspartate and arginine metabolism |
Down |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
| Aspartate and arginine metabolism |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
| Aspartate and arginine metabolism |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
| Aspartate and arginine metabolism |
Down |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
| Aspartate and arginine metabolism |
Down |
13.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN08) |
| Aspartate and arginine metabolism |
Down |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Aspartate and arginine metabolism |
Down |
15 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
trastuzumab (MSN02) |
dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Aspartate and arginine metabolism |
Down |
16 |
0.07692308 |
0.02173913 |
0.06692914 |
NaN |
NaN |
trastuzumab (MSN02) |
cetuximab (MSN01);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Aspartate and arginine metabolism |
Down |
22.5 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
lapatinib (MSN08);trastuzumab (MSN02) |
cetuximab (MSN01);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Aspartate and arginine metabolism |
Down |
24 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
lapatinib (MSN08);trastuzumab (MSN01;MSN02) |
cetuximab (MSN01);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Aspartate and arginine metabolism |
Down |
27 |
0.1875 |
0.06521739 |
0.1688742 |
NaN |
NaN |
lapatinib (MSN08);trastuzumab (MSN01;MSN02) |
ceritinib (MSN09);cetuximab (MSN01);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN01);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Biglycan synthesis |
Up |
11.5 |
0.2142857 |
0.1304348 |
0.2064777 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05);ruxolitinib (MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09 |
| Biglycan synthesis |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN08) |
| Biglycan synthesis |
Up |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN08);vemurafenib (MSN01) |
| Biglycan synthesis |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN08);tofacitinib (MSN01);vemurafenib (MSN01) |
| Biglycan synthesis |
Up |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN06;MSN08);tofacitinib (MSN01);vemurafenib (MSN01;MSN05) |
| Biglycan synthesis |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN09);vemurafenib (MSN01;MSN05;MSN06) |
| Biglycan synthesis |
Up |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05);tofacitinib (MSN01;MSN09);vemurafenib (MSN01;MSN05;MSN06) |
| Biglycan synthesis |
Up |
9 |
0.07692308 |
0.02173913 |
0.06692914 |
NaN |
NaN |
sunitinib (MSN05) |
crizotinib (MSN01;MSN05;MSN06;MSN08);imatinib (MSN09);rituximab (MSN05);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06) |
| Biglycan synthesis |
Up |
9.5 |
0.05882353 |
0.02173913 |
0.05345912 |
NaN |
NaN |
sunitinib (MSN05) |
crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Biglycan synthesis |
Up |
10 |
0.1428571 |
0.06521739 |
0.1335078 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05) |
afatinib (MSN09);axitinib (MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Biglycan synthesis |
Up |
10.5 |
0.1818182 |
0.08695652 |
0.1708543 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN01;MSN02;MSN05) |
afatinib (MSN09);axitinib (MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Biglycan synthesis |
Up |
11 |
0.1923077 |
0.1086956 |
0.1839827 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Bicarbonate transmembrane transport |
Up |
18 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01);cabozantinib (MSN02;MSN09);dasatinib (MSN05;MSN09) |
| Biglycan synthesis |
Up |
12 |
0.2068966 |
0.1304348 |
0.2 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08 |
| Biglycan synthesis |
Up |
12.5 |
0.2333333 |
0.1521739 |
0.2262357 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08 |
| Biglycan synthesis |
Up |
13 |
0.2580645 |
0.173913 |
0.2509225 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08 |
| Biglycan synthesis |
Up |
13.5 |
0.25 |
0.173913 |
0.2437276 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN06 |
| Biglycan synthesis |
Up |
14 |
0.2424242 |
0.173913 |
0.2369338 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);cetuximab (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01;MSN05 |
| Biglycan synthesis |
Up |
15 |
0.2352941 |
0.173913 |
0.2305085 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);cetuximab (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN01 |
| Biglycan synthesis |
Up |
16.5 |
0.2285714 |
0.173913 |
0.2244224 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);ceritinib (MSN01);cetuximab (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN09); |
| Biglycan synthesis |
Up |
18.5 |
0.25 |
0.1956522 |
0.2459807 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);ceritinib (MSN01);cetuximab (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN09); |
| Biglycan synthesis |
Up |
19 |
0.2432432 |
0.1956522 |
0.2398119 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);ceritinib (MSN01);cetuximab (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);regorafenib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08;MSN09);tofacitinib (MSN01 |
| Biglycan synthesis |
Up |
21 |
0.2368421 |
0.1956522 |
0.2339449 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);regorafenib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08;MSN09);tofacitinib |
| Biglycan synthesis |
Up |
23 |
0.225 |
0.1956522 |
0.2230321 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN08);bosutinib (MSN01);ceritinib (MSN01;MSN08);cetuximab (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);nilotinib (MSN05);regorafenib (MSN05);rituximab (MSN05;MSN09);ruxolitinib (MSN02;MSN06;M |
| Basement membrane assembly and organization |
Down |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN09) |
| Base excision repair |
Down |
20 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN06;MSN09) |
| Base excision repair |
Down |
21 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN05) |
ceritinib (MSN06;MSN09) |
| Base excision repair |
Down |
23 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN05) |
ceritinib (MSN06;MSN09);erlotinib (MSN09) |
| Base excision repair |
Down |
26 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
dabrafenib (MSN05) |
ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN09) |
| Base excision repair |
Down |
35 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05) |
ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN09) |
| Base excision repair |
Down |
36 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN08) |
ceritinib (MSN05;MSN06;MSN09);erlotinib (MSN09) |
| Basement membrane assembly and organization |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Basement membrane assembly and organization |
Up |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08;MSN09) |
| Basement membrane assembly and organization |
Up |
9.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN01) |
rituximab (MSN08;MSN09) |
| Basement membrane assembly and organization |
Up |
11.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN01) |
cabozantinib (MSN08);rituximab (MSN08;MSN09) |
| Basement membrane assembly and organization |
Up |
25 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
dabrafenib (MSN01) |
cabozantinib (MSN01;MSN08);ceritinib (MSN08);rituximab (MSN08;MSN09) |
| Collagen fibril organization by fibril-associated bridges |
Up |
13.5 |
0.2195122 |
0.1956522 |
0.2179487 |
NaN |
NaN |
bevacizumab (MSN09);lapatinib (MSN01);ponatinib (MSN06;MSN09);trastuzumab (MSN01;MSN02;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06;MSN08);cetuximab (MSN08);dasatinib (MSN01;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofaciti |
| Basement membrane assembly and organization |
Down |
14 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02);crizotinib (MSN09) |
| Basement membrane assembly and organization |
Down |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02;MSN09);crizotinib (MSN09) |
| Basement membrane assembly and organization |
Down |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02;MSN09);crizotinib (MSN01;MSN09) |
| Basement membrane assembly and organization |
Down |
18 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02;MSN09);crizotinib (MSN01;MSN05;MSN09) |
| Basement membrane attachment to cell surface |
Up |
8 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Betaglycan signaling |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02) |
| Betaglycan signaling |
Down |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN06) |
| Bicarbonate transmembrane transport |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02) |
| Bicarbonate transmembrane transport |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02);dasatinib (MSN09) |
| Bicarbonate transmembrane transport |
Up |
11.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02);dasatinib (MSN05;MSN09) |
| Bicarbonate transmembrane transport |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN02;MSN09);dasatinib (MSN05;MSN09) |
| Fibrillar collagen core structure organization |
Down |
28 |
0.3484848 |
0.5 |
0.3548094 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);gefitinib (M |
| Fibrillar collagen core structure organization |
Down |
8 |
0.3541667 |
0.3695652 |
0.3550369 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN05);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regorafenib |
| Fibrillar collagen core structure organization |
Down |
9 |
0.36 |
0.3913043 |
0.3617021 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN05);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regora |
| Fibrillar collagen core structure organization |
Down |
9.5 |
0.372549 |
0.4130435 |
0.37471 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);bosutinib (MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);erlotinib (MSN05);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regora |
| Fibrillar collagen core structure organization |
Down |
10 |
0.3454545 |
0.4130435 |
0.348812 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN05);imatinib (MSN05);nilotinib (MSN01;MSN05;M |
| Fibrillar collagen core structure organization |
Down |
11.5 |
0.368421 |
0.4565217 |
0.3726513 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN05);imatinib (MSN05);nilotinib (MSN01;MSN05;M |
| Fibrillar collagen core structure organization |
Down |
13 |
0.362069 |
0.4565217 |
0.3665298 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN05);imatinib (MSN05);nilotinib (MSN01;M |
| Fibrillar collagen core structure organization |
Down |
14.5 |
0.3559322 |
0.4565217 |
0.3606061 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN05);imatinib (MSN05);nilotinib (MSN01;M |
| Fibrillar collagen core structure organization |
Down |
17 |
0.35 |
0.4565217 |
0.3548708 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);imatinib (MSN05);nilotinib (M |
| Fibrillar collagen core structure organization |
Down |
20 |
0.3442623 |
0.4565217 |
0.3493151 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);imatinib (MS |
| Fibrillar collagen core structure organization |
Down |
23 |
0.3548387 |
0.4782609 |
0.3603083 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);imatinib (MS |
| Fibrillar collagen core structure organization |
Down |
24 |
0.359375 |
0.5 |
0.3654206 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);gefitinib (M |
| Fibrillar collagen core structure organization |
Down |
27.5 |
0.3538462 |
0.5 |
0.3600368 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);gefitinib (M |
| Fibrillar collagen core structure organization |
Down |
7.5 |
0.3409091 |
0.326087 |
0.34 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08 |
| Fibrillar collagen core structure organization |
Down |
30 |
0.3432836 |
0.5 |
0.3497317 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);gefitinib (M |
| Fibrillar collagen core structure organization |
Down |
32 |
0.3529412 |
0.5217391 |
0.3597884 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN05;MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05);gefitinib (M |
| Fibrillar collagen core structure organization |
Down |
34.5 |
0.3478261 |
0.5217391 |
0.3547826 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN05;MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05);gefiti |
| Fibrillar collagen core structure organization |
Down |
36 |
0.3428572 |
0.5217391 |
0.3499143 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN05;MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN05);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (M |
| Fibrillar collagen core structure organization |
Down |
36.5 |
0.3380282 |
0.5217391 |
0.3451777 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN05;MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN05);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (M |
| Fibrillar collagen core structure organization |
Down |
38 |
0.3333333 |
0.5217391 |
0.3405676 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN01;MSN08);lapatinib (MSN05;MSN06;MSN09);pazopanib (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN05;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01;MSN09);axitinib (MSN08);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN05);cetuximab (MSN02;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (M |
| Fibrillin synthesis |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN08) |
| Fibrillin synthesis |
Up |
15.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN08) |
| Fibrillin synthesis |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN08);ruxolitinib (MSN05) |
| Fibrillin synthesis |
Up |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN08);ruxolitinib (MSN05) |
| Fibrillin synthesis |
Up |
18.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05) |
| Fibrillin synthesis |
Up |
22 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN08) |
| Fibrillar collagen core structure organization |
Up |
10.5 |
0.2753623 |
0.4130435 |
0.2808695 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MS |
| Fibrillar collagen core structure organization |
Up |
2 |
0.3191489 |
0.326087 |
0.3195488 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN09);dasatinib (MSN09);gefitinib (MSN06);rituximab (MSN06);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Fibrillar collagen core structure organization |
Up |
2.5 |
0.3125 |
0.326087 |
0.3132678 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN09);dasatinib (MSN08;MSN09);gefitinib (MSN06);rituximab (MSN06);ruxolitinib (MSN01;MSN05;MSN06;MSN08; |
| Fibrillar collagen core structure organization |
Up |
3 |
0.3035714 |
0.3695652 |
0.306794 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MSN06);regorafenib (MSN06);rituximab ( |
| Fibrillar collagen core structure organization |
Up |
3.5 |
0.2982456 |
0.3695652 |
0.3016701 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MSN06);regorafenib (MSN06);ritux |
| Fibrillar collagen core structure organization |
Up |
4 |
0.2931035 |
0.3695652 |
0.2967146 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MSN06);regorafenib (MSN06);ritux |
| Fibrillar collagen core structure organization |
Up |
5 |
0.2833333 |
0.3695652 |
0.2872763 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MSN06);regorafenib (MSN05; |
| Fibrillar collagen core structure organization |
Up |
5.5 |
0.295082 |
0.3913043 |
0.2994129 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MSN06);regorafenib (MSN05; |
| Fibrillar collagen core structure organization |
Up |
6 |
0.2857143 |
0.3913043 |
0.2903226 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MSN06);imatinib (MSN09);re |
| Fibrillar collagen core structure organization |
Up |
7 |
0.2769231 |
0.3913043 |
0.281768 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MSN06);i |
| Fibrillar collagen core structure organization |
Up |
7.5 |
0.2727273 |
0.3913043 |
0.277677 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MS |
| Fibrillar collagen core structure organization |
Up |
8 |
0.2686567 |
0.3913043 |
0.273703 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MS |
| Fibrillar collagen core structure organization |
Up |
8.5 |
0.2794118 |
0.4130435 |
0.2848325 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN01;MS |
| Fibroblast growth factor receptor signaling |
Up |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN05) |
| Fibrillar collagen core structure organization |
Up |
11 |
0.2714286 |
0.4130435 |
0.2770155 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitin |
| Fibrillar collagen core structure organization |
Up |
12 |
0.2777778 |
0.4347826 |
0.2838064 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN06);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitin |
| Fibrillar collagen core structure organization |
Up |
12.5 |
0.2876712 |
0.4565217 |
0.2940692 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN06);pazopanib (MSN06);ponatinib (MSN05);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN08;MSN09);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN08);gefitin |
| Fibrillar collagen core structure organization |
Down |
1 |
0.2631579 |
0.1086956 |
0.2428571 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05);trastuzumab (MSN02;MSN09) |
bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08);crizotinib (MSN01;MSN05);dasatinib (MSN01;MSN05);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN05;MSN06);rituximab (MSN05) |
| Fibrillar collagen core structure organization |
Down |
1.5 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05);trastuzumab (MSN02;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08);crizotinib (MSN01;MSN05);dasatinib (MSN01;MSN05);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN05;MSN06);rituximab (MSN05) |
| Fibrillar collagen core structure organization |
Down |
2 |
0.2962963 |
0.173913 |
0.2845188 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05);ponatinib (MSN05);sorafenib (MSN08);trastuzumab (MSN01;MSN02;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN01;MSN05;MSN06);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN05;MSN06;MSN08);rituximab (MSN05) |
| Fibrillar collagen core structure organization |
Down |
3 |
0.2647059 |
0.1956522 |
0.259322 |
NaN |
NaN |
dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05);ponatinib (MSN05);sorafenib (MSN08);trastuzumab (MSN01;MSN02;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN01;MSN05;MSN06);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05);vemu |
| Fibrillar collagen core structure organization |
Down |
4 |
0.2777778 |
0.2173913 |
0.2733119 |
NaN |
NaN |
dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05);ponatinib (MSN05);sorafenib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN01;MSN05;MSN06);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN08 |
| Fibrillar collagen core structure organization |
Down |
4.5 |
0.2972973 |
0.2391304 |
0.2931035 |
NaN |
NaN |
dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05);ponatinib (MSN05);sorafenib (MSN01;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN01;MSN05;MSN06);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN08 |
| Fibrillar collagen core structure organization |
Down |
5 |
0.3076923 |
0.2608696 |
0.3044776 |
NaN |
NaN |
dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN01;MSN05;MSN06);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN08 |
| Fibrillar collagen core structure organization |
Down |
6 |
0.325 |
0.2826087 |
0.3221574 |
NaN |
NaN |
bevacizumab (MSN08);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN01;MSN05;MSN06);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN05;MSN08 |
| Fibrillar collagen core structure organization |
Down |
7 |
0.3333333 |
0.3043478 |
0.3314763 |
NaN |
NaN |
bevacizumab (MSN08);dabrafenib (MSN01;MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN08);ponatinib (MSN02;MSN05);sorafenib (MSN01;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN01);bosutinib (MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);cetuximab (MSN02);crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN01;MSN05;MSN06);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ritu |
| G2 M transition checkpoint |
Up |
7.5 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
ponatinib (MSN06;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN06) |
| Fibulin receptor signaling |
Down |
14 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
sunitinib (MSN06;MSN08);vandetanib (MSN09) |
|
| Fibulin receptor signaling |
Down |
15 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
sunitinib (MSN05;MSN06;MSN08);vandetanib (MSN09) |
|
| Fibulin receptor signaling |
Down |
16 |
1 |
0.1304348 |
0.7183099 |
NaN |
NaN |
dabrafenib (MSN06);sunitinib (MSN01;MSN05;MSN06;MSN08);vandetanib (MSN09) |
|
| Fibulin receptor signaling |
Down |
16.5 |
1 |
0.1521739 |
0.7531646 |
NaN |
NaN |
dabrafenib (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08);vandetanib (MSN09) |
|
| Fibulin receptor signaling |
Down |
17 |
1 |
0.1956522 |
0.8052632 |
NaN |
NaN |
dabrafenib (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN09) |
|
| Fibulin receptor signaling |
Down |
22.5 |
0.9 |
0.1956522 |
0.7427185 |
NaN |
NaN |
dabrafenib (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN09) |
cabozantinib (MSN05) |
| Fibulin receptor signaling |
Down |
26.5 |
0.8181818 |
0.1956522 |
0.6891892 |
NaN |
NaN |
dabrafenib (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN09) |
cabozantinib (MSN05);cetuximab (MSN01) |
| Filopodium organization |
Up |
17 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Filopodium organization |
Down |
15.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05) |
| Folate cycle |
Down |
7.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| G2 M transition checkpoint |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN09) |
| G2 M transition checkpoint |
Up |
6.5 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
ponatinib (MSN06;MSN08;MSN09) |
cabozantinib (MSN09) |
| Fibulin receptor signaling |
Down |
13.5 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sunitinib (MSN06;MSN08) |
|
| G2 M transition checkpoint |
Up |
8 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
ponatinib (MSN06;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN06) |
| G2 M transition checkpoint |
Up |
8.5 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
ponatinib (MSN02;MSN06;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN06) |
| G2 M transition checkpoint |
Up |
9.5 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN06) |
| G2 M transition checkpoint |
Up |
12 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06) |
| G2 M transition checkpoint |
Up |
12.5 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN08) |
| G2 M transition checkpoint |
Up |
13.5 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN08;MSN09) |
| G2 M transition checkpoint |
Up |
14 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);vandetanib (MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN08;MSN09);regorafenib (MSN01) |
| G2 M transition checkpoint |
Up |
14.5 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);vandetanib (MSN09) |
axitinib (MSN08);cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01) |
| G2 M transition checkpoint |
Up |
15 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01) |
| G2 M transition checkpoint |
Up |
15.5 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN08);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01) |
| G2 M transition checkpoint |
Up |
16.5 |
0.4444444 |
0.173913 |
0.4071856 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN08);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01);ruxolitinib (MSN06) |
| G2 M transition checkpoint |
Up |
17 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN08);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01);ruxolitinib (MSN01;MSN06) |
| Fibulin receptor signaling |
Up |
14.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN05;MSN08) |
| Fibroblast growth factor receptor signaling |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN06);cabozantinib (MSN05) |
| Fibroblast growth factor receptor signaling |
Up |
13.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN06);cabozantinib (MSN05;MSN08) |
| Fibroblast growth factor receptor signaling |
Up |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN06);cabozantinib (MSN05;MSN06;MSN08) |
| Fibroblast growth factor receptor signaling |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02) |
| Fibroblast growth factor receptor signaling |
Down |
12.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02);imatinib (MSN09) |
| Fibroblast growth factor receptor signaling |
Down |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02);imatinib (MSN09);regorafenib (MSN05) |
| Fibroblast growth factor receptor signaling |
Down |
14 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
lapatinib (MSN01) |
cetuximab (MSN02);imatinib (MSN09);regorafenib (MSN05) |
| Fibroblast growth factor receptor signaling |
Down |
16.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
lapatinib (MSN01) |
cetuximab (MSN02);imatinib (MSN09);regorafenib (MSN05);vemurafenib (MSN08) |
| Fibroblast growth factor receptor signaling |
Down |
21 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
lapatinib (MSN01;MSN06) |
cetuximab (MSN02);imatinib (MSN09);regorafenib (MSN05);vemurafenib (MSN08) |
| Fibronectin synthesis and extracellular assembly |
Down |
1 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN09) |
|
| Fibronectin synthesis and extracellular assembly |
Down |
4 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
vandetanib (MSN09) |
cabozantinib (MSN06) |
| Fibulin receptor signaling |
Up |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN08) |
| Fibrillar collagen core structure organization |
Up |
1.5 |
0.3714286 |
0.2826087 |
0.3646865 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);sunitinib (MSN05;MSN08;MSN09);trametinib (MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN08);cetuximab (MSN01;MSN02;MSN05;MSN09);gefitinib (MSN06);rituximab (MSN06);ruxolitinib (MSN09);tofacitinib (MSN01;MSN05;MSN08);vemurafenib (MSN01;MSN05;MSN06) |
| Fibulin receptor signaling |
Up |
15 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
lapatinib (MSN06) |
tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
17 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
lapatinib (MSN06) |
ruxolitinib (MSN08);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
18.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
lapatinib (MSN01;MSN06) |
ruxolitinib (MSN08);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
22.5 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
lapatinib (MSN01;MSN06) |
ruxolitinib (MSN06;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
23.5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
lapatinib (MSN01;MSN06) |
ceritinib (MSN01);ruxolitinib (MSN06;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
25.5 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
lapatinib (MSN01;MSN06);sorafenib (MSN09) |
ceritinib (MSN01);ruxolitinib (MSN06;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
28.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
lapatinib (MSN01;MSN06);sorafenib (MSN05;MSN09) |
ceritinib (MSN01);ruxolitinib (MSN06;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
29.5 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
lapatinib (MSN01;MSN06);sorafenib (MSN05;MSN09) |
ceritinib (MSN01);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
30.5 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
lapatinib (MSN01;MSN06);sorafenib (MSN05;MSN09) |
ceritinib (MSN01);nilotinib (MSN09);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Up |
31 |
0.3076923 |
0.08695652 |
0.2677165 |
NaN |
NaN |
lapatinib (MSN01;MSN06);sorafenib (MSN05;MSN09) |
ceritinib (MSN01);nilotinib (MSN09);regorafenib (MSN08);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN05;MSN08) |
| Fibulin receptor signaling |
Down |
11.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
sunitinib (MSN06) |
|
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN06);rituximab (MSN05;MSN08) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Up |
11.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
lapatinib (MSN01) |
ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Up |
16 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
lapatinib (MSN01) |
ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN06) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
3 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN05) |
|
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
4.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
ponatinib (MSN05) |
axitinib (MSN06) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
6 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
ponatinib (MSN05) |
axitinib (MSN06);dasatinib (MSN01) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
6.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
ponatinib (MSN05) |
axitinib (MSN06);dasatinib (MSN01;MSN05) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
8.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
ponatinib (MSN05) |
axitinib (MSN06);cabozantinib (MSN02);dasatinib (MSN01;MSN05) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
9 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
ponatinib (MSN05) |
axitinib (MSN05;MSN06);cabozantinib (MSN02;MSN05);dasatinib (MSN01;MSN05) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
9.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
ponatinib (MSN05) |
axitinib (MSN05;MSN06);cabozantinib (MSN02;MSN05);dasatinib (MSN01;MSN05);imatinib (MSN05) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
15.5 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
ponatinib (MSN05);trametinib (MSN05;MSN09) |
axitinib (MSN05;MSN06);cabozantinib (MSN02;MSN05);dasatinib (MSN01;MSN05);imatinib (MSN05) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
18.5 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09) |
axitinib (MSN05;MSN06);cabozantinib (MSN02;MSN05);dasatinib (MSN01;MSN05);imatinib (MSN05) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Down |
21.5 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
ponatinib (MSN05);trametinib (MSN05;MSN08;MSN09) |
axitinib (MSN05;MSN06);cabozantinib (MSN02;MSN05);ceritinib (MSN05);dasatinib (MSN01;MSN05);imatinib (MSN05) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Up |
5.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
lapatinib (MSN01) |
crizotinib (MSN01;MSN05;MSN08;MSN09) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
2 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
sunitinib (MSN02;MSN05) |
cetuximab (MSN06);rituximab (MSN05;MSN08;MSN09) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
3 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
sunitinib (MSN02;MSN05;MSN06;MSN08) |
cetuximab (MSN06);rituximab (MSN05;MSN08;MSN09);ruxolitinib (MSN05;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
4 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cetuximab (MSN06);erlotinib (MSN01);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
6 |
0.3529412 |
0.1304348 |
0.3207547 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cetuximab (MSN06);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
7.5 |
0.3333333 |
0.1304348 |
0.3053892 |
NaN |
NaN |
sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
afatinib (MSN06);cetuximab (MSN06);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
8 |
0.375 |
0.1956522 |
0.355814 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN09);cetuximab (MSN06);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Decorin synthesis |
Up |
8 |
0.2222222 |
0.08695652 |
0.2035928 |
NaN |
NaN |
lapatinib (MSN08;MSN09);trametinib (MSN05;MSN09) |
crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN09);erlotinib (MSN08);gefitinib (MSN06;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN09);vemurafenib (MSN01;MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
9.5 |
0.3461539 |
0.1956522 |
0.3311689 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN06;MSN09);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
10 |
0.3571429 |
0.2173913 |
0.3441296 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN06;MSN09);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
11 |
0.3793103 |
0.2391304 |
0.3666666 |
NaN |
NaN |
bevacizumab (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN06;MSN09);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
12 |
0.3666667 |
0.2391304 |
0.3555134 |
NaN |
NaN |
bevacizumab (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01);cetuximab (MSN06;MSN09);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
13 |
0.3548387 |
0.2391304 |
0.3450184 |
NaN |
NaN |
bevacizumab (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN06;MSN09);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by cathepsins |
Down |
5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
sorafenib (MSN01;MSN08) |
bosutinib (MSN01);imatinib (MSN06) |
| Extracellular matrix breakdown by cathepsins |
Up |
8.5 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
sunitinib (MSN05;MSN08);trastuzumab (MSN02;MSN05) |
crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
9 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
dabrafenib (MSN05);sunitinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN06;MSN09);crizotinib (MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
11.5 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
dabrafenib (MSN05;MSN08);sunitinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN06;MSN09);crizotinib (MSN06);rituximab (MSN05;MSN09);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
12.5 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
dabrafenib (MSN05;MSN08);sunitinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN06;MSN09);crizotinib (MSN06);rituximab (MSN05;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
13 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
dabrafenib (MSN05;MSN08);ponatinib (MSN09);sunitinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN06;MSN09);crizotinib (MSN06);rituximab (MSN05;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
14 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
dabrafenib (MSN05;MSN08);ponatinib (MSN09);sunitinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN06;MSN09);cetuximab (MSN09);crizotinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
16 |
0.45 |
0.1956522 |
0.4180328 |
NaN |
NaN |
dabrafenib (MSN05;MSN08;MSN09);ponatinib (MSN09);sunitinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN06;MSN09);cetuximab (MSN09);crizotinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
16.5 |
0.4761905 |
0.2173913 |
0.4450262 |
NaN |
NaN |
dabrafenib (MSN05;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN09);sunitinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN06;MSN09);cetuximab (MSN09);crizotinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
17.5 |
0.4545455 |
0.2173913 |
0.4271357 |
NaN |
NaN |
dabrafenib (MSN05;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN09);sunitinib (MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN06;MSN09);cetuximab (MSN06;MSN09);crizotinib (MSN06);rituximab (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN01) |
| Extracellular matrix breakdown by cathepsins |
Down |
4 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sorafenib (MSN08) |
bosutinib (MSN01) |
| Extracellular matrix breakdown by cathepsins |
Down |
4.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
sorafenib (MSN01;MSN08) |
bosutinib (MSN01) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
14 |
0.34375 |
0.2391304 |
0.3351255 |
NaN |
NaN |
bevacizumab (MSN06;MSN08);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN06;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by cathepsins |
Down |
8 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
sorafenib (MSN01;MSN05;MSN08) |
bosutinib (MSN01);imatinib (MSN06) |
| Extracellular matrix breakdown by cathepsins |
Down |
10 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN08) |
bosutinib (MSN01);imatinib (MSN06) |
| Extracellular matrix breakdown by cathepsins |
Down |
10.5 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN08) |
axitinib (MSN01);bosutinib (MSN01);imatinib (MSN06) |
| Extracellular matrix breakdown by cathepsins |
Down |
15 |
0.6666667 |
0.1304348 |
0.5368421 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);lapatinib (MSN06);sorafenib (MSN01;MSN05;MSN08) |
axitinib (MSN01);bosutinib (MSN01);imatinib (MSN06) |
| Extracellular matrix breakdown by cathepsins |
Down |
22.5 |
0.7 |
0.1521739 |
0.5776699 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);lapatinib (MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08) |
axitinib (MSN01);bosutinib (MSN01);imatinib (MSN06) |
| Extracellular matrix breakdown by cathepsins |
Down |
28 |
0.6363636 |
0.1521739 |
0.5360361 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);lapatinib (MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08) |
axitinib (MSN01);bosutinib (MSN01);gefitinib (MSN06);imatinib (MSN06) |
| Extracellular matrix breakdown by cathepsins |
Down |
32 |
0.6666667 |
0.173913 |
0.5714285 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);lapatinib (MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08) |
axitinib (MSN01);bosutinib (MSN01);gefitinib (MSN06);imatinib (MSN06) |
| Extracellular matrix breakdown by cathepsins |
Down |
36 |
0.6153846 |
0.173913 |
0.535433 |
NaN |
NaN |
dabrafenib (MSN05;MSN06);lapatinib (MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08) |
axitinib (MSN01);bosutinib (MSN01);ceritinib (MSN05);gefitinib (MSN06);imatinib (MSN06) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Up |
1.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN09) |
| Extracellular matrix breakdown by heparanases and sulfatases |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN08;MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN01);erlotinib (MSN01;MSN08;MSN09) |
| Extracellular matrix breakdown by serine proteases |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN01) |
| Extracellular matrix breakdown by serine proteases |
Down |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05);nilotinib (MSN01) |
| Extracellular matrix breakdown by serine proteases |
Down |
7.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05);dasatinib (MSN06);nilotinib (MSN01) |
| Extracellular matrix breakdown by serine proteases |
Down |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01;MSN09);crizotinib (MSN05);dasatinib (MSN06);nilotinib (MSN01) |
| Extracellular matrix breakdown by serine proteases |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01;MSN09);crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN06);nilotinib (MSN01) |
| Extracellular matrix breakdown by serine proteases |
Down |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01;MSN09);crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN01;MSN06);nilotinib (MSN01) |
| Extrinsic apoptosis pathway |
Up |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01) |
| Extrinsic apoptosis pathway |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN01) |
| Fanconi anemia interstrand cross-link repair pathway |
Up |
20 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02) |
| Fanconi anemia interstrand cross-link repair pathway |
Up |
30 |
0 |
0 |
NaN |
NaN |
NaN |
|
regorafenib (MSN01);ruxolitinib (MSN02) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN01;MSN09) |
| Extracellular matrix breakdown by serine proteases |
Up |
13 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
bevacizumab (MSN09);pazopanib (MSN09) |
axitinib (MSN05);bosutinib (MSN08);regorafenib (MSN06);vemurafenib (MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN01;MSN05);erlotinib (MSN01;MSN08;MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
10 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
dabrafenib (MSN05) |
ceritinib (MSN01;MSN05);erlotinib (MSN01;MSN08;MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
11 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05) |
ceritinib (MSN01;MSN05;MSN06);erlotinib (MSN01;MSN08;MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
13 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN08) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
17 |
0.3076923 |
0.08695652 |
0.2677165 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
19 |
0.3571429 |
0.1086956 |
0.3148148 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
24 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Fanconi anemia interstrand cross-link repair pathway |
Down |
29 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Fatty acid elongation |
Up |
4 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN08) |
|
| Fatty acid transfer between membranes |
Up |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06) |
| Fatty acid transfer between membranes |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01) |
| Fibrillar collagen core structure organization |
Up |
1 |
0.3636364 |
0.2608696 |
0.3554007 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);sunitinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN01;MSN06;MSN09);axitinib (MSN01;MSN05;MSN06;MSN09);ceritinib (MSN08);cetuximab (MSN01;MSN02;MSN05;MSN09);gefitinib (MSN06);rituximab (MSN06);ruxolitinib (MSN09);tofacitinib (MSN01;MSN05;MSN08);vemurafenib (MSN01;MSN05;MSN06) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
10 |
0.3478261 |
0.173913 |
0.3285024 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN01;MSN05;MSN06);bosutinib (MSN01;MSN05);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05);vemurafenib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
14.5 |
0.3636364 |
0.2608696 |
0.3554007 |
NaN |
NaN |
bevacizumab (MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN06;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
19 |
0.3529412 |
0.2608696 |
0.3457627 |
NaN |
NaN |
bevacizumab (MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN01;MSN06);cetuximab (MSN06;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
24 |
0.3428572 |
0.2608696 |
0.3366337 |
NaN |
NaN |
bevacizumab (MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN01);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN06;MSN09);dasatinib (MSN08;MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05;MSN06);cabozantinib (MSN02;MSN05;MSN06);dasatinib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
3 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
lapatinib (MSN06) |
axitinib (MSN05;MSN06);bosutinib (MSN05);cabozantinib (MSN02;MSN05;MSN06;MSN09);dasatinib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
4 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
lapatinib (MSN06);ponatinib (MSN02);trastuzumab (MSN02) |
axitinib (MSN05;MSN06);bosutinib (MSN05);cabozantinib (MSN02;MSN05;MSN06;MSN09);dasatinib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
5 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN06);ponatinib (MSN02);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN05;MSN06);bosutinib (MSN05);cabozantinib (MSN02;MSN05;MSN06;MSN09);dasatinib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
7 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN05;MSN06);bosutinib (MSN05);cabozantinib (MSN02;MSN05;MSN06;MSN09);dasatinib (MSN05);imatinib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
8 |
0.4444444 |
0.173913 |
0.4071856 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN05;MSN06);bosutinib (MSN05);cabozantinib (MSN02;MSN05;MSN06;MSN09);dasatinib (MSN05);imatinib (MSN05);regorafenib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
8.5 |
0.4210526 |
0.173913 |
0.3885714 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN05;MSN06);bosutinib (MSN01;MSN05);cabozantinib (MSN02;MSN05;MSN06;MSN09);dasatinib (MSN05);imatinib (MSN05);regorafenib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
9 |
0.3809524 |
0.173913 |
0.356021 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN01;MSN05;MSN06);bosutinib (MSN01;MSN05);cabozantinib (MSN02;MSN05;MSN06;MSN09);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05) |
| G2 M transition checkpoint |
Up |
18 |
0.4285714 |
0.1956522 |
0.4005235 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01);ruxolitinib (MSN01;MSN06;MSN09) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
10.5 |
0.3333333 |
0.173913 |
0.3162791 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN01;MSN05;MSN06);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05);vemurafenib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
11 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN01;MSN05;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05);vemurafenib (MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
12 |
0.2962963 |
0.173913 |
0.2845188 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN01;MSN05;MSN06;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05);vemurafenib (MSN01;MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
17 |
0.2857143 |
0.173913 |
0.2753036 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05);vemurafenib (MSN01;MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
23 |
0.2758621 |
0.173913 |
0.2666667 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05);gefitinib (MSN08);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05);vemurafenib (MSN01;MSN05) |
| Extracellular matrix breakdown by matrix metalloproteases |
Down |
29 |
0.2666667 |
0.173913 |
0.2585552 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN06);ponatinib (MSN02;MSN08);trametinib (MSN01);trastuzumab (MSN02) |
axitinib (MSN01;MSN05;MSN06;MSN08;MSN09);bosutinib (MSN01;MSN05;MSN09);cabozantinib (MSN02;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN01;MSN05);gefitinib (MSN05;MSN08);imatinib (MSN05);nilotinib (MSN01);regorafenib (MSN05);vemurafenib (MSN01;MSN05) |
| Extracellular matrix breakdown by serine proteases |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN09) |
| Extracellular matrix breakdown by serine proteases |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);vemurafenib (MSN09) |
| Extracellular matrix breakdown by serine proteases |
Up |
6.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
pazopanib (MSN09) |
axitinib (MSN05);vemurafenib (MSN09) |
| Extracellular matrix breakdown by serine proteases |
Up |
8 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
pazopanib (MSN09) |
axitinib (MSN05);bosutinib (MSN08);vemurafenib (MSN09) |
| Extracellular matrix breakdown by serine proteases |
Up |
10 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
bevacizumab (MSN09);pazopanib (MSN09) |
axitinib (MSN05);bosutinib (MSN08);vemurafenib (MSN09) |
| G-protein coupled receptor signaling pathway |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06;MSN08);cetuximab (MSN02) |
| Glycolysis and Gluconeogenesis |
Down |
9 |
0.3333333 |
0.1521739 |
0.3115183 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN05;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09) |
| Glycolysis and Gluconeogenesis |
Down |
10 |
0.3181818 |
0.1521739 |
0.298995 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN05;MSN09);gefitinib (MSN08);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09) |
| Glycolysis and Gluconeogenesis |
Down |
11 |
0.2916667 |
0.1521739 |
0.2767442 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN06;MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN05;MSN09);gefitinib (MSN08);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);vemurafenib (MSN01) |
| Glycolysis and Gluconeogenesis |
Down |
12 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN01;MSN02;MSN09) |
axitinib (MSN06;MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN05;MSN09);gefitinib (MSN08);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);vemurafenib (MSN01) |
| Glycolysis and Gluconeogenesis |
Down |
13 |
0.3 |
0.1956522 |
0.2908745 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN06;MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN01;MSN05;MSN09);erlotinib (MSN09);gefitinib (MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);vemurafenib (MSN01) |
| Glycolysis and Gluconeogenesis |
Down |
14 |
0.2903226 |
0.1956522 |
0.2822879 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN06;MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN01;MSN05;MSN09);erlotinib (MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);vemurafenib (MSN01) |
| Glycolysis and Gluconeogenesis |
Down |
18 |
0.28125 |
0.1956522 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN06;MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN01;MSN05;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);vemurafenib ( |
| Glycolysis and Gluconeogenesis |
Down |
24 |
0.3030303 |
0.2173913 |
0.2961673 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN05;MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN06;MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN01;MSN05;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);vemurafenib ( |
| Glycolysis and Gluconeogenesis |
Down |
31 |
0.3235294 |
0.2391304 |
0.3169491 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN05;MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trametinib (MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
axitinib (MSN06;MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN01;MSN09);dasatinib (MSN01;MSN05;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);vemurafenib ( |
| GPI-anchor synthesis and attachment to protein |
Down |
21.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN01) |
| G-protein coupled receptor signaling pathway |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN02) |
| G-protein coupled receptor signaling pathway |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06);cetuximab (MSN02) |
| Glycolysis and Gluconeogenesis |
Down |
8 |
0.35 |
0.1521739 |
0.3251366 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05;MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN09);dasatinib (MSN05;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09) |
| G-protein coupled receptor signaling pathway |
Up |
19 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN06;MSN08);cetuximab (MSN02);nilotinib (MSN01) |
| G-protein coupled receptor signaling pathway |
Down |
6 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09) |
|
| G-protein coupled receptor signaling pathway |
Down |
11.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09) |
imatinib (MSN06) |
| G-protein coupled receptor signaling pathway |
Down |
12 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN09) |
crizotinib (MSN09);imatinib (MSN06) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN08) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
cetuximab (MSN06;MSN08) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
10.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN01) |
cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
12 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN05) |
cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
12.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN05) |
afatinib (MSN09);cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
13 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
sunitinib (MSN05);trametinib (MSN01);trastuzumab (MSN05) |
afatinib (MSN09);axitinib (MSN05);cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
13.5 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
sunitinib (MSN01;MSN05);trametinib (MSN01);trastuzumab (MSN05) |
afatinib (MSN09);axitinib (MSN05);cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
14 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN06);cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Glycogen synthesis and glycogenolysis |
Down |
14.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN09);ponatinib (MSN05) |
cabozantinib (MSN06);ceritinib (MSN08) |
| Glutamate and glutamine metabolism |
Down |
17.5 |
0.2173913 |
0.1086956 |
0.205314 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05);sorafenib (MSN05) |
axitinib (MSN05;MSN06;MSN08);bosutinib (MSN05;MSN09);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN05;MSN09);tofacitinib (MSN06;MSN09) |
| Glutamate and glutamine metabolism |
Down |
18.5 |
0.2083333 |
0.1086956 |
0.1976744 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05);sorafenib (MSN05) |
axitinib (MSN05;MSN06;MSN08);bosutinib (MSN05;MSN09);cabozantinib (MSN05);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN05;MSN09);tofacitinib (MSN06;MSN09) |
| Glutamate and glutamine metabolism |
Down |
19 |
0.2 |
0.1086956 |
0.1905829 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05);sorafenib (MSN05) |
axitinib (MSN05;MSN06;MSN08);bosutinib (MSN05;MSN09);cabozantinib (MSN05);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN05;MSN09);tofacitinib (MSN06;MSN09);vemurafenib (MSN08) |
| Glutamate and glutamine metabolism |
Down |
22 |
0.1923077 |
0.1086956 |
0.1839827 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05);sorafenib (MSN05) |
afatinib (MSN06);axitinib (MSN05;MSN06;MSN08);bosutinib (MSN05;MSN09);cabozantinib (MSN05);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN05;MSN09);tofacitinib (MSN06;MSN09);vemuraf |
| Glutamate and glutamine metabolism |
Down |
25.5 |
0.2222222 |
0.1304348 |
0.2133891 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN09);pazopanib (MSN01);ponatinib (MSN05);sorafenib (MSN05) |
afatinib (MSN06);axitinib (MSN05;MSN06;MSN08);bosutinib (MSN05;MSN09);cabozantinib (MSN05);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN05;MSN09);tofacitinib (MSN06;MSN09);vemuraf |
| Glutamate and glutamine metabolism |
Down |
27 |
0.25 |
0.1521739 |
0.2408907 |
NaN |
NaN |
lapatinib (MSN01;MSN06;MSN08;MSN09);pazopanib (MSN01);ponatinib (MSN05);sorafenib (MSN05) |
afatinib (MSN06);axitinib (MSN05;MSN06;MSN08);bosutinib (MSN05;MSN09);cabozantinib (MSN05);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN05;MSN09);tofacitinib (MSN06;MSN09);vemuraf |
| Gluthatione conjugation |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN01) |
| Glycogen synthesis and glycogenolysis |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN08) |
| Glycogen synthesis and glycogenolysis |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN08);imatinib (MSN05) |
| Glycogen synthesis and glycogenolysis |
Down |
5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| Glycogen synthesis and glycogenolysis |
Down |
10 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN09) |
ceritinib (MSN08) |
| Glycogen synthesis and glycogenolysis |
Down |
13 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN09);ponatinib (MSN05) |
ceritinib (MSN08) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
15 |
0.5714286 |
0.173913 |
0.5037037 |
NaN |
NaN |
lapatinib (MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN09);axitinib (MSN05;MSN06);cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Glycogen synthesis and glycogenolysis |
Down |
20 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
dabrafenib (MSN06;MSN09);ponatinib (MSN05) |
cabozantinib (MSN06);ceritinib (MSN08) |
| Glycolysis and Gluconeogenesis |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08) |
| Glycolysis and Gluconeogenesis |
Up |
2 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
pazopanib (MSN01) |
afatinib (MSN08) |
| Glycolysis and Gluconeogenesis |
Up |
6 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
pazopanib (MSN01) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN02) |
| Glycolysis and Gluconeogenesis |
Up |
7 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
pazopanib (MSN01);trametinib (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN02) |
| Glycolysis and Gluconeogenesis |
Up |
9 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
pazopanib (MSN01);sunitinib (MSN06);trametinib (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN02) |
| Glycolysis and Gluconeogenesis |
Up |
10 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
pazopanib (MSN01);sunitinib (MSN06);trametinib (MSN01) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN02;MSN06) |
| Glycolysis and Gluconeogenesis |
Down |
1 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
dabrafenib (MSN09) |
axitinib (MSN09);cabozantinib (MSN06;MSN09);dasatinib (MSN09);imatinib (MSN09);rituximab (MSN06) |
| Glycolysis and Gluconeogenesis |
Down |
2 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
dabrafenib (MSN09);trastuzumab (MSN09) |
axitinib (MSN09);cabozantinib (MSN06;MSN08;MSN09);dasatinib (MSN09);imatinib (MSN09);rituximab (MSN05;MSN06) |
| Glycolysis and Gluconeogenesis |
Down |
3 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
dabrafenib (MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN09);cabozantinib (MSN06;MSN08;MSN09);dasatinib (MSN09);imatinib (MSN09);rituximab (MSN05;MSN06) |
| Glycolysis and Gluconeogenesis |
Down |
5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
dabrafenib (MSN09);trastuzumab (MSN02;MSN09) |
axitinib (MSN09);cabozantinib (MSN06;MSN08;MSN09);dasatinib (MSN05;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06) |
| Glycolysis and Gluconeogenesis |
Down |
6 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
dabrafenib (MSN09);lapatinib (MSN09);pazopanib (MSN09);sorafenib (MSN05);trastuzumab (MSN02;MSN09) |
axitinib (MSN08;MSN09);bosutinib (MSN05);cabozantinib (MSN06;MSN08;MSN09);ceritinib (MSN09);dasatinib (MSN05;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09) |
| Growth differentiation factor receptor signaling |
Up |
12 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
dabrafenib (MSN05);trastuzumab (MSN01) |
axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN01;MSN06) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01);ruxolitinib (MSN02);tofacitinib (MSN05) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01;MSN09);ruxolitinib (MSN02);tofacitinib (MSN05) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01;MSN09);ruxolitinib (MSN02);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01;MSN09);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
12.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01;MSN09);ruxolitinib (MSN02;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
13 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01;MSN09);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
15 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01;MSN09);ruxolitinib (MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Growth differentiation factor receptor signaling |
Up |
8 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN05) |
axitinib (MSN05) |
| Growth differentiation factor receptor signaling |
Up |
8.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN05);trastuzumab (MSN01) |
axitinib (MSN05) |
| Growth differentiation factor receptor signaling |
Up |
10.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN05);trastuzumab (MSN01) |
axitinib (MSN05);ceritinib (MSN01) |
| Growth differentiation factor receptor signaling |
Up |
11 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
dabrafenib (MSN05);trastuzumab (MSN01) |
axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN01) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08);bosutinib (MSN01) |
| Growth differentiation factor receptor signaling |
Up |
13 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
dabrafenib (MSN05);ponatinib (MSN02);trastuzumab (MSN01) |
axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN01;MSN06) |
| Growth differentiation factor receptor signaling |
Up |
20.5 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
dabrafenib (MSN05);ponatinib (MSN02);trastuzumab (MSN01) |
axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN01;MSN06);nilotinib (MSN01) |
| Growth differentiation factor receptor signaling |
Up |
21 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
dabrafenib (MSN05);ponatinib (MSN02);trastuzumab (MSN01) |
axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN01;MSN06);nilotinib (MSN01;MSN05) |
| Growth differentiation factor receptor signaling |
Up |
22.5 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
dabrafenib (MSN05);ponatinib (MSN02);trastuzumab (MSN01) |
axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN01;MSN06);nilotinib (MSN01;MSN05;MSN06) |
| Growth differentiation factor receptor signaling |
Up |
23 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
dabrafenib (MSN05);ponatinib (MSN02);trastuzumab (MSN01) |
axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN01;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN09) |
| Growth differentiation factor receptor signaling |
Up |
25.5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
dabrafenib (MSN05);ponatinib (MSN02);trastuzumab (MSN01) |
axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN01;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Growth differentiation factor receptor signaling |
Down |
5.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN09) |
|
| Growth differentiation factor receptor signaling |
Down |
6 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
ponatinib (MSN08);vandetanib (MSN09) |
|
| Growth differentiation factor receptor signaling |
Down |
7 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
ponatinib (MSN08;MSN09);vandetanib (MSN09) |
|
| Growth differentiation factor receptor signaling |
Down |
8 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN08;MSN09);vandetanib (MSN09) |
|
| Growth differentiation factor receptor signaling |
Down |
8.5 |
1 |
0.1304348 |
0.7183099 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01;MSN06;MSN08;MSN09);vandetanib (MSN09) |
|
| Growth differentiation factor receptor signaling |
Down |
9 |
0.8888889 |
0.173913 |
0.7157895 |
NaN |
NaN |
lapatinib (MSN01);ponatinib (MSN01;MSN06;MSN08;MSN09);sunitinib (MSN08;MSN09);vandetanib (MSN09) |
crizotinib (MSN05) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
6.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01) |
cabozantinib (MSN01) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
16 |
0.5333334 |
0.173913 |
0.4755246 |
NaN |
NaN |
lapatinib (MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
16.5 |
0.5 |
0.173913 |
0.4503311 |
NaN |
NaN |
lapatinib (MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);ceritinib (MSN09);cetuximab (MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
17 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
lapatinib (MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
18 |
0.5 |
0.1956522 |
0.4580838 |
NaN |
NaN |
lapatinib (MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
18.5 |
0.55 |
0.2391304 |
0.5109289 |
NaN |
NaN |
bevacizumab (MSN06);lapatinib (MSN01;MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
19.5 |
0.5714286 |
0.2608696 |
0.5340314 |
NaN |
NaN |
bevacizumab (MSN05;MSN06);lapatinib (MSN01;MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
20 |
0.5909091 |
0.2826087 |
0.5552764 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
20.5 |
0.5652174 |
0.2826087 |
0.5338164 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
21 |
0.5416667 |
0.2826087 |
0.5139536 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);cabozantinib (MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Up |
24.5 |
0.56 |
0.3043478 |
0.5336323 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06);sunitinib (MSN01;MSN05;MSN09);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN06;MSN09);axitinib (MSN05;MSN06);cabozantinib (MSN06);ceritinib (MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08);erlotinib (MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
2 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN01) |
|
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
6 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01) |
|
| Glutamate and glutamine metabolism |
Down |
16.5 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05);sorafenib (MSN05) |
axitinib (MSN06;MSN08);bosutinib (MSN05;MSN09);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN02;MSN05);tofacitinib (MSN06) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
10.5 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN08) |
cabozantinib (MSN01) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
11 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN06;MSN08) |
cabozantinib (MSN01) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
13 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN06;MSN08) |
cabozantinib (MSN01);nilotinib (MSN06;MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
13.5 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN06;MSN08);sorafenib (MSN08) |
cabozantinib (MSN01);nilotinib (MSN06;MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
14 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN06;MSN08);sorafenib (MSN08) |
cabozantinib (MSN01);dasatinib (MSN08);nilotinib (MSN05;MSN06;MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
14.5 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN06;MSN08);sorafenib (MSN08) |
cabozantinib (MSN01);dasatinib (MSN08);nilotinib (MSN05;MSN06;MSN08;MSN09) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
15 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
dabrafenib (MSN01);pazopanib (MSN01;MSN06;MSN08);sorafenib (MSN08) |
cabozantinib (MSN01);dasatinib (MSN08);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN08) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
15.5 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
dabrafenib (MSN01;MSN08);pazopanib (MSN01;MSN06;MSN08);sorafenib (MSN08) |
bosutinib (MSN01);cabozantinib (MSN01);dasatinib (MSN08);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN08) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
17 |
0.3888889 |
0.1521739 |
0.3562874 |
NaN |
NaN |
dabrafenib (MSN01;MSN08);pazopanib (MSN01;MSN06;MSN08);sorafenib (MSN01;MSN08) |
bosutinib (MSN01;MSN05);cabozantinib (MSN01);dasatinib (MSN08);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN06;MSN08) |
| Granulocyte macrophage colony-stimulating factor receptor signaling |
Down |
19.5 |
0.45 |
0.1956522 |
0.4180328 |
NaN |
NaN |
dabrafenib (MSN01;MSN08);pazopanib (MSN01;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09) |
bosutinib (MSN01;MSN05);cabozantinib (MSN01);dasatinib (MSN08);imatinib (MSN01);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN06;MSN08) |
| Granulocyte-colony stimulating factor receptor signaling |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN08) |
| GABA metabolism |
Up |
8.5 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
dabrafenib (MSN08) |
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);ruxolitinib (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| G2 M transition checkpoint |
Down |
25 |
0.2727273 |
0.1304348 |
0.2562815 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
25.5 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN01) |
| G2 M transition checkpoint |
Down |
29 |
0.3076923 |
0.173913 |
0.2943723 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN01;MSN08) |
| G2 M transition checkpoint |
Down |
30 |
0.2962963 |
0.173913 |
0.2845188 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN01;MSN06;MSN08) |
| G2 M transition checkpoint |
Down |
31 |
0.2857143 |
0.173913 |
0.2753036 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
34 |
0.3103448 |
0.1956522 |
0.3 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN01;MSN06;MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
34.5 |
0.3 |
0.1956522 |
0.2908745 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| GABA metabolism |
Up |
2.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN09) |
| GABA metabolism |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
imatinib (MSN09);ruxolitinib (MSN06);vemurafenib (MSN06) |
| GABA metabolism |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);ruxolitinib (MSN05;MSN06);vemurafenib (MSN06) |
| GABA metabolism |
Up |
5.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);ruxolitinib (MSN05;MSN06;MSN08);vemurafenib (MSN06) |
| GABA metabolism |
Up |
7.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
dabrafenib (MSN08) |
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);ruxolitinib (MSN05;MSN06;MSN08);vemurafenib (MSN06) |
| G2 M transition checkpoint |
Down |
24 |
0.3 |
0.1304348 |
0.2786885 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| GABA metabolism |
Up |
10 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
dabrafenib (MSN08) |
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| GABA metabolism |
Up |
10.5 |
0.1818182 |
0.04347826 |
0.1531532 |
NaN |
NaN |
dabrafenib (MSN08;MSN09) |
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| GABA metabolism |
Up |
17.5 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
dabrafenib (MSN08;MSN09) |
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);nilotinib (MSN05);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| GABA metabolism |
Up |
19 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
dabrafenib (MSN08;MSN09) |
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);nilotinib (MSN05;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| GABA metabolism |
Up |
21 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
dabrafenib (MSN08;MSN09) |
axitinib (MSN05);cabozantinib (MSN05);imatinib (MSN09);nilotinib (MSN05;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| GABA metabolism |
Down |
2.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN09) |
|
| GABA metabolism |
Down |
3 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
vandetanib (MSN05;MSN09) |
|
| GABA metabolism |
Down |
8.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
vandetanib (MSN05;MSN09) |
cetuximab (MSN08) |
| GABA metabolism |
Down |
9.5 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN09) |
cetuximab (MSN08) |
| GABA metabolism |
Down |
10.5 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN09) |
cetuximab (MSN08;MSN09) |
| GABA metabolism |
Down |
11 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN09) |
cetuximab (MSN06;MSN08;MSN09) |
| GABA metabolism |
Down |
13 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
cetuximab (MSN06;MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
13.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
trametinib (MSN01;MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN08) |
| G2 M transition checkpoint |
Up |
19.5 |
0.4090909 |
0.1956522 |
0.3844221 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01);ruxolitinib (MSN01;MSN06;MSN09) |
| G2 M transition checkpoint |
Up |
21 |
0.4347826 |
0.2173913 |
0.410628 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01);ruxolitinib (MSN01;MSN06;MSN09) |
| G2 M transition checkpoint |
Up |
22 |
0.4166667 |
0.2173913 |
0.3953488 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| G2 M transition checkpoint |
Up |
23 |
0.44 |
0.2391304 |
0.4192825 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN06;MSN09) |
| G2 M transition checkpoint |
Up |
27 |
0.4230769 |
0.2391304 |
0.4047619 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| G2 M transition checkpoint |
Up |
27.5 |
0.4074074 |
0.2391304 |
0.3912134 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| G2 M transition checkpoint |
Up |
28 |
0.3928571 |
0.2391304 |
0.3785425 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| G2 M transition checkpoint |
Up |
28.5 |
0.3793103 |
0.2391304 |
0.3666666 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN08);cabozantinib (MSN09);dasatinib (MSN08);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN06;MSN09) |
| G2 M transition checkpoint |
Down |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN08) |
| G2 M transition checkpoint |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN05;MSN08) |
| G2 M transition checkpoint |
Down |
11.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN01) |
ceritinib (MSN05;MSN08) |
| G2 M transition checkpoint |
Down |
13 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN01) |
afatinib (MSN09);ceritinib (MSN05;MSN08) |
| GABA metabolism |
Down |
13.5 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN08);cetuximab (MSN06;MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
14 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
trametinib (MSN01;MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN08);cetuximab (MSN08) |
| G2 M transition checkpoint |
Down |
16.5 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
trametinib (MSN01;MSN08;MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN08);cetuximab (MSN08) |
| G2 M transition checkpoint |
Down |
17.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN06;MSN08) |
| G2 M transition checkpoint |
Down |
18.5 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN06;MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
19 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN05;MSN06;MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
19.5 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
20.5 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN05;MSN08;MSN09);cetuximab (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
21 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
21.5 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
22 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| G2 M transition checkpoint |
Down |
22.5 |
0.3157895 |
0.1304348 |
0.2914286 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02) |
afatinib (MSN06;MSN09);ceritinib (MSN01;MSN05;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN08;MSN09) |
| Glutamate and glutamine metabolism |
Up |
25 |
0.52 |
0.2826087 |
0.4955157 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN06);ponatinib (MSN01;MSN06;MSN08);sorafenib (MSN08);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);cabozantinib (MSN06);ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);nilotinib (MSN06;MSN08);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Glutamate and glutamine metabolism |
Up |
8 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08;MSN09) |
ceritinib (MSN01);erlotinib (MSN09);rituximab (MSN06) |
| Glutamate and glutamine metabolism |
Up |
9 |
0.5555556 |
0.1086956 |
0.4473684 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
ceritinib (MSN01);erlotinib (MSN01;MSN09);rituximab (MSN06) |
| Glutamate and glutamine metabolism |
Up |
10 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
dabrafenib (MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);rituximab (MSN06) |
| Glutamate and glutamine metabolism |
Up |
11 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);rituximab (MSN06) |
| Glutamate and glutamine metabolism |
Up |
11.5 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01) |
ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);rituximab (MSN05;MSN06) |
| Glutamate and glutamine metabolism |
Up |
13.5 |
0.5384616 |
0.1521739 |
0.468504 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01);vandetanib (MSN08) |
ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);rituximab (MSN05;MSN06) |
| Glutamate and glutamine metabolism |
Up |
15 |
0.4666667 |
0.1521739 |
0.4160839 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN09) |
| Glutamate and glutamine metabolism |
Up |
17 |
0.4705882 |
0.173913 |
0.427673 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09) |
| Glutamate and glutamine metabolism |
Up |
17.5 |
0.5 |
0.1956522 |
0.4580838 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);sorafenib (MSN08);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);nilotinib (MSN08);rituximab (MSN05;MSN06;MSN09) |
| Glutamate and glutamine metabolism |
Up |
18 |
0.4285714 |
0.1956522 |
0.4005235 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06);sorafenib (MSN08);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);cabozantinib (MSN06);ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);nilotinib (MSN06;MSN08);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Glutamate and glutamine metabolism |
Up |
21 |
0.4782609 |
0.2391304 |
0.4516909 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN06);ponatinib (MSN06);sorafenib (MSN08);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);cabozantinib (MSN06);ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);nilotinib (MSN06;MSN08);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Glutamate and glutamine metabolism |
Up |
24 |
0.5 |
0.2608696 |
0.4744186 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN06);ponatinib (MSN01;MSN06);sorafenib (MSN08);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);cabozantinib (MSN06);ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);nilotinib (MSN06;MSN08);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Glutamate and glutamine metabolism |
Up |
7 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
dabrafenib (MSN05;MSN08;MSN09) |
ceritinib (MSN01);erlotinib (MSN09);rituximab (MSN06) |
| Glutamate and glutamine metabolism |
Up |
29 |
0.5 |
0.2826087 |
0.478355 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN06);ponatinib (MSN01;MSN06;MSN08);sorafenib (MSN08);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);cabozantinib (MSN06);ceritinib (MSN01);erlotinib (MSN01;MSN09);gefitinib (MSN05);nilotinib (MSN06;MSN08;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Glutamate and glutamine metabolism |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN09) |
| Glutamate and glutamine metabolism |
Down |
3.5 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
lapatinib (MSN01) |
bosutinib (MSN09) |
| Glutamate and glutamine metabolism |
Down |
4 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
lapatinib (MSN01);pazopanib (MSN01) |
bosutinib (MSN09) |
| Glutamate and glutamine metabolism |
Down |
4.5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
lapatinib (MSN01);pazopanib (MSN01) |
bosutinib (MSN09);crizotinib (MSN01) |
| Glutamate and glutamine metabolism |
Down |
6 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01) |
bosutinib (MSN09);crizotinib (MSN01);ruxolitinib (MSN01) |
| Glutamate and glutamine metabolism |
Down |
7 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01) |
bosutinib (MSN09);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN06);ruxolitinib (MSN01;MSN05) |
| Glutamate and glutamine metabolism |
Down |
8 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01) |
axitinib (MSN08);bosutinib (MSN09);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN06);ruxolitinib (MSN01;MSN05) |
| Glutamate and glutamine metabolism |
Down |
11 |
0.3076923 |
0.08695652 |
0.2677165 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05) |
axitinib (MSN08);bosutinib (MSN09);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01);ruxolitinib (MSN01;MSN05) |
| Glutamate and glutamine metabolism |
Down |
12.5 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05) |
axitinib (MSN08);bosutinib (MSN05;MSN09);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01);ruxolitinib (MSN01;MSN05) |
| Glutamate and glutamine metabolism |
Down |
14 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05) |
axitinib (MSN06;MSN08);bosutinib (MSN05;MSN09);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN05) |
| Glutamate and glutamine metabolism |
Down |
15.5 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
lapatinib (MSN01;MSN06);pazopanib (MSN01);ponatinib (MSN05);sorafenib (MSN05) |
axitinib (MSN06;MSN08);bosutinib (MSN05;MSN09);crizotinib (MSN01);dasatinib (MSN01);imatinib (MSN01;MSN06);regorafenib (MSN01;MSN05;MSN06);ruxolitinib (MSN01;MSN05) |
| Gap junction organization |
Up |
17 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
sorafenib (MSN09);trastuzumab (MSN09) |
afatinib (MSN08);cetuximab (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| GABA metabolism |
Down |
14 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN06;MSN08);cetuximab (MSN06;MSN08;MSN09) |
| GABA metabolism |
Down |
14.5 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08);cetuximab (MSN06;MSN08;MSN09) |
| GABA metabolism |
Down |
18 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN06;MSN08;MSN09) |
| GABA metabolism |
Down |
18.5 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN06;MSN08;MSN09) |
| GABA metabolism |
Down |
22.5 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN06;MSN08;MSN09);gefitinib (MSN05) |
| Gap junction organization |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
vemurafenib (MSN06) |
| Gap junction organization |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN01);vemurafenib (MSN06) |
| Gap junction organization |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
gefitinib (MSN01;MSN06;MSN09);vemurafenib (MSN06) |
| Gap junction organization |
Up |
10 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
sorafenib (MSN09) |
gefitinib (MSN01;MSN06;MSN09);vemurafenib (MSN06) |
| Gap junction organization |
Up |
11 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
sorafenib (MSN09) |
gefitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN05;MSN06) |
| Gap junction organization |
Up |
12 |
0.2 |
0.04347826 |
0.1650486 |
NaN |
NaN |
sorafenib (MSN09);trastuzumab (MSN09) |
afatinib (MSN08);gefitinib (MSN01;MSN05;MSN06;MSN09);vemurafenib (MSN05;MSN06;MSN09) |
| Gap junction organization |
Up |
13.5 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
sorafenib (MSN09);trastuzumab (MSN09) |
afatinib (MSN08);gefitinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown by matrix metalloproteases |
Up |
8.5 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
bevacizumab (MSN06);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);cetuximab (MSN06);dasatinib (MSN09);erlotinib (MSN01);gefitinib (MSN05);rituximab (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN05;MSN06;MSN08) |
| Gap junction organization |
Up |
19 |
0.2 |
0.06521739 |
0.1783217 |
NaN |
NaN |
sorafenib (MSN01;MSN09);trastuzumab (MSN09) |
afatinib (MSN08);cetuximab (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09);ruxolitinib (MSN01);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Gap junction organization |
Up |
19.5 |
0.1875 |
0.06521739 |
0.1688742 |
NaN |
NaN |
sorafenib (MSN01;MSN09);trastuzumab (MSN09) |
afatinib (MSN08);cetuximab (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09);rituximab (MSN06);ruxolitinib (MSN01);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Gap junction organization |
Up |
25 |
0.2352941 |
0.08695652 |
0.2138365 |
NaN |
NaN |
sorafenib (MSN01;MSN05;MSN09);trastuzumab (MSN09) |
afatinib (MSN08);cetuximab (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN09);rituximab (MSN06);ruxolitinib (MSN01);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Gastric inhibitory polypeptide receptor signaling |
Up |
12.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN09) |
|
| Gastric inhibitory polypeptide receptor signaling |
Up |
15 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
pazopanib (MSN05;MSN09) |
|
| Glucuronidation |
Down |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Glucuronidation |
Down |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN06;MSN08) |
| Glucuronidation |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN05;MSN06;MSN08) |
| Glutamate and glutamine metabolism |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN06) |
| Glutamate and glutamine metabolism |
Up |
4 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN05) |
rituximab (MSN06) |
| Glutamate and glutamine metabolism |
Up |
5 |
0.5 |
0.04347826 |
0.3090909 |
NaN |
NaN |
dabrafenib (MSN05;MSN08) |
erlotinib (MSN09);rituximab (MSN06) |
| Elastin cross-linking and assembly |
Down |
7.5 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Elastin cross-linking and assembly |
Up |
12.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN08) |
bosutinib (MSN05);ceritinib (MSN08) |
| Elastin cross-linking and assembly |
Up |
16 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trametinib (MSN08) |
bosutinib (MSN05);ceritinib (MSN08);ruxolitinib (MSN05) |
| Elastin cross-linking and assembly |
Up |
16.5 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trametinib (MSN08) |
axitinib (MSN05);bosutinib (MSN05);ceritinib (MSN08);ruxolitinib (MSN05) |
| Elastin cross-linking and assembly |
Up |
22 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trametinib (MSN08) |
axitinib (MSN05);bosutinib (MSN05);ceritinib (MSN08);ruxolitinib (MSN05;MSN08) |
| Elastin cross-linking and assembly |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN08) |
| Elastin cross-linking and assembly |
Down |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN08);crizotinib (MSN01;MSN05;MSN08) |
| Elastin cross-linking and assembly |
Down |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08) |
| Elastin cross-linking and assembly |
Down |
4.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN08);crizotinib (MSN01;MSN05;MSN06;MSN08) |
| Elastin cross-linking and assembly |
Down |
5 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN08);cetuximab (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08) |
| Elastin cross-linking and assembly |
Down |
5.5 |
0.1111111 |
0.02173913 |
0.08947368 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN05;MSN08);cetuximab (MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Elastin cross-linking and assembly |
Down |
7 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
lapatinib (MSN09) |
cabozantinib (MSN05;MSN08);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Elastin cross-linking and assembly |
Up |
9.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05);ceritinib (MSN08) |
| Elastin cross-linking and assembly |
Down |
14 |
0.1666667 |
0.04347826 |
0.1428572 |
NaN |
NaN |
lapatinib (MSN05;MSN09) |
cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Elastin cross-linking and assembly |
Down |
14.5 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
lapatinib (MSN05;MSN09) |
cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05) |
| Elastin cross-linking and assembly |
Down |
16.5 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
lapatinib (MSN05;MSN09) |
cabozantinib (MSN05;MSN08;MSN09);cetuximab (MSN06;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN05;MSN08) |
| Electron transport chain |
Up |
3 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
pazopanib (MSN01) |
|
| Electron transport chain |
Up |
8 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
pazopanib (MSN01;MSN05) |
|
| Electron transport chain |
Up |
12 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
pazopanib (MSN01;MSN05) |
imatinib (MSN05) |
| Electron transport chain |
Up |
13 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN08) |
imatinib (MSN05) |
| Electron transport chain |
Up |
14 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
pazopanib (MSN01;MSN05;MSN08) |
afatinib (MSN01);imatinib (MSN05) |
| Electron transport chain |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN09) |
| Endogenous control of complement activity |
Up |
3.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01) |
| Dopamine-mediated control of postsynaptic potential |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
cabozantinib (MSN01) |
| DNA replication initiation |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN06;MSN09) |
| DNA replication initiation |
Up |
6 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN06;MSN08;MSN09) |
| DNA replication initiation |
Up |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02);tofacitinib (MSN06;MSN08;MSN09) |
| DNA replication initiation |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN01);erlotinib (MSN05;MSN08;MSN09) |
| DNA replication initiation |
Down |
2 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
dabrafenib (MSN05) |
ceritinib (MSN01;MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication initiation |
Down |
3 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN08) |
ceritinib (MSN01;MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication initiation |
Down |
4 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08) |
ceritinib (MSN01;MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication initiation |
Down |
5 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication initiation |
Down |
7 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication initiation |
Down |
8 |
0.4 |
0.1304348 |
0.3566433 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01) |
| DNA replication initiation |
Down |
9 |
0.368421 |
0.1521739 |
0.3399999 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN09) |
| Endogenous control of complement activity |
Up |
4 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN08) |
| Drug and toxin export via membrane transport proteins |
Up |
7 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05) |
| Drug and toxin export via membrane transport proteins |
Down |
14 |
0 |
0 |
NaN |
NaN |
NaN |
|
nilotinib (MSN01) |
| Eicosanoid metabolism |
Up |
15 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trastuzumab (MSN05) |
bosutinib (MSN05) |
| Eicosanoid metabolism |
Up |
17 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
bevacizumab (MSN08);trastuzumab (MSN05) |
bosutinib (MSN05) |
| Eicosanoid metabolism |
Up |
21 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
bevacizumab (MSN08);lapatinib (MSN01);trastuzumab (MSN05) |
bosutinib (MSN05) |
| Eicosanoid metabolism |
Down |
12 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
vandetanib (MSN09) |
|
| Eicosanoid metabolism |
Down |
14 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
sunitinib (MSN02);vandetanib (MSN09) |
|
| Eicosanoid metabolism |
Down |
17 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
sorafenib (MSN09);sunitinib (MSN02);vandetanib (MSN09) |
|
| Eicosanoid metabolism |
Down |
19 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
sorafenib (MSN09);sunitinib (MSN02);vandetanib (MSN05;MSN09) |
|
| Elastin cross-linking and assembly |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
bosutinib (MSN05) |
| Epithelial intermediate filament dynamics |
Down |
10 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN09) |
dasatinib (MSN06;MSN08);erlotinib (MSN05;MSN08);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09) |
| Epithelial intermediate filament dynamics |
Up |
15 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
ponatinib (MSN06);sunitinib (MSN02);trastuzumab (MSN02;MSN09) |
axitinib (MSN06);bosutinib (MSN05;MSN08;MSN09);ceritinib (MSN09);rituximab (MSN05;MSN09) |
| Epithelial intermediate filament dynamics |
Up |
17 |
0.4615385 |
0.1304348 |
0.4015748 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08);sunitinib (MSN02);trastuzumab (MSN02;MSN09) |
axitinib (MSN06);bosutinib (MSN05;MSN08;MSN09);ceritinib (MSN09);rituximab (MSN05;MSN09) |
| Epithelial intermediate filament dynamics |
Up |
22.5 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08);sunitinib (MSN02);trastuzumab (MSN02;MSN09) |
axitinib (MSN06);bosutinib (MSN05;MSN08;MSN09);ceritinib (MSN09);nilotinib (MSN06);rituximab (MSN05;MSN09) |
| Epithelial intermediate filament dynamics |
Down |
1 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sorafenib (MSN01) |
dasatinib (MSN06;MSN08) |
| Epithelial intermediate filament dynamics |
Down |
3 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
sorafenib (MSN01) |
dasatinib (MSN06;MSN08);tofacitinib (MSN06) |
| Epithelial intermediate filament dynamics |
Down |
4 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
sorafenib (MSN01;MSN05) |
dasatinib (MSN06;MSN08);tofacitinib (MSN06) |
| Epithelial intermediate filament dynamics |
Down |
4.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
sorafenib (MSN01;MSN05) |
dasatinib (MSN06;MSN08);nilotinib (MSN09);tofacitinib (MSN06) |
| Epithelial intermediate filament dynamics |
Down |
5 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
sorafenib (MSN01;MSN05) |
dasatinib (MSN06;MSN08);nilotinib (MSN05;MSN09);tofacitinib (MSN06) |
| Epithelial intermediate filament dynamics |
Down |
6 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
sorafenib (MSN01;MSN05;MSN09) |
dasatinib (MSN06;MSN08);erlotinib (MSN05);nilotinib (MSN05;MSN09);tofacitinib (MSN06) |
| Epithelial intermediate filament dynamics |
Down |
6.5 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN09) |
dasatinib (MSN06;MSN08);erlotinib (MSN05);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN06) |
| Epithelial intermediate filament dynamics |
Down |
7 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN09) |
dasatinib (MSN06;MSN08);erlotinib (MSN05;MSN08);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN06) |
| Epithelial intermediate filament dynamics |
Up |
9.5 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
sunitinib (MSN02);trastuzumab (MSN02;MSN09) |
axitinib (MSN06);bosutinib (MSN05;MSN08;MSN09);ceritinib (MSN09);rituximab (MSN05;MSN09) |
| Epithelial intermediate filament dynamics |
Down |
10.5 |
0.25 |
0.08695652 |
0.2251656 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN09) |
dasatinib (MSN06;MSN08);erlotinib (MSN05;MSN08);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Epithelial intermediate filament dynamics |
Down |
11 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
dasatinib (MSN06;MSN08);erlotinib (MSN05;MSN08);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Epithelial intermediate filament dynamics |
Down |
11.5 |
0.2631579 |
0.1086956 |
0.2428571 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN05;MSN08);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Epithelial intermediate filament dynamics |
Down |
12 |
0.25 |
0.1086956 |
0.2322404 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
cetuximab (MSN05);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN05;MSN08);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Epithelial intermediate filament dynamics |
Down |
13 |
0.2380952 |
0.1086956 |
0.222513 |
NaN |
NaN |
dabrafenib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
cabozantinib (MSN05);cetuximab (MSN05);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN05;MSN08);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Epithelial intermediate filament dynamics |
Down |
14 |
0.25 |
0.1304348 |
0.2372093 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
cabozantinib (MSN05);cetuximab (MSN05);dasatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Epithelial intermediate filament dynamics |
Down |
14.5 |
0.2307692 |
0.1304348 |
0.2207792 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
axitinib (MSN08);cabozantinib (MSN05);cetuximab (MSN05);dasatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09);vemurafenib (MSN06;MSN08) |
| Epithelial intermediate filament dynamics |
Down |
15 |
0.2142857 |
0.1304348 |
0.2064777 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
axitinib (MSN08);cabozantinib (MSN05);ceritinib (MSN05);cetuximab (MSN05);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08;MSN09);vemurafeni |
| Epithelial intermediate filament dynamics |
Down |
21 |
0.2068966 |
0.1304348 |
0.2 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
afatinib (MSN09);axitinib (MSN08);cabozantinib (MSN05);ceritinib (MSN05);cetuximab (MSN05);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);tofacitinib (MSN01;MSN06;MSN08; |
| Epithelial intermediate filament dynamics |
Down |
21.5 |
0.1935484 |
0.1304348 |
0.1881919 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
afatinib (MSN09);axitinib (MSN08);cabozantinib (MSN05);ceritinib (MSN05);cetuximab (MSN05);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08);gefitinib (MSN06;MSN08);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);tofacit |
| Endogenous control of complement activity |
Down |
11.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
dabrafenib (MSN08) |
axitinib (MSN05);cabozantinib (MSN02);imatinib (MSN05);ruxolitinib (MSN05;MSN08) |
| Endogenous control of complement activity |
Up |
4.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
vandetanib (MSN08;MSN09) |
crizotinib (MSN01;MSN05;MSN08) |
| Endogenous control of complement activity |
Up |
5.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
vandetanib (MSN05;MSN08;MSN09) |
crizotinib (MSN01;MSN05;MSN08) |
| Endogenous control of complement activity |
Up |
6.5 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
vandetanib (MSN05;MSN08;MSN09) |
crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN08) |
| Endogenous control of complement activity |
Up |
7.5 |
0.5 |
0.08695652 |
0.3908046 |
NaN |
NaN |
lapatinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN08) |
| Endogenous control of complement activity |
Up |
15.5 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
lapatinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN08) |
| Endogenous control of complement activity |
Up |
18.5 |
0.4 |
0.08695652 |
0.3300971 |
NaN |
NaN |
lapatinib (MSN01);vandetanib (MSN05;MSN08;MSN09) |
ceritinib (MSN08);crizotinib (MSN01;MSN05;MSN08);dasatinib (MSN08);imatinib (MSN06) |
| Endogenous control of complement activity |
Down |
3.5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN08) |
|
| Endogenous control of complement activity |
Down |
7 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
dabrafenib (MSN08) |
ruxolitinib (MSN08) |
| Endogenous control of complement activity |
Down |
9 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
dabrafenib (MSN08) |
ruxolitinib (MSN05;MSN08) |
| Endogenous control of complement activity |
Down |
10.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
dabrafenib (MSN08) |
cabozantinib (MSN02);ruxolitinib (MSN05;MSN08) |
| Endogenous control of complement activity |
Down |
11 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
dabrafenib (MSN08) |
axitinib (MSN05);cabozantinib (MSN02);ruxolitinib (MSN05;MSN08) |
| DNA replication elongation |
Down |
21 |
0.4375 |
0.1521739 |
0.3940398 |
NaN |
NaN |
dabrafenib (MSN05;MSN09);lapatinib (MSN05;MSN09);trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN01;MSN05;MSN06;MSN09);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Endoplasmic reticulum quality control system |
Up |
5 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN06) |
|
| Endoplasmic reticulum quality control system |
Up |
8 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
dabrafenib (MSN01;MSN06) |
|
| Ephrin receptor signaling |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
dasatinib (MSN05);ruxolitinib (MSN05) |
| Ephrin receptor signaling |
Up |
16.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);dasatinib (MSN05);ruxolitinib (MSN05) |
| Ephrin receptor signaling |
Up |
22 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);dasatinib (MSN05);ruxolitinib (MSN05;MSN08) |
| Epithelial intermediate filament dynamics |
Up |
4 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trastuzumab (MSN02) |
rituximab (MSN05) |
| Extracellular matrix breakdown by cathepsins |
Up |
8 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
sunitinib (MSN05;MSN08);trastuzumab (MSN05) |
crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN01;MSN05;MSN09) |
| Epithelial intermediate filament dynamics |
Up |
6 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
trastuzumab (MSN02;MSN09) |
axitinib (MSN06);bosutinib (MSN09);rituximab (MSN05) |
| Epithelial intermediate filament dynamics |
Up |
7 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
sunitinib (MSN02);trastuzumab (MSN02;MSN09) |
axitinib (MSN06);bosutinib (MSN09);rituximab (MSN05;MSN09) |
| Epithelial intermediate filament dynamics |
Up |
9 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
sunitinib (MSN02);trastuzumab (MSN02;MSN09) |
axitinib (MSN06);bosutinib (MSN08;MSN09);ceritinib (MSN09);rituximab (MSN05;MSN09) |
| Decorin synthesis |
Down |
12 |
0.4117647 |
0.1521739 |
0.3742138 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN08) |
bosutinib (MSN01;MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Decorin synthesis |
Up |
25 |
0.2545455 |
0.3043478 |
0.2570195 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);nilot |
| Decorin synthesis |
Up |
26.5 |
0.25 |
0.3043478 |
0.2526539 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);nilot |
| Decorin synthesis |
Down |
6.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
rituximab (MSN08) |
| Decorin synthesis |
Down |
8 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
sorafenib (MSN08) |
nilotinib (MSN05);rituximab (MSN08) |
| Decorin synthesis |
Down |
8.5 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN08) |
nilotinib (MSN05);rituximab (MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
9 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN01;MSN08) |
cetuximab (MSN02);nilotinib (MSN05);rituximab (MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
9.5 |
0.3333333 |
0.06521739 |
0.2684211 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN01;MSN08) |
bosutinib (MSN08);cetuximab (MSN02);nilotinib (MSN05);rituximab (MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
10 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN01;MSN08) |
bosutinib (MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
10.5 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN08) |
bosutinib (MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
11 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN08) |
bosutinib (MSN01;MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
11.5 |
0.375 |
0.1304348 |
0.3377483 |
NaN |
NaN |
bevacizumab (MSN06);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN08);sunitinib (MSN08) |
bosutinib (MSN01;MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Decorin synthesis |
Up |
23.5 |
0.2592593 |
0.3043478 |
0.2615385 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);nilot |
| Decorin synthesis |
Down |
12.5 |
0.45 |
0.1956522 |
0.4180328 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08) |
bosutinib (MSN01;MSN08);cabozantinib (MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
13 |
0.4761905 |
0.2173913 |
0.4450262 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09) |
bosutinib (MSN01;MSN08);cabozantinib (MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
15 |
0.5 |
0.2391304 |
0.4698493 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN09) |
bosutinib (MSN01;MSN08);cabozantinib (MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
15.5 |
0.4782609 |
0.2391304 |
0.4516909 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN09) |
bosutinib (MSN01;MSN08);cabozantinib (MSN05;MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09) |
| Decorin synthesis |
Down |
16.5 |
0.4615385 |
0.2608696 |
0.4415585 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN05;MSN09) |
bosutinib (MSN01;MSN08);cabozantinib (MSN02;MSN05;MSN08);cetuximab (MSN02);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Decorin synthesis |
Down |
17.5 |
0.4444444 |
0.2608696 |
0.4267782 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN05;MSN09) |
bosutinib (MSN01;MSN08);cabozantinib (MSN02;MSN05;MSN08);cetuximab (MSN02);dasatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Decorin synthesis |
Down |
18 |
0.4285714 |
0.2608696 |
0.4129555 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN05;MSN09) |
bosutinib (MSN01;MSN08);cabozantinib (MSN02;MSN05;MSN08);cetuximab (MSN02);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Decorin synthesis |
Down |
18.5 |
0.4482759 |
0.2826087 |
0.4333333 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
bosutinib (MSN01;MSN08);cabozantinib (MSN02;MSN05;MSN08);cetuximab (MSN02);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Decorin synthesis |
Down |
21 |
0.4333333 |
0.2826087 |
0.4201521 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09) |
afatinib (MSN05);bosutinib (MSN01;MSN08);cabozantinib (MSN02;MSN05;MSN08);cetuximab (MSN02);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Decorin synthesis |
Down |
22 |
0.4516129 |
0.3043478 |
0.4391144 |
NaN |
NaN |
bevacizumab (MSN06;MSN09);dabrafenib (MSN08);ponatinib (MSN05);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09) |
afatinib (MSN05);bosutinib (MSN01;MSN08);cabozantinib (MSN02;MSN05;MSN08);cetuximab (MSN02);dasatinib (MSN05);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);rituximab (MSN05;MSN06;MSN08;MSN09);vemurafenib (MSN06) |
| Decorin synthesis |
Up |
14.5 |
0.225 |
0.1956522 |
0.2230321 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN0 |
| Decorin synthesis |
Up |
8.5 |
0.2105263 |
0.08695652 |
0.1942857 |
NaN |
NaN |
lapatinib (MSN08;MSN09);trametinib (MSN05;MSN09) |
crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN09);vemurafenib (MSN01;MSN05) |
| Decorin synthesis |
Up |
9 |
0.1904762 |
0.08695652 |
0.1780105 |
NaN |
NaN |
lapatinib (MSN08;MSN09);trametinib (MSN05;MSN09) |
crizotinib (MSN01;MSN05;MSN06;MSN08);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01;MSN05) |
| Decorin synthesis |
Up |
9.5 |
0.2083333 |
0.1086956 |
0.1976744 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);trametinib (MSN05;MSN09) |
crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN09) |
| Decorin synthesis |
Up |
10 |
0.2142857 |
0.1304348 |
0.2064777 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN01;MSN06;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN09) |
| Decorin synthesis |
Up |
11 |
0.2068966 |
0.1304348 |
0.2 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN08) |
axitinib (MSN01;MSN06;MSN09);cetuximab (MSN01);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01;MSN05;MSN09) |
| Decorin synthesis |
Up |
11.5 |
0.21875 |
0.1521739 |
0.2132617 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01;MSN |
| Decorin synthesis |
Up |
12 |
0.2424242 |
0.173913 |
0.2369338 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN01;MSN |
| Decorin synthesis |
Up |
12.5 |
0.2352941 |
0.173913 |
0.2305085 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN06;MSN09);vemurafenib (MSN |
| Decorin synthesis |
Up |
13 |
0.25 |
0.1956522 |
0.2459807 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN08);tofacitinib (MSN01;MSN06;MSN09);vemurafeni |
| Decorin synthesis |
Up |
13.5 |
0.2432432 |
0.1956522 |
0.2398119 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08);tofacitinib (MSN01;MSN06;MSN09);vemu |
| Decorin synthesis |
Up |
14 |
0.2307692 |
0.1956522 |
0.2283582 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN05;MSN06;MSN08);tofacitin |
| Desaturation of fatty acids |
Down |
9 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN09) |
vemurafenib (MSN05) |
| Decorin synthesis |
Up |
15 |
0.2325581 |
0.2173913 |
0.2316076 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN02);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN0 |
| Decorin synthesis |
Up |
16 |
0.25 |
0.2391304 |
0.2493333 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN02;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN0 |
| Decorin synthesis |
Up |
16.5 |
0.2391304 |
0.2391304 |
0.2391304 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN02;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib |
| Decorin synthesis |
Up |
17.5 |
0.2553191 |
0.2608696 |
0.255639 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN02;MSN06;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);ruxolitinib |
| Decorin synthesis |
Up |
18 |
0.25 |
0.2608696 |
0.2506143 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN02;MSN06;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);regorafenib |
| Decorin synthesis |
Up |
19 |
0.244898 |
0.2608696 |
0.2457832 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN02;MSN06;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);regorafenib |
| Decorin synthesis |
Up |
20.5 |
0.26 |
0.2826087 |
0.2612293 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);regorafenib |
| Decorin synthesis |
Up |
21 |
0.254902 |
0.2826087 |
0.2563805 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);regor |
| Decorin synthesis |
Up |
21.5 |
0.2692308 |
0.3043478 |
0.2710707 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);regor |
| Decorin synthesis |
Up |
23 |
0.2641509 |
0.3043478 |
0.2662192 |
NaN |
NaN |
lapatinib (MSN05;MSN08;MSN09);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
axitinib (MSN01;MSN06;MSN09);cabozantinib (MSN06);ceritinib (MSN01;MSN06;MSN08);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN06;MSN08;MSN09);erlotinib (MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);regor |
| DNA replication elongation |
Up |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);ruxolitinib (MSN02);tofacitinib (MSN06;MSN09) |
| Discoidin domain receptor signaling |
Up |
18.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN05;MSN08;MSN09) |
| DNA cleavage |
Up |
26 |
0 |
0 |
NaN |
NaN |
NaN |
|
ruxolitinib (MSN02) |
| DNA cleavage |
Down |
33.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
ceritinib (MSN09) |
| DNA cleavage |
Down |
35 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
trametinib (MSN08) |
ceritinib (MSN09) |
| DNA cleavage |
Down |
36 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trametinib (MSN08;MSN09) |
ceritinib (MSN09) |
| DNA cleavage |
Down |
37 |
0.75 |
0.06521739 |
0.4636364 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN09) |
| DNA cleavage |
Down |
39 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN05;MSN09) |
| DNA cleavage |
Down |
41.5 |
0.5 |
0.06521739 |
0.3591549 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09) |
ceritinib (MSN05;MSN09);erlotinib (MSN09) |
| DNA replication elongation |
Up |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN09) |
| DNA replication elongation |
Up |
2.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);tofacitinib (MSN09) |
| DNA replication elongation |
Up |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN05);tofacitinib (MSN06;MSN09) |
| Discoidin domain receptor signaling |
Up |
17.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN01;MSN05;MSN06);erlotinib (MSN05;MSN08;MSN09) |
| DNA replication elongation |
Down |
2 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN09) |
|
| DNA replication elongation |
Down |
3 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
dabrafenib (MSN05;MSN09) |
erlotinib (MSN05) |
| DNA replication elongation |
Down |
4 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
dabrafenib (MSN05;MSN09) |
ceritinib (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication elongation |
Down |
5 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
dabrafenib (MSN05;MSN09) |
ceritinib (MSN05);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication elongation |
Down |
6 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
dabrafenib (MSN05;MSN09) |
ceritinib (MSN01;MSN05);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication elongation |
Down |
8 |
0.3 |
0.06521739 |
0.2475728 |
NaN |
NaN |
dabrafenib (MSN05;MSN09);trametinib (MSN05) |
ceritinib (MSN01;MSN05);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication elongation |
Down |
12 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
dabrafenib (MSN05;MSN09);lapatinib (MSN09);trametinib (MSN05) |
ceritinib (MSN01;MSN05);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication elongation |
Down |
14.5 |
0.3333333 |
0.08695652 |
0.2857143 |
NaN |
NaN |
dabrafenib (MSN05;MSN09);lapatinib (MSN09);trametinib (MSN05) |
ceritinib (MSN01;MSN05;MSN06);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication elongation |
Down |
18.5 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
dabrafenib (MSN05;MSN09);lapatinib (MSN09);trametinib (MSN05;MSN09) |
ceritinib (MSN01;MSN05;MSN06);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| DNA replication elongation |
Down |
19 |
0.4285714 |
0.1304348 |
0.3777778 |
NaN |
NaN |
dabrafenib (MSN05;MSN09);lapatinib (MSN05;MSN09);trametinib (MSN05;MSN09) |
ceritinib (MSN01;MSN05;MSN06);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| Desaturation of fatty acids |
Down |
20 |
0.1333333 |
0.04347826 |
0.1188811 |
NaN |
NaN |
trametinib (MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01;MSN06;MSN08);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
9.5 |
0.3333333 |
0.02173913 |
0.1808511 |
NaN |
NaN |
trametinib (MSN09) |
axitinib (MSN06);vemurafenib (MSN05) |
| Desaturation of fatty acids |
Down |
10 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trametinib (MSN09) |
axitinib (MSN06);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
11.5 |
0.1666667 |
0.02173913 |
0.1197183 |
NaN |
NaN |
trametinib (MSN09) |
axitinib (MSN06);cabozantinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
13 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trametinib (MSN09) |
axitinib (MSN06;MSN08);cabozantinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
13.5 |
0.125 |
0.02173913 |
0.09770115 |
NaN |
NaN |
trametinib (MSN09) |
axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
16 |
0.1 |
0.02173913 |
0.08252428 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
16.5 |
0.09090909 |
0.02173913 |
0.07657658 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
17 |
0.08333334 |
0.02173913 |
0.07142857 |
NaN |
NaN |
trametinib (MSN09) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
19 |
0.1538462 |
0.04347826 |
0.1338583 |
NaN |
NaN |
trametinib (MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
19.5 |
0.1428571 |
0.04347826 |
0.1259259 |
NaN |
NaN |
trametinib (MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01;MSN08);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Epithelial intermediate filament dynamics |
Up |
5.5 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
trastuzumab (MSN02;MSN09) |
rituximab (MSN05) |
| Desaturation of fatty acids |
Down |
23 |
0.125 |
0.04347826 |
0.1125828 |
NaN |
NaN |
trametinib (MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01;MSN06;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
24.5 |
0.1764706 |
0.06521739 |
0.1603774 |
NaN |
NaN |
trametinib (MSN05;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01;MSN06;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
25 |
0.2222222 |
0.08695652 |
0.2035928 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01;MSN06;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
26 |
0.2105263 |
0.08695652 |
0.1942857 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Desaturation of fatty acids |
Down |
29.5 |
0.2 |
0.08695652 |
0.1857923 |
NaN |
NaN |
trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN05;MSN06;MSN08);axitinib (MSN05;MSN06;MSN08);cabozantinib (MSN05);erlotinib (MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN06);vemurafenib (MSN01;MSN05) |
| Discoidin domain receptor signaling |
Up |
8 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05) |
| Discoidin domain receptor signaling |
Up |
10.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN05;MSN08) |
| Discoidin domain receptor signaling |
Up |
15.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05);erlotinib (MSN05;MSN08) |
| Discoidin domain receptor signaling |
Up |
16 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05);erlotinib (MSN05;MSN08;MSN09) |
| Discoidin domain receptor signaling |
Up |
17 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN05;MSN06);erlotinib (MSN05;MSN08;MSN09) |
| Eukaryotic kinetochore dynamics |
Up |
7 |
0.4 |
0.173913 |
0.3715847 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02) |
| Equatorial RhoA activation |
Up |
12.5 |
0.8333333 |
0.1086956 |
0.5985914 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
nilotinib (MSN01) |
| Equatorial RhoA activation |
Up |
13.5 |
0.7142857 |
0.1086956 |
0.5379746 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
nilotinib (MSN01);regorafenib (MSN08) |
| Equatorial RhoA activation |
Up |
15 |
0.5 |
0.1086956 |
0.4126213 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
nilotinib (MSN01;MSN05;MSN08);regorafenib (MSN01;MSN08) |
| Eukaryotic kinetochore dynamics |
Up |
10 |
0.4090909 |
0.1956522 |
0.3844221 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02) |
| Eukaryotic kinetochore dynamics |
Up |
9 |
0.4285714 |
0.1956522 |
0.4005235 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02) |
| Equatorial RhoA activation |
Up |
15.5 |
0.4545455 |
0.1086956 |
0.3828829 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
nilotinib (MSN01;MSN05;MSN08;MSN09);regorafenib (MSN01;MSN08) |
| Equatorial RhoA activation |
Up |
16 |
0.4166667 |
0.1086956 |
0.3571428 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
imatinib (MSN06);nilotinib (MSN01;MSN05;MSN08;MSN09);regorafenib (MSN01;MSN08) |
| Equatorial RhoA activation |
Up |
16.5 |
0.3846154 |
0.1086956 |
0.3346457 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
imatinib (MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08) |
| Equatorial RhoA activation |
Up |
12 |
0.8 |
0.08695652 |
0.5396825 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN09);sorafenib (MSN05) |
nilotinib (MSN01) |
| Eukaryotic kinetochore dynamics |
Up |
6 |
0.3888889 |
0.1521739 |
0.3562874 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
imatinib (MSN05;MSN06);nilotinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02) |
| Eukaryotic kinetochore dynamics |
Up |
4 |
0.4117647 |
0.1521739 |
0.3742138 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05;MSN09) |
imatinib (MSN06);nilotinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02) |
| Equatorial RhoA activation |
Down |
8.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08) |
| Equatorial RhoA activation |
Down |
9 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN08);cetuximab (MSN05) |
| Equatorial RhoA activation |
Down |
10 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05;MSN08);cetuximab (MSN05) |
| Equatorial RhoA activation |
Down |
11 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05;MSN08);cetuximab (MSN05);gefitinib (MSN01) |
| Equatorial RhoA activation |
Down |
12 |
0 |
0 |
NaN |
NaN |
NaN |
|
afatinib (MSN05;MSN08);ceritinib (MSN01;MSN06);cetuximab (MSN05);gefitinib (MSN01) |
| Equatorial RhoA activation |
Down |
13 |
0.1428571 |
0.02173913 |
0.1075949 |
NaN |
NaN |
trametinib (MSN01) |
afatinib (MSN05;MSN08);ceritinib (MSN01;MSN06);cetuximab (MSN05);gefitinib (MSN01) |
| Eukaryotic kinetochore dynamics |
Down |
3 |
0.32 |
0.173913 |
0.3049327 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05);erlotinib (MSN01;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
1 |
0.5 |
0.02173913 |
0.2179487 |
NaN |
NaN |
sunitinib (MSN01) |
rituximab (MSN09) |
| Eukaryotic kinetochore dynamics |
Down |
20 |
0.2647059 |
0.1956522 |
0.259322 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Eukaryotic kinetochore dynamics |
Down |
12 |
0.2727273 |
0.1956522 |
0.2665506 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Eukaryotic kinetochore dynamics |
Down |
8 |
0.28125 |
0.1956522 |
0.2741936 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Eukaryotic kinetochore dynamics |
Down |
7 |
0.2903226 |
0.1956522 |
0.2822879 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN08;MSN09);cetuximab (MSN01;MSN05;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Eukaryotic kinetochore dynamics |
Down |
6 |
0.3 |
0.1956522 |
0.2908745 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01) |
afatinib (MSN01;MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Eukaryotic kinetochore dynamics |
Down |
5 |
0.2962963 |
0.173913 |
0.2845188 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Eukaryotic kinetochore dynamics |
Down |
4 |
0.3076923 |
0.173913 |
0.2943723 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN06;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Equatorial RhoA activation |
Down |
14 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN01) |
afatinib (MSN05;MSN08);ceritinib (MSN01;MSN06);cetuximab (MSN05);gefitinib (MSN01) |
| Eukaryotic kinetochore dynamics |
Down |
2 |
0.3333333 |
0.1521739 |
0.3115183 |
NaN |
NaN |
dabrafenib (MSN05);lapatinib (MSN05;MSN08);trametinib (MSN01;MSN05;MSN08;MSN09) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN05;MSN06;MSN09);cetuximab (MSN01;MSN05);erlotinib (MSN01;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Eukaryotic kinetochore dynamics |
Down |
1 |
0.2857143 |
0.04347826 |
0.2151899 |
NaN |
NaN |
dabrafenib (MSN05);trametinib (MSN08) |
afatinib (MSN05;MSN08);ceritinib (MSN05;MSN09);erlotinib (MSN01) |
| Eukaryotic kinetochore dynamics |
Up |
15 |
0.36 |
0.1956522 |
0.3430493 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Eukaryotic kinetochore dynamics |
Up |
11 |
0.375 |
0.1956522 |
0.355814 |
NaN |
NaN |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN09);imatinib (MSN01;MSN05;MSN06);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN08);ruxolitinib (MSN01;MSN02;MSN09) |
| Equatorial RhoA activation |
Up |
8 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN09) |
|
| Equatorial RhoA activation |
Up |
10 |
1 |
0.04347826 |
0.4358974 |
NaN |
NaN |
ponatinib (MSN06;MSN09) |
|
| Equatorial RhoA activation |
Up |
11 |
1 |
0.06521739 |
0.5425532 |
NaN |
NaN |
ponatinib (MSN06;MSN09);sorafenib (MSN05) |
|
| Equatorial RhoA activation |
Up |
11.5 |
1 |
0.08695652 |
0.6181818 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN09);sorafenib (MSN05) |
|
| ER unfolded protein response pathway |
Down |
6 |
0.6666667 |
0.08695652 |
0.4788733 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);vandetanib (MSN09) |
axitinib (MSN01);regorafenib (MSN01) |
| ER unfolded protein response pathway |
Up |
11 |
0.45 |
0.1956522 |
0.4180328 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN05;MSN06;MSN08) |
afatinib (MSN01);bosutinib (MSN05);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN06;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
12 |
0.4545455 |
0.2173913 |
0.4271357 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN05;MSN06;MSN08);sorafenib (MSN08) |
afatinib (MSN01);bosutinib (MSN05);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
13 |
0.4347826 |
0.2173913 |
0.410628 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN05;MSN06;MSN08);sorafenib (MSN08) |
afatinib (MSN01);bosutinib (MSN05);ceritinib (MSN01;MSN06);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
17 |
0.4166667 |
0.2173913 |
0.3953488 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN05;MSN06;MSN08);sorafenib (MSN08) |
afatinib (MSN01);bosutinib (MSN05);cabozantinib (MSN01);ceritinib (MSN01;MSN06);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
20.5 |
0.4 |
0.2173913 |
0.3811659 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN05;MSN06;MSN08);sorafenib (MSN08) |
afatinib (MSN01);bosutinib (MSN05);cabozantinib (MSN01);ceritinib (MSN01;MSN06);dasatinib (MSN08);erlotinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| ER unfolded protein response pathway |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN01) |
| ER unfolded protein response pathway |
Down |
4 |
0.6666667 |
0.04347826 |
0.3617021 |
NaN |
NaN |
bevacizumab (MSN05;MSN08) |
axitinib (MSN01) |
| ER unfolded protein response pathway |
Down |
5.5 |
0.6 |
0.06521739 |
0.4047619 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);vandetanib (MSN09) |
axitinib (MSN01);regorafenib (MSN01) |
| ER unfolded protein response pathway |
Up |
9.5 |
0.5 |
0.1956522 |
0.4580838 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN05;MSN06;MSN08) |
afatinib (MSN01);bosutinib (MSN05);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN08) |
| ER unfolded protein response pathway |
Down |
7.5 |
0.5714286 |
0.08695652 |
0.4303798 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);vandetanib (MSN09) |
axitinib (MSN01);regorafenib (MSN01;MSN08) |
| ER unfolded protein response pathway |
Down |
8 |
0.6 |
0.1304348 |
0.4951456 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN01);vandetanib (MSN09) |
axitinib (MSN01);regorafenib (MSN01;MSN08);ruxolitinib (MSN02) |
| ER unfolded protein response pathway |
Down |
11 |
0.5454546 |
0.1304348 |
0.4594595 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN01);vandetanib (MSN09) |
axitinib (MSN01);regorafenib (MSN01;MSN08);ruxolitinib (MSN02;MSN09) |
| ER unfolded protein response pathway |
Down |
11.5 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);trastuzumab (MSN01);vandetanib (MSN09) |
axitinib (MSN01);regorafenib (MSN01;MSN08);ruxolitinib (MSN02;MSN06;MSN09) |
| Eukaryotic kinetochore dynamics |
Up |
1 |
1 |
0.02173913 |
0.2741936 |
NaN |
NaN |
ponatinib (MSN09) |
|
| Eukaryotic kinetochore dynamics |
Up |
2 |
0.25 |
0.04347826 |
0.1954023 |
NaN |
NaN |
ponatinib (MSN01;MSN09) |
nilotinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01);ruxolitinib (MSN02) |
| Eukaryotic kinetochore dynamics |
Up |
3 |
0.3636364 |
0.08695652 |
0.3063064 |
NaN |
NaN |
ponatinib (MSN01;MSN09);sorafenib (MSN05;MSN09) |
nilotinib (MSN01;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN08);ruxolitinib (MSN02) |
| Epithelial intermediate filament dynamics |
Down |
24.5 |
0.1875 |
0.1304348 |
0.1827957 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN09) |
afatinib (MSN09);axitinib (MSN08);cabozantinib (MSN05);ceritinib (MSN05);cetuximab (MSN05);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08);gefitinib (MSN06;MSN08;MSN09);imatinib (MSN05);nilotinib (MSN05;MSN06;MSN09);t |
| Equatorial RhoA activation |
Down |
21 |
0.2631579 |
0.1086956 |
0.2428571 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Equatorial RhoA activation |
Down |
15 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
trametinib (MSN01);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN05);gefitinib (MSN01) |
| Equatorial RhoA activation |
Down |
15.5 |
0.2727273 |
0.06521739 |
0.2297298 |
NaN |
NaN |
trametinib (MSN01;MSN05);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN05);gefitinib (MSN01;MSN06) |
| Equatorial RhoA activation |
Down |
16 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
trametinib (MSN01;MSN05);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN05);gefitinib (MSN01;MSN06;MSN09) |
| Equatorial RhoA activation |
Down |
16.5 |
0.2857143 |
0.08695652 |
0.2518519 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN05);erlotinib (MSN05);gefitinib (MSN01;MSN06;MSN09) |
| Equatorial RhoA activation |
Down |
17.5 |
0.2666667 |
0.08695652 |
0.2377623 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN05);erlotinib (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Equatorial RhoA activation |
Down |
18.5 |
0.3125 |
0.1086956 |
0.2814569 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06);cetuximab (MSN05);erlotinib (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Equatorial RhoA activation |
Down |
19 |
0.2941177 |
0.1086956 |
0.2672956 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Equatorial RhoA activation |
Down |
20.5 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| Equatorial RhoA activation |
Up |
14.5 |
0.625 |
0.1086956 |
0.4885057 |
NaN |
NaN |
ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
nilotinib (MSN01;MSN08);regorafenib (MSN08) |
| Equatorial RhoA activation |
Down |
21.5 |
0.2380952 |
0.1086956 |
0.222513 |
NaN |
NaN |
lapatinib (MSN05);trametinib (MSN01;MSN05;MSN08);trastuzumab (MSN01) |
afatinib (MSN05;MSN08;MSN09);ceritinib (MSN01;MSN05;MSN06;MSN09);cetuximab (MSN05);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN01;MSN05;MSN06;MSN09) |
| ER unfolded protein response pathway |
Up |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
erlotinib (MSN01;MSN05;MSN08) |
| ER unfolded protein response pathway |
Up |
2 |
0.4444444 |
0.08695652 |
0.3578947 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06);lapatinib (MSN08) |
ceritinib (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
3 |
0.5 |
0.1304348 |
0.4285714 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN09);lapatinib (MSN08);pazopanib (MSN08) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
4 |
0.5384616 |
0.1521739 |
0.468504 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN08) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
5 |
0.5714286 |
0.173913 |
0.5037037 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN06;MSN08) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
7 |
0.5625 |
0.1956522 |
0.5066226 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN05;MSN06;MSN08) |
afatinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09) |
| ER unfolded protein response pathway |
Up |
9 |
0.5294118 |
0.1956522 |
0.4811321 |
NaN |
NaN |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);lapatinib (MSN08);pazopanib (MSN05;MSN06;MSN08) |
afatinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);nilotinib (MSN08) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
6.5 |
0.2142857 |
0.06521739 |
0.1888889 |
NaN |
NaN |
lapatinib (MSN06);pazopanib (MSN05;MSN06) |
axitinib (MSN06);cabozantinib (MSN09);crizotinib (MSN08;MSN09);imatinib (MSN05);nilotinib (MSN08;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
16.5 |
0.4 |
0.3913043 |
0.3994778 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN09);dasatinib (MSN01;MSN06;MSN08);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);regorafenib (MSN06);ritux |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
19 |
0.3913043 |
0.3913043 |
0.3913043 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN05;MSN09);dasatinib (MSN01;MSN06;MSN08);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);regorafenib (MSN06) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
22 |
0.375 |
0.3913043 |
0.3759214 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN01;MSN05;MSN09);dasatinib (MSN01;MSN06;MSN08);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);regorafenib ( |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
23 |
0.3673469 |
0.3913043 |
0.3686747 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN01;MSN05;MSN09);dasatinib (MSN01;MSN06;MSN08);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);regorafenib ( |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
24 |
0.36 |
0.3913043 |
0.3617021 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08;MSN09);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN01;MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN01;MSN05;MSN09);dasatinib (MSN01;MSN06;MSN08);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);regoraf |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
1 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN06) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
2 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN06);nilotinib (MSN08);vemurafenib (MSN06;MSN08) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
3 |
0 |
0 |
NaN |
NaN |
NaN |
|
axitinib (MSN06);crizotinib (MSN09);nilotinib (MSN08);vemurafenib (MSN06;MSN08) |
| Extracellular matrix breakdown by cathepsins |
Up |
4.5 |
0 |
0 |
NaN |
NaN |
NaN |
|
tofacitinib (MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
23 |
0.2121212 |
0.1521739 |
0.2073171 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN06);ponatinib (MSN06);trametinib (MSN01) |
axitinib (MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN05;MSN06);crizotinib (MSN01;MSN05;MSN06;MSN08;MSN09);dasatinib (MSN05);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09 |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
4 |
0.2222222 |
0.04347826 |
0.1789474 |
NaN |
NaN |
lapatinib (MSN06);pazopanib (MSN05) |
axitinib (MSN06);crizotinib (MSN08;MSN09);imatinib (MSN05);nilotinib (MSN08);vemurafenib (MSN06;MSN08) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
5 |
0.25 |
0.06521739 |
0.2142857 |
NaN |
NaN |
lapatinib (MSN06);pazopanib (MSN05;MSN06) |
axitinib (MSN06);cabozantinib (MSN09);crizotinib (MSN08;MSN09);imatinib (MSN05);nilotinib (MSN08);vemurafenib (MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
6 |
0.2307692 |
0.06521739 |
0.2007874 |
NaN |
NaN |
lapatinib (MSN06);pazopanib (MSN05;MSN06) |
axitinib (MSN06);cabozantinib (MSN09);crizotinib (MSN08;MSN09);imatinib (MSN05);nilotinib (MSN08);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
2 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
sunitinib (MSN01) |
rituximab (MSN05;MSN09);vemurafenib (MSN05) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
22 |
0.21875 |
0.1521739 |
0.2132617 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN06);ponatinib (MSN06);trametinib (MSN01) |
axitinib (MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN05;MSN06);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN05);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
21 |
0.1935484 |
0.1304348 |
0.1881919 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN05;MSN06);crizotinib (MSN01;MSN05;MSN08;MSN09);dasatinib (MSN05);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Epithelial intermediate filament dynamics |
Down |
27.5 |
0.2058824 |
0.1521739 |
0.201695 |
NaN |
NaN |
dabrafenib (MSN06);lapatinib (MSN06);sorafenib (MSN01;MSN05;MSN09);trametinib (MSN05;MSN09) |
afatinib (MSN09);axitinib (MSN08);cabozantinib (MSN05);ceritinib (MSN05);cetuximab (MSN05);crizotinib (MSN06);dasatinib (MSN05;MSN06;MSN08;MSN09);erlotinib (MSN01;MSN05;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN05);nilotinib (MSN05;MSN06;MS |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
7 |
0.2777778 |
0.1086956 |
0.254491 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN06);cabozantinib (MSN02;MSN09);ceritinib (MSN06);crizotinib (MSN08;MSN09);imatinib (MSN05);nilotinib (MSN08;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
8 |
0.2272727 |
0.1086956 |
0.2135678 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN06);crizotinib (MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
10 |
0.2173913 |
0.1086956 |
0.205314 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN06);crizotinib (MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
12 |
0.2083333 |
0.1086956 |
0.1976744 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN06);crizotinib (MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
13 |
0.2 |
0.1086956 |
0.1905829 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN06);crizotinib (MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
15.5 |
0.1923077 |
0.1086956 |
0.1839827 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN06);crizotinib (MSN05;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
16 |
0.1851852 |
0.1086956 |
0.1778243 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
18 |
0.2068966 |
0.1304348 |
0.2 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN06);crizotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Down |
20 |
0.2 |
0.1304348 |
0.1939164 |
NaN |
NaN |
dabrafenib (MSN08);lapatinib (MSN06;MSN09);pazopanib (MSN05;MSN06);ponatinib (MSN06) |
axitinib (MSN05;MSN06;MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN09);ceritinib (MSN01;MSN05;MSN06);crizotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN05;MSN09);nilotinib (MSN01;MSN08;MSN09);vemurafenib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
15 |
0.3953488 |
0.3695652 |
0.393733 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN09);dasatinib (MSN01;MSN06;MSN08);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MS |
| Extracellular matrix breakdown by cathepsins |
Up |
7.5 |
0.4285714 |
0.06521739 |
0.3227848 |
NaN |
NaN |
sunitinib (MSN05;MSN08);trastuzumab (MSN05) |
crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN01;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
7 |
0.3333333 |
0.04347826 |
0.2394366 |
NaN |
NaN |
sunitinib (MSN05);trastuzumab (MSN05) |
crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN01;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
6 |
0.2 |
0.02173913 |
0.1349206 |
NaN |
NaN |
trastuzumab (MSN05) |
crizotinib (MSN06);rituximab (MSN05);tofacitinib (MSN01;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
5.5 |
0.25 |
0.02173913 |
0.1545454 |
NaN |
NaN |
trastuzumab (MSN05) |
crizotinib (MSN06);tofacitinib (MSN01;MSN09) |
| Extracellular matrix breakdown by cathepsins |
Up |
5 |
0 |
0 |
NaN |
NaN |
NaN |
|
crizotinib (MSN06);tofacitinib (MSN01;MSN09) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
2.5 |
0.4 |
0.04347826 |
0.2698413 |
NaN |
NaN |
sunitinib (MSN01);trametinib (MSN09) |
rituximab (MSN05;MSN09);vemurafenib (MSN05) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
3 |
0.375 |
0.06521739 |
0.2931035 |
NaN |
NaN |
lapatinib (MSN09);sunitinib (MSN01);trametinib (MSN09) |
afatinib (MSN09);dasatinib (MSN01);rituximab (MSN05;MSN09);vemurafenib (MSN05) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
4 |
0.5714286 |
0.173913 |
0.5037037 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN09);sunitinib (MSN01;MSN05;MSN06);trametinib (MSN09);trastuzumab (MSN05) |
afatinib (MSN09);dasatinib (MSN01);rituximab (MSN05;MSN09);tofacitinib (MSN08);vemurafenib (MSN05) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
5 |
0.4761905 |
0.2173913 |
0.4450262 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN09);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN09);trastuzumab (MSN05) |
afatinib (MSN09);crizotinib (MSN09);dasatinib (MSN01);gefitinib (MSN05;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);tofacitinib (MSN08);vemurafenib (MSN05) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
6 |
0.4347826 |
0.2173913 |
0.410628 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN09);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN09);trastuzumab (MSN05) |
afatinib (MSN09);crizotinib (MSN09);dasatinib (MSN01);erlotinib (MSN01);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);tofacitinib (MSN08);vemurafenib (MSN05) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
6.5 |
0.48 |
0.2608696 |
0.4573991 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN05;MSN09);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN09);crizotinib (MSN09);dasatinib (MSN01);erlotinib (MSN01);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);tofacitinib (MSN08);vemurafenib (MSN05) |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
7 |
0.4 |
0.2608696 |
0.3878327 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN05;MSN09);sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09);trametinib (MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN09);axitinib (MSN05);ceritinib (MSN08);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06);tofacitinib (MSN05;MSN08);vemurafenib (MSN05 |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
8 |
0.3939394 |
0.2826087 |
0.3850174 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN05;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN09);axitinib (MSN05);ceritinib (MSN06;MSN08);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08);tofacitinib (MSN05;MSN08);vemura |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
8.5 |
0.4 |
0.3043478 |
0.3927393 |
NaN |
NaN |
bevacizumab (MSN05;MSN08);lapatinib (MSN05;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN09);axitinib (MSN05);ceritinib (MSN06;MSN08);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08);tofacitinib (MSN05;MSN08); |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
10 |
0.4210526 |
0.3478261 |
0.4159021 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);ceritinib (MSN06;MSN08);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08);tofacitinib (MSN05;M |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
16 |
0.3863636 |
0.3695652 |
0.3853333 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN09);dasatinib (MSN01;MSN06;MSN08);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);regorafenib (MSN06);ritux |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
13 |
0.4047619 |
0.3695652 |
0.402507 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);r |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
12 |
0.3902439 |
0.3478261 |
0.3874643 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);cabozantinib (MSN06);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN06;MSN09);r |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
11 |
0.4102564 |
0.3478261 |
0.4059701 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN08;MSN09);axitinib (MSN05);ceritinib (MSN06;MSN08);cetuximab (MSN09);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08);to |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
9.5 |
0.4324324 |
0.3478261 |
0.4263323 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN05;MSN06;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN09);axitinib (MSN05);ceritinib (MSN06;MSN08);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08);tofacitinib (MSN05;MSN08); |
| Extracellular matrix breakdown and membrane shedding by adamalysins |
Up |
9 |
0.4166667 |
0.326087 |
0.4099679 |
NaN |
NaN |
bevacizumab (MSN05;MSN06;MSN08);lapatinib (MSN05;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN05;MSN09);trastuzumab (MSN02;MSN05) |
afatinib (MSN09);axitinib (MSN05);ceritinib (MSN06;MSN08);crizotinib (MSN09);dasatinib (MSN01;MSN06);erlotinib (MSN01;MSN08);gefitinib (MSN05;MSN06;MSN08;MSN09);imatinib (MSN09);rituximab (MSN05;MSN09);ruxolitinib (MSN06;MSN08);tofacitinib (MSN05;MSN08); |
| Water transmembrane transport |
Down |
18 |
0.8333333 |
0.1086956 |
0.5985914 |
48.86391 |
9 |
dabrafenib (MSN06;MSN08);pazopanib (MSN06);ponatinib (MSN06;MSN08) |
ceritinib (MSN01) |
| Water transmembrane transport |
Down |
8.5 |
1 |
0.1086956 |
0.674603 |
48.86391 |
9 |
dabrafenib (MSN06;MSN08);pazopanib (MSN06);ponatinib (MSN06;MSN08) |
|
| Water transmembrane transport |
Down |
6.5 |
1 |
0.08695652 |
0.6181818 |
48.86391 |
9 |
dabrafenib (MSN06;MSN08);pazopanib (MSN06);ponatinib (MSN08) |
|
| Water transmembrane transport |
Down |
4 |
1 |
0.02173913 |
0.2741936 |
48.86391 |
9 |
pazopanib (MSN06) |
|
| Water transmembrane transport |
Down |
6 |
1 |
0.06521739 |
0.5425532 |
48.86391 |
9 |
dabrafenib (MSN08);pazopanib (MSN06);ponatinib (MSN08) |
|
| Adrenergic receptor signaling |
Down |
13 |
0.7272727 |
0.173913 |
0.6126125 |
50.70718 |
8 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN09);lapatinib (MSN01);ponatinib (MSN06;MSN09) |
cabozantinib (MSN06);rituximab (MSN09);tofacitinib (MSN05) |
| Adrenergic receptor signaling |
Down |
18 |
0.6428571 |
0.1956522 |
0.5666665 |
50.70718 |
8 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN09);lapatinib (MSN01);ponatinib (MSN01;MSN06;MSN09) |
cabozantinib (MSN06);rituximab (MSN09);tofacitinib (MSN05;MSN08);vemurafenib (MSN06) |
| Adrenergic receptor signaling |
Down |
15 |
0.6923077 |
0.1956522 |
0.6023622 |
50.70718 |
8 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN09);lapatinib (MSN01);ponatinib (MSN01;MSN06;MSN09) |
cabozantinib (MSN06);rituximab (MSN09);tofacitinib (MSN05;MSN08) |
| Adrenergic receptor signaling |
Down |
13.5 |
0.75 |
0.1956522 |
0.6428572 |
50.70718 |
8 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN09);lapatinib (MSN01);ponatinib (MSN01;MSN06;MSN09) |
cabozantinib (MSN06);rituximab (MSN09);tofacitinib (MSN05) |
| Adrenergic receptor signaling |
Down |
9.5 |
0.7777778 |
0.1521739 |
0.6263158 |
50.70718 |
8 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN09);lapatinib (MSN01);ponatinib (MSN09) |
cabozantinib (MSN06);rituximab (MSN09) |
| Adrenergic receptor signaling |
Down |
9 |
0.75 |
0.1304348 |
0.5862069 |
50.70718 |
8 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN09);lapatinib (MSN01) |
cabozantinib (MSN06);rituximab (MSN09) |
| Adrenergic receptor signaling |
Down |
7 |
0.6 |
0.06521739 |
0.4047619 |
50.70718 |
8 |
bevacizumab (MSN05;MSN08;MSN09) |
cabozantinib (MSN06);rituximab (MSN09) |
| Adrenergic receptor signaling |
Down |
6 |
1 |
0.04347826 |
0.4358974 |
50.70718 |
8 |
bevacizumab (MSN05;MSN09) |
|
| Adrenergic receptor signaling |
Down |
2 |
1 |
0.02173913 |
0.2741936 |
50.70718 |
8 |
bevacizumab (MSN09) |
|
| Potassium transmembrane transport |
Up |
17 |
0.7272727 |
0.173913 |
0.6126125 |
51.69457 |
7 |
bevacizumab (MSN09);lapatinib (MSN05;MSN06);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
bosutinib (MSN08);erlotinib (MSN01;MSN08) |
| Potassium transmembrane transport |
Up |
2 |
1 |
0.02173913 |
0.2741936 |
51.69457 |
7 |
trametinib (MSN08) |
|
| Potassium transmembrane transport |
Up |
2.5 |
1 |
0.04347826 |
0.4358974 |
51.69457 |
7 |
trametinib (MSN08;MSN09) |
|
| Potassium transmembrane transport |
Up |
3 |
0.6666667 |
0.04347826 |
0.3617021 |
51.69457 |
7 |
trametinib (MSN08;MSN09) |
bosutinib (MSN08) |
| Potassium transmembrane transport |
Up |
6.5 |
0.8 |
0.08695652 |
0.5396825 |
51.69457 |
7 |
lapatinib (MSN05);trametinib (MSN08;MSN09);trastuzumab (MSN02) |
bosutinib (MSN08) |
| Potassium transmembrane transport |
Up |
8.5 |
0.7142857 |
0.1086956 |
0.5379746 |
51.69457 |
7 |
lapatinib (MSN05);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02) |
bosutinib (MSN08);erlotinib (MSN08) |
| Potassium transmembrane transport |
Up |
9.5 |
0.75 |
0.1304348 |
0.5862069 |
51.69457 |
7 |
lapatinib (MSN05;MSN06);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN02) |
bosutinib (MSN08);erlotinib (MSN08) |
| Potassium transmembrane transport |
Up |
10 |
0.7777778 |
0.1521739 |
0.6263158 |
51.69457 |
7 |
lapatinib (MSN05;MSN06);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
bosutinib (MSN08);erlotinib (MSN08) |
| Potassium transmembrane transport |
Up |
16.5 |
0.8 |
0.173913 |
0.6601941 |
51.69457 |
7 |
bevacizumab (MSN09);lapatinib (MSN05;MSN06);trametinib (MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02) |
bosutinib (MSN08);erlotinib (MSN08) |
| Myofibril formation |
Down |
3 |
1 |
0.02173913 |
0.2741936 |
54.00643 |
6 |
ponatinib (MSN01) |
|
| Myofibril formation |
Down |
11.5 |
0.6923077 |
0.1956522 |
0.6023622 |
54.00643 |
6 |
bevacizumab (MSN05);dabrafenib (MSN06;MSN08);pazopanib (MSN09);ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN05) |
nilotinib (MSN06);regorafenib (MSN01;MSN05;MSN08) |
| Myofibril formation |
Down |
4 |
1 |
0.04347826 |
0.4358974 |
54.00643 |
6 |
ponatinib (MSN01;MSN06) |
|
| Myofibril formation |
Down |
7.5 |
1 |
0.06521739 |
0.5425532 |
54.00643 |
6 |
bevacizumab (MSN05);ponatinib (MSN01;MSN06) |
|
| Myofibril formation |
Down |
8 |
0.7142857 |
0.1086956 |
0.5379746 |
54.00643 |
6 |
bevacizumab (MSN05);ponatinib (MSN01;MSN06;MSN09);sorafenib (MSN05) |
nilotinib (MSN06);regorafenib (MSN01) |
| Myofibril formation |
Down |
9 |
0.75 |
0.1304348 |
0.5862069 |
54.00643 |
6 |
bevacizumab (MSN05);pazopanib (MSN09);ponatinib (MSN01;MSN06;MSN09);sorafenib (MSN05) |
nilotinib (MSN06);regorafenib (MSN01) |
| Myofibril formation |
Down |
9.5 |
0.6363636 |
0.1521739 |
0.5360361 |
54.00643 |
6 |
bevacizumab (MSN05);dabrafenib (MSN08);pazopanib (MSN09);ponatinib (MSN01;MSN06;MSN09);sorafenib (MSN05) |
nilotinib (MSN06);regorafenib (MSN01;MSN05;MSN08) |
| Myofibril formation |
Down |
10 |
0.6666667 |
0.173913 |
0.5714285 |
54.00643 |
6 |
bevacizumab (MSN05);dabrafenib (MSN06;MSN08);pazopanib (MSN09);ponatinib (MSN01;MSN06;MSN09);sorafenib (MSN05) |
nilotinib (MSN06);regorafenib (MSN01;MSN05;MSN08) |
| Myofibril formation |
Down |
12 |
0.7142857 |
0.2173913 |
0.6296296 |
54.00643 |
6 |
bevacizumab (MSN05);dabrafenib (MSN06;MSN08);pazopanib (MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN05) |
nilotinib (MSN06);regorafenib (MSN01;MSN05;MSN08) |
| Leptin receptor signaling |
Up |
5 |
1 |
0.08695652 |
0.6181818 |
54.60929 |
5 |
lapatinib (MSN05;MSN06;MSN09);trastuzumab (MSN01) |
|
| Leptin receptor signaling |
Up |
5.5 |
1 |
0.1086956 |
0.674603 |
54.60929 |
5 |
lapatinib (MSN01;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
|
| Leptin receptor signaling |
Up |
4 |
1 |
0.04347826 |
0.4358974 |
54.60929 |
5 |
lapatinib (MSN05);trastuzumab (MSN01) |
|
| Leptin receptor signaling |
Up |
3 |
1 |
0.02173913 |
0.2741936 |
54.60929 |
5 |
lapatinib (MSN05) |
|
| Leptin receptor signaling |
Up |
7.5 |
0.8333333 |
0.1086956 |
0.5985914 |
54.60929 |
5 |
lapatinib (MSN01;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
rituximab (MSN08) |
| Polyol pathway |
Down |
1 |
1 |
0.08695652 |
0.6181818 |
54.78032 |
4 |
bevacizumab (MSN05;MSN06;MSN08;MSN09) |
|
| Polyol pathway |
Down |
4 |
0.8 |
0.08695652 |
0.5396825 |
54.78032 |
4 |
bevacizumab (MSN05;MSN06;MSN08;MSN09) |
dasatinib (MSN08) |
| Restriction point |
Up |
9 |
0.8333333 |
0.1086956 |
0.5985914 |
56.36274 |
3 |
sunitinib (MSN01;MSN05;MSN08;MSN09);vandetanib (MSN09) |
vemurafenib (MSN09) |
| Restriction point |
Up |
7 |
0.8 |
0.08695652 |
0.5396825 |
56.36274 |
3 |
sunitinib (MSN01;MSN05;MSN08;MSN09) |
vemurafenib (MSN09) |
| Restriction point |
Up |
5.5 |
1 |
0.08695652 |
0.6181818 |
56.36274 |
3 |
sunitinib (MSN01;MSN05;MSN08;MSN09) |
|
| Restriction point |
Up |
4 |
1 |
0.06521739 |
0.5425532 |
56.36274 |
3 |
sunitinib (MSN05;MSN08;MSN09) |
|
| Restriction point |
Up |
3 |
1 |
0.04347826 |
0.4358974 |
56.36274 |
3 |
sunitinib (MSN05;MSN09) |
|
| Restriction point |
Up |
1.5 |
1 |
0.02173913 |
0.2741936 |
56.36274 |
3 |
sunitinib (MSN09) |
|
| Restriction point |
Up |
10.5 |
0.8571429 |
0.1304348 |
0.6455697 |
56.36274 |
3 |
sunitinib (MSN01;MSN05;MSN06;MSN08;MSN09);vandetanib (MSN09) |
vemurafenib (MSN09) |
| Transamination pathways |
Up |
21.5 |
0.6666667 |
0.08695652 |
0.4788733 |
38.80473 |
25 |
pazopanib (MSN01;MSN05;MSN06;MSN08) |
imatinib (MSN06;MSN09) |
| Transamination pathways |
Up |
4 |
0 |
0 |
NaN |
38.80473 |
25 |
|
imatinib (MSN09) |
| Transamination pathways |
Up |
5.5 |
0.5 |
0.02173913 |
0.2179487 |
38.80473 |
25 |
pazopanib (MSN05) |
imatinib (MSN09) |
| Transamination pathways |
Up |
9.5 |
0.6666667 |
0.04347826 |
0.3617021 |
38.80473 |
25 |
pazopanib (MSN05;MSN08) |
imatinib (MSN09) |
| Transamination pathways |
Up |
10 |
0.75 |
0.06521739 |
0.4636364 |
38.80473 |
25 |
pazopanib (MSN05;MSN06;MSN08) |
imatinib (MSN09) |
| Transamination pathways |
Up |
11 |
0.8 |
0.08695652 |
0.5396825 |
38.80473 |
25 |
pazopanib (MSN01;MSN05;MSN06;MSN08) |
imatinib (MSN09) |
| Gap junction organization |
Down |
20 |
0.625 |
0.2173913 |
0.5629139 |
39.23112 |
24 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN08);ponatinib (MSN02;MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN05;MSN06) |
| Gap junction organization |
Down |
8 |
0.4 |
0.04347826 |
0.2698413 |
39.23112 |
24 |
pazopanib (MSN06;MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);regorafenib (MSN06) |
| Gap junction organization |
Down |
9 |
0.5 |
0.06521739 |
0.3591549 |
39.23112 |
24 |
pazopanib (MSN06;MSN08);vandetanib (MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);regorafenib (MSN06) |
| Gap junction organization |
Down |
12 |
0.4285714 |
0.06521739 |
0.3227848 |
39.23112 |
24 |
pazopanib (MSN06;MSN08);vandetanib (MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);imatinib (MSN01);regorafenib (MSN06) |
| Gap junction organization |
Down |
13 |
0.5 |
0.08695652 |
0.3908046 |
39.23112 |
24 |
bevacizumab (MSN08);pazopanib (MSN06;MSN08);vandetanib (MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);imatinib (MSN01);regorafenib (MSN06) |
| Gap junction organization |
Down |
14 |
0.6 |
0.1304348 |
0.4951456 |
39.23112 |
24 |
bevacizumab (MSN05;MSN06;MSN08);pazopanib (MSN06;MSN08);vandetanib (MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);imatinib (MSN01);regorafenib (MSN06) |
| Gap junction organization |
Down |
15 |
0.6666667 |
0.173913 |
0.5714285 |
39.23112 |
24 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN08);ponatinib (MSN08);vandetanib (MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);imatinib (MSN01);regorafenib (MSN06) |
| Gap junction organization |
Down |
15.5 |
0.6428571 |
0.1956522 |
0.5666665 |
39.23112 |
24 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN08);ponatinib (MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);imatinib (MSN01);regorafenib (MSN05;MSN06) |
| Gap junction organization |
Down |
17 |
0.6666667 |
0.2173913 |
0.5944056 |
39.23112 |
24 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN08);ponatinib (MSN02;MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN08);ceritinib (MSN08);imatinib (MSN01);regorafenib (MSN05;MSN06) |
| Gap junction organization |
Down |
22 |
0.5555556 |
0.2173913 |
0.5089821 |
39.23112 |
24 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN08);ponatinib (MSN02;MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN02;MSN08);ceritinib (MSN01;MSN08);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN05;MSN06) |
| Gap junction organization |
Down |
22.5 |
0.5263158 |
0.2173913 |
0.4857143 |
39.23112 |
24 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN08);ponatinib (MSN02;MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN02;MSN08);ceritinib (MSN01;MSN08);crizotinib (MSN08);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN05;MSN06) |
| Gap junction organization |
Down |
24 |
0.55 |
0.2391304 |
0.5109289 |
39.23112 |
24 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN05);pazopanib (MSN06;MSN08);ponatinib (MSN02;MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN02;MSN08);ceritinib (MSN01;MSN08);crizotinib (MSN08);dasatinib (MSN06);imatinib (MSN01);regorafenib (MSN05;MSN06) |
| Gap junction organization |
Down |
6 |
0.5 |
0.04347826 |
0.3090909 |
39.23112 |
24 |
pazopanib (MSN06;MSN08) |
cabozantinib (MSN08);regorafenib (MSN06) |
| Gap junction organization |
Down |
5 |
0.6666667 |
0.04347826 |
0.3617021 |
39.23112 |
24 |
pazopanib (MSN06;MSN08) |
cabozantinib (MSN08) |
| Gap junction organization |
Down |
3 |
1 |
0.04347826 |
0.4358974 |
39.23112 |
24 |
pazopanib (MSN06;MSN08) |
|
| Gap junction organization |
Down |
1 |
1 |
0.02173913 |
0.2741936 |
39.23112 |
24 |
pazopanib (MSN06) |
|
| Cellular cholesterol uptake and efflux |
Down |
4 |
0.7142857 |
0.1086956 |
0.5379746 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01);sunitinib (MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN01);rituximab (MSN06) |
| Cellular cholesterol uptake and efflux |
Down |
3.5 |
0.8333333 |
0.1086956 |
0.5985914 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01);sunitinib (MSN08;MSN09);vandetanib (MSN08) |
rituximab (MSN06) |
| Cellular cholesterol uptake and efflux |
Down |
3 |
0.75 |
0.06521739 |
0.4636364 |
39.69394 |
23 |
sunitinib (MSN08;MSN09);vandetanib (MSN08) |
rituximab (MSN06) |
| Cellular cholesterol uptake and efflux |
Down |
1 |
1 |
0.02173913 |
0.2741936 |
39.69394 |
23 |
vandetanib (MSN08) |
|
| Cellular cholesterol uptake and efflux |
Down |
4.5 |
0.625 |
0.1086956 |
0.4885057 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01);sunitinib (MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN01);crizotinib (MSN01);rituximab (MSN06) |
| Cellular cholesterol uptake and efflux |
Down |
7 |
0.6666667 |
0.1304348 |
0.5368421 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01);sunitinib (MSN01;MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN01);crizotinib (MSN01);rituximab (MSN06) |
| Cellular cholesterol uptake and efflux |
Down |
9 |
0.5454546 |
0.1304348 |
0.4594595 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01);sunitinib (MSN01;MSN08;MSN09);vandetanib (MSN08) |
cabozantinib (MSN01);crizotinib (MSN01;MSN09);rituximab (MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Down |
15 |
0.5833333 |
0.1521739 |
0.5 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01);sunitinib (MSN01;MSN08;MSN09);vandetanib (MSN05;MSN08) |
cabozantinib (MSN01);crizotinib (MSN01;MSN09);rituximab (MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Down |
17.5 |
0.5384616 |
0.1521739 |
0.468504 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01);sunitinib (MSN01;MSN08;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN05);cabozantinib (MSN01);crizotinib (MSN01;MSN09);rituximab (MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Down |
20 |
0.5 |
0.1521739 |
0.4407408 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01);sunitinib (MSN01;MSN08;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN05);cabozantinib (MSN01);crizotinib (MSN01;MSN08;MSN09);rituximab (MSN06;MSN08) |
| Cellular cholesterol uptake and efflux |
Down |
22 |
0.5333334 |
0.173913 |
0.4755246 |
39.69394 |
23 |
dabrafenib (MSN06);lapatinib (MSN01;MSN06);sunitinib (MSN01;MSN08;MSN09);vandetanib (MSN05;MSN08) |
axitinib (MSN05);cabozantinib (MSN01);crizotinib (MSN01;MSN08;MSN09);rituximab (MSN06;MSN08) |
| Cholesterol synthesis |
Up |
13.5 |
0.45 |
0.3913043 |
0.4460641 |
39.81315 |
22 |
dabrafenib (MSN01;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN06;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN06;MSN09);vandetanib (MSN05) |
cabozantinib (MSN01;MSN02;MSN06;MSN08;MSN09);ceritinib (MSN06);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Up |
13 |
0.4615385 |
0.3913043 |
0.4567164 |
39.81315 |
22 |
dabrafenib (MSN01;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN06;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN06;MSN09);vandetanib (MSN05) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN06);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Up |
8 |
0.4473684 |
0.3695652 |
0.441896 |
39.81315 |
22 |
dabrafenib (MSN01;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN06;MSN09);vandetanib (MSN05) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN06);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Up |
16 |
0.4390244 |
0.3913043 |
0.4358974 |
39.81315 |
22 |
dabrafenib (MSN01;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN06;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN06;MSN09);vandetanib (MSN05) |
cabozantinib (MSN01;MSN02;MSN06;MSN08;MSN09);ceritinib (MSN06);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN02;MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Up |
6 |
0.4324324 |
0.3478261 |
0.4263323 |
39.81315 |
22 |
dabrafenib (MSN01;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05) |
cabozantinib (MSN01;MSN02;MSN06;MSN08);ceritinib (MSN06);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Up |
2 |
0.4137931 |
0.2608696 |
0.4 |
39.81315 |
22 |
dabrafenib (MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN09);sorafenib (MSN01);sunitinib (MSN02;MSN06);vandetanib (MSN05) |
cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN06);imatinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Up |
1 |
0.3809524 |
0.173913 |
0.356021 |
39.81315 |
22 |
dabrafenib (MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN02;MSN06) |
cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN06);imatinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN05;MSN06);ruxolitinib (MSN05;MSN06;MSN08) |
| Cholesterol synthesis |
Up |
5 |
0.4444444 |
0.3478261 |
0.437299 |
39.81315 |
22 |
dabrafenib (MSN01;MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05) |
cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN06);erlotinib (MSN01);imatinib (MSN01;MSN05;MSN06;MSN09);nilotinib (MSN05);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Up |
4 |
0.4545455 |
0.326087 |
0.4442509 |
39.81315 |
22 |
dabrafenib (MSN06;MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN09);sorafenib (MSN01;MSN05);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05) |
cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN06);imatinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Cholesterol synthesis |
Up |
3 |
0.4193548 |
0.2826087 |
0.407749 |
39.81315 |
22 |
dabrafenib (MSN08);lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN06;MSN09);sorafenib (MSN01);sunitinib (MSN01;MSN02;MSN06);vandetanib (MSN05) |
cabozantinib (MSN01;MSN06;MSN08);ceritinib (MSN06);imatinib (MSN01;MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08);rituximab (MSN06;MSN08);ruxolitinib (MSN05;MSN06;MSN08;MSN09) |
| Thin myofilament organization |
Down |
22 |
0.5128205 |
0.4347826 |
0.5074626 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01;MSN06;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);trametinib (MSN09) |
cabozantinib (MSN02;MSN05;MSN06);erlotinib (MSN01);imatinib (MSN05);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Thin myofilament organization |
Down |
3 |
0.6 |
0.1956522 |
0.534965 |
40.06216 |
21 |
bevacizumab (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN06) |
nilotinib (MSN06;MSN09);ruxolitinib (MSN02);tofacitinib (MSN05;MSN08;MSN09) |
| Thin myofilament organization |
Down |
2.5 |
0.6363636 |
0.1521739 |
0.5360361 |
40.06216 |
21 |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN06) |
nilotinib (MSN06;MSN09);tofacitinib (MSN05;MSN09) |
| Thin myofilament organization |
Down |
2 |
0.5555556 |
0.1086956 |
0.4473684 |
40.06216 |
21 |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09) |
nilotinib (MSN06;MSN09);tofacitinib (MSN05;MSN09) |
| Thin myofilament organization |
Down |
1 |
0.8333333 |
0.1086956 |
0.5985914 |
40.06216 |
21 |
ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09) |
tofacitinib (MSN05) |
| Thin myofilament organization |
Down |
8.5 |
0.6538461 |
0.3695652 |
0.625541 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN06);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Thin myofilament organization |
Down |
7 |
0.68 |
0.3695652 |
0.6479821 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN06);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02);tofacitinib (MSN05;MSN08;MSN09) |
| Thin myofilament organization |
Down |
4 |
0.625 |
0.2173913 |
0.5629139 |
40.06216 |
21 |
bevacizumab (MSN05;MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06) |
nilotinib (MSN06;MSN09);ruxolitinib (MSN02);tofacitinib (MSN05;MSN08;MSN09) |
| Thin myofilament organization |
Down |
4.5 |
0.6470588 |
0.2391304 |
0.5880503 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06) |
nilotinib (MSN06;MSN09);ruxolitinib (MSN02);tofacitinib (MSN05;MSN08;MSN09) |
| Thin myofilament organization |
Down |
5 |
0.6315789 |
0.2608696 |
0.5828571 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08);dabrafenib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06) |
cabozantinib (MSN06);nilotinib (MSN06;MSN09);ruxolitinib (MSN02);tofacitinib (MSN05;MSN08;MSN09) |
| Thin myofilament organization |
Down |
6.5 |
0.6 |
0.2608696 |
0.5573771 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08);dabrafenib (MSN08);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN06) |
cabozantinib (MSN06);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02);tofacitinib (MSN05;MSN08;MSN09) |
| Thin myofilament organization |
Down |
16.5 |
0.5 |
0.4130435 |
0.4938838 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01;MSN06;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN02;MSN05;MSN06);erlotinib (MSN01);imatinib (MSN05);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Thin myofilament organization |
Down |
14 |
0.4864865 |
0.3913043 |
0.4796239 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01;MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN02;MSN05;MSN06);erlotinib (MSN01);imatinib (MSN05);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Thin myofilament organization |
Down |
13 |
0.5 |
0.3913043 |
0.4919614 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01;MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN02;MSN05;MSN06);erlotinib (MSN01);imatinib (MSN05);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Thin myofilament organization |
Down |
12 |
0.5294118 |
0.3913043 |
0.5186441 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01;MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN02;MSN05;MSN06);erlotinib (MSN01);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Thin myofilament organization |
Down |
11.5 |
0.5625 |
0.3913043 |
0.5483871 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01;MSN06);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN05;MSN06);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Thin myofilament organization |
Down |
10 |
0.5666667 |
0.3695652 |
0.5494297 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN06);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN06;MSN08;MSN09) |
| Thin myofilament organization |
Down |
9.5 |
0.5862069 |
0.3695652 |
0.5666667 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN06);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN06;MSN08;MSN09);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| Thin myofilament organization |
Down |
9 |
0.6071429 |
0.3695652 |
0.5850202 |
40.06216 |
21 |
bevacizumab (MSN05;MSN06;MSN08;MSN09);dabrafenib (MSN08);lapatinib (MSN01);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sunitinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09) |
cabozantinib (MSN06);nilotinib (MSN06;MSN08;MSN09);ruxolitinib (MSN02;MSN06;MSN09);tofacitinib (MSN01;MSN05;MSN08;MSN09) |
| HIF-1 receptor signaling pathway |
Down |
1 |
1 |
0.02173913 |
0.2741936 |
40.29001 |
20 |
pazopanib (MSN09) |
|
| HIF-1 receptor signaling pathway |
Down |
6 |
1 |
0.06521739 |
0.5425532 |
40.29001 |
20 |
pazopanib (MSN06;MSN08;MSN09) |
|
| HIF-1 receptor signaling pathway |
Down |
7 |
0.75 |
0.06521739 |
0.4636364 |
40.29001 |
20 |
pazopanib (MSN06;MSN08;MSN09) |
imatinib (MSN09) |
| HIF-1 receptor signaling pathway |
Down |
8 |
0.7142857 |
0.1086956 |
0.5379746 |
40.29001 |
20 |
dabrafenib (MSN06;MSN08);pazopanib (MSN06;MSN08;MSN09) |
imatinib (MSN09);nilotinib (MSN09) |
| HIF-1 receptor signaling pathway |
Down |
12.5 |
0.625 |
0.1086956 |
0.4885057 |
40.29001 |
20 |
dabrafenib (MSN06;MSN08);pazopanib (MSN06;MSN08;MSN09) |
imatinib (MSN09);nilotinib (MSN09);vemurafenib (MSN06) |
| Lysosomal glycoprotein degradation |
Up |
7.5 |
1 |
0.08695652 |
0.6181818 |
59.07953 |
2 |
pazopanib (MSN05;MSN06;MSN08;MSN09) |
|
| Lysosomal glycoprotein degradation |
Up |
4.5 |
1 |
0.06521739 |
0.5425532 |
59.07953 |
2 |
pazopanib (MSN05;MSN06;MSN09) |
|
| Lysosomal glycoprotein degradation |
Up |
8 |
1 |
0.1086956 |
0.674603 |
59.07953 |
2 |
pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09) |
|
| Lysosomal glycoprotein degradation |
Up |
3.5 |
1 |
0.02173913 |
0.2741936 |
59.07953 |
2 |
pazopanib (MSN05) |
|
| Lysosomal glycoprotein degradation |
Up |
4 |
1 |
0.04347826 |
0.4358974 |
59.07953 |
2 |
pazopanib (MSN05;MSN06) |
|
| Serine and glycine metabolism |
Up |
1 |
0.7142857 |
0.1086956 |
0.5379746 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN09);pazopanib (MSN05;MSN09) |
ceritinib (MSN01);erlotinib (MSN09) |
| Serine and glycine metabolism |
Up |
3 |
0.5 |
0.1956522 |
0.4580838 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN06;MSN09);sorafenib (MSN08) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN06;MSN08);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
9 |
0.4857143 |
0.3695652 |
0.4768977 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01) |
afatinib (MSN01);bosutinib (MSN01);cabozantinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
10 |
0.4722222 |
0.3695652 |
0.4646302 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01) |
afatinib (MSN01);bosutinib (MSN01);cabozantinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
11 |
0.4864865 |
0.3913043 |
0.4796239 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08);trametinib (MSN01) |
afatinib (MSN01);bosutinib (MSN01);cabozantinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
12 |
0.5 |
0.4347826 |
0.4956268 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08);sunitinib (MSN02);trametinib (MSN01);vandetanib (MSN08) |
afatinib (MSN01);bosutinib (MSN01);cabozantinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05);vemurafenib (MSN08) |
| Serine and glycine metabolism |
Up |
14 |
0.5121951 |
0.4565217 |
0.5085469 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08);sunitinib (MSN02);trametinib (MSN01);vandetanib (MSN05;MSN08) |
afatinib (MSN01);bosutinib (MSN01);cabozantinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05);vemurafenib (MSN08) |
| Serine and glycine metabolism |
Up |
16 |
0.4883721 |
0.4565217 |
0.486376 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08);sunitinib (MSN02);trametinib (MSN01);vandetanib (MSN05;MSN08) |
afatinib (MSN01);bosutinib (MSN01;MSN08);cabozantinib (MSN01;MSN06);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05);vemurafenib (MSN08) |
| Serine and glycine metabolism |
Up |
18.5 |
0.5 |
0.4782609 |
0.4986667 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08;MSN09);sunitinib (MSN02);trametinib (MSN01);vandetanib (MSN05;MSN08) |
afatinib (MSN01);bosutinib (MSN01;MSN08);cabozantinib (MSN01;MSN06);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05);vemurafenib (MSN08) |
| Serine and glycine metabolism |
Up |
20.5 |
0.5111111 |
0.5 |
0.5104438 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09);sunitinib (MSN02);trametinib (MSN01);vandetanib (MSN05;MSN08) |
afatinib (MSN01);bosutinib (MSN01;MSN08);cabozantinib (MSN01;MSN06);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN01;MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05);vemurafenib (MSN08) |
| Serine and glycine metabolism |
Up |
6 |
0.5151515 |
0.3695652 |
0.5034843 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01) |
afatinib (MSN01);cabozantinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN06;MSN08;MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
5 |
0.516129 |
0.3478261 |
0.501845 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01) |
afatinib (MSN01);cabozantinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN06;MSN08);nilotinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
7 |
0.5 |
0.3695652 |
0.4898305 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN02;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01) |
afatinib (MSN01);cabozantinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN05;MSN06;MSN08;MSN09);nilotinib (MSN05;MSN06;MSN08;MSN09);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
4.5 |
0.5 |
0.2391304 |
0.4698493 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN09);sorafenib (MSN08);trametinib (MSN01) |
afatinib (MSN01);ceritinib (MSN01;MSN06);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN06;MSN08);nilotinib (MSN05);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
4 |
0.5238096 |
0.2391304 |
0.4895289 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN09);sorafenib (MSN08);trametinib (MSN01) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN06;MSN08);nilotinib (MSN05);tofacitinib (MSN05) |
| Serine and glycine metabolism |
Up |
2 |
0.4375 |
0.1521739 |
0.3940398 |
41.76742 |
19 |
dabrafenib (MSN01;MSN05;MSN08;MSN09);pazopanib (MSN05;MSN09);sorafenib (MSN08) |
afatinib (MSN01);ceritinib (MSN01);erlotinib (MSN01;MSN05;MSN08;MSN09);gefitinib (MSN06;MSN08);tofacitinib (MSN05) |
| Biglycan synthesis |
Down |
29.5 |
0.6 |
0.4565217 |
0.5891089 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
33 |
0.5897436 |
0.5 |
0.5835821 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN05;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN05);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
32 |
0.6052632 |
0.5 |
0.5978593 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN05;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
31.5 |
0.6216216 |
0.5 |
0.6128526 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
30.5 |
0.6111111 |
0.4782609 |
0.6012862 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
27.5 |
0.6176471 |
0.4565217 |
0.6050848 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
35 |
0.575 |
0.5 |
0.5699708 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);ceritinib (MSN05;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);erlotinib (MSN05;MSN09);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
14 |
0.7857143 |
0.2391304 |
0.6925926 |
41.8958 |
18 |
dabrafenib (MSN08);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN08) |
| Biglycan synthesis |
Down |
26 |
0.59375 |
0.4130435 |
0.5788531 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trametinib (MSN01);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
21 |
0.5806451 |
0.3913043 |
0.5645756 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN06;MSN08;MSN09);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);gefitinib (MSN01);imatinib (MSN05) |
| Biglycan synthesis |
Down |
20.5 |
0.5862069 |
0.3695652 |
0.5666667 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN06;MSN08);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
afatinib (MSN08);bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05) |
| Biglycan synthesis |
Down |
18.5 |
0.6071429 |
0.3695652 |
0.5850202 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN06;MSN08);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05) |
| Biglycan synthesis |
Down |
18 |
0.5769231 |
0.326087 |
0.5519481 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09);imatinib (MSN05) |
| Biglycan synthesis |
Down |
17.5 |
0.6 |
0.326087 |
0.5717489 |
41.8958 |
18 |
dabrafenib (MSN08);lapatinib (MSN06);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN05;MSN06;MSN09) |
| Biglycan synthesis |
Down |
16.5 |
0.6086956 |
0.3043478 |
0.5748792 |
41.8958 |
18 |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trastuzumab (MSN05;MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN02;MSN05;MSN08;MSN09);dasatinib (MSN01;MSN06;MSN09) |
| Biglycan synthesis |
Down |
15.5 |
0.6190476 |
0.2826087 |
0.578534 |
41.8958 |
18 |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trastuzumab (MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN05;MSN08;MSN09);dasatinib (MSN01;MSN06;MSN09) |
| Biglycan synthesis |
Down |
15 |
0.7222222 |
0.2826087 |
0.6616766 |
41.8958 |
18 |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);trastuzumab (MSN09);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN08;MSN09);dasatinib (MSN09) |
| Biglycan synthesis |
Down |
14.5 |
0.7058824 |
0.2608696 |
0.6415094 |
41.8958 |
18 |
dabrafenib (MSN08);pazopanib (MSN05);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN08;MSN09);dasatinib (MSN09) |
| Biglycan synthesis |
Down |
4.5 |
1 |
0.02173913 |
0.2741936 |
41.8958 |
18 |
vandetanib (MSN08) |
|
| Biglycan synthesis |
Down |
13 |
0.7692308 |
0.2173913 |
0.6692914 |
41.8958 |
18 |
dabrafenib (MSN08);ponatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08;MSN09);cabozantinib (MSN08) |
| Biglycan synthesis |
Down |
12.5 |
0.8333333 |
0.2173913 |
0.7142857 |
41.8958 |
18 |
dabrafenib (MSN08);ponatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08);cabozantinib (MSN08) |
| Biglycan synthesis |
Down |
12 |
0.9090909 |
0.2173913 |
0.7657657 |
41.8958 |
18 |
dabrafenib (MSN08);ponatinib (MSN01;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08) |
| Biglycan synthesis |
Down |
11.5 |
0.9 |
0.1956522 |
0.7427185 |
41.8958 |
18 |
dabrafenib (MSN08);ponatinib (MSN01;MSN05;MSN06;MSN08);sorafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08) |
| Biglycan synthesis |
Down |
11 |
0.8888889 |
0.173913 |
0.7157895 |
41.8958 |
18 |
ponatinib (MSN01;MSN05;MSN06;MSN08);sorafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08) |
| Biglycan synthesis |
Down |
10 |
0.875 |
0.1521739 |
0.6839081 |
41.8958 |
18 |
ponatinib (MSN01;MSN05;MSN08);sorafenib (MSN08);vandetanib (MSN05;MSN08;MSN09) |
bosutinib (MSN08) |
| Biglycan synthesis |
Down |
9.5 |
0.8333333 |
0.1086956 |
0.5985914 |
41.8958 |
18 |
ponatinib (MSN05;MSN08);sorafenib (MSN08);vandetanib (MSN08;MSN09) |
bosutinib (MSN08) |
| Biglycan synthesis |
Down |
8.5 |
1 |
0.08695652 |
0.6181818 |
41.8958 |
18 |
ponatinib (MSN05);sorafenib (MSN08);vandetanib (MSN08;MSN09) |
|
| Biglycan synthesis |
Down |
8 |
1 |
0.06521739 |
0.5425532 |
41.8958 |
18 |
sorafenib (MSN08);vandetanib (MSN08;MSN09) |
|
| Biglycan synthesis |
Down |
7.5 |
1 |
0.04347826 |
0.4358974 |
41.8958 |
18 |
vandetanib (MSN08;MSN09) |
|
| Chloride transmembrane transport |
Down |
20.5 |
0.75 |
0.1304348 |
0.5862069 |
42.52474 |
17 |
ponatinib (MSN02;MSN06;MSN09);sunitinib (MSN02;MSN05);vandetanib (MSN08) |
ruxolitinib (MSN01);tofacitinib (MSN09) |
| Chloride transmembrane transport |
Down |
17.5 |
0.8571429 |
0.1304348 |
0.6455697 |
42.52474 |
17 |
ponatinib (MSN02;MSN06;MSN09);sunitinib (MSN02;MSN05);vandetanib (MSN08) |
tofacitinib (MSN09) |
| Chloride transmembrane transport |
Down |
16 |
1 |
0.1304348 |
0.7183099 |
42.52474 |
17 |
ponatinib (MSN02;MSN06;MSN09);sunitinib (MSN02;MSN05);vandetanib (MSN08) |
|
| Chloride transmembrane transport |
Down |
14 |
1 |
0.1086956 |
0.674603 |
42.52474 |
17 |
ponatinib (MSN06;MSN09);sunitinib (MSN02;MSN05);vandetanib (MSN08) |
|
| Chloride transmembrane transport |
Down |
12 |
1 |
0.06521739 |
0.5425532 |
42.52474 |
17 |
sunitinib (MSN02;MSN05);vandetanib (MSN08) |
|
| Chloride transmembrane transport |
Down |
7.5 |
1 |
0.02173913 |
0.2741936 |
42.52474 |
17 |
vandetanib (MSN08) |
|
| Chloride transmembrane transport |
Down |
11.5 |
1 |
0.04347826 |
0.4358974 |
42.52474 |
17 |
sunitinib (MSN02);vandetanib (MSN08) |
|
| Granulocyte-colony stimulating factor receptor signaling |
Up |
14.5 |
0.75 |
0.1304348 |
0.5862069 |
43.07553 |
16 |
bevacizumab (MSN09);lapatinib (MSN01;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
rituximab (MSN06;MSN08) |
| Granulocyte-colony stimulating factor receptor signaling |
Up |
8 |
1 |
0.04347826 |
0.4358974 |
43.07553 |
16 |
lapatinib (MSN05;MSN09) |
|
| Granulocyte-colony stimulating factor receptor signaling |
Up |
11 |
0.6666667 |
0.08695652 |
0.4788733 |
43.07553 |
16 |
lapatinib (MSN05;MSN06;MSN09);trastuzumab (MSN01) |
rituximab (MSN06;MSN08) |
| Granulocyte-colony stimulating factor receptor signaling |
Up |
12 |
0.7142857 |
0.1086956 |
0.5379746 |
43.07553 |
16 |
lapatinib (MSN01;MSN05;MSN06;MSN09);trastuzumab (MSN01) |
rituximab (MSN06;MSN08) |
| Granulocyte-colony stimulating factor receptor signaling |
Up |
7 |
1 |
0.02173913 |
0.2741936 |
43.07553 |
16 |
lapatinib (MSN09) |
|
| Cholesterol-sensitive control of SREBP activation |
Up |
6 |
0.5833333 |
0.1521739 |
0.5 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN09);imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
7 |
0.6153846 |
0.173913 |
0.535433 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN09);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN09);imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
7.5 |
0.6428571 |
0.1956522 |
0.5666665 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN05;MSN08;MSN09);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN09);imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
8 |
0.6875 |
0.2391304 |
0.6192054 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN09);imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
8.5 |
0.6470588 |
0.2391304 |
0.5880503 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN09);imatinib (MSN05;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
9 |
0.6111111 |
0.2391304 |
0.5598803 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN09);imatinib (MSN01;MSN05;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
10 |
0.5789474 |
0.2391304 |
0.5342858 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN06;MSN09);imatinib (MSN01;MSN05;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
13.5 |
0.6 |
0.2608696 |
0.5573771 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);sorafenib (MSN01);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN06;MSN09);imatinib (MSN01;MSN05;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
14.5 |
0.6190476 |
0.2826087 |
0.578534 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01);sorafenib (MSN01);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN06;MSN09);imatinib (MSN01;MSN05;MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
15 |
0.6086956 |
0.3043478 |
0.5748792 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN08);sorafenib (MSN01);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN06;MSN09);imatinib (MSN01;MSN05;MSN09);nilotinib (MSN01) |
| Cholesterol-sensitive control of SREBP activation |
Up |
17.5 |
0.5833333 |
0.3043478 |
0.5534883 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN08);sorafenib (MSN01);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN06;MSN09);imatinib (MSN01;MSN05;MSN09);nilotinib (MSN01;MSN05) |
| Cholesterol-sensitive control of SREBP activation |
Up |
20 |
0.56 |
0.3043478 |
0.5336323 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08;MSN09);pazopanib (MSN01;MSN05;MSN06;MSN08;MSN09);ponatinib (MSN01;MSN08);sorafenib (MSN01);sunitinib (MSN09) |
cabozantinib (MSN02;MSN08);ceritinib (MSN05;MSN06;MSN09);imatinib (MSN01;MSN05;MSN06;MSN09);nilotinib (MSN01;MSN05) |
| Cholesterol-sensitive control of SREBP activation |
Up |
2.5 |
0.5 |
0.02173913 |
0.2179487 |
43.48394 |
15 |
lapatinib (MSN01) |
imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
5 |
0.6 |
0.1304348 |
0.4951456 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06;MSN08);pazopanib (MSN05;MSN09) |
cabozantinib (MSN02);ceritinib (MSN05;MSN09);imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
2 |
1 |
0.02173913 |
0.2741936 |
43.48394 |
15 |
lapatinib (MSN01) |
|
| Cholesterol-sensitive control of SREBP activation |
Up |
3 |
0.6666667 |
0.04347826 |
0.3617021 |
43.48394 |
15 |
lapatinib (MSN01;MSN06) |
imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
3.5 |
0.6 |
0.06521739 |
0.4047619 |
43.48394 |
15 |
lapatinib (MSN01;MSN06);pazopanib (MSN05) |
cabozantinib (MSN02);imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
4 |
0.5714286 |
0.08695652 |
0.4303798 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06);pazopanib (MSN05) |
cabozantinib (MSN02);ceritinib (MSN05);imatinib (MSN09) |
| Cholesterol-sensitive control of SREBP activation |
Up |
4.5 |
0.5555556 |
0.1086956 |
0.4473684 |
43.48394 |
15 |
lapatinib (MSN01;MSN05;MSN06);pazopanib (MSN05;MSN09) |
cabozantinib (MSN02);ceritinib (MSN05;MSN09);imatinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
11 |
0.5909091 |
0.2826087 |
0.5552764 |
44.75258 |
14 |
pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06);sorafenib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN09) |
axitinib (MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01);erlotinib (MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
39 |
0.6176471 |
0.4565217 |
0.6050848 |
44.75258 |
14 |
lapatinib (MSN06);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01;MSN09);erlotinib (MSN01;MSN05;MSN08);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
10.5 |
0.65 |
0.2826087 |
0.6038251 |
44.75258 |
14 |
pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06);sorafenib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN09) |
axitinib (MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01);erlotinib (MSN05);imatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Down |
10 |
0.6315789 |
0.2608696 |
0.5828571 |
44.75258 |
14 |
pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06);sorafenib (MSN01;MSN05;MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
axitinib (MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01);erlotinib (MSN05);imatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Down |
9 |
0.6470588 |
0.2391304 |
0.5880503 |
44.75258 |
14 |
pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06);sorafenib (MSN01;MSN08);trastuzumab (MSN02;MSN05;MSN09);vandetanib (MSN09) |
axitinib (MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01);imatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Down |
8.5 |
0.6 |
0.1956522 |
0.534965 |
44.75258 |
14 |
ponatinib (MSN01;MSN02;MSN05;MSN06);sorafenib (MSN01;MSN08);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01);imatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Down |
41.5 |
0.6 |
0.4565217 |
0.5891089 |
44.75258 |
14 |
lapatinib (MSN06);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01;MSN09);erlotinib (MSN01;MSN05;MSN08;MSN09);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
1 |
0 |
0 |
NaN |
44.75258 |
14 |
|
crizotinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
2 |
0.5 |
0.02173913 |
0.2179487 |
44.75258 |
14 |
trastuzumab (MSN02) |
crizotinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
3.5 |
0.6666667 |
0.04347826 |
0.3617021 |
44.75258 |
14 |
trastuzumab (MSN02;MSN09) |
crizotinib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
4 |
0.6 |
0.06521739 |
0.4047619 |
44.75258 |
14 |
ponatinib (MSN01);trastuzumab (MSN02;MSN09) |
crizotinib (MSN05;MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
4.5 |
0.5 |
0.06521739 |
0.3591549 |
44.75258 |
14 |
ponatinib (MSN01);trastuzumab (MSN02;MSN09) |
crizotinib (MSN05;MSN09);dasatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Down |
5 |
0.625 |
0.1086956 |
0.4885057 |
44.75258 |
14 |
ponatinib (MSN01);sorafenib (MSN08);trastuzumab (MSN02;MSN05;MSN09) |
crizotinib (MSN05;MSN09);dasatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Down |
6 |
0.6923077 |
0.1956522 |
0.6023622 |
44.75258 |
14 |
ponatinib (MSN01;MSN02;MSN05;MSN06);sorafenib (MSN01;MSN08);trastuzumab (MSN02;MSN05;MSN09) |
cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Down |
6.5 |
0.6428571 |
0.1956522 |
0.5666665 |
44.75258 |
14 |
ponatinib (MSN01;MSN02;MSN05;MSN06);sorafenib (MSN01;MSN08);trastuzumab (MSN02;MSN05;MSN09) |
axitinib (MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01) |
| Platelet-derived growth factor receptor signaling |
Down |
37 |
0.6363636 |
0.4565217 |
0.6219512 |
44.75258 |
14 |
lapatinib (MSN06);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01;MSN05;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01;MSN09);erlotinib (MSN01;MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
36 |
0.625 |
0.4347826 |
0.609319 |
44.75258 |
14 |
lapatinib (MSN06);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01;MSN08;MSN09);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01;MSN09);erlotinib (MSN01;MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
30 |
0.6333333 |
0.4130435 |
0.6140684 |
44.75258 |
14 |
lapatinib (MSN06);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN01;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01;MSN09);erlotinib (MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
20 |
0.6206896 |
0.3913043 |
0.6 |
44.75258 |
14 |
lapatinib (MSN06);pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01;MSN09);erlotinib (MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
18 |
0.6071429 |
0.3695652 |
0.5850202 |
44.75258 |
14 |
pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01;MSN09);erlotinib (MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
15 |
0.6296296 |
0.3695652 |
0.6046025 |
44.75258 |
14 |
pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08;MSN09);trametinib (MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01);erlotinib (MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
13.5 |
0.6 |
0.326087 |
0.5717489 |
44.75258 |
14 |
pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN01;MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01);erlotinib (MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Platelet-derived growth factor receptor signaling |
Down |
13 |
0.625 |
0.326087 |
0.5930233 |
44.75258 |
14 |
pazopanib (MSN06);ponatinib (MSN01;MSN02;MSN05;MSN06;MSN08);sorafenib (MSN01;MSN05;MSN08);trastuzumab (MSN01;MSN02;MSN05;MSN09);vandetanib (MSN05;MSN09) |
axitinib (MSN05);cabozantinib (MSN02);crizotinib (MSN05;MSN09);dasatinib (MSN01);erlotinib (MSN05);imatinib (MSN01);rituximab (MSN06);vemurafenib (MSN09) |
| Hippo signaling |
Down |
3 |
1 |
0.02173913 |
0.2741936 |
44.93386 |
13 |
pazopanib (MSN01) |
|
| Hippo signaling |
Down |
5 |
1 |
0.04347826 |
0.4358974 |
44.93386 |
13 |
pazopanib (MSN01;MSN05) |
|
| Hippo signaling |
Down |
7 |
1 |
0.06521739 |
0.5425532 |
44.93386 |
13 |
pazopanib (MSN01;MSN05;MSN06) |
|
| Hippo signaling |
Down |
19 |
0.75 |
0.06521739 |
0.4636364 |
44.93386 |
13 |
pazopanib (MSN01;MSN05;MSN06) |
crizotinib (MSN01) |
| Vascular endothelial growth factor receptor signaling |
Up |
6.5 |
1 |
0.04347826 |
0.4358974 |
48.58871 |
12 |
dabrafenib (MSN01);pazopanib (MSN05) |
|
| Vascular endothelial growth factor receptor signaling |
Up |
5.5 |
1 |
0.02173913 |
0.2741936 |
48.58871 |
12 |
pazopanib (MSN05) |
|
| Vascular endothelial growth factor receptor signaling |
Up |
7 |
1 |
0.06521739 |
0.5425532 |
48.58871 |
12 |
dabrafenib (MSN01;MSN05);pazopanib (MSN05) |
|
| Vascular endothelial growth factor receptor signaling |
Up |
9.5 |
1 |
0.08695652 |
0.6181818 |
48.58871 |
12 |
dabrafenib (MSN01;MSN05);pazopanib (MSN05;MSN08) |
|
| Vascular endothelial growth factor receptor signaling |
Up |
10 |
1 |
0.1304348 |
0.7183099 |
48.58871 |
12 |
dabrafenib (MSN01;MSN05;MSN06);pazopanib (MSN05;MSN06;MSN08) |
|
| Vascular endothelial growth factor receptor signaling |
Up |
11 |
1 |
0.1521739 |
0.7531646 |
48.58871 |
12 |
dabrafenib (MSN01;MSN05;MSN06);pazopanib (MSN01;MSN05;MSN06;MSN08) |
|
| Vascular endothelial growth factor receptor signaling |
Up |
13 |
0.875 |
0.1521739 |
0.6839081 |
48.58871 |
12 |
dabrafenib (MSN01;MSN05;MSN06);pazopanib (MSN01;MSN05;MSN06;MSN08) |
ruxolitinib (MSN01) |
| Desaturation of fatty acids |
Up |
14 |
0.6666667 |
0.2173913 |
0.5944056 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);ceritinib (MSN06);imatinib (MSN05);regorafenib (MSN05;MSN06) |
| Desaturation of fatty acids |
Up |
3 |
1 |
0.06521739 |
0.5425532 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01);pazopanib (MSN08) |
|
| Desaturation of fatty acids |
Up |
2 |
1 |
0.02173913 |
0.2741936 |
48.83922 |
11 |
pazopanib (MSN08) |
|
| Desaturation of fatty acids |
Up |
4 |
1 |
0.08695652 |
0.6181818 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN08) |
|
| Desaturation of fatty acids |
Up |
6.5 |
1 |
0.1086956 |
0.674603 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN08;MSN09) |
|
| Desaturation of fatty acids |
Up |
7 |
1 |
0.1304348 |
0.7183099 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN08;MSN09);sorafenib (MSN08) |
|
| Desaturation of fatty acids |
Up |
8 |
1 |
0.1521739 |
0.7531646 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN08;MSN09);sorafenib (MSN01;MSN08) |
|
| Desaturation of fatty acids |
Up |
10 |
0.8888889 |
0.173913 |
0.7157895 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08) |
imatinib (MSN05) |
| Desaturation of fatty acids |
Up |
11 |
0.8 |
0.173913 |
0.6601941 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08) |
ceritinib (MSN06);imatinib (MSN05) |
| Desaturation of fatty acids |
Up |
13 |
0.7272727 |
0.173913 |
0.6126125 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN08) |
ceritinib (MSN06);imatinib (MSN05);regorafenib (MSN06) |
| Desaturation of fatty acids |
Up |
13.5 |
0.6428571 |
0.1956522 |
0.5666665 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08) |
cabozantinib (MSN01);ceritinib (MSN06);imatinib (MSN05);regorafenib (MSN05;MSN06) |
| Desaturation of fatty acids |
Up |
19.5 |
0.625 |
0.2173913 |
0.5629139 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);ceritinib (MSN06);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN05;MSN06) |
| Desaturation of fatty acids |
Up |
20.5 |
0.5882353 |
0.2173913 |
0.5345912 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);ceritinib (MSN06);imatinib (MSN05);nilotinib (MSN05);regorafenib (MSN05;MSN06;MSN08) |
| Desaturation of fatty acids |
Up |
21 |
0.5555556 |
0.2173913 |
0.5089821 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);ceritinib (MSN06);imatinib (MSN05);nilotinib (MSN05;MSN06);regorafenib (MSN05;MSN06;MSN08) |
| Desaturation of fatty acids |
Up |
21.5 |
0.4761905 |
0.2173913 |
0.4450262 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);ceritinib (MSN06);imatinib (MSN05;MSN06);nilotinib (MSN05;MSN06;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08) |
| Desaturation of fatty acids |
Up |
23.5 |
0.4545455 |
0.2173913 |
0.4271357 |
48.83922 |
11 |
dabrafenib (MSN08);lapatinib (MSN01;MSN06);pazopanib (MSN06;MSN08;MSN09);sorafenib (MSN01;MSN05;MSN08;MSN09) |
cabozantinib (MSN01);ceritinib (MSN06);imatinib (MSN05;MSN06);nilotinib (MSN05;MSN06;MSN08;MSN09);regorafenib (MSN01;MSN05;MSN06;MSN08) |
| Thyroid hormone receptor signaling |
Up |
3.5 |
1 |
0.04347826 |
0.4358974 |
48.84258 |
10 |
bevacizumab (MSN06;MSN09) |
|
| Thyroid hormone receptor signaling |
Up |
5.5 |
1 |
0.06521739 |
0.5425532 |
48.84258 |
10 |
bevacizumab (MSN05;MSN06;MSN09) |
|
| Citric acid cycle |
Up |
3 |
1 |
0.08695652 |
0.6181818 |
60.92883 |
1 |
pazopanib (MSN01;MSN05;MSN08;MSN09) |
|
| Citric acid cycle |
Up |
1 |
1 |
0.04347826 |
0.4358974 |
60.92883 |
1 |
pazopanib (MSN01;MSN08) |
|
| Citric acid cycle |
Up |
2 |
1 |
0.06521739 |
0.5425532 |
60.92883 |
1 |
pazopanib (MSN01;MSN05;MSN08) |
|
